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QUILL ON SCALPEL
This section provides a medium through which Canadian 
surgeons can declare themselves, briefly and informally, on 
the day-to-day affairs of surgery.
Percutaneous Transluminal Angioplasty: 
Under- or Overused?
In 1964, Dotter and Judkins1 reported a 
novel approach to the treatment of arterio­
sclerotic lesions of peripheral arteries. 
Arterial stenosis or occlusion was dilated 
percutaneously using a series of coaxial 
catheters. In 1968, Dotter and col­
leagues2 reported their experience with 
this technique in 155 patients. The suc­
cess rate was 80% in patients with focal 
stenosis of the femoropopliteal system but 
only 29% in patients who had complete­
ly occluded segments. In 1969,3 we re­
ported our experience of percutaneous 
transluminal dilatation in 15 patients with 
segmental stenoses of the femoral or 
popliteal arteries, using Dotter’s tech­
nique, with early success in 14 patients. 
In spite of these encouraging results, the 
procedure did not gain widespread accep­
tance because of its limited application. 
It was not until Griintzig and Hopff4 
developed the double-lumen catheter that 
the principle of percutaneous translumi­
nal dilatation was accepted. Now the 
technique is widely used. Although there 
have been numerous reports on the proce­
dure, its role in the management of 
patients with peripheral vascular disease 
has not been clearly defined.
In the March 1985 issue of this Jour­
nal (pages 150 to 152), Jones and her col­
leagues reported on their results of trans­
luminal angioplasty in a high-risk 
population — those with either rest pain, 
pregangrene or gangrene. Presumably, 
such a group, without any intervention, 
would require amputation in a relatively 
short time. Of their 85 patients, techni­
cal failure occurred in 16. Of the remain­
ing 69, symptomatic improvement was 
obtained in 40 patients. Nine patients 
required repeat dilatation from 2 to 51 
months after the initial procedure; in five 
of them, the repeat procedure was unsuc­
cessful. Consequently, of the 85 patients, 
only 35 (41 %) had a successful result for 
even a short period. The authors’ cri­
terion for success, namely avoiding sur­
gery, does not appear to be appropriate, 
since seven of the patients in whom 
angioplasty was a technical failure main­
tained their limbs without surgery. One
can only postulate how a similar group 
of high-risk patients operated on by 
experienced vascular surgeons, using local 
or regional anesthesia and both anatomic 
and extra-anatomic techniques, would 
have fared.
In our vascular unit we have learned, 
as have others, that patients with iliac 
lesions have higher success rates with 
transluminal dilatation than do patients 
with femoral or popliteal lesions; that 
patients who have stenoses have a higher 
success rate than do patients with com­
plete occlusions; and that the shorter the 
segment to be dilated and the better the 
distal runoff, the better is the result.
Since patients who have advanced 
ischemia generally have multiple levels 
of disease with poor runoff, in our ex­
perience such patients are not generally 
candidates for transluminal dilatation. In 
our unit, most patients who have limb- 
threatening ischemia have been managed 
surgically rather than by angioplasty. 
However, in some patients transluminal 
dilatation of a proximal stenosis has been
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combined with distal revascularization. 
The best results with transluminal dilata­
tion have been in patients with intermit­
tent claudication.
The advantages of transluminal dilata­
tion are that the cost is low and when per­
formed by an expert it is associated with 
low morbidity and mortality. In the care­
fully selected patient the results can be 
excellent. In the patient with advanced 
disease a more favourable result may be 
achieved with an appropriately selected 
operative procedure performed under 
local or regional anesthesia. There is no 
doubt that transluminal dilatation is
underused in some centres and overused 
in others. The right place for translumi­
nal dilatation in the spectrum of therapeu­
tic options for vascular disease remains 
to be determined.
Nathan M. Sheiner, md, frcsc
Member,
Editorial Board.
Surgeon-in-Chief,
The Sir Mortimer B. Davis- 
Jewish General Hospital,
3755 Cote Ste-Catherine,
Montreal, PQ 
H3T 1E2
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What Should the Practising Surgeon Do With Precancerous
and High-Risk Breast Lesions?
Segmental mastectomy or local tumour 
resection, with or without postoperative 
radiotherapy, is becoming increasingly 
accepted as an approach to stage I and 
stage II cancers of the breast. The con­
tributors to the symposium on precancer­
ous and high-risk breast lesions, which 
appears in this issue of the Journal (pages 
242 to 267), recommend a more aggres­
sive approach to these lesions than that 
practised by many surgeons today. There­
fore, I must ask myself whether I am 
comfortable carrying out total breast 
removal, either conventionally or sub­
cutaneously, in order to avoid cancer. 
Moreover, I must question whether any 
of these precancerous entities, which are 
so repeatedly referred to in the literature, 
have ever been proven to develop into 
invasive cancer.
Certainly there are high-risk lesions and 
high-risk patients. The risks relate to the 
epidemiologic, historical and clinical 
characteristics and to the microscopic 
interpretation of biopsied material. These 
factors must be considered when the deci­
sion is made, first, whether to biopsy and, 
second, whether to repeat the biopsy, fol­
low up conservatively or recommend fur­
ther surgery.
At one extreme is the case of an obese 
woman who has never experienced a full- 
term pregnancy; she has a 40-year-old sis-
Presented as part o f  a symposium on 
precancerous and high-risk lesions o f  the 
breast by the Royal College o f  Physicians 
and Surgeons o f  Canada, in cooperation 
with the Canadian Association o f  General 
Surgeons, the Canadian Oncology Society 
and the Canadian Society o f  Plastic Sur­
geons, Montreal, PQ, Sept. 11, 1984
ter with breast cancer and now, because 
a precancerous breast condition is diag­
nosed, total mastectomy is recommended. 
Whether the same recommendation 
would be made if the only clinical high- 
risk factor was diffuse mammographic 
change is questionable and would seldom 
be a determining factor in my judgement.
The confusion is further promoted by 
what I like to call the pathologic indeci­
siveness of the multiple diagnoses offered 
on biopsy material. Seven different 
categories of breast lesions are noted by 
the symposium panelists. What is the cli­
nician to understand when he hears the 
words carcinoma in situ, intraductal car­
cinoma, noninvasive ductal carcinoma, 
diffuse atypical hyperplasia, papilloma­
tosis, adenomatosis, sclerosing adenosis, 
lobular dysplasia, lobular carcinoma in 
situ or diffuse cystic hyperplasia with 
atypism? These confusing interpretations 
of biopsy specimens may not mean the 
same to pathologists and to clinicians.
I do not recommend, in the under­
standing, intelligent patient who can be 
followed up regularly, that, based upon 
the above diagnoses alone, she have 
prophylactic removal of her breast. 
However, some recommendation for 
management must be made. The patient 
must understand that there is no cook­
book answer to this dilemma and if she 
is not willing to assist us in finding the 
answer by being followed up conserva­
tively, then she should be encouraged to 
undergo definitive surgery. While con­
troversy exists as to what is, or is not, a 
precancerous condition of the breast, the 
patient must be aware of this dilemma
and assume some of the decision-making 
responsibility for her management.
Subcutaneous mastectomy should not 
be used to treat infiltrating breast cancer. 
Selectively, it may have a role in the 
management of severely atypical lesions 
as determined by clinical, mammographic 
or microscopic interpretation. Unfor­
tunately, the usual subcutaneous mastec­
tomy leaves a “ padded” layer of sub­
cutaneous tissue beneath the skin, 
particularly beneath the nipple, which 
contains isolated glandular and ductal ele­
ments of the breast. Whether 5%, 10% 
or 15% is left after subcutaneous mastec­
tomy, there still remains a risk of cancer, 
for that portion of remaining breast is at 
the same risk as was the entire breast. The 
more breast tissue removed, the less likely 
the patient is to get cancer, but also the 
less likely one is to achieve a satisfactory 
cosmetic result. With the placement of the 
implants beneath the pectoralis muscle, 
the plastic surgeon can often do what he 
calls a total mastectomy, leaving only a 
small amount of glandular tissue beneath 
the nipple-areolar complex, but breast tis­
sue is left unless, possibly, the nipple 
is transplanted. Under those circum­
stances, in order for the transplanted 
nipple to remain viable, essentially a full­
thickness or sometimes a split-thickness 
graft remains after debridement of all the 
tissue beneath the areola and the nipple. 
It has been my experience, however, that 
few patients are satisfied with the cos­
metic results of subcutaneous mastectomy 
or immediate implant after what I call a 
99% breast removal, leaving skin and nip­
ple intact. I recommend that if removal
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of breast tissue is indicated because of 
cancer or the high risk of cancer, then the 
breast tissue should be removed in its 
entirety and reconstruction undertaken 
immediately, or after a suitable interval. 
I find that cosmetic success is achieved 
more readily if the reconstruction is 
undertaken 6 to 10 weeks after breast 
removal. There are, of course, exceptions. 
When the patient and her husband 
express strong interests in preserving the 
original breast, skin, nipple and contour, 
we will agree to subcutaneous mastec­
tomy with multiple biopsies being care­
fully analysed, especially in those cases in 
which the breast is diffusely nodular, vir- 
ginally firm or difficult to evaluate.
When such prophylaxis is decided 
upon, there is the controversy over how 
the opposite breast should be handled. 
Both glands have the same embryologic 
origin and should therefore carry the 
same risk of tumour development. The 
opposite breast is not considered for sur­
gery unless it is biopsied for diagnostic 
reasons based upon the pathological find­
ings in the affected breast. If total mastec­
tomy is decided upon for the premalig- 
nant lesion, then the opposite breast 
should presumably be left intact except 
for biopsy. Further intervention would be 
indicated by the biopsy findings. Cos­
metic symmetry is difficult to obtain and 
as long as the contralateral breast remains 
clinically normal or minimally abnormal, 
it should be preserved.
Only with time, careful patient 
monitoring by cooperative group studies 
and appropriate interpretation and 
follow-up of the many pathologic entities 
will we know what to do with the breast 
containing “ precancerous” lesions. The 
intelligent, cooperative, understanding 
patient should be offered conservative 
treatment with regular follow-up and 
repeat biopsies at regular intervals. The 
biopsy can be done by needle, trocar or 
open technique. Semiannual low-dose 
mammography might be helpful. It is 
essential that these patients become 
meticulous self-breast examiners and with 
the help of their husbands carry out a 
conscientious weekly breast examination.
I recognize that cancer of the breast 
remains one of the more frequent causes 
of death in women. In spite of this, it is 
difficult to recommend aggressive surgery 
for a disease that has yet to be proven to 
be truly a precursor of cancer.
A lfred  S. Ketc h a m , md
W hen a 
living thing
Bactericidal dressing for burns, wounds, ulcers 
and graft sites
Effective against both gram-positive and gram­
negative infections of the skin, including Staphylo­
coccus aureus, Escherichia coli, and the Proteus 
group
Remains active in the presence of blood, pus 
and serum
Easy to apply and remove, avoids irritating 
sensitive wounds
Keeps the wound area soft and moist, preventing 
drying and cracking
Allows the wound to breathe while it heals, 
avoiding maceration
Conforms well to the 
body's contours
Chief, Division of Oncology,
Professor of Surgery and Oncology, 
American Cancer Society Professor of 
Clinical Oncology,
Department of Surgery,
University of Miami School of Medicine, 
PO Box 016310,
Miami, Fla. 33101 
USA
“Sofraftlle
Framycetin Sulphate B.P. 1 %
Antibiotic
PAAB |ROUSSEL i -
ROUSSEL CANADA INC.
MONTREAL. QUEBEC J K w W L
For prescribing information see page 271
in
The restoration of a work of art requires the right tools the hands of a master
URGICEL 
N U -K N ir
Absorbable hemostat
(oxidized regenerated cellulose)
Stronger, high density format. 
One ply effectively handles 
problem bleeding and can be 
easily removed or sutured if  
required.'
Unique bactericidal activity Only oxidized 
regenerated cellulose provides bactericidal 
protection against postoperative growth o f 
pathogens and wound infection in vivo.1 
Absorbable gelatin sponge, topical thrombin and 
microfibrillar collagen have been shown to 
actually enhance bacterial growth.23’4 
Rapid absorption Both SURGICEL N U -K N ir  
and SURGICEL* are rapidly absorbed in 7 to 
14 days, with virtually no tissue irritation as 
demonstrated in vivo.1
& SURGICEL*
Absorbablehemostat
(oxidized regenerated cellulose)
Versatile, low density knitted 
fabric. Multiple folds can be 
packed in hard-to-reach places 
and removed easily when 
hemostasis is achieved.
Rapid, dependable hemostasis Positive 
bleeding control is usually achieved in clinical 
situations in one to two minutes without the 
addition o f other agents. Under severe test 
conditions, bleeding is usually controlled within 
five minutes by SURGICEL N U -K N ir  and 
within eight by SURGICEL*5 
Easy to handle Oxidized regenerated cellulose 
conforms readily to irregular surfaces; won’t 
unravel or fray when cut; won’t stick to wet 
gloves or instruments.
I  hemostatique resorbable
| (cellulose regener^e oxyd6e)
S U R G IC E L  r i llN M L ■
absorbable hemostat
regenerated cellulose)
Contributions to the Correspondence section are welcomed. 
They should be typewritten and double spaced.
Human Bite Injuries 
of the Hand
To the editors.—My experience with 
human bite injuries of the hand at the 
Ottawa Civic Hospital over the past few 
years prompts me to respond to Dr. Bite’s 
article (Can J Surg 1984; 27: 616-8).
Through this experience we have 
adopted a policy whereby all these inju­
ries are referred to the plastic surgery 
service, whether the patient presents early 
or late after injury. All bites that have 
penetrated the full thickness of the dermis 
are extended and explored under local 
anesthesia to determine, as early as pos­
sible, whether or not the integrity of the 
underlying joint or tendon has been vio­
lated. Leaving the wound open and 
prescribing antibiotics orally is simply not 
adequate treatment in our experience. All 
patients with open joints who present with 
cellulitis or suppuration should, in our 
view, be admitted to hospital for paren­
teral administration of antibiotics. It is 
essential that the integrity of underlying 
joint and tendon be established as early 
as possible and this can only be done by 
exploring and visualizing the structures. 
Dr. Bite makes no mention of this as a 
policy although he does allude to the need 
for copious irrigation of wounds. Treat­
ing patients with active infection expec­
tantly as outpatients and giving antibiotics 
orally has almost always resulted in 
advanced complicated infections with 
severe morbidity and permanent disabil­
ity of the involved hand. To rely on clin­
ical evidence of septic arthritis will 
inevitably give a false sense of security to 
the surgeons dealing with these injuries. 
The time to establish joint integrity is as 
soon after injury as possible and before 
active septic arthritis supervenes.
I would, therefore, make a plea to all 
surgeons involved in the management of 
human bites to adopt this more aggres­
sive approach in the interests of superior 
results, lower morbidity and disability,
and, in the long run, a saving of health­
care resources.
G. A llan  Tay lo r , m d , frcsc
Chief, Division of Plastic Surgery,
Ottawa Civic Hospital,
Ottawa, Ont.
K1Y 4E9
To the editors.—Dr. Taylor raises some 
important points about the management 
of human bite injuries of the hand. I cer­
tainly agree with him that the wound 
should be examined under local anesthe­
sia at the time of initial assessment when 
irrigating it. If penetration of the joint 
capsule or tendon sheath is discovered, 
more aggressive management with paren- 
terally administered antibiotics, hospital 
admission and possibly formal operative 
exploration is warranted. However, in the 
absence of such findings, when the clini­
cal findings are minimal and the patient 
is seen within 24 hours of injury, I dis­
agree with Dr. Taylor. Statistical analy­
sis of my results showed no significant 
difference in outcome (as measured by 
duration of hospitalization, duration of 
outpatient follow-up required and com­
plication rate) between patients seen 
within 24 hours of injury, those assessed 
from 1 to 7 days following injury and 
those initially seen more than 7 days fol­
lowing injury. Furthermore, Malinowski 
and colleagues1 prospectively studied 265 
patients with human bite injuries of the 
hand and concluded that there was no 
difference in outcome and complication 
rates between 131 hospitalized patients 
treated parenterally with antibiotics and 
134 similar patients treated as outpatients 
and given antibiotics orally. All had 
minimal clinical findings at the time of 
initial assessment and, in fact, the highest 
complication rate (4.7%) occurred in the 
hospitalized group. Thus, if all patients 
with human bite injuries were admitted 
to hospital, at least 50% would be admit­
ted unnecessarily. I stress that I only
recommend outpatient management for 
those patients with minimal clinical find­
ings (no septic arthritis, no purulent 
drainage and no cellulitis) who are seen 
within 24 hours of injury. If such a course 
of management is adopted, the patient 
should be re-examined within 24 hours, 
preferably by the same physician. To 
admit all such patients to hospital is 
unjustified and an unnecessary expense 
on the basis of the available data.
U ldis B it e , m d , frcsc
Apt. C20,
2015 -  41st Street NW,
Rochester, MN 55901 
USA
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Head Injuries
To the editors.—I read with great interest 
the excellent article “ Head injuries: a 
prospective, computerized study” , by 
Parkinson, Stephenson and Phillips (Can 
J  Surg 1985; 28: 79-83). The article is full 
of valuable information that will make it 
widely read and cited. Nevertheless, the 
authors make two controversial state­
ments that can likely be buttressed by 
information collected in their study but 
which are made without reference to sup­
porting data.
The first deals with the effect of “ inten­
sive” therapy that includes “ intracranial 
pressure monitoring, paralysis, ventila­
tion and barbiturates” . When compared 
with that of patients treated by simply 
“ maintaining an airway and giving man­
nitol, based on clinical indications..., 
patients treated more intensively... did 
less well as a group than might have been 
expected” , the authors claim. One may 
surmise that among the 323 patients
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reported to have had cerebral contusion 
or intracranial hematomas, or both, there 
might have been approximately 100 
patients who had raised intracranial pres­
sure, as intracranial hypertension may be 
expected to develop in roughly one third 
o f patients with severe head injuries.1 
One hundred patients carefully studied 
would suffice to support or refute the 
contention that “ intensive” therapy is not 
effective. I should like to know how many 
patients were monitored, whether the 
patients who died did so because of 
intractable intracranial hypertension, 
whether the intensive and the noninten- 
sive groups were comparable with respect 
to coma scale, associated injuries, and so 
on. It is well known that random assign­
ment, even when formally done, may 
produce groups with significant differ­
ences in important features that make 
comparisons more difficult.
The second concept that I consider con­
troversial is the implication that with “no 
history of a lucid interval” patients “were 
unlikely to have been saved had they 
arrived in hospital earlier” . Dr. Parkin­
son and his colleagues do not cite the arti­
cle by Seelig and associates2 who 
presented data suggesting that early treat­
ment o f acute subdural hematomas was 
more likely to produce a favourable out­
come. At the very least, I should like to 
know how many patients died before 
arrival at the Health Sciences Centre in 
Winnipeg and, of those, how many were 
hospitalized at smaller hospitals before 
they were transferred.
Michael Schwartz, md, m sc, frcsc
Department of Neurosurgery,
Sunnybrook Medical Centre,
2075 Bayview Ave.,
Toronto, Ont.
M4N 3M5
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SESAP IV Question
118. Patients with major injury o f the liver associated with hemorrhage
(A) frequently require hepatic lobectomy
(B) require T-tube drainage of the biliary tract
(C) can usually be managed by local hemostasis and 
debridement
(D) rarely die with current management techniques
(E) often require ligation of the hepatic artery for control of 
bleeding
For the incomplete statement above select the one answer that is best o f the 
five given. For the critique of Item 118 see page 223.
(Reproduced by permission from SE SA P  IV  Syllabus; Surgical Education and 
Self-Assessment Program No. 4. For enrolment in the Surgical Education and 
Self-Assessment Program No. 4, please apply to the American College of Sur­
geons, 55 East Erie St., Chicago, 1L 60611.)
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What's new in surgery is the subject of this column. The short items are designed to let readers know 
who's doing what and why. Surgeons are interested in what other surgeons are doing in 
research, education, practice and administration. Surgery is a vibrant specialty, and, as 
its practitioners, you must be the source as well as the readers of this column.
Portrait of the Canadian Surgeon: Not a Young Man
Compared with other specialists in Cana­
da, surgeons and their colleagues in 
anesthesia are an aging group — of 
men — according to statistics emerging 
from the Canadian Medical Association’s 
data bank on practising physicians.
The figures show that almost 60% of 
surgeons are older than 45 years and, in 
the next 10 years, almost 30% will be 65 
years of age or older. In fact, in the next 
5 years, 20% will have reached or sur­
passed the age of retirement. The category 
“ surgery” encompasses cardiovascular, 
thoracic, orthopedic, plastic and vascu­
lar surgery as well as urology and neu­
rosurgery.
The statistics are part of an extensive 
report coauthored by Orvill Adams, 
CMA’s Director of Economics, and 
scheduled to appear in the Canadian 
Medical Association Journal this month. 
The report marks the first release of in­
formation compiled from 41 599 replies 
to a questionnaire sent out by the CMA 
in 1982 to all physicians residing in Can­
ada; 87.4% of them responded, indicat­
ing that the figures accurately reflect the 
medical profession in Canada.
According to the data, just over 9% of 
Canada’s physicians are surgeons; 85% 
work full-time and almost all the rest are 
semiretired. Although women account for 
about 14% of all physicians, they 
represent only 1.8% of surgeons, possi­
bly as much a reflection of the age distri­
bution of surgeons as any other reason, 
since women have only recently entered 
the medical profession in large numbers.
The data leave no question about who 
is practising surgery in Canada; the im­
plications of what they portray are less 
clear. Whether the rate of attrition cur­
rently being experienced will put surgical
Contributions to this column are welcome. 
Please send your material to: Mrs. Amy 
Chouinard, Canadian Journal o f  Surgery, PO 
Box 8650, Ottawa, Ont. K1G 0G8.
services at a premium is particularly 
nebulous because the data do not show 
how much time surgeons now spend in 
primary practice. What they do show is 
how much time general practitioners 
spend performing surgical interventions. 
Of the 12 276 general practitioners who 
stated that the word “ general” best 
described their practices, 46.3% spend at 
least 4 hours each week in the operating 
room. Of the 2411 who noted that their 
practice was not general, 3.1% catego­
rized their work as general surgery.
Shortage of Surgeons Offset 
by Oversupply of GPs
The Federal/Provincial Advisory Com­
mittee on Health Manpower has forecast 
a shortage of surgeons by the year 2000 
but apparently expects general practition­
ers and other medical specialists to meet 
the demand for services. Not yet formal­
ly released, that committee’s findings 
were circulated internally in a preliminary 
report last fall and recently attracted me­
dia attention because it predicted an 18% 
surplus of general practitioners and med­
ical specialists.
The committee recognized the inade­
quacy of its data but believed they were 
sufficient to indicate overall trends 
towards an oversupply. Allowing for 
shortages in surgical and laboratory 
specialties, the committee forecasts a to­
tal surplus of 12%. The methods the com­
mittee used to calculate future require­
ments for physicians have been criticized, 
since they were based primarily on 
physician-to-population ratios and past 
supplies.
“ The ratio is so crude... I prefer not 
to use it,” commented Adams who went 
on to explain that his department shies 
away from the use of physician-to-popu­
lation ratios mainly because they have 
become the sole measure and “ they don’t 
really show what you need to know. You
Adams: “ physician-to-population ratios 
crude” .
need to know what resources you have in 
an area and the population you are try­
ing to serve. But you also need to know 
what type of health system you are work­
ing toward.” The big question is: What 
does one compare the figures to? Com­
paring them to those of the past assumes 
that the system was perfect previously, 
and comparing them to those in other 
countries is probably even less useful. 
Said Adams, “ It’s ridiculous to compare 
physician-to-population ratios in Canada 
with those in the US. The countries 
deliver health care in a different way.” 
Nevertheless, based on its figures, the 
committee recommended measures to 
avert the future oversupply of physicians 
by curbing increments from every source. 
It called for cutbacks in annual immigra­
tion of physicians recruited to fill posi­
tions for which no Canadian can be 
found, in licences being given to foreign- 
trained graduates (including Canadian 
citizens), in postgraduate training in 
medicine and in medical school enrol­
ment. The committee also recommended 
that postgraduate training be rationalized
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to fill the ranks of specialties in which 
shortages are perceived.
If implemented, the across-board 
reductions will likely affect some 
provinces more than others. In the past, 
Saskatchewan and Newfoundland have 
been particularly dependent on immigrant 
physicians. For example, according to 
Adams’s figures, more than half of sur­
geons in the age group 55 to 65 years who 
are practising in Saskatchewan received 
their education outside Canada, and the 
percentage for all surgeons in Saskatche­
wan is 46%. The latter compares with 
26% for surgeons country-wide and 28% 
for all physicians. As might be expected, 
the United Kingdom was the source of 
almost half the surgeons aged 55 to 65 
years and, together with India, account­
ed for nearly half of all surgeons trained 
outside Canada.
These figures suggest that, in the not- 
too-distant future, surgeons will be scarce 
in some areas of the country. Trends in 
the popularity of different fields of medi­
cine may be partly responsible for the cur­
rent picture, although the number of sur­
gical residents trained annually has not 
changed much over the past 10 years. 
According to data from the Royal Col­
lege of Physicians and Surgeons of 
Canada, an average 190 residents have 
gained certification yearly for the past 
decade in the specialties constituting the 
surgical category referred to by the 
federal/provincial committee.
Overall, fluctuations have been offset 
from year to year, but the tendency has 
been away from general surgery towards 
greater specialization. In 1975, 94 general 
surgeons gained certification, whereas the 
figure for 1984 was 60, reflecting a rela­
tively steady decline over the years. In 
other words, the supply of surgeons is 
likely dwindling, and the ones being 
trained differ in focus and skills from 
those trained in the past.
Couture: “Strengthen 
Broad-Based Specialties”
It is this change in the shape of speciali­
zation that was the focus of discussions 
in mid-March when the medical special­
ties’ boards of the United States and 
Canada met in Chicago.
Speaking to the group during a plenary 
session of the day-long meeting, Royal 
College President Jean G. Couture said 
that the move towards increasing sub­
specialization was taxing the resources of 
the medical schools and undermining the 
schools’ mission to produce well-rounded 
physicians.
He noted that the number of operat­
ing procedures done by general surgeons 
has decreased and he called for a strength­
ening of the broad-based specialties. Cou­
ture, who is head of surgery at Laval
University, said the approach to patients 
is “ microscopic and fractionated” , and 
the effects on teaching and research have 
probably been compounded by the efforts 
of medical faculties to seek out renowned 
experts in particular fields. The result is 
an absence of generalists as role models 
and an increase in the costs of care.
The high costs of subspecialization 
came up again and again at the meeting, 
with speakers focusing on the large sums 
of money involved even in the develop­
ment of an examination for certification 
in a new specialty. The questionable cost- 
effectiveness of a pulmonologist’s doing 
general medicine 85% of the time was 
raised as an example.
The consensus seemed to be that sub­
specialization is inevitable as a response 
to scientific advances in knowledge and 
equipment, but that public needs should 
be a major criterion in the creation of a 
subspecialty.
No one argued that specialization was 
not just a response but often a source of 
technical and scientific advances. Univer­
sity staff with narrowly specialized skills 
often attract funds for research and de­
velopment.
Two University-Affiliated 
Centres Get Funds 
for Research and Development
Both University Hospital, London, 
Ont., and Sunnybrook Medical Centre, 
Toronto, have recently announced invest­
ments from nongovernment groups to 
develop sophisticated techniques and 
equipment. Scientists at University Hospi­
tal will be collaborating with Biomedical 
Instrumentation Inc. to produce a cardiac 
mapping device that will simplify surgi­
cal management of patients with heart 
rhythm disorders. The computer-assisted 
device will be used in the operating room 
to identify the location of malfunctions 
causing cardiac arrhythmias.
In Toronto, Sunnybrook Medical 
Centre has obtained funds from a major 
European foundation to develop a 
biomechanical laboratory in which 
biomaterials for bone surgery, joint 
replacement and fracture fixation will 
receive special a ttention . Joseph 
Schatzker, MD, FRCSC, who has 
recently been appointed head of ortho­
pedic surgery at the centre, will direct the 
work, drawing on his expertise in joint 
reconstruction and musculoskeletal 
trauma.
Schatzker replaces Marvin Tile, MD, 
FRCSC, who has been promoted to 
deputy head of surgery at Sunnybrook 
Medical Centre.
Other Appointments 
and Honours
S.J. Peerless recently became the first 
appointee to the C.G. Drake Professor­
ship in Neurosurgery at the University of 
Western Ontario; the position is for 5 
years and was established to honour 
Drake for his achievements in brain 
surgery.
Clement McCulloch, MD, FRCSC, 
was the 1985 recipient of the medical 
achievement award, given out annually 
since 1979 by the Canadian Association 
of manufacturers of Medical Devices. 
The award, presented at the association’s 
annual general meeting on Apr. 15, 1985, 
was recognition for McCulloch’s work in 
ophthalmological research.
Amy Chouinard
Drs. Drake (left) and Peerless honoured at Western.
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Syme’s Amputation in Adults: a Long-Term Review
A retrospective study was undertaken in 
two patient populations to establish the 
failure rate of Syme's amputation. Failure 
was defined as an amputation requiring 
revision to a more proximal level. For 
traumatic lesions of the foot the failure 
rate was 29% and for dysvascular 
lesions it was 41 %.
The long-term functional results in 55 
patients who underwent Syme's amputa­
tion for traumatic, dysvascular or conge­
nital lesions were studied. Overall, 73% 
had good function. The ideal Syme's 
stump, where the fat pad is centred 
securely over the distal tibia, was noted 
in only 22% of patients. The authors 
conclude that, in the past, technical 
details may have been overemphasized, 
because in this study the functional 
results of Syme's amputation were more 
dependent on prosthetic fitting. This 
type of amputation is not recommended 
for patients with dysvascular lesions 
because of the high failure rate.
Une etude retrospective a ete faite au 
sein de deux populations de patients 
dans le but d'etablir le taux d'echec de 
la technique d'amputation de Syme. 
L'echec a et6 defini d'apres la necessite 
de proceder a une revision a un niveau 
plus proximal. Le pourcentage d'echec 
fut de 29% dans les cas de lesions trau- 
matiques du pied et de 41%  pour les 
problemes d'origine vasculaire.
On a etudie les resultats fonctionnels a 
long terme de 55 amputations de Syme
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pour lesions traumatiques, dysvasculaires 
ou congenitales. Dans I'ensemble, de 
bons resultats ont ete obtenus dans 
73% des cas. Le moignon ideal dans la 
technique de Syme est obtenu quand le 
tissu adipeux est bien centre autour de la 
partie distale du tibia; un moignon ideal 
n'a ete observe que chez 22% des 
patients. Les auteurs concluent que, 
dans le passe, les details techniques de 
I'operation ont possiblement ete exage- 
res puisque, dans cette etude, les resul­
tats fonctionnels de I'amputation de 
Syme ont ete davantage relies a I'ajuste- 
ment de la prothese. Ce type d'amputa­
tion n'est pas indique pour les patients 
souffrant de lesions dysvasculaires, vu le 
haut taux d'echec.
The continuing role of Syme’s amputa­
tion in treating traumatic injuries to the 
foot, peripheral vascular disease, diabetes 
mellitus, and congenital and neurologic 
problems is still debated in the literature. 
Despite its advantages, it has not gained 
total acceptance or popularity since it was 
first introduced by Syme' in 1843. 
Many2'5 have found that long-term func­
tion is satisfactory in most amputees, 
except those in whom the amputation is 
performed for peripheral vascular disease 
and diabetes mellitus. In these circum­
stances the high revision rate is unac­
ceptable.6
The success of Syme’s amputation in 
children is well documented.7'9 It has 
unique end-bearing characteristics, it per­
mits continued growth of the tibia so that 
the patient may walk with or without a 
prosthesis and the stump has proved 
durable, enabling the patient to lead a 
normal life.
Because of the study of H arris,10 
Syme’s amputation has enjoyed consider­
able popularity in North America. 
Reviewing the history of the amputation 
and the various modifications, he out­
lined the importance of attention to tech­
nical detail, which includes disarticulation 
through the ankle, preserving the blood 
supply to the flap, transecting the tibia 
parallel to the floor and not perpendicu­
lar to the tibial shaft, avoiding button­
holing the skin and preventing migration 
of the fat pad in the early postoperative 
period. Emphasis on surgical technique 
has been reported by others,1112 con­
firming that the success of this procedure 
depends on meticulous attention to tech­
nical detail.
Over the years, dissatisfaction and the 
revision rate have increased among 
patients with traumatic amputations 
attending the Workers’ Compensation 
Board Rehabilitation Centre of Ontario. 
In this retrospective review, patients who 
underwent Syme’s amputation for trau­
matic and nontraumatic lesions were stu­
died to establish the overall revision rate 
and to evaluate long-term function.
Patients
The medical records of 132 patients 
attending The Workers’ Compensation 
Board Rehabilitation Centre in Toronto 
and 56 patients attending Sunnybrook 
Medical Centre who underwent Syme’s 
amputation were reviewed. The factors 
considered were the number of surgical 
procedures performed before the defini­
tive Syme’s amputation, the number of 
amputations revised to a more proximal 
level, the time of revision (early or late) 
and the reason for revision. If the revi­
sion was undertaken within 3 months of 
amputation it was considered early, the­
reafter it was regarded as late.
A total of 54 patients with 55 amputa­
tions were personally reviewed (J.McE.). 
These form the basis for much of this 
report. Four were women, the remainder 
were men. Of the 55 amputations, 35 were 
for injury, 6 for congenital or neurologic 
lesions and the remaining 14 were for 
peripheral vascular disease and diabetes 
mellitus. The average follow-up was 29 
years (range from 1.5 to 65 years) for the 
patients with trauma, 6.5 years (1.5 to 10 
years) for the dysvascular patients and 31 
years for those with congenital and neu­
rologic lesions. The average age at follow­
up was 56 years, patients with dysvascu­
lar limbs being on average 8 years older.
One patient had a bilateral Syme’s 
amputation. Eleven had contralateral
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amputations (7 below-knee, 1 Gritti- 
Stokes, 1 ray resection, 1 transmetatar­
sal amputation and 1 toe resection). All 
patients were assessed with regard to pain, 
use of a prosthesis, size, shape, position 
and mobility of the stump, employment 
and overall function, including recrea­
tional activities. The need for further sur­
gical procedures was also recorded. We 
used a modification of the Hornby and 
Harris13 functional rating system. For a 
good result, the patient had to be fully 
employed at his original occupation or a 
similar one, wearing a prosthesis full-time 
with no restriction of social activities. 
Minor stump pain, not necessitating regu­
lar prosthetic adjustments, was tolerated 
in this group. Change of occupation to 
a more sedentary job, pain necessitating 
regular prosthetic changes and restriction 
of social and recreational activities were 
considered a fair result only. Poor results 
were those in which the patient com­
plained of persistent pain and discomfort, 
did not wear the prosthesis full time and 
was unemployed or retired prematurely 
as a direct result of the amputation. 
Modifications in this rating system were 
made for patients who had retired 
because of old age.
The shape of the stump was described 
as either conical, round, bulbous or flat. 
The mobility of the stump was classified 
using the criteria outlined by Murdoch,5 
as follows: grade 1 — the heel pad was 
securely fixed to the tibia; grade 2 — the 
substance of the pad could be moved 
from side to side without uncovering the 
peripheral bone; grade 3 — the heel pad 
could be displaced in all directions, leav­
ing part of the peripheral bone unpro­
tected; grade 4 — the heel pad was grossly 
mobile and permanently displaced (Figs.
1 to 4). Bone irregularities of the lower 
tibia were assessed by standard antero­
posterior and lateral roentgenograms.
Results (Table I)
Trauma Group
Twenty-two of the 35 patients com­
plained of pain in the stump, but it was 
severe in only 10. Eighty-two percent of 
the amputees returned to their original 
jobs, 31 % of them doing heavy labour­
ing work such as underground mining. 
Walking supports were used by eight 
patients because of old age. Patients with 
contralateral amputations tended to use 
supports when walking long distances; 20 
patients could walk an unlimited distance. 
Only 17% of patients considered that they 
were end weight bearing on the stump 
while wearing the prosthesis; the re­
mainder bore more weight proximally.
Further minor surgical procedures were 
necessary in 17% of the patients in this 
group. Technically, 22% of patients had 
good stumps and 3% had poor stumps.
The remaining stumps, although func­
tional in most cases, tended to migrate, 
predominantly to the medial side of the 
tibia. The major long-term complication, 
as related by the patient, was migration 
of the fat pad.
Dysvascular Group
All but 1 of the 14 patients in this group 
wore a prosthesis full time. This includes 
four patients with contralateral amputa­
tions requiring prostheses. Only two 
patients could weight bear at the end of 
the stump. All but three patients had 
retired, either because of old age or gene­
ralized systemic disease.
Three patients could walk an unlimited 
distance while the remainder were res­
tricted by intermittent claudication. 
Twelve of the 14 patients thought they 
bore more weight at the knee.
Congenital Group
Three patients suffered stump pain, but 
it did not compromise their activity. All 
six in this group had worked at some 
stage, although two have now retired.
FIG. 1—Grade 1 mobility. Heel pad is 
securely fixed to tibia.
V__- j
FIG. 2—Grade 2 mobility. Substance of heel 
pad can be moved anteriorly without uncover­
ing peripheral bone.
End weight bearing on the stump without 
the prosthesis was possible in four 
patients but not by the two who have 
retired. None of the patients had an ideal 
Syme’s stump, but all were functional. 
Every patient was satisfied with the end 
result. No further surgical procedures 
were performed in this group.
Failure Rate
This was defined as the number of 
Syme’s amputations requiring a revision 
to a more proximal level. Of 132 trau­
matic amputees, 38 (29%) amputations 
were revised either to a standard below- 
knee or a long below-knee amputation. 
Approximately 60% of the revisions were 
performed for stump pain, the remainder 
for prosthetic problems and stump infec­
tion. The interval between the initial 
amputation and revision ranged from 2 
months to 61 years. In this group of 
failures, the average number of operative 
procedures before the elective Syme’s
FIG. 3—Grade 3 mobility. Heel pad is dis­
placed laterally, leaving medial side un­
protected.
FIG. 4—Grade 4 mobility. Heel pad is per­
manently displaced anteromedially.
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operation was 5 (ranging from 2 to 14) 
compared with an average of 3.3 proce­
dures for the whole group of trauma- 
related amputations.
Of the 56 amputations for dysvascular 
lesions, 23 (41%) were converted to a 
higher level (20 below the knee, 2 above 
the knee and 1 through the knee). All but 
three were performed within 3 months of 
the original procedure for infection and 
wound breakdown. Of patients in this 
group, 22 (40%) died within 6 months of 
the revision; 12 of them had a two-stage 
procedure carried out before failure 
occurred.
Discussion
The failure rate of Syme’s amputation 
in this series for both traumatic and dys­
vascular lesions was high. Many of the 
failures have been ascribed to poor sur­
gical technique and patient selec­
tion.2’10'12 It is understandable that infec­
tion in the dysvascular limb predisposes 
to failure, and the clinical diagnosis of tis­
sue viability in this group is not reliable. 
Because this study is retrospective, we 
cannot comment on the condition of the 
stump at the time of revision. We do 
know from the clinical results that a tech­
nically inferior Syme’s stump is compat­
ible with good function when the prosthe­
sis is modified. Because pain was the 
major reason for revision in the traumatic 
group, and because each patient had had 
an average of five operations before their 
elective Syme’s amputation, it is possible 
that these patients fit into a special 
chronic pain category, for example, 
mania operativa.14 If one could identify 
these difficult patients, it may be prudent 
to proceed with an early elective ampu­
tation in preference to multiple proce­
dures to preserve a severely injured foot.
Good clinical results were recorded in 
73% of the entire series of patients. Pain 
was a predominant reason for poor func­
tion. If modifications in the prosthesis 
had not been made, it is possible that an 
even greater number of patients would 
have been in this category because of the 
condition of their stumps.
The ideal Syme’s amputation accord­
ing to the literature consists of securely 
fixing the fat pad to the broadest area of 
the cut end of the tibia — the cut end 
being parallel to the floor and not perpen­
dicular to the tibial shaft. Centrally posi­
tioned fat pads on weight bearing were 
recorded in only 22% of amputations in 
the entire series; all gave good function. 
Medial, lateral and posterior migration of 
the fat pad predominated in the re­
mainder but did not preclude a good 
functional result. End weight bearing, 
with or without the prosthesis, was pos­
sible only in a minority of these patients, 
suggesting that good prosthetic fitting was 
probably the reason why these amputees 
functioned so well.
Modern Syme’s amputation involves 
disarticulation of the ankle joint com­
bined with excision of both malleoli, as 
a one- or two-stage procedure.15 The 
articular cartilage is not removed and con­
sequently because of the shape of the dis­
tal tibia its surface is not parallel to the 
ground in both the anteroposterior and 
transverse planes. How securely the fat 
pad can be centred over the cartilaginous 
distal tibia is questionable. It appears to 
us that both these modifications account 
for the frequent migration of the fat pad.
In the presence of infection, two-stage 
amputations have been advised.15'16 Of 
the 17 such procedures performed for 
infection in dysvascular limbs in this ser­
ies, only 5 were successful. This success 
rate was considerably lower than in other 
reported series. It has been our policy in 
the past to try and preserve as much of 
the foot as possible, and the elected site 
of amputation was based on clinical 
grounds only. We are now using the Dop­
pler ischemic index15 in an effort to 
evaluate the most suitable level for ampu­
tation, and select suitable patients for 
ankle disarticulation.
Undoubtedly, the best results for 
Syme’s amputation were for the congen­
ital lesions. These patients are younger, 
well motivated and adapt to the prosthe­
sis quickly. They do not regard their 
amputation as a handicap and often par­
ticipate in contact sports.
Conclusions
Our findings suggest that a functional 
Syme’s amputation depends more or 
good prosthetic fitting than on meticulous 
technical detail. Poor technique is inex­
cusable, but we think too much empha­
sis has been placed on technical imperfec­
tions as the cause of failure.
In patients with dysvascular limbs, 
Syme’s amputation cannot be recom­
mended because of the high failure rate. 
Better preoperative assessment may help 
to predict the probability of success in 
these patients. For traumatic lesions of 
the foot, consideration should be given 
to early elective Syme’s amputation in 
preference to multiple procedures to 
preserve it. The risk of a more proximal 
amputation increases with the number of 
foot procedures performed.
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Table I—Clinical Results of Syme's Amputation
Amputation group, no. of patients
Finding
Traumatic 
(n -  35)
Dysvascular
(n -  14)
Congenital
(n -= 6)
Stump pain 22 8 3
Phantom pain 24 11 3
Prosthetic users (full time) 35 13 6
End weight bearing (without prosthesis) 18 2 4
Shape of stump
Bulbous 30 10 4
Round 3 2 1
Conical - 2 -
Flat 2 - 1
Mobility of stump
Grade 1 7 5 0
2 16 4 2
3 11 4 3
4 1 1 1
Functional result
Good 24 10* 5
Fair 6 2 1
Poor 5 1 0
*11 amputations.
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Neuropathology of Chronic Pancreatitis in Humans
To investigate the pathogenesis o f pain 
in chronic pancreatitis, tissue resected 
from  50 patients w ith  th is condition was 
examined by light m icroscopy. An 
examiner, blinded to  clinical and patho­
logical data, graded perineural fibrosis, 
inflam m ation and the com position of 
in flam m atory in filtra te  in 2132  separate 
perineural fields.
Correlation o f perineural fibrosis and 
inflam m ation grading w ith  alcohol inges­
tion and pain severity was insignificant. 
Pain severity did correlate w ith  the  tim ­
ing o f alcohol consum ption. A lthough 
calcification sign ificantly affected pain 
severity, the status o f duct d ilatation 
was not significant.
Eosinophils were observed in d is­
proportionate numbers in the perineural 
in filtra te . The correlation o f percentage 
eosinophilic in filtra te  and pain severity 
was highly significant. Tim ing o f alcohol 
consum ption also correlated significantly 
w ith  the percentage eosinophilic 
in filtra tion.
As eosinophils are know n to  be cy to ­
tox ic  and injurious to  tissue by liberation 
o f enzymes through degranulation, the 
findings o f this study suggest th a t the 
pain o f chronic pancreatitis may be medi­
ated by perineural eosinophils, through a 
chem otactic mechanism involving 
alcohol.
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A fin  de rechercher la pathogenese de la 
douleur dans la pancreatite chronique, on 
a examine au m icroscope optique les tis- 
sus reseques de 50 patients affliges de 
cette  maladie. Ignorant des donnees cli- 
niques et pathologiques, un exam inateur 
a evalue la fibrose perineurale, I'in flam - 
m ation et la com position de I 'in filtra t 
inflam m atoire dans 2 1 3 2  champs peri- 
neuraux.
La correlation entre la fibrose perineu­
rale et I'in flam m ation d 'une  part, e t 
I'ingestion  d 'a lcoo l et l'in tensite  de la 
douleur d 'au tre  part, s 'e s t averee sans 
im portance. L 'in tensite  de la douleur 
s 'e s t m ontree tou te fo is  reliee au m om ent 
de la prise d 'a lcoo l. Si la ca lc ification 
avait une influence significative sur 
l'in tens ite  de la douleur, le degre de la 
d ila tation du canal pancr£atique e ta it 
sans im portance.
Des eosinophiles ont ete observes 
dans un nombre disproportionne d 'in fil-  
tra ts  perineuraux. La correlation entre le 
pourcentage des in filtra ts  eosinophiles et 
l'in tens ite  de la douleur e ta it hautem ent 
s ign ifica tive . Le m om ent de la prise 
d 'a lcoo l a aussi m ontre une correlation 
im portante avec le pourcentage des in fil­
tra tions eosinophiles.
Puisqu'on sait que les eosinophiles 
sont cyto tox iques et lesent les tissus par 
une liberation d 'enzym es consecutive a 
un processus de degranulation, les resui- 
ta ts  de cette  etude m ontrent que les 
eosinophiles perineuraux sont suscepti- 
bles de participer a la douleur de la pan­
creatite  chronique par un mecanisme chi- 
m iotaxique im pliquant I'alcool.
Although pain is the predominant clini­
cal feature of chronic pancreatitis, its 
pathogenesis is poorly understood. Pain 
relief may be obtained following various 
surgical procedures that treat different 
pathologic effects of chronic inflamma­
tion, but complete freedom from pain is 
achieved only by total pancreatec­
tomy. 1-7
Various abnormalities of the pancreatic 
ducts are recognized in chronic pancrea­
titis.8 Painless pancreatitis occurs with 
gross dilatation of the ducts, while severe 
pain may accompany chronic pancreati­
tis without dilatation. The severity of the 
pain does not correlate with duct dilata­
tion, strictures or obstruction.9-12
Bradley13 reported elevated pressures 
in dilated ducts studied during surgery for 
chronic pancreatitis. He suggested that 
the pain correlated with increased 
hydrostatic pressure. However, normal 
pressures have been recorded in patients 
with chronic pancreatitis with dilated 
ducts, and manometric values in patients 
with chronic pancreatitis equalled those 
in normal patients.14’15 Pancreatic stimu­
lation tests do not increase pancreatic 
pain in many subjects with chronic pan­
creatitis.16
Painful pancreatitis occurs without cal­
cification in up to 50% of patients. 
Ammann and colleagues17 described 
decreased severity of pain with accom­
panying increased calcification during 
long-term follow-up of patients with 
chronic pancreatitis. It is doubtful that 
calcification alone causes pancreatic pain.
Sensory afferent fibres leaving the pan­
creas follow the sympathetic nerves, 
which pass through the celiac ganglia and 
splanchnic nerves. Celiac ganglionectomy 
and anesthetic nerve blocks abolish pan­
creatic pain.6’7 Apparently, neural com­
ponents are involved in transmitting pain 
associated with chronic pancreatitis.
This study was conducted to examine 
the histopathology of chronic pancreati­
tis, with particular reference to the neu­
ral elements within the gland. To evalu­
ate the mechanism of pain, clinical 
features of the disease were correlated 
with histologic observations.
Patients and Methods
Tissue obtained from 50 patients who 
underwent pancreatic resection or decom­
pression was examined histologically by
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a single observer, blinded to clinical and 
gross pathological data. In all, 2132 
separate perineural fields were examined. 
One perineural field was represented by 
a x  150 magnification surrounding at 
least one nerve fibril within the pancreatic 
tissue (Fig. 1). Recordings were made of 
the distribution and grading of fibrosis 
and the distribution, grading and cell 
composition of the inflammatory infil­
trate and the findings were compared with 
those of control tissue made of histori­
cally normal pancreatic tissue and pan­
creas obtained at autopsy from trauma 
victims.
Gross pathologic data was previously 
recorded for each patient, based on 
preoperative radiologic examination, 
operative examination and gross patho­
logical examination. Documentation in 
each case included tissue sample sites, 
pancreatic duct status and the presence of 
calcification. These data were withheld 
from the histologic examiner.
Fibrosis was graded as follows: grade 
1 — a minimal excess of loosely arranged 
fibrous tissue in direct contact with the 
perineurium; grade 2 — more densely 
arranged fibrous tissue surrounding the 
nerve fibril, usually associated with an 
increased inflammatory component (Fig. 
2); grade 3 — excessive perineural 
proliferation of fibrous tissue, widely 
separating the acinar lobules (Fig. 3).
The perineural inflammatory infiltrate 
was graded according to the cellular den­
sity of the inflammation: grade 1 — 
minimal infiltration by occasional lym­
phocytes and histiocytes in the perineu­
ral region; grade 2 — moderate density 
of cellular infiltration (Fig. 2); grade 3 — 
marked infiltration of the perineural field 
(Fig. 3); grade 4 — infiltration of the 
entire perineural field.
Clinical information was previously 
recorded for each patient. Pain was 
graded according to outpatient records, 
pharmaceutical prescription review and 
inhospital records. Grading of pain was 
tabulated as the mean number of 30-mg 
codeine equivalents required every 24 
hours. Alcohol intake was recorded from 
the patient history, referring physician 
history and history by family members. 
Intake of alcohol greater than 50 g/d was 
considered significant. The length of 
abstinence before tissue sampling was 
used to compute an alcohol grading score. 
Total abstinence was graded 0, recent 
alcohol intake was given a maximum 
grade of 30. Grading between 30 and 0 
depended on quantity consumed and 
duration of abstinence before operation. 
The score was biased towards the dura­
tion of abstinence preoperatively, with 
each month of abstinence lowering the 
score by one point.
The status of the pancreatic duct was 
compared to the mean grading of pain 
severity and to the composition of the
inflammatory infiltrate using the paired 
Student’s f-test. The presence or absence 
of calcification was similarly compared. 
Fibrosis grading and inflammatory infil­
trate grading were compared separately 
to grading of severity of pain by calcu­
lating correlation coefficients; the signi­
ficance of each r value was determined 
from probability tables. Similarly, corre­
lation coefficients were determined com­
paring alcohol scoring with severity of 
pain, composition of inflammatory infil­
trate with severity of pain and composi­
tion of infiltrate with alcohol scoring.
Where correlation coefficients were
found to be significant, a linear relation­
ship was plotted by calculating the slope 
and intercept values for the data under 
consideration. The linear relationship was 
illustrated graphically.
Findings
The histopathologic features were 
equivalent in the same subject, regardless 
of the sites from which the tissue samples 
were obtained. Consistently, all histologic 
examinations showed that the fibrosis and 
inflammation were distributed in the 
interlobular planes. There was minimal
FIG. 1—Photomicrograph of normal pancreas illustrating one perineural field around nerve 
fibril (arrow) (hematoxylin and eosin, reduced by 29% from x 150).
FIG. 2—Perineural field illustrating grade 2 fibrosis (large arrow) and grade 2 inflamma­
tion (small arrows) (hematoxylin and eosin, reduced by 32% from x 150).
208 VOLUME 28, NO. 3, M A Y  1985 /  THE CANADIAN JOURNAL OF SURGERY
intralobular fibrosis or inflammation 
within preserved acinar tissue (Figs. 2 and 
3). No inflammation or fibrosis was noted 
around intralobular ducts. Fibrosis was 
continuous in the interlobular plane, sur­
rounding neural and vascular structures. 
However, inflammatory infiltrate was 
precisely restricted to perineural locations 
(Fig. 3).
The pancreatic duct was considered to 
be dilated when preoperative pancreato­
graphy, operative pancreatography or 
gross pathological examination revealed 
a duct diameter greater than 1.0 cm. 
When the mean grading of pain severity 
was compared between 19 subjects with 
dilated pancreatic ducts and 31 with non-
dilated ducts, the difference was not sig­
nificant (mean 30-mg codeine equivalents 
daily, 3.9 and 4.4, respectively, p > 0.2).
There was a significant correlation 
(r = 0.34, p < 0.02) between alcohol 
scores and the severity of pain. The linear 
relation between these two features was 
plotted (Fig. 4). Alcohol scores were well 
distributed with 13 abstainers and 13 sub­
jects consuming more than 50 g of alco­
hol daily, within 6 months of operation. 
Eleven subjects had painless pancreatitis, 
while the remainder required from 2 to 
20 codeine equivalents daily.
Calcification of the pancreas was noted 
in the parenchyma and within ducts by 
pancreatography, operative observation
or pathological examination. The mean 
severity of pain was compared between 
24 patients of the sample group of 50 who 
did not have calcification (2.83 ± 3.4 
[standard error] codeine equivalents) and 
the remainder who had documented cal­
cification of the gland (5.52 ± 4.0 
codeine equivalents). The difference was 
significant (p <  0.02).
Fibrosis was abnormal in all cases com­
pared with controls. Fibrosis was graded 
for each perineural field and was consis­
tent throughout all samples for each case; 
thus, median fibrosis grading could be 
recorded for each subject. Grade 3 fibro­
sis was recorded in the majority of exami­
nations (64%), grade 1 in 8% and grade 
2 in 28%. Correlation between grading of 
fibrosis and mean grading of pain severity 
was not significant (r = 0.123, p > 0.1).
As was observed with fibrosis, the 
grading of the perineural inflammatory 
infiltrate remained consistent in all sam­
ples from the same patient. It was only 
found around nerve fibrils in the inter­
lobular plane; no infiltrate was noted in 
the acinar or periductular tissues (Figs. 2, 
3, 5 and 6).
The majority of patients (76%) had 
grade 2 inflammation (Table I). None of 
the perineural fields examined showed 
grade 4 inflammation. Correlation 
between the grading of inflammation and 
the severity of pain was not significant 
(r = 0.179, p > 0.1).
When the composition of the inflam­
matory infiltrate was analysed for each
FIG. 4—Significant correlation (r = 0.34, 
p <  0.02) between alcohol score and pain 
severity.
Table I— Grading of Perineural 
Inflammatory Infiltrate
Grade Description % of samples
1 Minimal 10
2 Moderate 76
3 Marked 14
4 Severe 0
•S i* !'# '? -/
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FIG. 3—Perineural field illustrating grade 3 inflammation restricted to perineural region 
(arrows) and grade 3 fibrosis (hematoxylin and eosin, reduced by 32% from x 60).
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FIG. 5—Perineural infiltrates were composed of lymphocytes, histiocytes, occasional plasma 
cells and neutrophils (hematoxylin and eosin, reduced by 32% from X 250).
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FIG. 6—Disproportionate numbers of eosinophils were observed in perineural infiltrate 
(arrows) (hematoxylin and eosin, reduced by 32% from X 250).
FIG. 7—Degranulation of eosinophils (arrows) (hematoxylin and eosin, reduced by 32% 
from x 500).
perineural field, the chronic infiltrate was 
noted to be composed predominantly of 
lymphocytes, histiocytes with occasional 
plasma cells and neutrophils (Fig. 5). A 
startling observation was the dispropor­
tionate numbers of eosinophils present in 
the perineural infiltrate (Fig. 6). This has 
not been reported before. With higher 
grades of inflammation, a correspond­
ingly greater number of eosinophils was 
observed. The presence of the eosinophils 
bore no relation to the size of the nerve 
fibril, or to the number of fibrils in each 
perineural field. The eosinophils were dis­
tributed close to the nerve fibril and on 
several examinations the cells were noted 
within the perineurium. Several scattered 
observations were recorded, suggesting 
degranulation of the eosinophils (Fig. 7).
For each subject, the eosinophilic com­
ponent of the infiltrate was analysed in 
two ways. Percentage eosinophilic con­
centration documented the total number 
of perineural fields with eosinophils com­
pared with the total number of perineural 
fields examined. The eosinophil density 
was the total number of eosinophils per 
total number of perineural fields with an 
eosinophilic component. The density 
number and the percentage eosinophilic 
infiltration were similar for each subject; 
the percentage eosinophilic infiltration 
was the index chosen for analysis.
On analysis of the mean grading of 
pain severity and percentage eosinophilic 
infiltration, the correlation coefficient 
was highly significant (r = 0.56, p < 
0.001). The slope and intercept were cal­
culated for the data and the linear rela­
tion was illustrated graphically (Fig. 8).
Similarly, the relation between the alco­
hol score and the percentage eosinophilic 
infiltration was calculated. The correla­
tion coefficient was again significant 
(r = 0.44, p < 0.01) (Fig. 9).
The relation between the pancreatic 
duct status and the eosinophilic compo­
sition of the perineural infiltrate was ana­
lysed by comparing percentage eosino­
philic infiltration between the 19 patients 
with dilated and 31 with nondilated ducts. 
There was no significant difference (mean 
eosinophilic infiltration 30% versus 
43.2%, p > 0.1).
When the 26 subjects with pancreatic 
calcification were compared with the 24 
patients without, no significant difference 
was noted in the mean percentage 
eosinophilic infiltration (46.4% versus 
31.6%, p > 0.1).
Discussion
Changes in pancreatic secretion and 
ultrastructure due to long-term consump­
tion of alcohol are well recognized. Vari­
able patterns of duct dilatation and stric­
ture have been described in chronic 
alcoholic pancreatitis.810 Chronic fibros­
ing pancreatitis does not always pro-
FIG. 8—Significant correlation (r = 0.56, 
p < 0.001) between percentage eosinophilic 
infiltration and pain severity.
FIG. 9—Significant correlation (r = 0.44, 
p < 0.01) between alcohol score and percen­
tage eosinophilic infiltration.
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duce duct dilatation. Noronha and co­
workers18 have described progressive 
perilobular fibrosis and variable acinar 
atrophy in association with long-term 
alcohol consumption. Calculus formation 
in chronic calcific pancreatitis has been 
extensively investigated by Sahel and 
Sarles,19 since changes in pancreatic pro­
tein secretion were identified in man and 
experimental animals, following long­
term alcohol intake. The recent identifi­
cation of the pancreatic stone protein has 
consolidated the theory that abnormal 
pancreatic secretion leads to calculus for­
mation in chronic calcific pancreati­
tis.20'21 These morphologic and secretory 
abnormalities are accepted sequelae of 
long-term alcohol ingestion. Our study 
confirmed universal interlobular fibrosis 
in all specimens examined. However, it 
failed to document any correlation of 
pain severity with the grading of peri­
neural fibrosis. Similarly, it did not 
differentiate grading of pain based on 
pancreatic duct dilatation or stricture.
Pancreatic calcification was present in 
only half our cases. Although pain 
increased substantially with calcific pan­
creatitis, whether calcification alone can 
produce pain is controversial. From our 
study, it is important to recognize the lack 
of significant difference in eosinophilic 
composition of the perineural infiltrate 
comparing calcific pancreatitis to noncal- 
cific pancreatitis. This suggests that the 
eosinophil is not responsible for increased 
pain associated with calcification.
The specific perineural location of the 
chronic inflammatory infiltrate observed 
in all specimens has not been documented 
previously. The chemotactic factors 
responsible for this localization are 
unknown. Grading of the inflammatory 
infiltrate (cellular density) did not corre­
late significantly with the grading of pain 
severity. Discovery of the previously 
unrecognized eosinophilic composition of 
the infiltrate prompted a measurement of 
percentage eosinophilic infiltration for 
each perineural field. Correlation of 
previously graded clinical features of pain 
severity and alcohol score was found to 
be significant (Fig. 4), as it was also 
between the eosinophilic infiltrate and 
pain severity. Moreover, the eosinophilic 
infiltration correlated significantly with 
the alcohol score, which was biased 
towards the timing of recent alcohol con­
sumption. There was no significant rela­
tion between eosinophilic infiltration and 
pancreatic duct morphology.
From analysis of our data, the 
eosinophilic component of the perineural 
infiltrate appears to be involved in the 
pathogenesis of pain in chronic pancrea­
titis.
Although the role of the eosinophil is 
poorly understood, it is believed to have 
a physiologic and pathologic role in col­
lagen degradation.22 An eosinophilic 
chemotactic factor has been identified 
that will attract and enhance the action 
of the eosinophil.23 Its subsequent 
cytotoxicity depends upon antibody bind­
ing.24 The surface-binding proteins of 
the eosinophil likely combine with the 
immunoglobulins.25 Cell and tissue 
injury are mediated by eosinophilic 
release of eosinophil cationic protein and 
major basic protein. Recent investigations 
have suggested that new proteins are 
released from the eosinophil, with vary­
ing enzyme action.26 Pertinent to this 
study is a recent description of an 
eosinophilic protein that is injurious to 
nerve tissue, the eosinophil-derived neu­
rotoxin.27
Although the main area of interest in 
the cytotoxic action of the eosinophil con­
cerns parasitology, spontaneous lung 
parenchymal cell and collagen matrix 
damage by eosinophils has recently been 
reported.28 Our study may suggest that 
chemotactic factors in the interlobular 
spaces, specifically near nerve fibrils, 
attract an eosinophil-rich inflammatory 
infiltrate. It is also suggested by the sig­
nificant clinical correlation that such a 
mechanism is alcohol-related. Degranu­
lation of the eosinophil (Fig. 7) results in 
enzyme activation that may be responsi­
ble for the nerve-mediated pain mechan­
ism in chronic pancreatitis.
References
1. Keith  RG, Sheppard  r h , Saibil FG, brow  JR: 
Resection for chronic alcoholic pancreatitis. Can J  Surg 
1981; 24: 119-24
2. Frey CF, Child CG, Fry W: Pancreatectomy for 
chronic pancreatitis. Ann Surg 1976; 184: 403-13
3. Eckhauser FE, Strodel w e , Knol JA, Harper M, 
Turcotte JG: Near-total pancreatectomy for chronic 
pancreatitis. Surgery 1984; 96: 599-607
4. Gall FP, MUHE E, GEBHARDT C: Results of partial 
and total pancreaticoduodenectomy in 117 patients with 
chronic pancreatitis. World J  Surg 1981; 5: 269-75
5. WHITE TT, Keith  RG: Long term follow-up study of 
fifty patients with pancreaticojejunostomy. Surg Gynecol 
Obstet 1973; 136: 353-8
6. WHITE TT, Slavotinek AH: Results of surgical treat­
ment of chronic pancreatitis. Report of 142 cases. Ann  
Surg 1979; 189: 217-24
7. Mallet-Guy PA: Late and very late results of resec­
tions of the nervous system in the treatment of chronic 
relapsing pancreatitis. Am  J  Surg 1983; 145: 234-8
8. Nag ata  A, HOMMA T, T a m ai K, U eno  K, 
Shimakura K, Oguchi H, Furuta S, O da M: a  
study of chronic pancreatitis by serial endoscopic pan­
creatography. Gastroenterology 1981; 81: 884-9L
9. Sarles H, Sahel J: Pathology of chronic calcifying 
pancreatitis. Am  J  Gastroenterol 1976; 66: 117-39
10. Nakamura K, Sarles H, Payan H: Three-dimen­
sional reconstruction of the pancreatic ducts in chronic 
pancreatitis. Gastroenterology 1972; 62: 942-9
11. G rodsinsky C, Schuman BM, Block MA: Absence 
of pancreatic duct dilation in chronic pancreatitis: surgi­
cal significance. Arch Surg 1977; 112: 444-9
12. Bornman PC, Marks IN, Girdwood AH, Clain JE, 
Narunsky L, Clain DJ, Wright JP: Is pancreatic 
duct obstruction or stricture a major cause of pain in cal­
cific pancreatitis? Br J Surg 1980; 67: 425-8
13. Bradley EL ill: Pancreatic duct pressure in chronic 
pancreatitis. Am  J  Surg 1982; 144: 313-6
14. KEITH RG: Effect of a low fat elemental diet on pan­
creatic secretion during pancreatitis. Surg Gynecol Obstet 
1980; 151: 337-43
15. N ovis B, Bornman P, Girdwood A, Marks I: 
Pancreatico-biliary manometry in patients with chronic 
pancreatitis (abstr). Scand J Gastroenterol 1982; 17 
(suppl): 320
16. WORNING H: Chronic pancreatitis: pathogenesis, natural 
history and conservative treatment. Clin Gastroenterol 
1984; 13: 871-94
17. Ammann RW, akovbia ntz  A, Larg iader  F, 
SCHUELER G: Course and outcome of chronic pancrea­
titis. Longitudinal study of a mixed medical-surgical series 
of 245 patients. Gastroenterology 1984; 86(5 pt 1): 820-8
18. Noronha M, Bordalo O, Dreiling DA: Alcohol and 
the pancreas. II. Pancreatic morphology of advanced 
alcoholic pancreatitis. Am  J  Gastroenterol 1981; 76: 
120-4
19. Sahel J, Sarles H: Modifications of pure human pan­
creatic juice induced by chronic alcohol consumption. Dig 
Dis Sci 1979; 24: 897-905
20. Multigner L, De Caro A, Lombardo D, Cam pese 
D, Sarles H: Pancreatic stone protein, a phos- 
phoprotein which inhibits calcium carbonate precipita­
tion from human pancreatic juice. Biochem Biophys Res 
Commun 1983; 110: 69-74
21. G uy O, Robles-Diaz G, A drich Z, Sahel  J, Sarles 
H: Protein content of precipitates present in pancreatic 
juice of alcoholic subjects and patients with chronic cal­
cifying pancreatitis. Gastroenterology 1983; 84: 102-7
22. Bassett  EG: Eosinophils and connective tissue 
catabolism (C). Biochem J  1983; 213: 769-70
23. Vadas MA, Nicola NA, Metcalf D: Activation of 
antibody-dependent cell-mediated cytotoxicity of human 
neutrophils and eosinophils by separate colony- 
stimulating factors. J  Immunol 1983; 130: 795-9
24. Hallam C, P ritchard  DI, Trigg S, Eady RP: Rat 
eosinophil-mediated antibody-dependent cellular cytotox­
icity: investigations of the mechanisms of target cell lysis 
and inhibition by glucocorticoids. Clin Exp Immunol 
1982; 48: 641-8
25. Thorne KJ, Franks D: Surface proteins of the human 
eosinophil. I. Isolation of eosinophil IgG binding pro­
teins. Clin Exp Immunol 1984; 56: 464-72
26. PETERSON CG, Venge P: Purification and characteri­
zation of a new cationic protein — eosinophil protein-X 
(EPX) — from granules of human eosinophils. Im mu­
nology 1983: 50: 19-26
27. DURACK DT, ACKERMAN SJ, LOEGERING DA, GLEICH 
GJ: Purification of human eosinophil-derived neurotoxin. 
Proc Natl Acad Sci USA 1981; 78: 5165-9
28. Davis w b , Fells GA, Sun XH, Gadek JE, Venet a , 
CRYSTAL RG: Eosinophil-mediated injury to lung paren­
chymal cells and interstitial matrix. A possible role for 
eosinophils in chronic inflammatory disorders of the 
lower respiratory tract. J  Clin Invest 1984; 74: 269-78
BOOKS RECEIVED
This list is an acknowledgement of 
books received. It does not preclude 
review at a later date.
Advances in Gastrointestinal Surgery. From 
the Forty-seventh Annual Continuation 
Course in Surgery, University of Minnesota 
Medical School, Minneapolis. Edited by 
John S. Najarian and John P. Delaney. 640 
pp. lllust. Year Book Medical Publishers, 
Inc., Chicago, 1984. Price not stated. ISBN 
0-8151-6336-3.
Clinical Neurosurgery. Volume 31. Proceed­
ings of the Congress of Neurological Sur­
geons, Chicago, Illinois, 1983. 592 pp. 
lllust. Williams & Wilkins, Baltimore, 
1984. $52 (US). ISBN 0-683-02026-9.
Fluids and Electrolytes in the Surgical Patient.
3rd ed. Carlos Pestana. 245 pp. lllust. Wil­
liams & Wilkins, Baltimore, 1985. $18.95 
(US). ISBN 0-683-06861-X.
Genitourinary Cancer. Contemporary Issues in 
Clinical Oncology, Volume 5. Edited by 
Marc B. Garnick. 280 pp. lllust. Academic 
Press Canada, Don Mills, Ont., 1985. 
$55.50. ISBN 0-443-08350-9.
continued on page 226
VOLUME 28, NO. 3, M A Y  1985 /  THE CANADIAN JOURNAL OF SURGERY 211
Parke-Davis Glycerin Suppositories
A non-systemic laxative for the gentle, yet 
timely evacuation of the lower bowel within 
15 minutes to 1 hour.
Its natural ingredient makes it a preferred 
laxative for many patients, particularly
pregnant women, seniors and children.
Parke-Davis Glycerin Suppositories are 
the laxative often chosen by physicians 
who require fast yet gentle relief in a non- 
systemic form.
m l
P A R K E -D A V IS
GLYCERIN
SUPPOSITORIES
PAR KE-D AVIS Std.
INFANT AND CHILD SIZE
A  gentle laxative that 
relieves the discomforts 
of constipation in 
15 minutes to 1 hour.
24 Suppositories
Available in adult and child forms. For 
best results, insert and allow to melt 
naturally.
PARKE-DAVIS
GLYCERIN
SUPPOSITORIES
PARKE-DAVIS Std.
adult size
A  gentle laxative that relieves 
the discomforts of constipatioi
in 15 minutes to 1 hour
24 Suppositories
PARKE-DAVIS
Parke-Davis Canada Inc., Scarborough, Ontario
PAAB
CCPP
'R eg. T.M. Parke, Davis & Company 
Parke-Davis Canada Inc., auth. user
For prescribing information see page 231
Brian W. Loggie, md;* G. Hauer-Pollack, m sc; 
E. John Hinchey, md, m sc, frcsc, facs
Influence of Splenectomy on Lethal Effects 
of Pneumococcal Infection
To determine whether the splenec- 
tomized host is more sensitive to the 
toxic effects of pneumococcal infection 
and whether the known clearance defect 
accounts for the early, increased mortal­
ity seen in postsplenectomy infection, 
the authors studied 8-week-old C57B1 
mice. They were divided into two 
groups: seven control nonsplenectomized 
mice and six splenectomized mice. All 
animals were inoculated intravenously 
with 103 colony forming units of Strep­
tococcus pneumoniae. Microaliquots of 
blood were drawn from the tail of all 
mice into sterile, heparinized, capillary 
tubes at 1, 4, 8 and 16 hours. Blood 
bacteria were quantitated using a drop 
dilution method. The time to death was 
recorded. A form of survival analysis 
using the Cox proportional hazards 
model was performed on the data.
The infection was uniformly fatal. An 
early decrease in the numbers of blood 
bacteria was seen in nonsplenectomized 
mice followed by a logarithmic linear 
increase. In splenectomized mice, there 
was early rapid bacterial growth greater 
than that in control mice. Splenec­
tomized mice died earlier than control 
mice (p <  0.05 at 24 hours, Fisher's 
exact test). The bacterial count had a 
highly significant effect upon mortality 
overall (p = 0.0017). A  function 
describing the risk of dying versus bac-
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terial numbers was generated and was 
the same for both groups.
The splenectomized host does not 
appear to be more susceptible to the 
toxic effects of pneumococcal infection. 
Early mortality in bacteremic pneumococ­
cal infection can be attributed to 
impaired bacterial clearance alone.
Cette etude a ete realisee afin de verifier 
si le sujet splenectomise est davantage 
sensible aux effets toxiques de I’infec- 
tion pneumococcique et si le defaut de 
clairance que Ton connaTt, explique 
^augmentation de la mortality precoce 
post-splenectomie. Des souris C57B1 
agees de 8 semaines ont ete reparties en 
deux groupes, soit sept souris temoins 
non splenectomisees et six souris sple­
nectomisees. Tous les animaux ont recu 
par voie intraveineuse 103 unites for­
mant des colonies de Streptococcus 
pneumoniae. Des micro-aliquotes de 
sang ont ete prelevees de la veine cau­
date des souris a ('aide de tubes capil- 
laires heparinSs steriles apres 1, 4, 8 et 
16 heures. La numeration des bact£ries 
du sang a ete faite par la methode de la 
dilution de la goutte. Le temps du deces 
a ete enregistre. Une forme d'analyse de 
survie reposant sur le modele des risques 
proportionnels de Cox a ete effectuee 
sur les donnees.
Dans tous les cas, I'infection fut mor- 
telle. Chez les souris non splenectomi­
sees, une diminution precoce du nombre 
de bacteries du sang fut suivie d'une 
augmentation lineaire logarithmique.
Chez les souris splenectomisees, on 
observa une croissance bacterienne pre­
coce plus rapide que chez les souris 
temoins. Les souris splenectomisees sont 
mortes plus tot que les temoins (p < 
0.05 a 24 heures, test de probability 
exacte de Fisher). La numeration bacte­
rienne a montre un effet hautement 
significatif sur la mortality globale (p = 
0.0017). Une equation decrivant le ris­
que de mortality en fonction de la nume­
ration bacterienne fut derivee; celle-ci 
etait la meme pour les deux groupes.
Les sujets splenectomises ne parais 
sent pas avoir une sensibility accrue aux 
effets toxiques de I'infection pneumococ­
cique. La mortality precoce rattachee a la 
bacterie pneumococcique peut etre attri­
bute au seul defaut de la clairance bac­
terienne.
The syndrome o f overwhelming post­
splenectomy infection has been based 
predominantly on case reports o f severe 
pneumococcal infections occurring in 
splenectomized patients. The patients are 
often young and in apparent good health 
when mild prodromes develop that 
progress rapidly to severe illness and early 
death.' Features of the illness include 
the Waterhouse-Friderichsen syndrome 
(bilateral adrenal hemorrhage), which has 
frequently been described, often in associ­
ation with disseminated intravascular 
coagulation.2-4 These lesions have 
usually been attributed to infections 
caused by gram-negative endotoxin- 
producing organisms such as menin­
gococci. Pneumococci are gram-positive 
organisms and by definition do not 
produce endotoxin.
Experimental studies have shown that 
after splenectomy, bacterial clearance is 
impaired.5 We have hypothesized that, 
in addition to the known defect o f bac­
terial clearance, the clearance of toxins or 
bacterial degradation products may also 
be impaired. Theoretically, such a defect 
could synergistically contribute to the 
patient’s early death and might account 
for some of the unusual clinical mani­
festations noted in the course o f over­
whelming postsplenectomy infection. If 
this hypothesis is true, then it is expected 
that the absence of the spleen would con­
fer an additional disadvantage on the 
splenectomized host, synergistic with the 
known clearance defect and hastening a 
fatal outcome. If this hypothesis is false, 
then no difference in susceptibility to the 
fatal effects of pneumococcal infection is 
expected and the fatal bacterial load will 
be similar for splenectomized and non­
splenectomized animals.
We can predict that the fatally infected 
splenectomized host will die earlier than 
the fatally infected normal host on the 
basis o f differences in ability to clear bac­
teria. However, by closely following fatal
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bacteremic pneumococcal infections, it 
may be possible to determine whether an 
increased susceptibility to the lethal 
effects of pneumococcal infection exists. 
We have used a mouse model to examine 
our hypothesis.
Methods
Bacteria
Streptococcus pneumoniae, type III, 
smooth (ATCC), were maintained in 
frozen liquid subculture containing 20% 
glycerol. A vial was thawed and plated 
onto blood agar overnight (at 37°C in 5% 
carbon dioxide). Sidearm flasks contain­
ing sterile Todd-Hewitt broth were inocu­
lated with fresh colonies and incubated 
in a standing rack. Growth was assessed 
by following changes in optical density at 
600 nm. Organisms were harvested in the 
logarithmic growth phase and diluted in 
Hanks’ balanced salt solution before 
inoculating the animals. The inoculum 
dose was confirmed by quantitative cul­
ture. Optimal virulence was assured by 
this technique as measured by the ability 
of small inocula to cause death after 
intraperitoneal injection as well by 
microscopic examination using India-ink 
counterstain, which demonstrated uni­
form encapsulation and chain-length.
Mice
Age-matched 8-week-old C57B1 mice 
were randomly assigned to two groups: 
seven control nonsplenectomized and six 
splenectomized mice. Splenectomies had 
been performed 3 weeks before inocula­
tion and the mice had regained the weight 
lost postoperatively. All mice were inocu­
lated intravenously with 1.6 x 103 
colony forming units of S. pneumoniae. 
At 1,4, 8 and 16 hours, microaliquots of 
blood were drawn from the tail vein of 
each mouse and placed into heparinized, 
precalibrated, sterile, glass capillary 
tubes. Serial dilutions in duplicate were
FIG. 1—Cumulative mortality versus time. 
Dashed line = splenectomized animals, solid 
line = nonsplenectomized animals. Difference 
in mortality is statistically significant (p < 0.05 
at 24 hours, using Fisher’s exact test).
plated to quantitate blood bacterial num­
bers accurately. The time to death was 
noted for each animal.
Statistical Analysis
Statistical differences were measured by 
Fisher’s exact test for overall survival at 
24 hours and Cox’s proportional hazards 
regression analysis. The hazard function, 
the probability of dying at a certain time, 
conditional upon survival until that time, 
was first calculated using bacterial count 
as a covariate.
Results
By 24 hours, all splenectomized mice 
were dead, but only 29% of the non­
splenectomized mice (Fig. 1). This differ­
ence is statistically significant, p < 0.05 
by Fisher’s exact test.
When the course of infection in 
individual animals is correlated with the 
time to death (Fig. 2), the slope is steeper 
for splenectomized than for nonsplenec­
tomized mice. The spectrum of bacterial 
clearance can be seen, showing that the 
earlier times of death in splenectomized 
mice correlate with the slopes of the bac­
terial counts.
The survival characteristics of the two 
groups were examined using Cox’s 
proportional hazards model of regression 
analysis. The bacterial count had a highly 
significant effect upon the probability of 
death overall (p = 0.0017). When 
attempting to verify whether a factor 
other than the bacterial clearance defect 
could contribute to the earlier mortality
of the splenectomized group, we added 
the group factor to the model containing 
the bacterial count factor. The effect of 
this was insignificant, indicating that 
nothing other than bacterial clearance 
appears to distinguish between the groups 
with respect to mortality. Moreover, there 
was no significant interaction between 
group and bacterial count, suggesting that 
the bacterial count affects the mortality 
of control and splenectomized animals in 
a similar fashion. Differences in bacterial 
clearance rates are sufficient to account 
for the difference in blood bacterial num-
FIG. 3—Risk of death versus bacterial num­
ber. Using information from Fig. 2, risk of 
death was calculated for both groups, using 
Cox’s proportional hazards model for survival 
analysis. Comparison of curves revealed no sig­
nificant difference. Result of combined anal­
ysis is shown and demonstrates no inherent 
difference in risk of death, based on blood bac­
terial numbers between nonsplenectomized and 
splenectomized animals.
FIG. 2—Numbers of bacteria in fatal bacteremic infection and corresponding times to 
death. Logarithmic bacterial numbers (cfu/mL of blood, assay limit [ ^ ]  7.53) have been plotted 
versus time (h). Arrow on ordinate indicates initial bacterial inoculum corrected for circulating 
mouse blood volume. Each line represents single animal: dotted lines = splenectomized mice, 
solid lines = nonsplenectomized mice. Also included are approximate times to death ( t) , grou­
ped according to whether animal was dead by less than or equal to 16, 24, 36 or 48 hours after 
inoculation. TNC = too numerous to count.
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bers with time seen between the two 
groups. The risk of dying, plotted against 
bacterial numbers (Fig. 3), gave a curve 
that climbed exponentially and was iden­
tical for nonsplenectomized and splenec- 
tomized animals. This suggests that no 
inherent difference in susceptibility to the 
lethal effects of pneumococcal infection 
exists after splenectomy.
Discussion
That exotoxins and bacterial degrada­
tion products must play a role in the 
pathophysiology of pneumococcal infec­
tion seems certain but remains unproven. 
The pathophysiology of pneumococcal 
infection, especially those events leading 
to the death of the host, are poorly under­
stood.6 It has been shown clinically that 
death from pneumococcal infection can 
still occur after sterility has been achieved 
through the use of appropriate antibi­
otics. This fact has been attributed to cir­
culating pneumococcal polysaccharide.3 
Acute anemia has been reported infre­
quently,3,7 and it is not known whether 
this is due to elaboration of the hemolytic 
toxin, pneumolysin, or is related to some­
thing else.
In this study, fatally infected splenec- 
tomized mice died earlier and demon­
strated a more rapid increase in numbers 
of bacteria than fatally infected non­
splenectomized animals. The risk of dying 
was determined solely by bacterial num­
ber and the calculated curve of relative 
risk for death was the same for both 
groups. This indicates that the fatal bac­
terial load was similar for both.
It is of interest that the introduction of 
antibiotics has not been shown to have a 
significant effect on early mortality from 
bacteremic pneumococcal infection.8 
Mortality remains high from pneumococ­
cal infections in both the predisposed and 
the unpredisposed host. In a recent Cana­
dian study,9 there was a 41% mortality 
in adult patients without pre-existing 
underlying conditions and 43% in 
patients with known predisposing factors 
such as splenectomy. Our experimental 
findings are in keeping with these clini­
cal observations since they suggest that 
outcome in the presence of an established 
infection is based on bacterial number 
and not on the presence or absence of 
splenectomy.
We conclude that the splenectomized 
host is not more susceptible to the lethal
effects of pneumococcal infection. It 
seems, at least in the context of these 
experiments, that early mortality can be 
attributed to impaired pneumococcal 
clearance alone.
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Reliability of the Total Lymphocyte Count 
as a Parameter of Nutrition
To evaluate the total lymphocyte count 
as a means of nutritional assessment, 
body composition studies (a proven 
method of nutritional assessment) and 
total lymphocyte determinations were 
performed simultaneously in 153 
patients. The total lymphocyte count 
correlated poorly with both the body cell 
mass and the nutritional state measured 
by the Nae to Ke ratio. For diagnosing 
malnutrition, the total lymphocyte count 
had a false-positive rate of 34% and a 
false-negative rate of 50%. In a group of 
78 patients who received total parenteral 
nutrition for 2 weeks, the total lympho­
cyte count did not accurately reflect the 
nutritional changes. Due to its poor sen­
sitivity and specificity, the total lympho­
cyte count is of no value as a measure 
of the nutritional state.
Afin d'evaluer I'interet de la numeration 
lymphocytaire totale comme moyen 
d'etablir I'etat nutritionnel des patients, 
les auteurs ont pratique simultanement 
chez 153 d'entre-eux une etude de la 
composition corporelle (une methode 
eprouvee pour etablir I'etat nutritionnel) 
et une numeration lymphocytaire totale. 
Une faible correlation a ete observee 
entre la numeration lymphocytaire totale 
et la masse cellulaire corporelle, de 
meme qu'avec I'etat nutritionnel mesure 
par le rapport Nae/Ke. Dans le diagnostic 
de la malnutrition, la numeration 
lymphocytaire totale a eu un taux de 
faux resultats positifs de 34% , et 50%
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de faux negatifs. Chez un groupe de 78 
patients qui ont recu une alimentation 
parenterale totale pendant 2 semaines, la 
numeration lymphocytaire totale n'a pas 
bien reflete les changements nutrition- 
nels. Vu sa faible sensibilite et sa mau- 
vaise specificite, la numeration 
lymphocytaire totale n'a aucune valeur 
comme mesure de I'etat nutritionnel.
An accurate assessment of a patient’s 
nutritional status is important in both the 
application and evaluation of nutritional 
support. The association between mal­
nutrition and an altered immune system 
is supported by a number of population 
surveys.1,2 As a result, various parame­
ters of the immune system have been 
employed as measures of nutrition in the 
hospitalized patient. One such application 
has been skin testing with recall antigens. 
This immune test has been used widely for 
nutritional assessment. We have recently 
reviewed this parameter and found that 
although the results of skin testing cor­
related well with malnutrition, the meth­
od did not have the sensitivity to meas­
ure the nutritional state of the individual 
patient.3
The total lymphocyte count has also 
been used clinically for nutritional assess­
ment of the individual patient. This was 
based on earlier studies, showing that 
malnutrition caused a decrease in the total 
lymphocyte count and that nutritional 
support returned the count to normal.4 
Recent studies have not shown that the 
association between the nutritional state 
and the lymphocyte count is absolute.5,6 
Despite this, the lymphocyte count is still 
widely used and recommended for nutri­
tional assessment in hospitalized pa­
tients.7 This study was undertaken to 
determine the validity of using the total 
lymphocyte count as a measure of 
nutrition.
Patients and Methods
On 313 separate occasions, data were 
collected from 153 patients (64 men, 89 
women, mean age 53.9 ± 0.9 years),
most of whom were malnourished. The 
measurements were made before and dur­
ing a course of total parenteral nutrition. 
Measurements were also made on a group 
of morbidly obese patients at varying 
intervals following weight-reduction sur­
gery. The nutritional state of these 
patients was determined by measuring the 
various components of body composi­
tion. A multiple-isotope dilution tech­
nique was used to determine the body 
composition.8 The patients were injected 
with 500 pC\ of tritiated water and 8 pCi 
of sodium 22. Blood samples were drawn 
before and at 4 and 24 hours after injec­
tion. Plasma tritium concentration at 24 
hours corrected for urine loss was used 
to calculate the total body water (TBW). 
The plasma 22Na activity, also corrected 
for urine loss, was used to calculate the 
exchangeable sodium (Nae). An indirect 
method was used to calculate the total 
exchangeable potassium (Ke),8 according 
to the following equation: Ke = 
R(TBW) - Nae, where R is the ratio of 
the sum of sodium and potassium divided 
by the water content, as measured in an 
aliquot of whole blood.8 This technique 
has been established experimentally in 
both animals and man.8 To correct for 
body size, these data are expressed as a 
function of total body water, which is 
more accurate than body weight, since it 
is linearly related to the lean body mass 
and the resulting measurement is thus 
independent of the degree of adiposity. 
Additional measurements of body com­
position were obtained by the following 
calculations: LBM = TBW/0.73, BF = 
body weight -  LBM, BCM = 0.00833 
Ke and ECM = LBM -  BCM, where 
LBM = lean body mass, BF = body fat, 
BCM = body cell mass and ECM = 
extracellular mass.
The total lymphocyte counts were 
determined either by manual counting of 
a Wright’s smear or automated counting 
with a Coulter counter. The lymphocyte 
count was correlated with the nutritional 
state, as measured by the body composi­
tion parameters, by a standard linear 
regression.9 All means are listed with the 
standard error of the mean. Differences
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between the two sets of measurements, 
which were made twice in the same 
patient at different times, were analysed 
by the paired Student’s /-test. A p value 
of less than 0.05 indicated a significant 
difference.
Results
The total lymphocyte count was cor­
related with the body cell mass (Fig. 1). 
The body cell mass is represented by the 
total exchangeable potassium divided by 
total body water to normalize for body
FIG. 1—Correlation between lymphocyte 
count and body cell mass (i.e., total exchange­
able potassium/total body water [Ke/TBW]), 
313 measurements. Correlation was significant 
(p <  0.01, r = 0.12); 95% confidence limits 
for correlation are included.
FIG. 2—Correlation between lymphocyte 
count and nutritional state measured by ratio 
of total exchangeable sodium to total exchan­
geable potassium (Nae/K e), 313 measure­
ments. Correlation was not significant (r = 
-0.09); 95% confidence limits are included.
size (Ke/TBW) which in 25 normal 
volunteers was 80.0 ±1 . 0  mmol/L with 
95% confidence limits of 69.9 to 90.1 
mmol/L.2 The study patients had a 
mean Ke/TBW of 64.4 ± 0.7 mmol/L 
(ranging from 39.0 to 89.8 mmol/L), 
indicating that a large proportion had a 
depleted body cell mass. The total lym­
phocyte count was 1.807 ± 0.66 X 
109/L (normal range in our laboratory 
1.5 to 3.0 x 109/L). The regression was 
significant (p < 0.05), but the regression 
coefficient of r = 0.12 was poor. 
Moreover, the data were very scattered, 
resulting in wide 95% confidence limits. 
Consequently, for a normal Ke/TBW of 
80.0 mmol/L, regression indicated a lym­
phocyte count of from 0, abnormally low, 
to 4.26 x 109/L, abnormally high. In 
Fig. 2, the lymphocyte count is correlated 
with the Nae to Ke ratio. In malnutrition, 
the extracellular mass expands as the body 
cell mass is depleted. Consequently, the 
Nae to Ke ratio is a sensitive index of the 
nutritional state. In the 25 healthy volun­
teers, the mean ratio was 0.98 ± 0.02, 
with 95% confidence limits of 0.74 ±
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FIG. 3—One hundred and forty-seven meas­
urements for patients who were nutritionally 
normal and 166 measurements for patients w ho 
were malnourished are represented in this histo­
gram. Dotted area represents normal lympho­
cyte counts. Lymphocyte count in 50 of 147 
measurements incorrectly indicated that nor­
mal patients were malnourished, for false­
positive rate of 34%. Lymphocyte count incor­
rectly indicated in 83 of 166 measurements that 
malnourished patients were normal, for false­
negative rate of 50%.
1.22.2 Malnutrition is thus defined as a 
Nae to Ke ratio greater than 1.22. In this 
group of patients, the mean ratio was 1.45 
± 0.04, indicating that a large propor­
tion of patients in our study were mal­
nourished. The regression between the 
Nae to Ke ratio and the lymphocyte 
count was not significant (r = -0.09). This 
lack of correlation was supported by the 
wide scatter of data about the regression 
line.
The patients were divided into those 
with a normal nutritional state and those 
with malnutrition based on their body 
composition (Fig. 3). The lymphocyte 
count correctly identified a normal nutri­
tional state in 97 of 147 measurements 
(66%) but incorrectly indicated that mal­
nourished patients were normal in 83 of 
166 measurements, for a false-negative 
rate of 50%. Malnourished patients were 
correctly identified by the lymphocyte 
count in 83 measurements but in 50 meas­
urements in which the patients had nor­
mal nutritional state, the measurement 
incorrectly identified the patients as mal­
nourished, for a false-positive rate of 
34% (50 of 147).
Seventy-eight patients with 97 pairs of 
measurements separated by a substantial 
time interval were divided into three 
groups based on the observed changes in 
their nutritional state (Table I). This per­
mitted a comparison of changes in body 
composition, and thus the nutritional 
state, with changes in the lymphocyte 
count. There was nutritional improve­
ment in 54 measurements. The body cell 
mass significantly (p < 0.001) increased 
from 15.4 ± 0.6 kg to 18.0 ± 0.8 kg, as 
reflected by the significant (p < 0.001) 
increase in Ke/TBW. This nutritional 
improvement was accompanied by a sig­
nificant (p < 0.01) decrease in the extra­
cellular mass and a significant (p < 0.001) 
decrease in the Nae/TBW from 92.6 ± 
1.0 mmol/L to 86.0 ±1.1 mmol/L. The 
significant (p < 0.001) decrease in the 
Nae to Ke ratio from 1.71 ± 0.06 to 1.39 
± 0.04 reflects the nutritional changes in 
body composition. The lymphocyte count 
increased from 1.6 ± 0.12 x 109/L  to
Table -B ody Composition and Total Lymphocyte Count for 78 Patients With 97 Sequential Studies
Measurement
Malnourished improved 
(n -  54)
Malnourished deteriorated
(n -  28)
Normal deteriorated 
(n = 15)
M l M2 M1 M2 M l M2
Weight, kg 67.3 ±  3.0 68.1 ±  2.9 60.2 ±  3.4 6 2 .4  ±  3.7 77.7 ±  9.4 73.7 ±  7.4
Body fat, kg 21.6 ±  2.1 22.2 ±  1.9 16.4 ±  3.5 16.1 ±  3.6 30.1 ±  6.2 28 .5  ±  5.4
Lean body mass, kg 45.7 ±  1.7 45 .9  ±  1.6 46.9 ±  2.2 4 9 .3  ±  2.5 4 7 .6  ±  3.7 45 .2  ±  2.6
Body cell mass, kg 15.4 ±  0.6 18.0 ±  0 .8* 16.5 ±  0.8 15.0 ±  0 .7 * 20 .7  ±  2.1 16.3 ±  1 .0*
Extracellular mass, kg 30.3 ±  1.3 27.9 ±  1.0* 30.3 ±  1.6 34 .3  ±  2 .1* 26 .9  ±  1.7 28 .9  ±  1 .9*
Nae)TBW, mmol/L 92.6 ±  1.0 86.0 ±  1.1* 90.9 ±  1.6 9 7 .5  ±  1.7* 77 .8  ±  1.0 87.8 ±  1.3*
Ke/TBW, mmol/L 55.8 ±  1.1 64.1 ±  1.3* 58.2 ±  1.4 51 .2  ±  1.7* 70.2 ±  1.7 59 .6  ±  1 .7*
Nas : Ke 1.71 ±  0.06 1.39 ±  0 .0 4 * 1.60 ±  0.07 2 .00  ± 0 . 1 1 * 1.12 ±  0.03 1.50 ±  0 .0 7 *
Total lymphocytes, X 10 9/L 1.60 ±  0.12 1.88 ±  0.17 1.99 ±  0.25 2.01 ±  0.19 1.60 ±  0.22 1.58 ±  0 .18
M -  measurement, Nae -  total exchangeable sodium, Ke -  total exchangeable potassium, TBW = total body water. 
“Significant difference (p <  0.05) from M L
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The thought foremost in the minds 
of hemorrhoid sufferers
jHemorrhoid sufferers want 
an end to the pain and itching; fast 
relief that lasts. ANUCAINE-HC 
can provide that relief.
ANUCAINE-HC contains lidocaine, 
a widely used local anesthetic, plus an 
astringent and hydrocortisone acetate.
Also available without hydrocortisone 
as ANUCAINE!MIt is available in non­
staining ointment and suppositories.
SEARLE
Searle Pharmaceuticals
A Division of G.D. Searle & Co. of Canada, Limited 
400 Iroquois Shore Road, Oakville, Ontario L6H 1M5
Anucaine-HC
the beginning of the end
Anucaine
ANUCAINE™ and ANUCAINE™-HC 
COMBINED PRESCRIBING INFORMATION
Lidocaine HCI, Zinc Sulfate (Hydrocortisone Acetate)
Anorectal Therapy
INDICATIONS
1. For the relief of pain and discomfort associated with the 
acute phase of common anorectal disorders, including, 
-hemorrhoids, internal and external (including those
accompanying pregnancy), whether or not compli­
cated by thrombosis and prolapse 
-pruritis ani 
-proctitis
-fissures and incomplete fistulas
-other congestive or inflammatory conditions
2. For the relief of pain and discomfort following 
anorectal surgery of all types, including,
-pre- and post-operative hemorrhoidectomy 
-pre- and post-operative repair of fissures 
-after incision of thrombosed or sclerosed anorectal 
veins
3. May also be used before rectal examination to 
anesthetize the area where it is too tender or where there 
is too much spasm to admit the examining finger.
CONTRAINDICATIONS
History of sensitivity to any of the product’s components 
or a sensitivity to local anesthetics of the amide type. 
ANUCAINE-HC should not be used in the presence of 
existing tuberculous, fungal and viral lesions of the skin. 
PRECAUTIONS
Until an adequate proctologic examination is completed 
and a diagnosis made, any preparation containing 
hydrocortisone should not be used. In addition, specific 
measures against infection, allergy and other causal 
factors must not be neglected. Prolonged use of this 
medication could produce systemic corticosteroid effects. 
As with all medication that is applied locally, if idiosyn­
cratic reactions occur, medication should be discontinued. 
Although lidocaine has been shown to be relatively free 
from allergic and/or sensitizing properties, these 
possibilities should not be overlooked and appropriate 
precautions should be observed. Lidocaine should be 
used with caution in patients with severely traumatized 
mucosa and sepsis in the region of proposed application. 
The safe use of topical corticosteroids during pregnancy 
has not been fully established. Therefore, during 
pregnancy, they should not be used unnecessarily on 
extended areas, in large amounts, or for prolonged periods 
of time.
Keep in a safe place out of the reach of children. 
ADVERSE EFFECTS
Occasionally patients may experience burning upon 
application, especially if the anodermis is not intact. 
Local sensitivity reactions may occur.
OVERDOSE
Symptoms: No toxic effects have been reported. 
Treatment: In case of accidental ingestion, perform gastic 
lavage.
DOSAGE
Administer in the morning and again at bedtime, and after 
each evacuation. Continue this treatment until the acute 
phase of pain and discomfort passes and the inflammation 
subsides. Treatment with ANUCAINE-HC should be 
followed by maintenance management with regular 
ANUCAINE as required.
Suppositories: Bathe and dry the affected anal area. Then 
insert one suppository into the rectum. Suppositories 
are most easily administered in a stooped or squatting 
position, or while lying on the side with knees flexed. 
The exertion of a slight bearing down pressure relaxes 
the anal sphincter wnich permits painless insertion of 
the suppository.
Ointment: Bathe and dry the affected anal area. Attach the 
plastic applicator to the tube and insert into the rectum 
to its full extent. Then slowly withdraw while gently 
squeezing the tube.
Regardless of whether the suppository or ointment form is 
used for internal medication, the ointment may also be 
applied to the exterior surface of the anus for relief of any 
external anorectal discomfort often associated with the 
former conditions.
AVAILABILITY
ANUCAINE
Ointment: Lidocaine HCI 2.0% and zinc sulfate 0.5% in a 
petrolatum ointment base. Available in 30 g tubes, with 
applicator.
Suppositories: Each suppository contains lidocaine HCI 
40 mg and zinc sulfate 10 mg in a triglyceride base. 
Available in boxes of 12s.
ANUCAINE-HC
Ointment: Lidocaine HCI 2.0%, zinc sulfate 0.5% and 
hydrocortisone acetate 0.5% in a petrolatum ointment 
base. Available in 15 g tubes, with applicator. 
Suppository: Each suppository contains lidocaine HCI 
40 mg. zinc sulfate 10 mg and hydrocortisone acetate 
10 mg, in a triglyceride base. Available in boxes of 12s. 
Store ANUCAINE preparations below 30°C (86°F).
SEARLE
Searle Pharmaceuticals •———
A Division of G.D. Searle & Co. of Canada, Limited 
400 Iroquois Shore Road, Oakville, Ontario L6H 1M5
1.88 ± 0.17 x 109/L , but not signifi­
cantly. Also, both the initial and final 
mean lymphocyte counts were within the 
normal range.
In the second group, 28 pairs of meas­
urements were obtained from mal­
nourished patients in which the nutri­
tional state deteriorated. There was a 
significant (p < 0.01) decrease of the 
body cell mass with the mean Ke/TBW 
decreasing from 58.2 ± 1.4 mmol/L to 
51.2 ± 1.7 mmol/L (p < 0.001). This 
was associated with a significant (p < 
0.01) increase in the extracellular mass 
and the Nae/TBW from 90.9 ± 1.6 
mmol/L to 97.5 ± 1.7 mmol/L (p < 
0.001). The mean Nae to Ke ratio 
increased significantly (p < 0.001) from 
1.60 ± 0.07 to 2.0 ± 0.11, indicating the 
deterioration. Again, the lymphocyte 
count did not change: both the initial lym­
phocyte count of 1.99 ± 0.25 x 109/L  
and the final mean of 2.01 ± 0.19 x 
109/L  were within the normal range.
In the last group of initially normal 
patients who subsequently became mal­
nourished, there were 15 pairs of meas­
urements. The deterioration was indicated 
by the significant (p < 0.001) increase in 
the Nae to Ke ratio from a normal value 
of 1.12 ± 0.03 to a ratio of 1.50 ± 0.07. 
There was a significant (p < 0.001) 
decrease in the Ke/TBW and a signifi­
cant (p < 0.001) increase in the 
Nae/TBW. The lymphocyte count again 
remained basically unchanged with both 
the initial mean of 1.6 ± 0.22 X 109/L  
and the final mean of 1.58 ± 0.18 x 
109/L  being within normal limits.
Discussion
Malnutrition in hospitalized patients is 
not uncommon, but as nutritional sup­
port systems become more complex and 
more widely used, nutritional assessment 
must be accurate. This is important not 
only to identify the malnourished patient 
but also to follow the nutritional progress 
of these patients. Body composition 
measurements are an accurate assessment 
of the nutritional state.10 Although pre­
cise, they are complex and difficult to per­
form. The total lymphocyte count is one 
of a number of readily available methods 
that are inexpensive and easy to measure. 
Reports have indicated that malnutrition 
can modify the immune response and thus 
alter measurements such as the total lym­
phocyte count.3 In this study the lym­
phocyte count was evaluated as a nutri­
tional parameter.
The total lymphocyte count did not 
correlate well with body cell mass. The 
correlation coefficient was poor and the 
scatter of the data was wide. Also, the 
total lymphocyte count had no correla­
tion with the Nae to Ke ratio, a sensitive 
index of nutritional state. This would
indicate that the total lymphocyte count 
is not affected by malnutrition in these 
hospitalized patients. This indication was 
further supported by the sequential 
studies in which, despite significant 
changes in the nutritional state, the lym­
phocyte count did not change signifi­
cantly. As a result of this poor associa­
tion between the nutritional state and the 
total lymphocyte count, there was a false­
positive rate of 34% and a false-negative 
rate of 50% when the lymphocyte count 
was used to detect malnutrition.
The results of this study indicate that 
the total lymphocyte is not affected by 
malnutrition. This does not mean that the 
immune response is not affected, since the 
total lymphocyte count is a poor meas­
ure of immunity. In previous studies of 
this type, the immune response was evalu­
ated in terms of nutritional assessment of 
a population as well as the individual 
patient.3 The lack of good correlation of 
the total lymphocyte count to the body 
composition, the wide confidence limits 
and the poor results of sequential studies 
indicate that the total lymphocyte count 
is of no value in assessing the nutritional 
state of an individual patient.
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Blunt Liver Trauma at the Sunnybrook Regional Trauma Unit
Between June 1, 1976 and Mar. 31, 
1983, the Sunnybrook Medical Centre 
Regional Trauma Unit in Toronto, Ont., 
admitted 145 patients with liver trauma; 
of these, 141 (97%) had sustained blunt 
liver trauma. Of 113 patients who under­
went open peritoneal lavage, 112 had a 
true-positive lavage.
Resuscitation was successful in 137 
patients and 134 of these underwent 
laparotomy. Seventy-nine (59%) of the 
134 patients required only minor surgical 
treatment; the other 55 (41%) required 
major surgical procedures.
The overall mortality was 32% (47 of 
145). Eight patients died during resusci­
tation but only one of them died of liver 
hemorrhage. Of the 39 patients who 
died after admission, the cause of death 
was head injury in 22, while 6 died of 
liver hemorrhage and 11 of other causes. 
Overall, liver hemorrhage was the cause 
of death in 15% of cases (7 of 47).
Entre le 1er juin 1976 et le 31 mars 
1983, 145 patients victimes de trauma- 
tismes hepatiques sont entres a I'Unite 
regionale de soins pour traumatises du 
Sunnybrook Medical Centre a Toronto. 
Parmi ceux-ci, 141 (97%) avaient subi 
des contusions hdpatiques. Sur 113 
patients chez qui on pratiqua un lavage 
peritoneal, 112 eurent un resultat positif 
certain.
Cent trente-sept patients furent rea- 
nimes et 134 subirent une laparotomie. 
De ce dernier groupe, 79 (59%) ne
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necessiterent qu'une chirurgie mineure 
alors que les 55 (41%) autres devaient 
subir une intervention chirurgicale 
majeure.
La mortalite globale fut de 32% (47 
sur 145). Huit patients sont decedes 
pendant les tentatives de reanimation 
mais un seul d'entre-eux est mort 
d'hemorragie hepatique. Des 39 patients 
qui sont decedes apres leur hospitalisa­
tion, 22 sont decedes des suites d'un 
traumatisme cranien, 6 d'hemorragie 
hepatique et 11 d'autres causes. Dans 
I'ensemble, I'hemorragie hepatique fut la 
cause de deeds dans 15% des cas (7 sui 
47).
Motor vehicle accidents are the major 
cause of blunt abdominal trauma in 
Canada and, as such, constitute a serious 
health-care problem.1 After the spleen, 
the liver is the most commonly injured 
organ and is associated with multiple 
organ injuries in about 50% of pa­
tients.2,3 Although the prognosis for 
these critically injured patients has 
improved markedly, considerable dis­
agreement still exists among experienced 
trauma surgeons as to the preferred 
method of management after blunt 
hepatic injury.
The purpose of this communication is 
to review our experience with liver trauma 
at Sunnybrook Medical Centre Regional 
Trauma Unit, with emphasis on blunt 
trauma, in order to evaluate current 
methods of diagnosis and treatment, and 
the complications and mortality of 
hepatic trauma. We are the major trauma 
centre for southern Ontario, with 85% of 
our patients being referred from other 
institutions.
Methods
The charts of all patients with liver 
injuries admitted between June 1, 1976 
and Mar. 31, 1983 were reviewed to deter­
mine age, sex, length of hospital stay, 
type of trauma, diagnosis, type of liver 
injury, treatment, complications, asso­
ciated injuries, injury severity scores and 
cause of death.
Patients with liver injuries who could 
not be successfully resuscitated and died 
in the emergency room were included. All 
patients who were treated elsewhere for 
liver injury but were transferred to Sun­
nybrook Medical Centre for postopera­
tive care or care of associated injuries 
were excluded.
Open peritoneal lavage was considered 
positive when the fluid was either grossly 
bloody or the erythrocyte count was 
greater than 10.0 x 109/L.* All patients 
with a positive peritoneal lavage were 
operated upon to treat the intra­
abdominal hemorrhage. Liver-related 
mortality was calculated by reviewing the 
cause of death. An abbreviated injury 
severity score (ISS 1980 version) for each 
patient was calculated according to the 
rules of the American Association for 
Automotive Medicine.4 Injury severity 
scores were compared by Student’s /-test.
Findings
During the study period, Sunnybrook 
Medical Centre Regional Trauma Unit 
admitted 1173 trauma patients. Of these, 
145 (101 males, 44 females) had sustained 
liver trauma; 141 (97%) had blunt injury, 
while 4 (3%) had sustained a penetrating 
stab injury.
Cause o f  Injury
Motor vehicle accidents were the cause 
of injury in 127 (90%) of those with blunt 
trauma. The other causes of blunt trauma 
were accidental or suicidal falls, a kick by 
a horse and a crush injury in a ferris 
wheel. Of the 145 patients with liver 
trauma, 79 (54%) were between 10 and 
30 years old.
Lavage
Open peritoneal lavage was done in 
113 patients, with a true-positive lavage in 
112; 1 patient had a false-negative result. 
This patient had signs of peritoneal injury
’Currently, only lavage counts greater than 
20.0 x 109/L erythrocytes are considered 
positive.
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2 days after admission and the liver injury 
was discovered at operation.
Diagnosis and Treatment
Of the 145 patients with liver trauma 
who were brought to the emergency 
room, 137 were successfully resuscitated. 
Laparotomy was done in 134 of these, 
while 3 patients in whom a diagnosis of 
subcapsular hematoma was made clini­
cally were treated conservatively. The lat­
ter did well on follow-up. Sixteen of the 
134 patients required immediate 
laparotomy for obvious intra-abdominal 
injuries (4 patients had penetrating inju­
ries). Two had laparotom y after 
laparoscopy. Three others with liver inju­
ries who had laparotomy had incomplete 
records as to how the diagnosis of 
intraperitoneal bleeding was made.
Ninety-six (74%) of 130 patients who 
underwent laparotomy were found to be 
bleeding from their liver injury at opera­
tion, whereas in 34 (26%) the bleeding 
had already stopped. The records did not 
elaborate on this point in the other four 
patients. Liver injury was limited to the 
right lobe in 65 patients (54%), to the left 
lobe in 35 (29%), both lobes were injured 
in 19 patients (16%) and 1 patient (0.8%) 
had injury limited to the portal vein which
Table 1—Surgical Treatment
Type of treatment
No. of 
patients
(%)
No treatment 22(16)
Minor surgical treatment
Drainage only 13(10)
Hemostatic agents only 20(15)
Hemostatic agents and drainage 24(18)
Major surgical treatment
Suture and drainage 36(27)
Suture only 12(9)
Resectional debridement 7(5)
Totals 134(100)
Table II—Causes of Death in Eight Patients 
Who Died During Resuscitation
No. of
Cause patients
Severe cardiopulmonary injuries 3
Head injury 2
Aortic -  inferior vena caval tears 2
Liver hemorrhage 1
Table Ill-Miscellaneous Causes of Death 
After Admission in 11 Patients
No. of
Cause patients
Shock from nonhepatic causes 3
Expanding retroperitoneal hematoma 2
Lung injury and respiratory failure 2
Myocardial contusion 2
Pulmonary embolism 1
Ruptured thoracic aorta 1
was bleeding profusely. This was repaired 
and the patient did well. The location of 
injury was not noted in the other 14.
In 22 (16%) patients whose bleeding 
was found to have ceased when 
laparotomy was done, no definitive treat­
ment was necessary. Minor surgical treat­
ment, which consisted of peritoneal 
drainage or use of hemostatic agents, or 
both, was necessary in 57 patients (43%) 
(Table I). Of 55 patients who needed 
major intervention, the liver wound was 
sutured and drained in 36. In 12 patients, 
the liver was only sutured. The other 
seven patients required resectional 
debridement.
Deaths
The mortality for the series of 145 
patients with liver injury was 32% (47 
patients). Eight died during resuscitation 
but in only one was death due to liver 
hemorrhage (Table II). Of the 39 patients 
who died after admission, head injury 
was the cause in 22 and various other 
causes in 11 (Table III). Six patients died 
of liver hemorrhage (Table IV). Overall, 
therefore, hepatic bleeding was the cause 
of death in 7 of the 47 patients (15%). 
The other 40 patients died of various 
other causes, mostly head injuries (24 
patients). The mean ISS for the 98 sur­
vivors was 40 ± 11 (standard deviation) 
which differed significantly (p < 0.0005) 
from that for the 47 nonsurvivors, 57 ± 
12 .
There were 45 complications in 29 of 
the 98 surviving patients (Table V). 
However, only five patients required 
reoperation, two for subphrenic abscess, 
one for a pancreatic pseudocyst, one for 
gallbladder necrosis and one for abdomi­
nal wall bleeding. All these patients did 
well after reoperation.
Discussion
At Sunnybrook Medical Centre 
Regional Trauma Unit, 12% (145) of our 
1173 trauma patients suffered a liver 
injury; 97% a blunt liver injury and 3%
a penetrating stab wound. There were no 
gunshot wounds to the liver. These 
figures, although similar to those reported 
from the United Kingdom,5 Sweden6 and 
Malaysia,7 are in sharp contrast to the 
figures reported from  the United 
States,8' 16 where penetrating injuries 
form the majority of traumatic injuries 
to the liver. The finding that 54% of our 
patients were between 10 and 30 years of 
age compares closely with other reported 
series.17'20
Often the diagnosis of hepatic injury 
is not made until laparotomy is per­
formed, since the signs of liver injury, 
which include shock, contusion over 
lower chest and upper abdom en, 
shoulder-tip pain and positive peritoneal 
lavage, are all nonspecific. Open 
peritoneal lavage is extremely useful in the 
diagnosis of intra-abdominal bleeding. 
We had true-positive findings in 112 of 
113 patients in whom open peritoneal 
lavage was performed. Moon and 
Federle21 suggested that computerized 
tomography combines the best features of 
all available diagnostic techniques in 
evaluating the patient with hepatic injury. 
It is rapid, noninvasive, accurately defines 
the extent of hepatic or other abdominal 
injuries and quantifies the size of 
associated hemoperitoneum. We have 
recently begun a study using this tech­
nique in the diagnosis of blunt abdomi­
nal trauma.
The incidence of subcapsular hema­
toma following blunt abdominal trauma 
has been reported to range from 0.33% 
to 12% of all liver trauma. Conservative 
treatment of subcapsular hematoma is 
favoured by some,2,22,23 while others cau­
tion against it for the fear of delayed rup­
ture, infection or hemobilia.10 Our three 
patients with subcapsular hematoma were 
treated conservatively and all did well.
The surgical treatment of a patient with 
hepatic trauma depends on the type of 
wound encountered at operation.24 Some 
minor lacerations that have stopped 
bleeding may not require repair, but it is 
impossible to select preoperatively 
patients with minor injuries that will stop
Table IV-Surgical Procedures and Complications in Six Patients Who Died of 
Liver Hemorrhage After Laparotomy
First procedure Complication Second procedure
Injury
severity
score
Suture and drainage Rebleeding and disseminated Suture and drainage 59
Suture and drainage
intravascular coagulation 
Rebleeding and disseminated None 66
Resectional debridement
intravascular coagulation 
Continued shock None 59
Resectional debridement Rebleeding and disseminated Resectional debridement 59
Packing elsewhere
intravascular coagulation 
Rebleeding and disseminated Resectional debridement 33
Packing elsewhere
intravascular coagulation 
Cirrhotic liver
at Sunnybrook 
Suture and drainage 34
at Sunnybrook
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bleeding. Use of hemostatic agents like 
Avitene, Surgicel, Oxycel, liquid throm ­
bin or packing were sufficient to control 
bleeding in patients with minor injuries. 
O f the patients who required major sur­
gical treatment, sutures had to be applied 
to the liver in 87% and resectional 
debridement was needed in 13%. Initial 
management o f severe lacerations is aided 
by digital or atraumatic clamp compres­
sion o f the hepatoduodenal ligament as 
described by Pringle in 1908.25 This will 
permit ligation of small vessels and 
debridem ent.24
The role o f hepatic artery ligation in 
controlling hemorrhage has frequently 
been supported18’22’26'27 and disputed.9,10 
W alt9 has suggested that we may be 
trading short-term gains in hemostasis for 
long-term hepatic sepsis with delayed 
m ortality. We did not use hepatic artery 
ligation in any of our patients; we believe 
that although this method is occasionally 
useful, it is overused.
The rate o f hepatic resectional debride­
ment, which consists of limited resection
Table V—Complications in the 98 
Surviving Patients (n -  291
Complication
No. of 
episodes
Sepsis 10*
Liver failure 6
Disseminated intravascular 
coagulation 6
Biliary fistula 4
Renal failure 4
Pulmonary embolism 4
Other 11
‘ Includes 3 subphrenic abscesses.
of devitalized tissue along the lines of 
injury, has declined progressively from a 
high of 46% 7 to as low as 3% .28 It was 
used in 5% of our patients who under­
went laparotomy for hepatic trauma. This 
rate compares well with those of other 
series.
After bleeding has been controlled and 
the wound debrided, adequate drainage 
should be provided. Few communications 
have questioned the value of peritoneal 
drainage,29,30 which was used in 60% of 
our patients who underwent laparotomy.
Merendino and colleagues31 recom­
mended drainage of the common bile duct 
using a T tube in severe liver traum a to 
decrease likelihood of biliary fistulas. 
Lucas and Ledgerwood32 have shown a 
striking increase in morbidity following 
T-tube drainage, and we agree that it 
should not be used.
Shotgun wounds are the most lethal 
liver injuries, followed in descending 
order by blunt trauma and gunshot and 
stab wounds.6,9 Isolated hepatic injury 
occurs in less than 10% of patients with 
blunt traum a and is associated with a 
mortality o f 5% which increases to over 
55% when six or more organs are in­
volved.13,14 Our overall mortality was 
32% (47 of 145). True liver-related mor­
tality due to hemorrhage was seen in 15% 
(7 of 47) o f those who died. This was 
mostly due to the development o f pro­
found coagulopathy associated with long­
standing shock that did not respond to 
correction of blood volume and clotting 
factors.11,22 The other 40 who died could 
be divided into two main groups: those 
who died of severe head injuries either 
before or after resuscitation (24 patients) 
and those who died of miscellaneous
Table VI—Mortality for Blunt Liver Trauma Reported in Literature
Authors
Location 
of study
Schrock and associates, 19688 San Francisco
Walt, 1969,12 19789 Detroit
Walt, 19789 Detroit
Balasegaram, 19767 Malaysia
Defore and associates, 197613 Houston
Levin and associates, 197814 New Orleans
Fischer and associates, 197829 
Elerding and associates,
Minnesota
1979 ,15 198020 Denver
Aldrete and associates, 197916 Alabama
Pachter and Spencer, 197928 New York
Miller and Bernstein, 198018 
Hasselgren and associates,
Irving (Calif)
19816 Sweden
Caine and associates, 19825 Cambridge
(UK)
Thomas, 198334 Hamilton
Corica and Powers, 197533 Albany
Witte and Zokoski, 198319 Arizona
Current series Toronto
MVA = motor vehicle accident.
Total 
no. of 
patients
No. of
patients with 
blunt trauma
Mortality, %
Overall Blunt trauma
61 20 24 65
436 50 11 30
637 57 15 —
331 40 12 20
179 90 (MVA 71) 17 14
1590 240 13 30
546 76 (MVA 75%) 10 28
303 “ 22 29
225 66 15 20
108 48 17 —
85 8 7 _
56 34 9 -
58 20 (MVA 9) 19 30
26 25 (MVA 25) 15 __
82 - 17 —
? 75 — 33
? 26 — 8
145 141 (MVA 127) 32 32
causes (16 patients). Our figures compare 
well with blunt trauma mortality in other 
series (Table VI).5'9’12' 16’18'20’28’29,33’34 At 
Sunnybrook Medical Centre, approxi­
mately 70% of patients admitted with 
multiple injuries have a serious head 
injury, which is an important cause of 
morbidity and death.35 In view of the 
severe type of blunt hepatic trauma at our 
centre, it is not surprising that our over­
all mortality is higher than that of some 
reported series in which penetrating liver 
injury dominates and carries a mortality 
o f less than 5%.
Conclusions
Most blunt hepatic traum a can be 
managed adequately using a simple con­
servative approach, based on well- 
established principles. Early diagnosis, 
prompt hemostasis, restoration of blood 
volume and coagulation, prevention of 
hypothermia, hypotension and acidosis 
and treatment o f associated injuries are 
crucial in saving the patient. Surgical 
principles o f management include direct 
control o f hemorrhage, debridement of 
devitalized liver tissue and adequate 
drainage.
References
1. BURNS CM: Symposium on trauma for the general sur­
geon. 1. An accident health care program: the organiza­
tion and development of regional trauma units. Can J 
Surg 1978; 21: 507-9
2. Cheatham JE jr , Smith El, Tunell w p , Elkins 
RC: Nonoperative management of subcapsular hema­
tomas of the liver. Am  J  Surg 1980; 140: 852-7
3. ALI J: Symposium on trauma for the general surgeon. 
3. Abdominal trauma with special reference to hepatic 
trauma. Can J Surg 1978; 21: 512-6
4. Committee on Injury Scaling: The Abbreviated Injury 
Scale, 1980 Revision, American Association of Automo­
tive Medicine, Morton Grove, 111., 1980
5. CALNE RY, WELLS FC, Forty J: Twenty-six cases of 
liver trauma. Br J  Surg 1982; 69: 365-8
6. Hasselgren PO, almersjo O, G ustavsson B, See- 
man T: Trauma to the liver during a ten-year period. 
With special reference to morbidity and mortality after 
blunt trauma and stab wounds. Acta Chir Scand 1981; 
147: 387-93
7. BALASEGARAM M: The surgical management of hepatic 
trauma. J  Trauma 1976; 16: 141-8
8. SCHROCK T, BLAISDELL FW, MATHEWSON C JR: 
Management of blunt trauma to the liver and hepatic 
veins. Arch Surg (Chicago) 1968; 96: 698-704
9. Walt AJ: Founder’s lecture: the mythology of hepatic 
trauma — or Babel revisited. Am  J Surg 1978; 135: 12-8
10. LUCAS CE, LEDGERWOOD AM: Prospective evaluation 
of hemostatic techniques for liver injuries. J Trauma 
1976; 16: 442-51
11. LUCAS CE, Walt AJ: Critical decisions in liver trauma. 
Experience based on 604 cases. Arch Surg 1970; 101: 
277-83
12. Walt AJ: The surgical management of hepatic trauma 
and its complications. Ann R Coll Surg Engl 1969; 45: 
319-39
13. Defore w w  jr , Mattox KL, Jordan GL jr , Beall 
AC JR: Management of 1,590 consecutive cases of liver 
trauma. Arch Surg 1976; 111: 493-7
14. levin A, Gover P, Nance FC: Surgical restraint in the 
management of hepatic injury: a review of Charity Hospi­
tal experience. J Trauma 1978; 18: 399-404
15. Elerding SC, Aragon GE, Moore EE: Fatal hepatic 
hemorrhage after trauma. Am  J Surg 1979; 138: 883-8
16. Aldrete JS, Halpern NB, Ward S, Wright JO: 
Factors determining the mortality and morbidity in 
hepatic injuries. Analysis of 108 cases. Ann Surg 1979; 
189: 466-74
17. Bluett MK, Woltering E, Adkins RB: Management 
of penetrating hepatic injury. A review of 102 consecu­
tive patients. Am  Surg 1984; 50: 132-42
222 VOLUM E 28, NO. 3, M A Y  1985 /  THE CANADIAN JOURNAL OF SURGERY
18. Miller DR, Bernstein JM: Hepatic trauma. A review 
of 56 consecutively treated patients. Arch Surg 1980; 115: 
175-8
19. Witte CL, ZUKOSKI CF: a  rational approach to seri­
ous blunt hepatic injury. Am  Surg 1983; 49: 446-53
20. Elerding SC, Moore EE JR: Recent experience with 
trauma of the liver. Surg Gynecol Obstet 1980; 150: 853-5
21. MOON KL JR, FEDERLE MP: Computed tomography in 
hepatic trauma. AJR  1983; 141: 309-14
22. DUNHAM CM, MlLlTELLO P: Surgical management of 
liver trauma. Am  Surg 1982; 48: 435-9
23. ATHEY GN, Rahman SU: Hepatic haematoma follow­
ing blunt injury: non-operative management. Injury 1982; 
13: 302-6
24. Hanna SS, J irsch DW: Management of hepatic injury. 
Can Med /4ssoc J  1977; 117: 352-3
25. PRINGLE JH: Notes on the arrest of hepatic hemorrhage 
due to trauma. Ann Surg 1908; 48: 541-9
26. Mays ET: The hazards of suturing certain wounds of 
the liver. Surg Gynecol Obstet 1976; 143: 201-4
27. Idem: Hepatic trauma. N  Engl J  Med 1973; 288: 402-5
28. Pachter HL, Spencer FC: Recent concepts in the 
treatment of hepatic trauma: facts and fallacies. Ann 
Surg 1979; 190: 423-9
29. F ischer RP, O’Farrell KA, Perry JF: The value of 
peritoneal drains in the treatment of liver injuries. J 
Trauma 1978; 18: 393-8
30. Cerise EJ, P ierce w a , Diamond DL: Abdominal 
drains. Their role as source of infection following splenec­
tomy. Ann Surg 1970; 171: 764
31. MERENDINO KA, DILLARD DH, CAMMQCK EE: The 
concept of surgical biliary decompression in the manage­
ment of liver trauma. Surg Gynecol Obstet 1963; 117: 
285-93
32. Lucas CE, Ledgerwood AM: Controlled biliary 
drainage for large injuries of the liver. Surg Gynecol 
Obstet 1973; 137: 585-9
33. CORICA A, POWERS SR JR: Blunt liver trauma: an anal­
ysis of 75 treated patients. J  Trauma 1975; 15: 751-6
34. THOMAS EJ: Symposium on trauma. 4. Major liver 
trauma. Can J  Surg 1983; 26: 27-30
35. SCHWARTZ ML: Symposium on trauma. 3. Head injury 
in multiple trauma. Ibid: 23-6
SESAP IV Critique
ITEM 118
In the management of severe hepatic injuries, enthusiasm for resection 
has been replaced by the belief that persistence in local hemostasis and 
debridement will control most hepatic bleeding. Routine T-tube 
drainage of the common duct has been shown to be both unnecessary 
and detrimental for these patients, most of whom have ducts of nor­
mal size. If T-tube drainage is used, postoperative sepsis and gastroin­
testinal bleeding are increased.
Major liver injury is associated with a mortality in excess of 15%. 
Bleeding from liver parenchyma in some instances can arise from 
branches of the hepatic artery. With local hemostatic measures, liga­
tion of the hepatic artery should only rarely be required for the manage­
ment of major liver injuries. If used, however, ligation has been shown 
to be safe, with no significant long-term effect on liver function.
0
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1. Pilonidal Disease
Many procedures have been advocated 
to treat pilonidal disease, suggesting that 
no one method is highly efficacious. In 
the office, the surgical approach is 
directed towards three aspects of the 
condition: pilonidal abscess, recurrent 
pilonidal disease following surgery and 
chronic pilonidal disease following spon­
taneous rupture of an abscess or secon­
dary to incision and drainage.
In managing the acute pilonidal 
abscess, an intradermal injection is given 
over the indurated, fluctuant area as well 
as the midline orifice which can almost 
always be identified. The midline orifice 
is incised and the incision carried into 
the abscess cavity. The edges of the 
cavity are excised. Healing takes place 
secondarily. A second procedure is rarely 
needed.
Plusieurs operations ont ete proposees 
pour traiter le kyste pilonidal, ce qui 
laisse supposer qu'aucune n'est tres effi- 
cace. Dans le cabinet de consultation, la 
chirurgie s'attaque a trois aspects de 
cette affection: I'abces pilonidal, la reci- 
dive post-chirurgicale du kyste pilonidal 
et le kyste pilonidal chronique consecutif 
a la rupture d'un abces ou secondaire a 
une incision avec drainage.
Devant un abces pilonidal aigu, on 
administre une injection intradermale au- 
dessus de la zone induree mobile de 
meme que de I'orifice median, lequel 
peut presque toujours etre identifie. Une
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incision est pratiquee par I'orifice median 
jusque dans I'abces. Les bords de la 
cavite sont excises. La guerison se fait 
par seconde intention. Une deuxieme 
operation est rarement necessaire.
Pilonidal disease has posed a problem in 
surgical management since Anderson1 in 
1847 first described marsupialization of 
the tract for cure. The etiology of the dis­
ease remains obscure. It does not occur 
before puberty and is rare in black peo­
ple and in Asiatics. It is far more com­
mon among hirsute individuals2 and 
there is a definite association with 
trauma. During World War II, soldiers 
lost many man hours due to “jeep dis­
ease” .3 The combination of poor per­
sonal hygiene due to battlefield conditions 
and the trauma of riding the hard seats 
of jeeps over difficult terrain were the 
main causative factors. The presence of 
the midline pits very evenly placed over 
the postsacral area suggests a congenital 
origin.4 With the development of secon­
dary sexual characteristics at puberty, the 
hair becomes more profuse and coarse. 
Shafts of exfoliated hair, particularly 
from the scalp, then penetrate the pits or 
theoretically can themselves cause pits 
and, with poor personal hygiene and 
trauma, a secondary infection develops. 
Pathologically, hair follicles have never 
been found in the sinus tracts, proving 
that the hair is extraneous to the area. 
Moreover, frequently no connection 
between adjacent midline orifices can be 
seen.
Treatment
Many procedures have been advocated 
to treat pilonidal disease, which suggests 
that no one method is highly efficacious. 
Sebrechts5 in his bibliography of piloni­
dal disease listed 936 separate papers, the 
majority of which described its manage­
ment. Excision and primary closure,6
marsupialization,7 split-thickness grafts,8 
Z-plasty,9 injection of sclerosing solu­
tions,10 excision and delayed closure," 
electrocoagulation,12 semiprimary clo­
sure,13 gluteal fascioplasty14 and incision 
and curettage15 have all been advocated. 
The management of this condition in the 
office has been suggested before and 
therefore is not new.16-18 The office sur­
gical approach revolves around three 
aspects of the condition: pilonidal 
abscess, recurrent pilonidal disease fol­
lowing surgery and chronic pilonidal dis­
ease following spontaneous rupture of an 
abscess or secondary to previous incision 
and drainage.
Acute Pilonidal Abscess
The acute pilonidal abscess presents as 
a painful swelling in the postsacral area 
cephalad to the coccyx and generally 
presenting to the right or the left of the 
midline. Induration or fluctuation, or 
both, can be seen and palpated and nearly 
always a midline orifice can be identified. 
The skin overlying the abscess cavity is 
injected with 1 to 2 mL of a solution of 
0.25% bupivacaine with 1:200 000 
epinephrine, using a 30-gauge dental nee­
dle. It is important to inject the anesthetic 
solution intradermally to achieve ade­
quate anesthesia. The skin will blanch if 
the injection is being given intradermally. 
Injection into the abscess cavity should 
be avoided since it will be painful and 
anesthesia will be inadequate due to the 
acid pH. A small probe is then inserted 
through the midline orifice into the 
abscess cavity. This midline pit can 
usually be identified. The incision is 
extended from the midline orifice the full 
length of the abscess cavity. The edges of 
the abscess cavity are excised to expose 
the posterior wall completely. It may be 
necessary to inject further local anesthetic 
into the skin edges to accomplish this. If 
a midline orifice cannot be identified, the 
incision should still be made through the
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midline and then extended into the 
abscess cavity. The posterior wall of the 
abscess is not incised and the granulation 
tissue is either cauterized with a silver 
nitrate stick or curetted out. A gauze 
dressing is placed into the wound, then 
cotton and a V pad that is taped into 
place. The patient should not remove the 
dressing until the following day since that 
may result in bleeding. Hot tub baths are 
started the following day and continued 
until the wound is healed. The healing 
time is generally 2 weeks and the patient 
experiences minimal discomfort. Recur­
rence of the pilonidal cyst managed in this 
way is unusual; thus, the treatment is 
definitive.
Recurrent Pilonidal Disease
Management of a recurrent pilonidal 
sinus after formal surgery can be adapted 
to office surgery. The recurrence in most 
cases develops in the caudal portion of the 
scar. A blind cavity or sinus tract is fre­
quently encountered through a midline 
opening. A local anesthetic is adminis­
tered and an incision made directly over 
the probe, exposing the sinus tract or 
cavity. The posterior wall of the tract is 
left intact but is scraped free of granula­
tion tissue and the edges of the tract are 
debrided. Frequently, the posterior wall 
is completely epithelialized and leaving it 
intact shortens the healing period. A 
dressing is applied as described and hot 
baths are begun the following day. If the 
wound is large, the patient is urged to use 
a Water Pik once daily to keep the wound 
clean as recommended by Hoexter.19 
The patient is seen at weekly intervals 
when the hair is shaved back from the 
skin edges of the wound, the granulation 
tissue removed and the wound cauterized 
with 10% silver nitrate. The healing time 
averages 3 to 4 weeks, depending on the 
size of the wound.
Chronic Pilonidal Disease
The chronically draining pilonidal cyst 
that develops after incision and drainage 
of an abscess or spontaneous rupture of 
a pilonidal abscess, can again, in most 
instances, be managed in the office. The 
anesthetic injection, however, is slightly 
different. To a 50-mL vial of 0.25% 
bupivacaine with 1:200 000 epinephrine, 
2 mL of hyaluronidase (300 turbidity 
reducing units) are added. The hyaluroni­
dase breaks down the intracellular cement 
and brings about rapid diffusion of the 
solution with immediate anesthesia. The 
hair about the cyst is first shaved and then 
the anesthetic is administered, placing the 
solution circumferentially about the cyst 
as well as deep to the cyst between the cyst 
and the postsacral fascia. With a no. 15 
blade disposable scalpel, a midline inci­
sion is made through all midline orifices,
exposing the cyst or sinus tract. The edges 
of the wound are cut back and bevelled. 
The posterior wall of the cyst is left intact, 
but all granulation tissue is vigorously 
removed. Hemostasis is secured by elec­
trocautery. A piece of Surgicel followed 
by cotton and several V pads are then 
applied. The dressing is removed the fol­
lowing day and hot baths are started. Fol­
lowing each hot bath, a 4 x 4-inch gauze 
soaked in 0.5% silver nitrate solution is 
applied to the wound followed by a dry 
gauze pad to hold it in place. The use of 
the silver nitrate solution keeps the wound 
clean and the granulation tissue down, 
thus speeding up the healing process. In 
the nervous, apprehensive patient, this 
same procedure is carried out in the 
hospital in a similar manner but with the 
addition of diazepam intravenously in 
increments of 2.5 mg up to 10 to 15 mg. 
The patient is seen at weekly intervals and 
is instructed to use a Water Pik if the 
wounds are not clean. The hair is always 
shaved back from the wound edges at 
these weekly visits. In a personal 
review20 of 126 patients treated in this 
manner in the hospital for pilonidal dis­
ease, the recurrence rate was 20.9% and 
the average healing time was less than 2 
months. The recurrences were treated by 
office procedures in all but one instance.
Discussion
I agree with Hurst21 that pilonidal dis­
ease is overtreated. Wide, radical excision 
down to the postsacral fascia under a 
major anesthetic leaving a wound that 
may take 3 to 6 months to heal has no 
place in the management of pilonidal dis­
ease. The high recurrence rate appears to 
be due to the development of new disease 
rather than recurrence of the old since it 
is difficult to believe that the surgeon 
leaves any cysts or sinus tracts behind. 
When healing time is prolonged and the 
wound is not kept meticulously clean and 
free of hair, new sinus tracts and cysts 
may be formed by the inclusion of hair 
deep in the wound with epithelializadon 
over the enclosed hair. The object should 
be to create as small a wound as possible 
and get it healed as quickly as possible. 
Cleanliness is the hallmark of success in 
the proper management of pilonidal 
disease.
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2. Lateral Internal Sphincterotomy: 
Rationale, Technique and Anesthesia
To determine the role of lateral internal 
sphincterotomy under local anesthesia in 
patients with anal fissures, a retrospec­
tive review of 133 patients (62 men, 71 
women) was conducted. They ranged in 
age from 19 to 79 years. The open tech­
nique described by Sir Alan Parks was 
adopted, except that the operation was 
performed under local anesthesia as an 
outpatient procedure. Associated opera­
tions were performed in nine patients 
(6.5%). Complications, which occurred 
in seven patients (5.3%), included 
difficulty controlling flatus, incomplete 
wound healing and thrombosed external 
and prolapsing internal hemorrhoids. 
Relief of pain was prompt. The advan­
tages of this operation are that hospitali­
zation is not necessary, it can be per­
formed under local anesthesia, 
postoperative discomfort is of short 
duration and wounds heal quickly. This 
report supports the use of lateral internal 
sphincterotomy for patients with a 
chronic anal fissure.
Une etude retrospective portant sur 133 
malades (62 hommes et 71 femmes) a 
6te menee dans le but de preciser le role 
de la sphincterotomie laterale interne 
sous anesthesie locale dans le traitement 
des fissures anales. Leur age allait de 19 
a 79 ans. On a adopte la technique 
ouverte decrite par Sir Alan Parks, a ceci 
pres que I'operation a ete pratiquee sous 
anesthesie locale en clinique externe.
Des operations associees ont ete faites 
chez neuf patients (6.5%). Des compli­
cations, qui sont survenues chez sept
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patients (5.3%), ont inclu difficulty a 
controler les gaz intestinaux, cicatrisation 
incomplete, thrombose des hemorroldes 
externes et prolapsus des hemorroldes 
internes. Le soulagement de la douleur 
fut rapide. Les avantages de cette opera­
tion resultent du fait que I’hospitalisation 
n'est pas necessaire, qu elle peut etre 
faite sous anesthesie locale, que la gene 
postoperatoire est de courte duree et 
que la plaie guerit rapidement. Cet article 
soutient I'utilisation de la sphincteroto­
mie laterale interne chez les patients 
souffrant de fissure anale chronique.
In the development of a fissure in ano, 
the initiating factor is generally consi­
dered to be trauma to the anal canal, in 
the form o f a hard stool.1 Usually the 
acute fissure heals, but under certain con­
ditions it persists. One perpetuating fac­
tor that is important in the formation of 
a chronic anal fissure is chronic consti­
pation. This is more likely an associated 
symptom but may continue to aggravate 
the anal canal, perpetuating the fissure. 
Inflammation has also been invoked as 
a perpetuating factor but this is unlikely 
because inflammation is no more florid 
in patients with very long-standing anal 
fissures than in those with fissures of 
recent onset. An abnormality of the inter­
nal anal sphincter is important. Studies 
by Nothmann and Shuster2 demon­
strated that, following rectal distension, 
the normal reflex relaxation of the inter­
nal sphincter is followed by an abnormal 
“ overshoot contraction” in patients with 
anal fissures. This phenomenon may 
account for the sphincter spasm and 
explain the pain that occurs during and 
after defecation. They further demon­
strated that following successful treat­
ment o f the fissure, the abnormal reflex 
contraction vanishes. This abnormality 
should then be considered when trying to 
arrive at a rationale treatment for the 
problem.
In 1959, Eisenhammer3 recommended 
lateral internal sphincterotomy to treat 
patients with a chronic fissure in ano, a 
procedure that was originally described by 
Brodie4 in 1835. There are many varia­
tions of Brodie’s procedure. It may be 
performed under local or general anesthe­
sia, through a radial or circumferential 
incision, or using a subcutaneous tech­
nique. The muscle may be divided from 
medial to lateral or vice versa.
Patients
To determine the results obtained with 
lateral internal sphincterotomy under 
local anesthesia, we reviewed retrospec­
tively 133 patients with anal fissure. There 
were 62 men (47%) and 71 women (53%), 
ranging in age from 19 to 79 years with 
most being in the third or fourth decades 
of life.
Technique
We adopted the technique described by 
Sir Alan Parks.5 However, we perform 
this operation under local anesthesia as 
an outpatient procedure unless there are 
extenuating circumstances such as an 
allergy to the local anesthetic.
With the patient in the prone jackknife 
position, the perianal region is prepared 
with a disinfectant solution and draped 
in the usual fashion. With a fine needle, 
an anesthetic solution of 0.5% xylocaine 
in 1:200 000 epinephrine or 0.25% 
bupivacaine in 1:200 000 epinephrine is 
infiltrated into the left lateral aspect near 
the anal verge, ensuring that the solution 
is directed to the level of the dentate line. 
The area of the fissure is then anesthe­
tized. A Pratt bivalve is inserted into the 
anal orifice. Should there still be some 
discomfort, the entire perianal region may 
be anesthetized. A short incision is made 
just distal to the intersphincteric groove, 
which can usually be palpated quite eas­
ily. The anoderm is lifted off the under­
lying internal sphincter to the level of the 
dentate line and the intersphincteric plane 
is developed. The full thickness of the 
internal sphincter is divided from its lower 
edge to the level of the dentate line using 
either a pair of Metzenbaum scissors or 
a scalpel. Hemostasis is obtained with 
cautery and the wound can be closed with 
a couple of interrupted sutures of 3-0 
chromic catgut.
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Results
The symptoms encountered in this ser­
ies are shown in Table I.
Thirty-one patients had associated 
problems: hemorrhoids in 24, anal steno­
sis in 4, Crohn’s disease in 2 and syphilis 
in 1 patient.
Associated operations were performed 
in nine patients (6.8%). In four, a one- 
or two-quadrant hemorrhoidectomy was 
performed and in one of these a hyper­
trophied anal papilla was excised. In five 
other patients, associated hypertrophied 
anal papillae and sentinel piles were 
excised. Another patient had his condy- 
lomata acuminata removed.
Complications occurred in seven 
patients (5.3%). Three patients had 
difficulty controlling flatus. In two, the 
problem was temporary and resolved 
spontaneously but one patient had uncon­
trollable flatus for at least 1 year
Table 1-Symptoms in 133 Patients 
With Anal Fissure
Symptom
No. of 
patients (%)
Pain 133(1001
Bright red rectal bleeding 74(55.6)
Straining 22(16.5)
Pruritus 11 (8.3)
Prolapse 10(7.5)
Mucus 4(3.0)
FIG. 1—Incomplete division of lower por­
tion of internal sphincter.
postoperatively; then she was lost to 
follow-up. There were three patients 
whose operative site did not heal. One 
patient was re-examined under general 
anesthesia and an unusual finding was 
demonstrated. It was noted during re­
exploration that the lowermost portion of 
the internal sphincter had not been 
divided at the original sphincterotomy, 
consequently the wound did not heal 
(Fig. 1). This problem was easily cor­
rected by completing the incision. 
Another wound did not heal because the 
operation was performed on a patient 
with Crohn’s disease. Although the 
wound did not heal, the patient was 
asymptomatic. One patient had persistent 
pain and the fissure did not heal. Conse­
quently, 1 month later a lateral internal 
sphincterotomy was performed on the 
opposite side, giving prompt relief of 
symptoms and complete healing of the 
fissure. One patient returned the day after 
the procedure with a complete ring of 
prolapsed, thrombosed internal hemor­
rhoids as well as a ring of thrombosed 
external hemorrhoids. Emergency hemor­
rhoidectomy was performed and his post­
operative course was smooth. Fortunate­
ly, no patient suffered postoperatively 
from hemorrhage, perianal abscesses or 
fistula in ano. Urinary retention was not 
encountered.
Postoperative Care
Patients were discharged home on a 
regular diet, advised to take sitz baths and 
a psyllium seed preparation as a stool 
softener; a non-constipating oral anal­
gesic was prescribed. Originally, patients 
were seen 1 week and again 1 month after 
the procedure, but later in the review it 
was deemed unnecessary to see them after 
a week so they were seen only 1 month 
following the procedure.
Although the exact duration of pain 
postoperatively was not documented for 
each patient, most had relief within 48 
hours and many within 24 hours.
Table II—Reported Results of Lateral Internal Sphincterotomy
% impaired
Authors No.
control of 
Flatus Feces
Fecal 
soiling, %
Unhealed or 
recurrence, %
Hawley, 1969® 24 - 0 0 0
Hoffmann and Goligher, 19707 99 6 1 7 3
Notaras, 19718 82 2 1 6 10
Millar, 1971® 99 2 0 1 0
Hunter, 197510 74 27 27 34 12
Rudd, 1975” 200 0 0 0 0.5
Oh, 197812 300 1 0.6 2 1.6
Bailey and colleagues, 197813 418 1 1.2 - 1
Marby and colleagues, 197914 78 0 0 0 29
Rosenthal, 1979's 125 Few 0 0 0.8
Abcarian, 198016 150 30 0 0 1.3
Vafai and Mann, 198117 272 16 0 12 3
Current series, 1983 133 2.3 0.8 0 1.5
Discussion
In recent years, lateral internal sphinc­
terotomy has increasingly been the treat­
ment of choice for patients with a chronic 
anal fissure. In a poll of the members of 
the American Society of Colon and Rec­
tal Surgeons in 1979, most respondants 
stated that their first or preferred opera­
tion of choice for chronic fissure in ano 
was the lateral internal sphincterotomy. 
Recently, many authors6'17 have reported 
their results with this operation (Table II). 
With only one exception (Hunter10) all 
reported satisfactory control of flatus and 
feces. In the series reported by Rosen­
th a l,15 A bcarian ,16 and Vafai and 
Mann,17 all of the problems relating to 
control of flatus and soiling were only 
temporary. Fecal soiling was reported in 
some series but varied in degree of con­
cern in different series. Hoffmann and 
Goligher7 studied three procedures — 
posterior in ternal sphincterotom y, 
sphincter stretch and lateral internal 
sphincterotomy — and, when comparing 
disturbances of anal continence follow­
ing these operations, found that lateral 
internal sphincterotomy fared the best.
In terms of the unhealed fissure or the 
patient who suffers a recurrence, the 
results of this operation are quite good. 
Abcarian16 compared the results of 
lateral internal sphincterotomy with fis- 
surectomy and midline sphincterotomy. 
He found that lateral internal sphinc­
terotomy offered rapid wound healing, a 
low recurrence rate and no permanent 
defect in continence, and concluded that 
it was the treatment of choice. The highest 
recurrence rates were reported by Marby 
and associates14 and Notaras.8 In both 
series, the lateral internal sphincteroto­
mies were performed in a blind manner. 
Oh12 pointed out that in his series the 
incidence of recurrence was slightly higher 
in patients who had sphincterotomy per­
formed in a subcutaneous blind manner 
than in those who had it performed using 
an open technique. This may explain the 
higher recurrence rates in the two cited 
series. The incidence of recurrence may 
also be related to the amount of internal 
sphincter divided.
Conclusions
Our experience, supported by that of 
others in the literature, strongly suggests 
that lateral internal sphincterotomy is a 
good operation for patients with a chronic 
fissure in ano. It has several definite 
advantages. There is no need for the 
patient to be hospitalized. The operation 
can be performed under local anesthesia. 
Postoperative discomfort is of short dura­
tion and wounds heal quickly. Fecal 
soiling is not a problem and recurrence 
following this mode of therapy is uncom-
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mon. Thus, less time is lost from work 
and fewer follow-up visits are required. 
Because of excellent results, we believe 
that lateral internal sphincterotomy is the 
treatment of choice for patients with a 
chronic anal fissure.
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3. Alternatives to Surgical Hemorrhoidectomy
Hemorrhoids are an extremely common 
affliction. The prevalence ranges from 1 
in 25 to 1 in 30 individuals. There was a 
20% decrease in the number of hemor­
rhoidectomies performed between 1978 
and 1982. Alternatives to formal hemor­
rhoidectomy are injection sclerotherapy 
and rubber-band ligation. High-fibre diets 
and bulk laxatives are effective in reliev­
ing the symptoms of hemorrhoids, eas­
ing defecation and regulating bowel habit 
and can be used liberally. Bleeding 
hemorrhoids can be treated by diet 
alone, or by injection or rubber-band liga­
tion. Prolapsing hemorrhoids are best 
treated by rubber-band ligation. The rela­
tively few patients in whom these more 
conservative measures fail can be consi­
dered for hemorrhoidectomy.
Les hemorroides sont une affection tres 
courante. La prevalence se situe entre 1 
sur 25 individus et 1 sur 30. On a cons­
tate une diminution de 20% du nombre
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des hemorroi'dectomies entre 1978 et 
1982. La sclerotherapie par injection et 
la ligature par bande eiastique sont des 
alternatives a I'hemorroidectomie clas- 
sique. Les regimes riches en fibres et les 
laxatifs mucillagineux soulagent efficace- 
ment les symptomes des hemorroides, 
facilitent la defecation et regularised les 
selles; ils peuvent etre largement utilises. 
Les saignements hemorroidaires peuvent 
etre traites par le regime seul, par injec­
tion ou par ligature par bande eiastique. 
Le meilleur traitement des hemorroides 
prolabees est la ligature par bande eias­
tique. Les quelques patients pour qui ces 
mesures conservatrices ne suffisent pas 
sont candidats a I'hemorroidectomie.
Hemorrhoidal disease is extremely com­
mon in westernized countries. In North 
America it has been estimated that one 
out of every two individuals over the age 
of 40 years has some degree of hemor­
rhoidal disease. In the third world 
this prevalence ranges from 1 in 25 to 1 
in 30.1 In the majority of cases the 
hemorrhoids are asymptomatic. In a 
study reported by Haas and associates,2 
198 (82%) of 241 asymptomatic persons 
were found to have hemorrhoids. For 
comparison, in the symptomatic group of 
594 patients, 522 (88%) had evidence of 
hemorrhoids.
Asymptomatic hemorrhoids appear 
with increasing age. The peak ages are 
from 40 to 80 years. Symptomatic hemor­
rhoids are similarly distributed although 
there are a greater number with sympto­
matic hemorrhoids under the age of 30 
years.3 In Ontario, the prevalence of 
hemorrhoids is the same as is mentioned 
above; however, there has been a steady 
decrease (20%) in the number of hemor­
rhoidectomies performed from 1978 to 
1982.4 In my own practice over a 6-year 
period, I have seen 412 patients with 
hemorrhoidal disease, only 26 of whom 
required hemorrhoidectomy; 156 under­
went rubber-band ligation, 21 injection 
sclerotherapy and 213 were managed by 
dietary manipulation alone.
Alternatives to Hemorrhoidectomy
The classifications that I use for hemor­
rhoids are: first degree — maintained per­
sistently at the proper level in the anal 
canal; second degree — prolapse with 
bowel movement but spontaneously 
reduced when straining ceases; third 
degree — prolapse out of the anal canal 
requiring manual reduction; fourth 
degree — prolapse, often thrombosis, and 
cannot be reduced manually.
The usual symptoms consist of consti­
pation, bleeding, discomfort, prolapse 
and occasionally an associated discharge 
with anal irritation. These symptoms can 
often be resolved by office treatment of 
the hemorrhoidal disease using a high- 
fibre diet, and injection sclerotherapy or 
rubber-band ligation, or both.
High-Fibre Diet
In 1978, Webster and associates5 corn-
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pared the effects of Fybogel and placebo 
on patients with hemorrhoidal disease. 
The end points were relief of symptoms, 
ease of defecation and regular bowel 
habits. For all of these end points, there 
was a clear indication that the majority 
of patients were improved with Fybogel 
compared to placebo, particularly in 
those who described greater ease of defe­
cation and better bowel habit. In my own 
experience, most patients who are com­
pliant and who will agree to be placed on 
a high-fibre diet supplemented by stool 
softeners can often minimize their symp­
toms, particularly if they are complain­
ing of only small amounts of bright red 
rectal bleeding and anal discomfort on 
defecation.
Injection Sclerotherapy
The indications for injection sclerother­
apy are first-degree hemorrhoids and 
small second-degree hemorrhoids where 
the major symptom is that of bleeding. 
The rationale for injection sclerotherapy 
is the use of an irritant solution that 
produces an inflammatory reaction and 
fibrosis with subsequent devasculariza­
tion, thus minimizing rectal bleeding.6 
The fibrosis increases the fixation of the 
hemorrhoid to the underlying muscle 
thereby also reducing prolapse. Injection 
sclerotherapy is a simple and safe method 
for decreasing hemorrhoidal bleeding. 
The needle should be placed in the sub­
mucosal layer well above the dentate mar­
gin and 3 to 4 mL of 5% phenol in oil 
can be used surrounding each of the 
hemorrhoids. The contraindications are 
external hemorrhoids, acute attacks of 
hemorrhoidal disease and repeated injec­
tion as well as associated anal lesions. The 
complications include necrosis and injec­
tion ulcers, submucosal abscess and 
parathenomas.6 All these complications 
are rare.
Injection sclerotherapy is more popu­
lar in Great Britain than it is in North 
America. However, in my practice I often 
inject hemorrhoids when the major symp­
tom is hemorrhoidal bleeding, as I have 
found that rubber-band ligation can be 
somewhat inaccurate when the exact site 
of bleeding is difficult to identify.
Rubber-Band Ligation
Rubber-band ligations can be used for 
second- and third-degree hemorrhoids, 
and occasionally following reduction of 
fourth-degree hemorrhoids. The tech­
nique is relatively easy. The discomfort 
that arises will be minimized if one per­
forms the procedure well above the den­
tate margin. I prefer to ligate only one or 
at most two hemorrhoids at each sitting. 
The ligation of three hemorrhoids will
produce substantial pain and discomfort.
Approximately 75% of patients in my 
practice either have no further symptoms 
or are greatly improved following one or 
two rubber-band applications. In a study 
performed at the Lahey Clinic in 1981 of 
266 patients, 113 (43%) had no further 
symptoms following rubber banding, 69 
(26%) were greatly improved, 29 (11%) 
were mildly improved and 20% were 
unchanged or worse.7
The complications following rubber- 
band ligation are mainly severe pain in 
6% to 10% and hemorrhage in 1% to 
2% of patients.6 Two of my patients 
returned to hospital with major lower gas­
trointestinal bleeding from the rubber- 
band ligation site 10 to 14 days after the 
procedure. The immediate treatment for 
this is to place pressure over the area or 
to insert a Foley catheter, inflate the bal­
loon and pull back to tamponade the 
bleeding until the bleeding site can be 
identified and oversewn.
Summary
The treatment of bleeding hemorrhoi­
dal disease is first injection sclerotherapy. 
The failures are considered for rubber- 
band ligation. When hemorrhoids are 
large and protruding, rubber-band liga­
tion is the procedure of choice.
For large prolapsing internal hemor­
rhoids, an attempt is made to ligate these 
using rubber bands. If this fails, hemor­
rhoidectomy is performed.
With conservative measures and the 
institution of a high-fibre diet and stool 
softeners, the majority of hemorrhoids 
can be treated nonsurgically with satisfac­
tory results.
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4. Flexible Fiberoptic Sigmoidoscopy: an Office Procedure
Patients w ho  had benign polyps and 
cancers were studied retrospectively to 
define w hether use o f the 60-cm  flexible 
sigmoidoscope w ould  markedly improve 
the diagnostic yield over the 25-cm  rigid 
sigmoidoscope. O f the polyps found, 
4 8 %  could have been seen by the rigid 
sigmoidoscope and 85%  by the flexible 
sigmoidoscope. Cancers were w ith in  
reach of digita l examination in 2 1 % , of 
the rigid sigmoidoscope in 3 8%  and of 
the flexible sigmoidoscope in 6 0 % . This 
verifies the  greater diagnostic yie ld by 
the flexible sigmoidoscope.
In 211 asym ptom atic patients w ho 
underw ent flexible fiberoptic s ig­
m oidoscopy, the scope reached to  25 
cm in all and to  50 cm in 7 5 % . The 
average tim e required for the examina­
tion  was 4 .9  m inutes. Of these patients, 
w ho  had also undergone rigid s ig­
m oidoscopy previously, 76%  preferred 
the flexible scope, 18%  preferred the 
rigid scope and 6%  could tell no d iffe r­
ence. The yield o f neoplasms w as 4%  in 
the distal 25  cm o f the colon and rec­
tum , but an additional 8%  were found in 
the sigmoid colon.
This review supports the need fo r fle x ­
ible sigm oidoscopy in the o ffice  as a 
screening tool fo r detection o f polyps 
and early diagnosis of cancer in the 
asym ptom atic patient over 40  years of 
age. Technique, costs and com plications 
are discussed.
A fin  de verifier si, par rapport au sigm oi­
doscope rigide de 25 cm, un sigmoidos-
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cope flexible de 60 cm e ta it capable 
d 'am eliorer sensiblement I'e fficac ite  dia- 
gnostique, I'auteur a etudie en re trospec­
tive  une serie de patients porteurs de 
polypes benins ou de cancers. De tous 
les polypes decouverts, 4 8 %  auraient pu 
etre trouves avec le sigmoidoscope rigide 
et 85%  avec le sigmoidoscope flexible. 
Les cancers etaient a la portee du touche  
rectal dans 21%  des cas, du sigm oidos­
cope rigide dans 38%  et du sigm oidos­
cope flexible dans 60% . Ceci met en ev i­
dence la meilleure e fficacite  diagnostique 
du sigmoidoscope flexible.
Parmi 211 patients asym ptom atiques 
soumis a une fibroscopie a I'aide du s ig ­
moidoscope flexible, ('instrum ent s 'es t 
rendu a 25 cm dans tous les cas et a 
a tte in t 50 cm dans 75% . Le temps 
moyen requis pour I'examen fu t de 4 .9  
m inutes. De ceux qui avaient deja subi 
un examen au sigmoidoscope rigide,
7 6%  ont prefere I'instrum ent flexible, 
18%  le sigmoidoscope rigide et 6%  
n 'ava ien t pas de preference. Le nombre 
de neoplasies decouvertes dans le 25  cm 
distal du colon et du rectum  fu t de 4 %  
mais un 8%  s u p p le m e n ta l fu t decou- 
vert dans le sigmoide.
Cette etude souligne la necessity d 'u ti-  
liser le sigmoidoscope flexible  dans le 
cabinet de consultation comme moyen 
de depistage des polypes et pour le d ia ­
gnostic precoce du cancer chez les 
patients asym ptom atiques de plus de 40  
ans. On com m ente la technique, ses 
couts et ses com plications.
One in 25 Americans suffers from cancer 
of the colon at some time. There are 
approximately 120 000 new cases of 
colonic and rectal cancer each year, and 
60 000 deaths.1 The number of deaths 
annually is consistently about half the 
incidence, reflecting the positive observa­
tion that 50% may be cured. However, 
cure is predicated upon detection of the 
cancer while it is still localized. Effective 
screening procedures are necessary to 
unmask occult cancers.
Is there an effective means of prevent­
ing colonic and rectal cancer? Morson2 
demonstrated that there is a sequence of
degeneration of the benign, tubular ade­
noma to cancer. Following this reason­
ing, the detection and removal of benign 
tubular or papillary adenomas is the only 
known means of preventing carcinoma of 
the colon or rectum. Evidence that this 
action prevents cancer was provided by 
Gilbertsen, at the Cancer Detection Clinic 
of the University of Minnesota.3 He 
reported a marked decrease from the 
predicted number of cancers as a result 
of detection and removal of all polyps.
If a cancer is detected earlier, is the out­
come of the disease influenced? As previ­
ously noted, approximately 50% of the 
patients in whom colonic or rectal cancer 
is diagnosed can be cured by surgical exci­
sion. The cure rates are greatest in those 
cancers that are small and have not yet 
metastasized. For example, cases of 
colonic and rectal cancer recorded at the 
National Naval Medical Center Tumor 
Registry in Bethesda, Md., were grouped 
by the Astler-Coller classification, a 
modification of Dukes’ classification 
(Table I).4 The 5-year survival for 
patients in these groups was as follows: 
A — 100%, B1 — 77%, B2 — 61%, Cl 
— 66%, C2 — 30%, D — 1%. Clearly, 
earlier detection of lesser stages of cancer 
would positively influence the cure of this 
disease.
In regard to cancer of the colon, the 
American Cancer Society has recom­
mended (a) annual digital rectal exami­
nation in patients over 40 years of age, 
(b) annual examination for occult blood 
in patients over 50 years of age and (c)
Table I—Astler-Coller Classification of 
Colonic and Rectal Cancer
Class Description
A Limited to mucosa.
B1 Extension into but not through 
muscularis propria, negative nodes.
B2 Extension through muscularis propria, 
negative nodes.
C1 Extension into but not through 
muscularis propria, positive nodes.
C2 Extension through muscularis propria, 
positive nodes.
D Distant metastases.
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sigmoidoscopy every 3 to 5 years in 
patients over age 50.
The rigid 25-cm sigmoidoscope is the 
instrument that is referred to in the last 
recommendation. If rigid sigmoidoscopy 
offers diagnostic benefit, would more 
benefit be provided by the flexible sig­
moidoscope, which examines up to 60 cm 
of colon?
This paper addresses the rationale, 
indication and techniques for using 
flexible fiberoptic sigmoidoscopy as a 
primary screening tool in the physician’s 
office.
Method
At the National Naval Medical Center, 
Bethesda, Md., 499 patients (336 men, 
153 women) who had polyps removed 
through either a rigid sigmoidoscope or 
colonoscope between 1974 and 1981 had 
their charts reviewed to determine the site 
of the lesion. All patients had undergone 
barium enema examination or colono­
scopy as part of the investigation. Lesions 
up to 25 cm from the anus were desig­
nated to be within view of the rigid sig­
moidoscope. The remainder were classi­
fied as to site by barium enema or 
colonoscopy. The polypoid lesions were 
classified as simple tubular, mixed tubu­
lar and papillary, papillary, simple tubu­
lar with cancer, mixed with cancer, papil­
lary with cancer, or metaplastic. The 
metaplastic polyps are not believed to 
have the potential to degenerate into 
cancer, as opposed to the other polyps.
The charts of 448 patients with cancer 
from 1970 to 1979 were reviewed to iden­
tify the site of the cancer. Cancers within 
10 cm were considered reachable by digi­
tal examination. Those from 10 to 25 cm 
were potentially reached by the rigid sig­
moidoscope. Those in the sigmoid were 
potentially within reach of the flexible 
fiberoptic sigmoidoscope.
In 1979, a subset of 211 asymptomatic 
patients at the United States Capitol 
Colon and Rectal Clinic, Washington, 
DC, were evaluated by flexible fiberop­
tic sigmoidoscopy. Prospective data 
regarding level reached in the colon at
examination, time required for examina­
tion, numbers of lesions identified and 
patient preference were gathered. Patient 
preference is meaningful because all 
patients had previously undergone rigid 
sigmoidoscopy as part of an annual phys­
ical examination. Time was kept by a stop 
watch; as the scope touched the anus time 
began, and as the scope was withdrawn 
from the anus the watch was stopped.
Technique
The procedure is performed during an 
office visit. Two small enemas are given
as preparation. The patient is placed on 
the power table in the jackknife position 
but is not tilted into a head-down posi­
tion. No sedation is necessary. A two- 
glove technique is used, the outer glove 
being worn only for digital examination 
and introduction of the well-lubricated 
sigmoidoscope. As a matter of personal 
preference, the scope dial controls were 
taken out of the locked mode so that the 
tip would advance freely. The scope is 
gently pushed blindly up to the 5- to 
10-cm level. Under direct vision, the rec­
tum can be traversed to the 15- to 20-cm 
level easily. The right hand is used to
Table Ill-Colon and Rectal Cancers in 448 Patients, 
1970 to 1979
Level
Potential 
detection by No. (%|
Cumulative gain, 
no. (%)
0-10 cm Digit 92 (211 92 (21)
11-25 cm Rigid scope 78(17) 170 (38)
Sigmoid Flexible scope 99(22) 269(60)
Table IV—Level of Examination Achieved by 
Flexible Fiberoptic Sigmoidoscopy in 211 Patients
Level, cm No. (%|
Cumulative 
reach, %
10-19 0(0) 100
20-29 4(2) 100
30-39 14(6) 98
40-49 39(19) 92
50-59 86(41) 73
> 60 68(32) 32
Table V-Site of Neoplasms Found by Flexible Fiberoptic Sigmoidoscopy 
in Asymptomatic Patients
Series
No. of 
patients
Level, no. (%) Totals, 
no. (%)< 25 cm > 25 cm
Bohlman and associates, 19775 120 8 (6.6) 28(23.3) 36(30)
Lipshutz and associates, 1979® 200 — - - (9 .5 )
Marks and associates, 19797 203 9 (4.4) 16(7.8) 25(12.2)
Meyer and associates, 1979® 122 3 (2.4) 13(10.6) 16(13)
Wherry, 19819 417 38(9.1) 35(8.4) 73(17.5)
Present study 211 10(4) 18(8.0) 14(12)
Table II—Polyps of the Colon and Rectum in 499 Patients, 1974 to 1981
Polyp type
Tubular Mixed Papillary
with with with
Site Tubular carcinoma Mixed carcinoma Papillary carcinoma Metaplastic Totals
Rectum 109 8 32 17 16 5 12 259
Sigmoid 83 6 35 8 3 3 30 168
Descending colon 15 0 2 1 0 0 3 21
Splenic flexure 1 0 0 1 0 1 2 5
Transverse colon 5 0 2 1 1 0 0 9
Hepatic flexure 2 0 2 0 0 2 0 6
Ascending colon 10 0 1 2 3 0 2 18
Cecum 3 0 0 2 5 3 0 13
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grasp the sigmoidoscope shaft near the 
anus, to pull or push and to torque the 
shaft of the scope. When the tip must be 
deflected to find the correct direction up 
the bowel lumen, the right hand is moved 
to the dials. The left hand supports the 
scope head, and the fingers are automat­
ically in position to apply suction or 
insufflation. Often the left thumb, cra­
dling the scope head, is used to rotate a 
dial, leaving the right hand free to apply 
torque. Examination is performed as the 
scope is withdrawn. The examiner leans 
away from the patient, drawing the scope 
out slowly. With this extracting action, 
both hands are free for fine movements 
of the dials to inspect the bowel wall. 
Insufflation is important to flatten out
folds for more complete examination. 
Before the scope is removed, all air is suc­
tioned out to decrease distension and the 
feeling of bloating that the patient 
experiences.
Results
Of the 499 patients who had polyps 
removed at the National Naval Medical 
Center between 1974 and 1981, 390 had 
epithelial neoplasms (tubular, mixed or 
papillary) and 109 had metaplastic polyps 
(Table II). Because metaplastic polyps do 
not degenerate into cancers, our attention 
focused on the tubular and papillary 
polyps. Of these neoplasms, 187 (48%) 
were in the rectum and presumably could
T a b l e  V I — L e v e l  R e a c h e d  b y  F l e x ib le  F i b e r o p t i c  S i g m o i d o s c o p y
S e r i e s
N o .  o f  
p a t i e n t s
L e v e l ,  %
<  2 5  c m >  4 5  c m
B o h lm a n  a n d  a s s o c i a t e s ,  1 9 7 7 s 1 3 9 _ 5 0
M a n i e r ,  1 9 7 8 12 1 4 0 1 0 0 6 7
C r e s p i  a n d  a s s o c i a t e s ,  1 9 7 8 13 4 6 8 — 6 3
L a m b e r t  a n d  a s s o c i a t e s ,  1 9 7 8 14 3 0 0 9 5 5 0
M a r k s  a n d  a s s o c i a t e s ,  1 9 7 9 7 1 0 1 2 9 9 6 6
W i n a w e r  a n d  a s s o c i a t e s ,  1 9 7 9 15 1 0 8 9 4 4 6
W in n a n  a n d  a s s o c i a t e s ,  1 9 8 0 16 3 4 2 9 9 5 2
P r e s e n t  s t u d y 2 1 1 9 8 7 3
T a b l e  V I I - M e a n  L e v e l  R e a c h e d  b y  R ig id  S i g m o i d o s c o p y
N o .  o f M e a n  l e v e l ,
S e r i e s p a t i e n t s c m
B o h lm a n  a n d  a s s o c i a t e s ,  1 9 7 7 s 1 3 9 2 0 . 4
M a r k s  a n d  a s s o c i a t e s ,  1 9 7 9 7 1 0 1 2 2 0 . 0
W in n a n  a n d  a s s o c i a t e s ,  1 9 8 0 16 2 4 3 2 0 . 0
N i v a t v o n g s  a n d  F r y d ,  1 9 8 0 17 5 0 0  m e n > 2 0
5 0 0  w o m e n 1 8
T a b l e  V I I I — D e g r e e  o f  D i s c o m f o r t  C a u s e d  b y  
F l e x ib le  F i b e r o p t i c  S i g m o i d o s c o p y
P a i n ,  %
N o .  o f M in im a l  t o
S e r i e s p a t i e n t s N o n e m o d e r a t e S e v e r e
L a m b e r t  a n d  a s s o c i a t e s ,  1 9 7 8 14 3 0 0 - — 3 . 6
M a r k s  a n d  a s s o c i a t e s ,  1 9 7 9 7 1 0 1 2 - — 1 0 . 8
W in n a n  a n d  a s s o c i a t e s ,  1 9 8 0 16 3 4 2 - 8 0 . 0 2 0 . 0
T r a u l  a n d  a s s o c i a t e s ,  1 9 8 3 18 5 0 0 0 3 1 6 8 . 4 0 . 6
T a b l e  I X - T i m e  R e q u ir e d  f o r  F l e x i b l e  F i b e r o p t i c  S i g m o i d o s c o p y
N o .  o f M e a n  t im e .
S e r i e s p a t i e n t s m in
B o h lm a n  a n d  a s s o c i a t e s ,  1 9 7 7 s 1 3 9 9 . 4
C r e s p i  a n d  a s s o c i a t e s ,  1 9 7 8 13 4 6 8 6
L a m b e r t  a n d  a s s o c i a t e s ,  1 9 7 8 14 3 0 0 5 . 1 5
L i p s h u t z  a n d  a s s o c i a t e s ,  1 9 7 9 6 2 0 0 7 . 5
M a r k s  a n d  a s s o c i a t e s ,  1 9 7 9 7 1 0 1 2 5
P r e s e n t  s t u d y 2 1 1 4 . 9
be seen by the rigid sigmoidoscope. There 
were 138 (35%) in the sigmoid, which 
could have been reached by the flexible 
fiberoptic sigmoidoscope.
The retrospective review of the charts 
of 448 patients with colonic and rectal 
cancer seen between 1970 and 1979 re­
vealed that 92 (21%) of the tumours were 
within reach of digital examination, 170 
(38%) within reach of the rigid sigmoido­
scope and 269 (60%) within reach of the 
flexible sigmoidoscope (Table III).
Of the 211 asymptomatic patients at the 
United States Capitol Colon and Rectal 
Clinic who underwent flexible sigmoid­
oscopy, all were examined up to the 
25-cm level, which could be examined by 
the rigid sigmoidoscope (Table IV). 
Seventy-seven percent were examined to 
the 50-cm level and higher.
The average time required to complete 
flexible fiberoptic sigmoidoscopy was 4.9 
minutes (range from 3 to 10 minutes). The 
patient preference for rigid sigmoid­
oscopy was 38 (18%) and for flexible 
sigmoidoscopy 160 (76%); 13 (6%) had 
no preference. Twenty-eight of the 
asymptomatic patients had neoplasms. 
Only 10 of these were below the 25-cm 
level, within reach of the rigid sigmoido­
scope (Table V5'9).
Discussion
A longer sigmoidoscope for screening 
has become necessary, because the loca­
tion of cancers has gradually shifted to 
sites higher in the colon.10’11 Formerly, it 
was believed that the rigid sigmoidoscope 
would detect over half of the cancers, 
whereas today, that number is only one 
third. The sigmoid colon now accounts 
for 30% of colonic and rectal cancers, a 
rate that previously was only 13%. A 
review of the literature reveals that the 
distal 25 cm of the rectum and colon are 
examined with the flexible sigmoidoscope 
in over 94% of cases (Table v i 5,7-12'16). 
The 45- to 50-cm level is achieved in 46% 
to 79% of patients in the same series; that 
doubles or triples the length of bowel exa­
mined by the rigid sigmoidoscope.
The rigid sigmoidoscope has gained a 
reputation as a torture instrument. Sel­
dom is the full 25 cm of the rigid sig­
moidoscope inserted, because patient 
tolerance is poor. The mean level reached 
has been reported by several authors 
to be approximately 20 cm (Table 
yjj5,7,i6,i7) However, Nivatvongs and 
Fryd17 stated that the 20-cm level applies 
to men, the mean level reached in females 
being only 18 cm. A less painful proce­
dure will allow a better examination.
Several authors have described severe 
patient discomfort, requiring examination 
with the flexible fiberoptic sigmoidoscope 
to be stopped. Severely painful examina­
tions range from 0.6% to 20% (Table 
VIII7’14’16’18). This wide range reflects the
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difficulty in evaluating such a subjective 
complaint as pain. A review of the liter­
ature shows that the yield of neoplasms 
when screening asymptomatic patients 
with the longer, less-painful flexible sig­
moidoscope is about 12% (Table V). 
Many of the benign neoplasms are poten­
tial cancers that have been prevented by 
early detection and excision.
What is the cost in terms of time and 
money? As experience is gained, the 
endoscopist will be able to perform the 
procedure quicker. For inexperienced 
endoscopists, double the appointment 
time must be allotted so that eye-hand 
coordination can be practised and the 
frustration of racing the clock can be 
avoided. The literature suggests that when 
the endoscopist is familiar with the proce­
dure, the time required will average 5 to 
6 minutes (Table IX5'7'13'14).
The initial cost of equipment is over 
$2500 for a complete system, and if repair 
is required, costs are high. However, the 
flexible fiberoptic sigmoidoscopes have 
proved to be quite durable. Over 600 uses 
can be expected, and often up to 1000 
examinations can be performed before 
the equipment fails.
An additional cost is the need for an 
assistant to set up the scope, to help 
steady the scope during insertion and to 
clean it.
The fee for flexible fiberoptic sig­
moidoscopy, as for other procedures, 
varies around the United States. It is 
usually two to three times the cost of sig­
moidoscopy with a rigid scope. Double 
the cost of sigmoidoscopy is reasonable, 
because twice as much bowel is examined, 
twice as many lesions are found, twice as 
much time is required and perhaps twice 
the risk is incurred.
Complications have been rare. Hemor­
rhage and perforation are the major pos­
sible complications. Hemorrhage occurs 
more easily in the presence of existing dis­
ease with friable mucosa. Stretching a 
loop of sigmoid can result in splitting the 
bowel wall, causing hemorrhage or per­
foration. This is prevented by avoiding 
force on the scope. The culprit is often 
the slide-by technique, which everyone 
uses to some degree. This technique 
results in entrapment of the tip against the 
bowel wall, which is recognized as a “ red 
out” by the endoscopist. Continued push­
ing may cause a perforation. Such con­
ditions as acute inflammatory bowel dis­
ease and radiated or ischemic bowel cause 
an abnormally weak colonic wall, and 
very gentle handling of the scope is neces­
sary. Fixed points in the sigmoid, such as 
adhesions from previous pelvic surgery, 
may tear easily.
The flexible sigmoidoscope is a diag­
nostic instrument. Polypectomy should 
not be attempted without complete bowel 
preparation, as for colonoscopy, because 
explosive gases such as methane and
hydrogen may be present and may 
explode if a spark is generated.
The flexible fiberoptic sigmoidoscope 
is not a substitute for the barium enema 
or colonoscope. When a patient has 
symptoms referable to the colon or is in 
a high-risk group of persons, such as 
those with polyposis syndromes or 
chronic ulcerative colitis or having a 
family history of cancer, complete exami­
nation of the colon is indicated.
The ideal candidate for flexible 
fiberoptic sigmoidoscopy as an office 
screening procedure is the asymptomatic 
person over 40 years of age who is not 
expected to need colonoscopy.
I thank Lisa D. Miller, my research techni­
cian, for compiling the data on cancers and 
polyps.
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Chairman: P. Belliveau , m d , frcsc*
Panelists: Z. Co h en , P .H . Go rdon , E .P . Salvati, L .E . Smith
Dr. Belliveau: I would like to thank the 
speakers for their excellent presentations 
and would welcome questions from the 
audience. While we are waiting, I would 
ask Dr. Cohen, who spoke on alternatives 
to hemorrhoidectomy, to tell us if he 
would consider banding in cases of acute, 
thrombosed, internal hemorrhoids.
Dr. Cohen: In such a case, I would be 
conservative and would not use rubber 
banding on the patient.
Question: When performing left internal 
sphincterotomy, do you do anything 
about the sentinel tag and the hyper­
trophied papilla that we see in chronic 
fissure in ano?
Dr. Gordon: For the most part I don’t. 
I don’t believe that it is necessary for heal­
ing of the fissure to excise the hyper­
trophied anal papilla or the sentinel pile. 
Occasionally if a patient has a very large 
pile and complains that it is pushing out 
and is very bothersome, I may excise it, 
but in terms of the procedure being neces­
sary to heal a fissure, no. I don’t remem­
ber the exact number, but 1 don’t think 
that in my 133 cases, I performed more 
than six such excisions.
Question: Dr. Salvati, first, what do you 
do with the chronically unhealed piloni­
dal wound, especially one that is deep in 
the interanal cleft near the anal verge? 
Then a question for Dr. Cohen: I noticed 
on your slides that you band the hemor­
rhoid directly and I wonder how many of 
the members of the panel actually band 
the hemorrhoid or include the prolapsing 
tissue and the mucosa above the hemor­
rhoid.
Dr. Salvati: I think we all have problems
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5. Panel Discussion
with unhealed wounds, particularly if 
they have been operated on a couple of 
times. Most of these wounds will heal if 
you are persistent and see that, first, you 
make the wound flat, second, that you 
have the patient use a Water Pik to keep 
the wound really clean and third, that you 
see them every week to shave the hair 
back. If you pay close attention to these 
points, you can eventually get the sinus 
healed. The technique described by 
Rosenberg of reverse strapping helps 
occasionally. To reverse strap the but­
tocks is to open the buttocks up. This will 
sometimes help in difficult cases.
Dr. Cohen: To answer your question, yes, 
I agree with you. I usually would try to 
get the upper portion of the hemorrhoid 
and the prolapsing tissue above it. 
Question: May I ask the panel if anyone 
uses a topical agent, such as Preparation 
H, on the symptomatic hemorrhoid? 
Dr. Salvati: No, if you are talking about 
symptomatic hemorrhoids. Most of the 
symptomatic hemorrhoids that we see are 
thrombosed externally. For every patient 
with bleeding and protrusion there are 
many more with thrombosed exter­
nal hemorrhoids. We ought to point out 
that the classification Dr. Cohen gave us 
is for internal hemorrhoids, which don’t 
cause pain unless they are irreducibly 
prolapsed. They give rise to bleeding and 
protrusion; pain from hemorrhoidal dis­
ease comes from thrombosed external 
hemorrhoids and they must be excised. 
Question: 1 sometimes have difficulty 
with patient compliance when I advise a 
high-fibre diet and I would like to poll the 
panel and ask them (a) what do they tell 
their patients and advise them to eat and 
(b) how do they maintain them?
Dr. Cohen: First, I think it is important 
to have some kind of dietary regimen to 
give the patient and instructions about 
various foods. If the patient has any 
problem understanding what we are try­
ing to say, we send them to our dietician 
who works quite closely with us. She will 
follow them up usually by seeing them 
every week for the first few weeks to 
ensure that they have adhered to their 
diet. I see them within 3 or 4 weeks to 
assess their progress, and 1 think by fre­
quent follow-up you can maintain that
person not only on high-fibre diet but on 
stool softeners if indicated.
Dr. Salvati: If you wish to give the patient 
a high-fibre diet for hemorrhoids and af­
ter 6 months or a year those hemorrhoids 
are still bleeding, they will continue to 
bleed. You can only keep them asympto­
matic just so long; then they will give 
trouble and you will have to either ligate 
or inject them. If you prescribe a high- 
fibre diet for constipation, you can moti­
vate the patient just a little bit better. 
Searle puts out a booklet of high-fibre 
items that the patient should eat and you 
can generally motivate them properly, but 
it’s not easy.
Dr. Gordon: I had a dietician list a whole 
series of foods and explain how much 
fibre there was in each food in the 
categories of various cereals (bran being 
the best), fruits and vegetables, so that the 
patients, by the end of the day, would 
have an idea of how much fibre they were 
consuming, depending upon what they 
had eaten from each category. This didn’t 
confine the patients to any one food or 
any one category of foods but it gave 
them an idea of which foods were highest 
in fibre and I think that this has been 
quite helpful.
Dr. Smith: In general, I tell the patient 
to go to a health-food store and buy raw 
unmilled bran. It costs about a dollar a 
pound. It’s about the cheapest thing you 
can buy. It isn’t really tasty, but they must 
try to disguise it — add it to soups, to 
salads, to yoghurt, add milk and sugar, 
fruit, be innovative. They should use a 
third of a cup a day, measure it out in the 
morning and by the end of the day it 
should be finished.
Dr. Belliveau: Dr. Gordon, if you do a 
lateral sphincterotomy in the office, first 
of all, I suppose, you don’t put any pack­
ing in?
Dr. Gordon: None at all.
Dr. Belliveau: And what do you tell your 
patients to do in the first 2 days if they 
have pain?
Dr. Gordon: I suggest they take sitz 
baths. Warm baths are helpful. I 
prescribe a nonconstipating agent, that is 
to say one that doesn’t have codeine in 
it. Most of the pain is on the first day; 
after that, there really is not a lot of dis-
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comfort. In fact, some patients who have 
had a lot of problems with the fissure will 
say that even their first bowel movement 
after the operation hurt them less than 
having the fissure itself.
Dr. Belliveau: Panelists, what do you do 
if you have a patient who has a fissure 
associated with hemorrhoids? Do you still 
do your sphincterotomy in the office or 
would you suggest something else?
Dr. Smith: Well, everyone has hemor­
rhoids, it’s just a question of whether they 
are symptomatic or not. I don’t do any­
thing if they aren’t symptomatic. Depend­
ing on the degree of prolapse of the inter­
nal hemorrhoids, I will band some 
subsequently or, if they are what I call 
third degree hemorrhoids that require 
manual reduction, I will do a hemor­
rhoidectomy at the same time.
Dr. Salvati: I believe that if you have a 
third degree hemorrhoid and a fissure, 
then you should operate on that particu­
lar patient because of what Dr. Gordon 
has pointed out. After all, if a patient 
comes to you in pain and you do a lateral 
sphincterotomy and all the hemorrhoids 
prolapse, you are going to end up oper­
ating anyhow, so you are far better off 
doing the hemorrhoidectomy for the third 
and fourth degree hemorrhoids and the 
lateral sphincterotomy at the same time. 
Dr. Cohen: I agree with that, if you have
an active fissure and third or fourth 
degree hemorrhoidal disease.
Question: Dr. Salvati, is there any place 
left for primary excision of pilonidal dis­
ease? And, secondly, when do you oper­
ate on a mass as was shown with the 
acutely prolapsed, thrombosed hemor­
rhoid?
Dr. Salvati: I really don’t see any indica­
tion for primary excision and closure. 
That requires generally a week of 
hospitalization. It’s just too costly and the 
recurrence rate is high. As far as treating 
the acute hemorrhoidal prolapse, we 
described a method a number of years ago 
in which, if you add 1 mL of hyaluroni- 
dase to 10 mL of marcaine or lidocaine, 
and inject it directly into the edematous 
mass, you can reduce the internal hemor­
rhoids within 30 or 40 seconds; then you 
must excise any external components that 
are thrombosed. Then you can do multi­
ple internal hemorrhoidal ligations, two, 
three or four at the same sitting, so you 
can very easily treat acute hemorrhoidal 
disease (i.e., prolapsed, thrombosed, gan­
grenous hemorrhoids) as an office proce­
dure. We do it all the time.
Dr. Belliveau: I would like to summarize 
briefly what was said this morning. It 
seems that pilonidal disease can be treated 
in the office by a simple laying-open 
procedure under local anesthesia. Lateral
internal sphincterotomy should replace 
anal dilatation for the treatment of anal 
fissure and that also can be done in the 
office. As alternatives to hemorrhoidec­
tomy, rubber-band ligation seems to be 
faring the best and may be followed by 
injection sclerotherapy. Finally, flexible 
sigmoidoscopy seems to be something to 
be explored. I don’t think it’s the recom­
mendation of Dr. Smith that we should 
all run out and buy one; the rigid scope 
still has a role to play, but if you are 
screening asymptomatic patients, you 
should consider adding this to your 
armamentarium. I would like to thank the 
panel and the audience for their partici­
pation.
In the Next Issue
The July 1985 issue of the Journal will con­
tain a number of papers presented at the 
1984 annual meeting of the Canadian 
Cardiovascular Society and at the 1984 an­
nual meeting of the Canadian Association 
of General Surgeons. Also included will be 
two papers (one on the management of 
pancreatic trauma and the other a report 
from a community hospital on fatal sepsis 
after splenectomy) originating from the 
1984 annual meeting of the Trauma As­
sociation of Canada.
The Canadian Association of General Surgeons wishes to announce the following postgraduate courses, to be held dur­
ing the 1985 meeting of the Royal College of Surgeons, Vancouver, British Columbia.
Sunday, September 8, 1985 
SURGICAL ENDOSCOPY
Course Chairman — Roger Keith, Toronto 
(416) 480-4736
********************************************
Monday, September 9, 1985 
PERIPHERAL VASCULAR SURGERY
Course Chairman — Wallace Chung, Vancouver 
(604) 228-7219
********************************************
Registration: Delegates — $125; Residents — $75
For further information contact:
THE ROYAL COLLEGE OF PHYSICIANS AND SURGEONS
74 Stanley Street 
Ottawa K1M 1P4
********************************************************************************
C.A.G.S. will sponsor additional symposia from September 10 — 12 inclusive, in association with the Royal Australasian Col­
lege of Surgeons:
Unexpected Findings at Laparotomy
Skin Cancer — The Royal Australasian College of Surgeons 
Surgical Infections
Problems for the Community Surgeon 
Alternatives to Conventional Ileostomy 
Management of Intra-Oral Malignancies 
Transplantation — An Overview 
Surgical Nutrition 
3 Paper Sessions
Registration: No Charge
For further information contact the C.A.G.S. Program Co-Chairmen:
Joel B. Freeman, M.D., Ottawa (416) 595-4952 until June 30 — (613) 737-8537 after June 30, 1985 
J. Trevor Sandy, M.D., Vancouver (604) 876-2268
The final C.A.G.S. program will be mailed to all C.A.G.S. members in May 1985.
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herpesvirus-specified DNA polymerase. Acyclovir is preferentially taken up and selectively 
converted to its active form by herpesvirus-infected cells. Thus, acyclovir has a very much lower 
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tion of pain in cutaneous herpes infections in immunocompromised patients. For example, 
61% of ZOVIRAX-treated immunocompromised patients were pain-free by day 10, whereas 
44% of placebo-treated patients were pain-free in the same period of time.
Whereas cutaneous lesions associated with herpes simplex infections are often pathogno­
monic, Tzanck smears prepared from lesion exudate or scrapings may assist in diagnosis. 
Positive cultures for herpes simplex virus offer the only absolute means for confirmation of 
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CONTRAINDICATIONS
ZOVIRAX Sterile Powder is contraindicated for patients who develop hypersensitivity to 
the drug.
WARNINGS
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Symposium: Breast Cancer 1984, Precancerous 
and High-Risk Lesions
Introduction
Every surgeon has, at some time, encoun­
tered the clinical problem of a small focus 
of abnormal, possibly precancerous tis­
sue in a breast biopsy specimen that con­
tains mainly benign fibrocystic disease. 
These foci may be atypical hyperplasia, 
lobular carcinoma in situ or intraductal 
carcinoma. Traditionally, these diagnoses 
are considered together and, until 
recently, were treated quite aggressively 
by surgical management.
The proper management of these 
lesions is now questioned, especially 
because of the evolving pattern of sur­
gical treatment for frank, invasive car­
cinoma. There has been a trend, based on 
ongoing scientific evaluation, to abandon
the more radical operations and move 
through a series of steps from radical 
mastectomy to modified radical mastec­
tomy to partial mastectomy for local con­
trol of the breast tumour.
If, as may appear, partial mastectomy 
is equivalent to total mastectomy for a 
carcinoma, is it appropriate to consider 
total mastectomy for precancerous 
lesions?
In the symposium that follows, input 
has been sought from epidemiology, 
pathology and surgery. While there may 
be some overlap in the statistics cited, the 
differences in interpretation and in 
recommendations will be largely because 
our data base is not sufficiently complete
for us to draw definitive conclusions. 
Therefore, the material presented here is 
offered not as guidelines for clinical 
management but as thoughtful and logi­
cal appraisals of the available knowledge, 
to help clinicians work towards better 
patient management.
R ich a rd  G. M a r g o lese , m d , frcsc
Symposium chairman
Department of Surgery,
Sir Mortimer B. Davis- 
Jewish General Hospital, 
Montreal, PQ 
H3T 1E2
M a rtin  T. Sc h e c h t e r , m d , m sc , ph  d
1. Breast Cancer Risk Factors:
Can We Select Women for Prophylactic Mastectomy?
Prophylactic procedures to prevent dis­
ease in women at high risk for breast 
cancer should be considered only when 
the benefits of prophylaxis outweigh its 
costs. The rational prophylactic use of 
mastectomy in these circumstances must 
await answers to several questions.
First, accurate estimates of the true risk
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associated with these lesions must be 
obtained, as current estimates are impre­
cise and potentially biased. Second, large 
ongoing trials of breast cancer screening 
and treatment may provide effective 
methods of distinguishing those women 
at exceptionally high risk in whom such 
procedures may be warranted. Finally, 
the question of conservative surgery as 
an acceptable treatment for breast 
cancer must be settled; otherwise, the 
prophylactic procedure may be more 
invasive and disfiguring than the treat­
ment of the disease it seeks to prevent.
Les interventions prophylactiques desti- 
nees a prevenir le cancer du sein chez 
les femmes a haut risque ne devrait etre 
envisagees que quand les benefices 
escomptes I'emportent sur les couts. 
[.'utilisation raisonnable de la mastecto- 
mie prophylactique dans ces circonstan- 
ces doit attendre les reponses & plusieurs 
questions. Tout d'abord, il faudra etablir 
une evaluation precise des risques reels 
rattaches a ces lesions puisque les esti­
mations actuelles sont imprecises et pos- 
siblement partiaies. En second lieu, les 
importants essais cliniques sur le depis- 
tage et le traitement du cancer du sein 
feront peut-etre ressortir des methodes 
efficaces permettant d'identifier les fem­
mes a risque exceptionnellement eleve 
chez qui de telles interventions pour- 
raient etre justifiees. Finalement, on 
devra regler la question de la chirurgie 
conservatrice comme traitement accepta­
ble du cancer du sein; autrement, I'inter- 
vention prophylactique est possiblement 
plus invasive et mutilante que le traite­
ment de la maladie qu'elle cherche a pre­
venir.
There are several different aspects to the 
selection of women who are at high risk 
for breast cancer. One question is which 
women are at highest risk? It is perhaps 
on these women that preventive and 
health-promotion measures could be con­
centrated for optimum results.
A second question pertains to issues in 
screening; which women are the most
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likely to have a breast cancer detected on 
screening? If a strategy for identifying 
such women was available, then the 
resources for screening as well as the haz­
ards of annual mammography could be 
concentrated only on the identified sub­
group of women at high risk. This would 
make better use of resources, lower the 
screening-related risk and, most impor­
tant, annual screening would be more 
widely accepted by healthy women and 
physicians.
Finally, a third related question is 
raised by this symposium. Which of the 
women with certain “ precancerous” 
lesions are at highest risk of subsequently 
having invasive carcinoma? Can we 
accurately estimate the risk in individual 
patients so as to guide our management 
better? Clearly, accurate estimates of risk 
are necessary if we are to make intelligent 
decisions regarding the use of such proce­
dures as prophylactic mastectomy.
For purposes of review, let us recall 
some of the characteristics necessary for 
successful surgical prophylactic proce­
dures, such as prophylactic mastectomy 
or colectomy. First, the prophylactic 
maneuver should effectively prevent the 
disease. Second, the population at high 
risk should be easily identifiable. Third, 
the benefit of the prophylactic maneuver 
should outweigh its cost in this high-risk 
population.
Here, benefit and cost should be viewed 
in their wider sense. Benefit refers to both 
financial and health benefits, including 
any morbidity and mortality avoided by
prophylaxis, while costs refer to both 
financial and health cost, including any 
morbidity and mortality, anxiety, label­
ling effects, and so on, caused by the 
maneuver.
Clearly, the more successful we are at 
identifying the high-risk population, the 
more likely it is that the cost-benefit equa­
tion will be satisfied. This can be seen 
most readily by the radical proposal that 
all women undergo prophylactic mastec­
tomy at the age of 30 years. This would 
do wonders for breast cancer mortality in 
our society but clearly cost would far out­
weigh benefit.
It is also critical to remember that it is 
the psychological and emotional profile 
of the individual woman that decides the 
utilities that are to be assigned to the var­
ious management options. There are 
patients who, for various reasons, will 
choose to avoid mastectomy at all costs 
no matter what the risk of subsequent 
cancer is, while others find greater benefit 
in eliminating the continuous anxiety and 
fear associated with repeated biopsies.
Selection
With regard to selection strategies, I 
would like to make three key points. First, 
I would emphasize that the etiology of 
breast cancer is exceptionally complex, 
representing a poorly understood inter­
play of reproductive, hormonal, genetic 
and environmental factors. Second, most 
risk factors have modest etiologic force; 
that is, their relative risks are modest, in
the neighbourhood of two to five times 
the normal, and it is their combination 
that determines overall risk. Haagensen1 
called this the “ cumulative predisposi­
tion” . Unlike cigarette smoking and its 
relation to lung cancer, there is no 
individual risk factor for breast cancer 
that is so highly culpable. Third, simplis­
tic approaches to selecting women at high 
risk will not suffice; that is, simple 
approaches to risk-factor information will 
provide only simple answers and, given 
the complexity of breast cancer, these will 
probably not be satisfactory.
Family History
An excellent example of the insight 
gained from a more complex analysis con­
cerns the question of family history. Con­
sider the example of a 31-year-old woman 
whose mother and three maternal aunts 
all have breast cancer. The question of 
prophylactic mastectomy is raised. To 
begin with, the overall cumulative lifetime 
risk for the average 31-year-old woman 
has been estimated to be about 7% to 
8%.2 The simple approach in the past in 
considering family history has been to 
assign an overall relative risk, usually 
around two, to women with a family his­
tory of breast cancer. The cumulative life­
time risk would therefore be around 15% 
for such a woman. If we add some com­
plexity, however, we find that the risk 
differs if the familial cancer was unilateral 
or bilateral and if it occurred before or 
after the menopause (Table I).3 If the 
familial cancer is premenopausal and 
bilateral, the relative risk is estimated to 
be almost nine and the cumulative risk is 
45%. On the other hand, if the familial 
cancer is postmenopausal and unilateral, 
which represents most familial cancers, 
there is virtually no increase in risk at all. 
The same holds true for multiple familial 
cancer. If two sisters have premenopausal 
bilateral breast cancer, the cumulative risk 
for another sister is estimated to be about 
50%. But if the sisters both have post­
menopausal, unilateral disease, there is 
again virtually no increase in risk.
Returning to our example, we find that 
all of our patient’s familial cancers were 
in fact unilateral and postmenopausal. 
From these data, she appears to be at very 
little, if any, increased risk of breast 
cancer. This is so despite what appears to 
be at first glance an extremely strong 
family history.
What has occurred here is that a risk 
factor, in this case family history, has 
been found to interact with menopausal 
status and laterality. As a result, instead 
of implicating family history to a mild 
degree in all women with family histories, 
the risk can be concentrated on the 
extremely small number of women with 
familial histories of premenopausal, 
bilateral disease, and the majority of
T a b le  1— R is k  to  F irs t  D e g re e  R e la t iv e  b y  
M e n o p a u s a l S ta t u s  a n d  L a t e r a l i t y  o f  F a m ilia l C a n c e r *
T im e U n ila te r a l B ila te ra l
P r e m e n o p a u s e 1 . 8 1 ( 1 0 % * ) 8 . 8  ( 4 5 % )
P o s tm e n o p a u s e 1 . 2 ( 7 % ) 4 . 0  ( 2 0 % )
'A d a p t e d  f r o m  K e lly  P T  a n d  A n d e rs o n  D E .3 
t  R e la t iv e  r is k .
^ C u m u la t iv e  r is k .
T a b le  I I — R is k  F a c to rs  fo r  B r e a s t  C a n c e r  in  W o m e n
R is k
R e la t iv e
F a c to r H ig h L o w ris k
A g e O ld  a g e Y o u n g  a g e > 4 . 0
A g e  a t  f i r s t  b ir th > 3 0  y r < 2 0  y r 2 . 0 - 4 . 0
O o p h o re c to m y N o Y es 2 . 0 - 4 . 0
B o d y  b u ild O b e s e T h in 2 . 0 - 4 . 0
A g e  a t  m e n a rc h e E a r ly L a te 1 . 1 - 1 . 9
A g e  a t  m e n o p a u s e
F a m ily  h is to r y  o f  p re m e n o p a u s a l b i la te ra l
L a te E a r ly 1 . 1 - 1 . 9
b r e a s t  c a n c e r Y e s N o > 4 . 0
H is to r y  o f  c a n c e r  in  o n e  b re a s t Y e s N o > 4 . 0
H is to r y  o f  f ib r o c y s t ic  d is e a s e Y es N o 2 . 0 - 4 . 0
A n y  f i r s t -d e g r e e  re la t iv e  w i t h  b r e a s t  c a n c e r Y es N o 2 . 0 - 4 . 0
H is to r y  o f  p r im a ry  c a n c e r  in  o v a ry  o r  e n d o m e tr iu m Y es N o 2 . 0 - 4 . 0
R a d ia t io n  t o  c h e s t L a rg e  d o s e s M in im a l  e x p o s u re 2 . 0 - 4 . 0
'A d a p t e d  f r o m  K e ls e y  J L .4
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women with family histories, that is those 
with familial histories of postmenopausal 
unilateral disease, are exonerated.
Risk Factors
There seem to be many risk factors for 
breast cancer: increasing age, premeno­
pausal bilateral breast cancer in a first- 
degree relative, a history of breast cancer 
in the contralateral breast and certain 
precancerous or high-risk lesions are as­
sociated with the largest relative risks. 
Late age at first live birth, early age at 
menarche, late age at menopause, a his­
tory of fibrocystic disease, low parity, 
radiation to the chest and obesity have 
also been implicated (Table II4). In addi­
tion, there are the emerging questions sur­
rounding the role of dietary fat consump­
tion, the possible role of smoking and a 
possible positive effect of long-term use 
of oral contraceptives in young women.
On another level, various pathological 
diagnoses may be predictors. With regard 
to fibrocystic disease, the specific diag­
noses that are thought to be associated 
with subsequent breast cancer are atypi­
cal epithelial hyperplasia, atypical lobu­
lar hyperplasia and diffuse papillomato­
sis with atypia. However, it is important 
to point out that the elevated risks 
associated with these diagnoses have not 
been demonstrated consistently and that 
if such elevations exist, they are likely 
only to be in the neighbourhood of a two- 
to fourfold increase. Clearly, this would 
not justify a consideration of prophylac­
tic mastectomy.
High-Risk Lesions
To approach the question of high-risk 
lesions, consider the example of a 42-year- 
old premenopausal woman with three 
children, whose first child was born when 
she was 21 years of age, whose menarche 
was at 14 years and who has just had 
lobular carcinoma in situ found on breast 
biopsy. Clearly, the question of manage­
ment for this patient depends on the 
underlying question of whether invasive 
breast cancer will develop. We know that 
this woman has a high-risk lesion and car­
ries an increased risk of breast cancer 
developing, but exactly how high is this 
risk?
Data from past studies5 suggest she 
has about a 35% chance of having inva­
sive cancer within 20 years. Is the increase 
in risk from 7% to 35% sufficient cause 
to consider prophylactic mastectomy in 
this patient? This study5 was retrospec­
tive so that there are problems with the 
cohort of women assembled for follow­
up. For example, the age ranged from 27 
to 55 years so it is difficult to know how 
to apply the results to any given age 
group. The most glaring deficiency is that 
only 50 patients were considered in this
study. The use of such small numbers 
results in a lack of statistical precision. 
The key estimate of 35%, for example, 
was based on only nine cases. In this 
study, 31 women were lost to follow-up 
so that after 10 years, only 15 women 
were being followed up. If one were to 
put 95% confidence limits around the 
estimates, one would obtain a range of 
from 12% to 57% for the average 20-year 
risk of invasive carcinoma. The lower end 
of this range is not much higher than the 
8% cumulative risk applicable to the 
general population. The results are fur­
ther confounded by the fact that in 45 of 
the 50 women biopsies were done because 
of the clinical presence of fibrocystic dis­
ease. Many of these criticisms hold as well 
for most other studies in this area. Fur­
thermore, we have no data on the 
influence of other risk factors such as age 
at first live birth, age at menarche, and 
so on, and how these risks might be modi­
fied. These data certainly suggest that 
women with lobular carcinoma in situ are 
at elevated risk for invasive breast cancer, 
but precise estimates of how high the risk 
is are lacking. However, ongoing clinical 
trials of breast cancer screening and of 
breast cancer therapies may provide more 
sound estimates in the future.
If we accept these estimates, then of 
100 women like our patient, 35 or so will 
suffer invasive cancer within 20 years. 
Just as a half-full glass is also half-empty, 
it is important to note that 65 of those 
women will not have invasive carcinoma. 
These constitute a fascinating group of 
women who have a known precursor and 
yet, perhaps for hormonal, dietary, 
reproductive or genetic reasons, invasive 
disease does not develop. An analysis of 
the factors that protect these women 
could be important to our understanding 
of breast cancer etiology.
Even among the unfortunate women 
with lobular carcinoma in situ who sub­
sequently have invasive cancer, the evi­
dence suggests that the invasive cancer is 
just as likely to occur in the contralateral 
as in the ipsilateral breast. Moreover, the 
invasive cancer that develops is more 
likely to be intraductal than lobular and 
is unlikely to be in the same site as the 
original lesion. These facts suggest that 
the hypothesis that the lobular carcinoma 
in situ progresses in a stepwise fashion to 
become the invasive cancer, is untenable. 
More reasonable is the hypothesis that 
lobular carcinoma in situ is a marker for 
women at high risk, in much the same 
way as a history of premenopausal 
bilateral breast cancer in a first-degree 
relative is.
Conclusions
Lobular Carcinoma in Situ
From these observations, there appear
to be some logical conclusions. First, 
since both breasts are at equal risk, the 
management of the contralateral breast 
should be identical to that of the 
ipsilateral one. Second, since lobular car­
cinoma in situ should be viewed as a risk 
factor or marker and not as a precursor, 
any management policy for this lesion 
should be applied as well to any risk fac­
tor of equal magnitude, such as pre­
menopausal bilateral breast cancer in a 
first-degree relative. Since the risk of sub­
sequent invasive cancer in women with 
such a family history has been estimated 
to be approximately of the same magni­
tude as the risk for women with lobular 
carcinoma in situ, then the management 
policy for each of these situations should 
be the same.
Does it logically follow from this that 
a policy of bilateral mastectomy is justi­
fied for lobular carcinoma in situ or any 
other risk factor of equal magnitude? 
Given the paucity of data and our current 
inability accurately to assess risk, I do not 
believe that such a policy can be justified.
Intraductal Carcinoma
The situation with regard to intraduc­
tal carcinoma may be clearer. This is not 
because the estimates of risk are any 
sounder than for lobular carcinoma in 
situ, since again the numbers of patients 
followed in studies are woefully inade­
quate. What is clearer is the observation 
that subsequent invasive cancer, when it 
occurs, tends to do so in the ipsilateral 
breast only and the histologic type of the 
subsequent cancer is usually ductal. These 
observations support the hypothesis that 
intraductal carcinoma is a precursor 
lesion with malignant potential. For these 
reasons, prophylactic mastectomy has 
been far less controversial as treatment 
for intraductal carcinoma than it has been 
for lobular carcinoma in situ. However, 
it is important to note that our knowledge 
of the true risk associated with intraduc­
tal lesions is imprecise. The methodologic 
problems cited earlier apply also to the 
follow-up studies of women with this type 
of lesion. There is evidence to suggest that 
in a significant proportion of women with 
intraductal cancer, the disease does not 
progress to invasive cancer.6
Prophylactic Mastectomy
Policies concerning prophylactic 
mastectomy become even more difficult 
in the light of recent changes in our atti­
tude concerning the primary therapy of 
breast cancer. If the recent trend towards 
more breast-conserving surgery such as 
lumpectomy continues, it may very well 
violate the cost-benefit equation to advo­
cate a prophylactic procedure that is far 
more aggressive and disfiguring than the 
eventual therapy of the disease that the
244 VOLUME 28, NO. 3, M A Y  1985 /  THE CANADIAN JOURNAL OF SURGERY
ADMINISTRATION
Intramuscular:
CEFOBID (cefoperazone sodium) should be administered by deep intramuscular injection into a large 
muscle mass such as the gluteus maximus or anterior thigh. The maximum dose of CEFOBID 
(cefoperazone sodium) should be two (2) grams.
Intravenous:
Direct Intravenous (bolus) Injection: The reconstituted solution should be injected slowly over a 
period of no less than three (3) minutes. The maximum dose of CEFOBID (cefoperazone sodium) 
should be two (2) grams.
Intermittent Intravenous Infusion: The reconstituted solution may be infused over a period of 15 
minutes to 1 hour through the tubing of an administration set while any of the intravenous solutions 
(See Solutions for I.V. Infusion) are being infused. During infusion of the solution containing 
CEFOBID (cefoperazone sodium), it is desirable to temporarily discontinue administration of the other 
solution.
Continuous Intravenous Infusion: CEFOBID (cefoperazone sodium) may also be administered over a 
longer period of time.
Note: If therapy with CEFOBID (cefoperazone sodium) is carried out in combination with an 
aminoglycoside antibiotic, each should be administered at different sites because of a physical in­
compatibility. An aminoglycoside should not be mixed with CEFOBID (cefoperazone sodium) in the 
same container.
PHARMACEUTICAL INFORMATION
CHEMISTRY
Trade Name: CEFOBID
Proper Name: Cefoperazone sodium
Chemical Name:
Sodium (6R,7R)-7-[(R)-2-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-2-(p-hydroxyphenyl) 
acetamido)-3 f[(1 -methyl- 1H-tetrazol-5-yl)thio]methyll-8-oxo-5-thia-1-azabicyclo(4.2.0] 
oct-2-ene-2-caiboxylate 1
N-----N
ch2sA n. n
ch3
Molecular Formula: C25H26Ng0gS2Na Molecular Weight: 667.65 
Description:
Cefoperazone sodium is a white powder, soluble in water, sparingly soluble in methanol, poorly soluble
in ethanol, and insoluble in ethyl ether, acetone, chloroform, or n-hexane
Composition:
CEFOBID vials contain cefoperazone sodium (expressed in terms of free acid). The sodium content of 
each gram of CEFOBID is approximately 34 mg (1.5 mEq sodium ion). The pH of a 25% (w /v ) solution 
is 4.5 to 6.5 and the solution is colorless to straw yellow depending on the concentration.
prophylactic procedure seeks to prevent.
The only way prophylactic mastectomy 
might be applied rationally is if more 
exact estimates of risk of subsequent inva­
sive cancer in women with these lesions 
were available and if methods were deve­
loped for identifying those women with 
such lesions who are at exceptionally high 
risk. Such methods are not yet available. 
The National Breast Screening Study o f  
Canada,7 a randomized controlled trial 
currently being conducted across Canada, 
is recruiting 90 000 women to assess the 
benefits o f annual screening. Using data 
from this study and a multivariate 
biostatistical technique known as logistic 
discriminant analysis, we were able to 
combine risk factors such as age at first 
live birth and family history, to discern 
women at high risk. These methods 
allowed us to identify 40% o f the popu­
lation in whom 85% o f all breast cancers 
occur. It is hoped that prospective data 
arising from this study as well as from 
ongoing clinical trials o f breast cancer 
therapy will provide more accurate esti­
mates o f risk for women with high-risk 
lesions and similar discriminants to iden-
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tify women at exceptionally high risk for 
whom prophylactic procedures may be 
warranted. Such discriminants may be 
complex, combining the risk-factor infor­
mation and histopathologic features of 
the original lesion. It is conceivable that 
methods will exist for selecting out o f all 
women with lobular carcinoma in situ, 
40% to 50% in whom most o f the inva­
sive cancers will occur. The cumulative 
risk in such women might approach 70% 
or beyond so that a prophylactic interven­
tion could be more easily justified. 
Moreover, it would reduce the number of 
women considered for prophylaxis by 
50% or more. Until these methods exist, 
however, and until the question o f breast 
conservation as an acceptable therapy for 
invasive cancer is settled, I do not believe 
there is sound epidemiologic evidence to 
support an overall policy o f prophylac­
tic mastectomy.
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2. Definition of Precancerous and 
High-Risk Mammary Lesions
Intraepithelial (noninvasive) neoplasia of 
breast, the most potent precursor of 
invasive carcinoma, comprises two 
types: lobular carcinoma in situ and duc­
tal carcinoma in situ. Their respective 
morphologic character, biologic sig­
nificance and natural history are dis­
cussed. Borderline lesions, such as atypi­
cal lobular hyperplasia and atypical 
ductal hyperplasia, are defined and their 
importance as risk factors for subse­
quent carcinoma is emphasized. Analysis 
of the concept of fibrocystic disease 
recognizes a lack of both pathologic 
specificity and predictive value as a risk 
factor for malignant disease. Rather than 
referring to fibrocystic disease, this com­
plex should be stratified in specific histo­
logic types to understand better its bio­
logic significance.
Les neoplasies intraepitheliales (non inva- 
sives) du sein, qui representent les plus 
serieux precurseurs d'un carcinome inva- 
sif, sont de deux types: les carcinomes 
lobulaires in situ et les carcinomes cana- 
liculaires in situ. On commente leurs 
caracteres morphologiques respectifs, 
leur importance biolologique et leur his- 
toire naturelle. Les cas limites, tels que 
I'hyperplasie lobulaire atypique et 
I'hyperpiasie canaliculaire atypique, sont 
definis, et leur importance en tant que 
facteur de risque d'un cancer subsequent
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est soulignee. A I'analyse, le concept de 
maladie fibrokystique du sein n'offre ni 
specificite pathologique, ni valeur previ- 
sionnelle comme facteur de risque. Plutot 
que d'en referer a la maladie fibrokysti­
que, il vaudrait mieux stratifier les cas 
d'aprfes le type histologique specifique 
afin de mieux comprendre Timportance 
biologique de celui-ci.
It is well established that lobular carci­
noma in situ and ductal carcinoma in situ 
(intraductal carcinoma) are the most sig­
nificant and potent precursors of invasive 
breast cancer. Their distinctive natural 
history has been elucidated through recent 
retrospective studies.1-4 Both lesions have 
been legitimately included in the concept 
of minimal breast cancer.
Lobular Carcinoma in Situ
Lobular carcinoma in situ represents 
28% to 37%5-6 of all cases of carcinoma 
in situ. It is defined as involvement of a 
variable number of terminal lobular units 
by a proliferation of monotonous cells 
that obliterate luminal spaces, with a vari­
able degree of distension (Fig. 1). It is 
usually an incidental finding on histologic 
examination of a biopsy specimen for 
such conditions as fibrocystic disease. A 
high degree of alertness and adequate fix­
ation of tissue are prerequisites for histo­
logic recognition. Noninvasion is assumed 
on the basis of insular groups of cells with 
a smooth and spherical contour, centred 
around the terminal ductule. There are 
two cytologic subtypes, which may be 
combined. The first is characterized by a 
monotonous population of polygonal 
cells with a pale or amphophilic cyto­
plasm. Intracytoplasmic globules or lu- 
mina are frequently noted.7 Nuclei are 
round, with little variation in size; they 
often display a finely dispersed chroma­
tin with inconspicuous nucleoli. Mitoses 
are sparse or absent. The second subtype 
is characterized by a population of more- 
pleomorphic, less-cohesive cells with 
anisocytosis that may display prominent 
nucleoli. These two subtypes have been 
designated types A and B respectively by 
Haagensen and colleagues.8 Retrograde 
ductal involvement is not unusual; 
tumour cells may be insinuated between 
the basement membrane, with or without
FIG. 1—Lobular carcinoma in silu. Distension of terminal lobular unit by solid popula­
tion of monotonous cells. Note frequent intracytoplasmic, clear globules (hematoxylin and eosin 
x 400).
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outer budding and preservation of inner 
lining epithelium.9'10 The pathologist 
should not confuse this pattern with duc­
tal carcinoma in situ (the clinging pat­
tern), a disease of distinct biologic sig­
nificance. The retrograde extension of 
lobular carcinoma in situ has been 
referred to as Pagetoid spread.9 On the 
other hand, it is important to distinguish 
between lobular carcinoma in situ and 
intraductal carcinoma within the lobular 
unit, since the latter may extend centrifu- 
gally and involve the terminal lobular 
unit. This process has been termed lobu­
lar canceration.9 Occasionally, this 
phenomenon is the only detectable topo­
graphic histologic pattern. A cribriform 
pattern, a more pleomorphic tumour cell 
population and cell necrosis are more
likely to indicate lobular canceration 
(Fig. 2).
The retrospective study of Rosen and 
colleagues1 has elucidated the biology of 
lobular carcinoma in situ. They analysed 
84 patients, treated by biopsy only and 
followed up for an average of 24 years. 
Subsequent invasive carcinoma developed 
in 28 (33%) of the patients, in the 
ipsilateral breast in 12, in the contralateral 
breast in 9 and in both breasts in 7. In 
regard to histiotype, there were 20 inva­
sive ductal carcinomas, 13 invasive lobu­
lar, 1 mucinous and 1 tubular carcinoma. 
Interestingly, the majority of subsequent 
carcinomas became evident 15 or more 
years after the original biopsy and 38% 
were not detected until 20 years later.1 
Still unexplained is why, although 60%
of subsequently studied mastectomy 
specimens harboured foci of residual 
lobular carcinoma in situ, less than half 
of the patients treated by biopsy only 
would subsequently have ipsilateral car­
cinoma.11 These findings suggest that 
lobular carcinoma in situ is a tissue mar­
ker for increased risk of subsequent inva­
sive carcinoma of any histiotype, in the 
whole bilateral mammary parenchyma. 
Lobular carcinoma in situ is a potent, 
anatomically defined risk factor for sub­
sequent invasive carcinoma, carrying a 
ninefold relative risk for the patient.1
Atypical Lobular Hyperplasia
Atypical lobular hyperplasia is best 
defined as a histologic entity that does not 
fulfil all the criteria for the definition of 
lobular carcinoma in situ. There is no 
detectable distension of the lobular unit 
and residual lumina are present (Fig. 3). 
Nuclei may appear partly ovoid and over­
lap.9 It has been suggested that this 
lesion could represent the “ early” or 
incomplete form of lobular carcinoma in 
situ .12 Recent studies have defined the 
relative risk.13’14 A retrospective analysis 
of 125 cases of atypical lobular hyperpla­
sia revealed that in 14% of these patients 
invasive carcinoma developed, represent­
ing a relative risk of 4.4, in contrast to 
the relative risk of 9 for lobular carci­
noma in situ.14
Intraductal Carcinoma
Intraductal carcinoma has a distinctive 
biologic and histologic character. Clini­
cally, it appears as a discrete or question­
able mass in about 75% of cases.15 
Symptoms are also more likely before 
invasion occurs if the lesion is central and 
subareolar. A minimal tumour sampling 
of 6 to 10 blocks has been suggested as 
basic requirement to rule out inva­
sion.16,17 It is most important to ensure 
a diagnosis of pure (noninvasive) 
intraductal carcinoma if the surgeon is 
not going to perform a nodal dissection. 
Intraductal proliferation of malignant 
cells depicting a solid, papillary or cribri­
form pattern of growth is characteristic 
(Fig. 4). Tumour cells are usually more 
pleomorphic than those found in lobular 
carcinoma in situ and necrosis, referred 
to as comedo-type, is frequently observed. 
The histologic judgement of noninvasion 
is based on a spherical ductal contour and 
sharp epithelial-stromal demarcation. An 
associated inflammatory cell response 
may be present. In spite of the absence 
of demonstrable stromal invasion, on rare 
occasions nodal metastasis may occur. 
This could be explained on the basis of 
inadequate tumour sampling or early 
escape of tumour cells from the basal 
lamina. Indeed, Ozzello18 demonstrated 
transgression of basal lamina by tumour
FIG. 2—Lobular canceration by ductal carcinoma in situ. Lobular unit displays malignant 
columnar cells surrounding well-formed holes. This should be distinguished from lobular car­
cinoma in situ (hematoxylin and eosin, x 400).
FIG. 3—Atypical lobular hyperplasia. Proliferation of monotonous cells without signifi­
cant lobular distension. Residual luminal spaces are present (hematoxylin and eosin, x 400).
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cells at the ultrastructural level. Intraduc­
tal carcinoma may occasionally depict the 
so-called clinging pattern, defined as one 
or a few layers of malignant cells lining 
the ductal system.9 The diagnosis often 
depends on the alertness of the patholo­
gist and may easily be missed. Extension 
to lobular unit (lobular canceration) or 
epidermotropism (Paget’s disease) are 
also possible pertinent findings on patho­
logical examination.
The natural history of intraductal car­
cinoma has been described in two major 
series in which patients were treated by 
biopsy only.3’4 In a series of 15 patients, 
7 had ipsilateral invasive carcinoma 
within 10 years.4 In a second series of 28 
patients, with average follow-up of 16 
years, 7 patients had ipsilateral invasive 
carcinoma within an average of 6 years. 
In none of these patients did cancer 
develop contralaterally and the invasive 
ductal carcinoma was of the conventional 
ductal histiotype.3 Although the overall 
risk for subsequent invasive carcinoma is 
similar to that for lobular carcinoma in 
situ, the ipsilateral localization and much 
shorter interval to the development of 
invasive cancer are quite distinct.
Fibrocystic Disease Complex
Fibrocystic disease as a risk factor for 
breast carcinoma is of dubious sig­
nificance. The main reason is that this 
lesion embraces a spectrum of hormonal, 
stromal and epithelial changes. Indeed, 
numerous histopathologic findings are 
included in this complex. It has been sug­
gested that the term fibrocystic disease be 
characterized by more specific histologic 
determinants in order to allow a better 
histologic classification and prospective 
analysis.19 Historically, it has been esti­
mated that fibrocystic disease carries a 
risk factor of no more than 1.5 to 2.5.9 
We have characterized the fibrocystic dis­
ease complex into specific histologic 
categories (Table I). That without 
epithelial hyperplasia is characterized by 
cysts, fibrosis and apocrine metaplasia. 
No significant risk for cancer develop­
ment has been convincingly demon­
strated. Fibrocystic disease with epithelial 
hyperplasia (intraductal or intraductular 
hyperplasia, or both, and epitheliosis) is 
characterized by a multicentric, benign 
proliferation of both epithelial and
Table I—Fibrocystic Disease Complex 
__ __  of the Breast
Without epithelial hyperplasia 
With epithelial hyperplasia 
Not otherwise specified 
Atypical 
Radial scar
Blunt duct and sclerosing adenosis
FIG. 4—Intraductal carcinoma. Intraductal proliferation of polygonal cells, displaying hyper- 
chromasia. solid papillary tufting and necrosis (N) (hematoxylin and eosin, x 400).
FIG. 5—Atypical ductal hyperplasia. Proliferation of monotonous cells with variable nuclear 
hyperchromasia and without distinct myoepithelial differentiation. Irregular luminal spaces are 
present. This represents minimal deviation from lobular carcinoma in situ (hematoxylin and 
eosin, x 400).
FIG. 6—Radial scar. Presence of fibroelastotic scar (right side) with radiating tubular struc­
tures (left side) (hematoxylin and eosin, x 160).
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myoepithelial cells. Most important in 
this category is the recognition of the 
atypical form of epithelial hyperplasia, 
referred to as atypical ductal hyperplasia. 
This condition is defined as a lesion dis­
playing cytoarchitectural features in the 
borderline zone between not-otherwise- 
specified epithelial hyperplasia and 
intraductal carcinoma (Fig. 5). The histo­
logic deviation from intraductal carci­
noma may be minimal and in some cases 
clear distinction is not feasible. The lesion 
may meet some but not all of the criteria 
for intraductal carcinoma.20 For exam­
ple, luminal spaces are not clearly slit-like 
or hole-like, the cell population is often 
monotonous and nuclear hyperchroma- 
sia is inconstant. A recent retrospective 
analysis of 149 such cases showed a 12% 
incidence of subsequent invasive carci­
noma and a relative risk factor of 4.2.14 
In fact, this risk is not substantially differ­
ent from that for atypical lobular hyper­
plasia.14 The overall risk for atypical 
proliferative lesions is about one half of 
that for carcinomas in situ but comes 
close to it if there is a positive family his­
tory.14 If the atypical group of prolifer­
ative lesions is excluded, there is no con­
vincing evidence that blunt duct, 
sclerosing adenosis and fibrocystic disease 
complex without hyperplasia are impor­
tant risk factors.
Radial scar is a lesion that has received 
close attention from pathologists lately. 
It is likely to be misinterpreted as a malig­
nant lesion on both radiologic21 and 
pathologic examination. Of unknown 
etiology, the lesion measures from 3 to 
16 mm in size and is frequently multicen­
tric.22>23 It is characterized by a central, 
fibroelastotic core from which radiate 
tubular structures, with or without papil­
lary proliferation (Fig. 6). A complex 
pathologic nomenclature has been used to 
describe this entity,22 but radial scar is 
the simplest descriptive term. Postulated 
to represent an early incipient tubular car­
cinoma,24 no convincing demonstration 
has been made. Its biologic significance 
as a histologic risk factor for cancer is 
controversial. In a retrospective study of 
32 cases with a mean follow-up of 19.5 
years, only one patient subsequently had 
ipsilateral invasive carcinoma. This is not 
significantly different from the expecta­
tion in normal control subjects.22 On the 
other hand, an autopsy study showed a 
higher incidence and greater number of 
radial scars in cancer-associated mam­
mary parenchyma than in breast pre­
sumed to be at low risk for development 
of cancer.23 The latter findings suggest 
that radial scar carries a risk factor for 
cancer development.
Although lobular and ductal carci­
nomas in situ are well understood in 
regard to their pathological definition and 
natural history, we await the emergence 
of new studies that should clarify the bio­
logic significance of fibrocystic disease. 
Histologic stratification in such a complex 
entity appears essential to delineate pre­
cise diagnostic criteria and for an under­
standing of biologic data.
References
1. ROSEN PP, KOSLOFF C, LlEBERMAN PH, ADAIR F, 
Braun DW jr : Lobular carcinoma in situ of the breast. 
Detailed analysis of 99 patients with average follow-up 
of 24 years. Am  J  Surg Pathol 1978; 2: 225-51
2. Rosen PP, Braun DW JR, Kinne DE: The clinical sig­
nificance of pre-invasive breast carcinoma. Cancer 1980; 
46(4 suppl): 919-25
3. Page d l , Dupont w d , Rogers LW, l and en- 
BERGER M: Intraductal carcinoma of the breast: follow­
up after biopsy only. Cancer 1982; 49: 751-8
4. BETSILL WL JR, ROSEN PP, LlEBERMAN PH, ROBBINS 
GF: Intraductal carcinoma. Long-term follow-up after 
treatment by biopsy alone. JAM A  1977; 239: 1863-7
5. BEDWAN1 R, VANA J, ROSNER D, SCHMITZ RL, MUR­
PHY GP: Management and survival of female patients 
with “ minimal”  breast cancer: as observed in the long­
term and short-term surveys of the American College of 
Surgeons. Cancer 1981; 47: 2769-78
6. Smart CR, Myers MH, Gloeckler LA: Implications 
from SEER data on breast cancer management. Cancer 
1978; 41: 787-9
7. ANDERSEN JA, VENDELBOE ML: Cytoplasmic mucous 
globules in lobular carcinoma in situ. Diagnosis and prog­
nosis. Am  J Surg Pathol 1981; 5: 251-5
8. HAAGENSEN CD, Lane N, Lattes R: Neoplastic 
proliferation of the epithelium of the mammary lobules: 
adenosis, lobular neoplasia, and small cell carcinoma. 
Surg Clin North Am  1972; 52: 497-524
9. AZZOPARDl JG: Problems in Breast Pathology, Saun­
ders, Philadelphia, 1979
10. Haagensen CD, Lane n , Lattes R, Bodian  C: 
Lobular neoplasia (so-called lobular carcinoma in situ) 
of the breast. Cancer 1978; 42: 737-69
11. ANDERSEN JA: Lobular carcinoma in situ. A long-term 
follow-up in 52 cases. Acta Pathol Microbiol Scand [A] 
1974; 82: 519-33
12. Wellings SR, J ensen HM, Marcum RG: An atlas of 
subgross pathology of the human breast with special refer­
ence to possible precancerous lesions. J  Natl Cancer Inst 
1975; 55: 231-73
13. Page DL, Vander Zwaag R, Rogers LW, Williams 
LT, Walker WE, Hartmann WH: Relation between 
component parts of fibrocystic disease complex and breast 
cancer. JNCI 1978; 61: 1055-63
14. Page DL, Dupont WD, Rogers LW: Atypical hyper­
plasia of the breast (abstr). Lab Invest 1984; 50: 44
15. WESTBROOK KC, Gallager HS: Intraductal carcinoma 
of the breast. A comparative study. Am  J  Surg 1975; 130: 
667-70
16. McDivitt RW, Stewart FW, berg JW: Tumors o f  
the Breast, Armed Forces Institute of Pathology, 
Washington, DC, 1968
17. SlLVERBERG SG, CHITALE AR: Assessment of sig­
nificance of proportions of intraductal and infiltrating 
tumor growth in ductal carcinoma of the breast. Cancer 
1973: 32: 830-7
18. OZZELLO L: The behavior of basement membranes in 
intraductal carcinoma of the breast. A m  J Pathol 1959; 
35: 887-99
19. LOVE SM, GELMAN RS, SlLEN W: Fibrocystic “ disease” 
of the breast — a nondisease? N  Engl J  Med 1982; 307: 
1010-4
20. ASHIKARl R, Huvos AG, SNYDER RE, LUCAS JC, 
Hutter RV, McDivitt RW, Schottenfeld  D. 
Proceedings: a clinicopathologic study of atypical lesions 
of the breast. Cancer 1974; 33: 310-7
21. KEEN M, MATTHIES H, MURAD T: Benign breast lesions 
with malignant clinical and mammographic presentations 
(abstr). Lab Invest 1984; 50: 30
22. ANDERSEN JA, G ram JB: Radial scar in the female 
breast. A long-term follow-up study of 32 cases. Cancer 
1984; 53: 2557-60
23. WELLINGS SR, Alpers CE: Subgross pathologic fea­
tures and incidence of radial scars in the breast. Hum  
Pathol 1984; 15: 475-9
24. F isher ER, Palekar AS, Kotwal n , Lipana N: a  
nonencapsulated sclerosing lesion of the breast. Am  J  Clin 
Pathol 1979; 71: 240-6
Bactrim “Roche
Rx Summary 
Indications
The follow ing infections when caused by susceptible 
pathogens:
■ upper and lower respiratory trac t (particu larly chronic 
bronchitis and including acute and chron ic  otitis 
media)
■ urinary tract: acute, recurrent and chronic
■ genital tract: uncomplicated gonococcal urethritis
■ gastrointestinal tract
■ skin and soft tissue
■ Pneumocystis carin ii pneumonitis in in fants and 
children.
Not indicated in infections due to  Pseudomonas, 
Mycoplasma or viruses.
Contraindications
Evidence of marked liver damage or renal impairment 
where repeated serum assays cannot be carried out; 
blood dyscrasias; known hypersensitivity to trimethoprim 
or sulfonamides.
During pregnancy, and in newborn or prem ature infants 
during first few weeks of life.
Precautions
Benefit should be critically appraised against risk in 
patients with liver damage, renal damage, urinary 
obstruction, blood dyscrasias, allergies, o r bronchial 
asthma. Reduce dosage in patients with renal impair­
ment. Do not administer if serum creatin ine level is above 
2 mg%. Consider possible superinfection w ith a non­
sensitive organism.
Adverse reactions
Most frequent: nausea, vomiting, gastric intolerance, 
and rash.
Less frequent: diarrhea, constipation, flatulence, anore­
xia, pyrosis, gastritis, gastroenteritis, urticaria, head­
ache, and liver changes (abnormal elevations in alkaline 
phosphatase and serum transaminase).
Occasionally reported: glossitis, oliguria, hematuria, 
tremor, vertigo, alopecia, and elevated BUN, NPN, and 
serum creatinine.
Hematological changes: primarily, neutropenia and 
thrombocytopenia, and less frequently, leukopenia, 
aplastic or hemolytic anemia, purpura, agranulocytosis, 
and bone marrow depression; occu r particu larly in the 
elderly and mostly prove reversible on withdrawal.
Dosage
Children: 6 mg trim ethoprim /kg body weight per day, 
plus 30 mg sulfam ethoxazole/kg body weight per day, 
divided into two equal doses.
Adults and children over 12 years o f age:
Standard dosage:
1 Bactrim ' DS Roche' tablet or 2 adult tablets, twice 
daily.
Minimum dosage and dosage fo r long-term treatment:
Vi Bactrim ’ DS Roche' tablet or 1 adult tablet, twice 
daily.
Maximum dosage (overwhelming infections):
1 Vz 'Bactrim ' D S 'R oche' tablets o r 3 adult tablets, twice 
daily.
In acute in fections treat for at least 5 days or until patient 
is asymptomatic fo r 48 hours; in urinary tract infections, 
until urine sterile.
Uncomplicated gonorrhea: 2 adu lt tablets or 
1 ‘Bactrim ’ DS Roche' tablet four times daily for 2 days. 
Pneumocystis ca rin ii pneumonitis: 20 m g /kg /d a y  tri­
methoprim and 100 m g /kg /d a y  sulfam ethoxazole in four 
divided doses for 14 days.
Supply
Adult tablets: White, capsule-shaped, biconvex tablet 
with ROCHE C engraved on one face and BACTRIM and 
indented score on the other, each conta in ing 80 mg tri­
methoprim and 400 mg sulfamethoxazole.
Bottles of 100 and 500. Unit dose, boxes of 100.
DS tablets: White, capsule-shaped, biconvex tablet with 
ROCHE engraved on one face and BACTRIM DS and 
indented score on the other, each containing 160 mg 
trimethoprim  and 800 mg sulfamethoxazole.
Bottles of 100 and 250.
Suspension: Cherry flavoured, 40 mg trim ethoprim  and 
200 mg sulfamethoxazole per 5 ml.
Bottles of 100 and 400 ml.
Pediatric tablets: / — \
White, cylindrical biplane tablet w i th v 0CHt/
engraved on one face, single scored on the other
with C above and below score line, each containing 20 mg
trimethoprim and 100 mg sulfamethoxazole.
Bottles of 100.
Solution for Infusion: 5 ml amber-coloured ampoules, 
containing 80 mg trimethoprim (16 mg/ml) and 400 mg 
sulfamethoxazole (80 mg/ml) for infusion with D5W,
Ringer's solution or NaCI 0.9% solution. Packs of 
25 ampoules.
Product monograph available on request.
TM: Trade Mark of Hoffmann-La Roche Limited 
®Reg. Trade Mark
Reference
1: New York Academy of Sciences, Proceedings, 
December 8, 1980, p. 15.
Can. 3034
‘Bactrim’ ‘Roche’ is listed in provincial formularies.
Hoffmann-La Roche Limited 
Vaudreuil, Quebec J7V 6B3
Original Research in Medicine 
and Chemistry
PAAB
CCPP
Norman Wolmark, md, frcsc, facs
3. Minimal Breast Cancer: Advance or Anachronism?
The author argues that minimal breast 
cancer does not represent a distinct dis­
ease entity but com prises three discrete 
com ponents, each with unique charac­
teristics. The natural history of lobular 
carcinoma in situ and intraductal cancer, 
tw o of the com ponents of minimal 
breast cancer, is described. The dangers 
of relying on a data base established on 
the strength of retrospective anecdotal 
information is underscored. Lobular carci­
noma in situ has a propensity for mul­
ticentricity and bilaterality. In 2 5 %  of 
patients with lobular carcinoma in situ, 
invasive breast cancer will develop sub­
sequently, and the majority of these 
tum ours will be of ductal origin. The 
average interval from the d iagnosis of 
lobular carcinoma in situ to the develop­
ment of subsequent invasive cancer is 
over 1 5 years and both breasts are at 
equal risk. Based on this information, the 
use of bilateral prophylactic mastectomy 
is unjustified. In contrast to lobular carci­
noma in situ, 2 5 %  to 5 0 %  of patients 
with intraductal carcinoma will subse­
quently have infiltrating cancer, at an 
average of 10 years after the initial 
biopsy. A lthough the putative incidence 
of multicentricity is 5 0 % ,  virtually all 
subsequent invasive cancers occur not 
only in the sam e breast but in the same 
quadrant as the initial lesion. In light of 
the mom entum  for breast-preserving 
operations in invasive cancer, clinical 
trials should be implemented to a sse ss 
the propriety of conservative manage-
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ment with and without radiotherapy in 
patients with intraductal carcinoma.
L'auteur argumente que le cancer cir- 
conscrit du sein n 'e st pas une entite dis- 
tincte mais qu'il comprend plutot trois 
com posantes discretes ayant chacune 
des caracteristiques uniques. L'histoire 
naturelle du cancer lobulaire in situ et du 
cancer intracanaliculaire, deux des com­
posantes du cancer circonscrit du sein, 
est decrite. On souligne les dangers de 
se fier a des donnees reposant sur des 
informations anecdotiques retrospecti­
ves. Le cancer lobulaire in situ a ten­
dance a devenir multicentrique et bilate­
ral. Dans 2 5 %  des cas de cancer 
lobulaire in situ, un cancer invasif du 
sein se developpe subsequemment, et la 
majorite de ces tumeurs prendra nais- 
sance dans les canaux galactophores. 
L'intervalle moyen entre le diagnostic de 
cancer lobulaire in situ et I'apparition 
d 'un  cancer invasif est de plus de 1 5 ans 
et chacun des seins est egalement 
menace. A  partir de ceci, on ne peut jus- 
tifier le recours a la mastectomie bilate 
rale prophylactique. A  I'oppose du can­
cer lobulaire in situ, 2 5 %  a 5 0 %  des 
patientes atteintes de cancer intracanali­
culaire developperont un cancer infiltrant 
dans les 10  ann^es qui suivront la biop- 
sie initiale. Bien que I'incidence putative 
des cancers multicentriques soit de 
5 0 % ,  pratiquement tous les cancers 
envahissants subsequents apparaissent 
non seulement dans le meme sein mais, 
encore, dans le quadrant qui avait ete 
soum is a la biopsie initiale. Devant la 
popularity actueile des operations visant 
a preserver le sein dans les cas de can­
cers envahissants, il y aurait lieu de met- 
tre sur pied des essais cliniques destines 
a evaluer la justesse d 'un  traitement con- 
servateur avec ou sans radiotherapie 
chez les patientes souffrant de cancer 
intracanaliculaire.
The formulation and adoption of new 
cancer terminology is associated with an 
inherent obligation — that the new defi­
nition describes a meaningful clinical 
entity, the study of which furthers the bio­
logic understanding of the disease process
in question. These prerequisites are not 
fulfilled by the term “ minimal breast 
cancer” . This definition was introduced 
in 1971 by Gallager and Martin1 to 
describe “ breast carcinoma that is read­
ily curable by available means” . They 
characterized minimal breast cancer as 
comprising three distinct processes: (a) 
lobular carcinoma in situ, (b) noninvasive 
intraductal carcinoma and (c) invasive 
adenocarcinoma having a maximum 
diameter of 0.5 cm. They selected 0.5 cm 
as the upper limit for compliance from 
their hypothetical estimation that the inci­
dence o f nodal metastasis for these 
tumours would be less than 5% and that 
the predicted 10-year survival rate would 
be about 90%.
More recently, the upper limit of 
tumour size for the invasive process has 
been expanded to include tumours as 
large as 1 cm in diameter,2 but of far 
greater importance is whether the term 
minimal breast cancer is one that defines 
a true entity. From a biologic standpoint, 
the grouping together of intraductal car­
cinoma, lobular carcinoma in situ and 
invasive cancer (regardless of diameter) 
appears inappropriate. Clearly, these 
three processes represent distinct diseases, 
having unique biologic characteristics. A 
possible justification for maintaining a 
definition that includes disparate compo­
nents might be to signify uniformity in 
therapeutic management, but since the 
therapeutic aspects of minimal breast 
cancer are more complex than the defi­
nition, it is unlikely that the term will sur­
vive on the strength of this aspect. 
In fairness to Gallager and Martin, the 
definition of minimal breast cancer was 
formulated at a time when insufficient 
attention was being paid to categories of 
breast cancer with favourable prognostic 
characteristics. Any criticism should be 
directed towards current investigators 
who have maintained the term in spite of 
a better understanding of the biology of 
the diseases. Accordingly, I shall empha­
size the individuality of the three compo­
nents of minimal breast cancer rather 
than attempt a collective analysis based 
on an outmoded concept.
Even if one were to accept the term
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minimal breast cancer, it has been argued 
that the number of patients meeting the 
specified criteria would be very small 
indeed. Data from well-established 
tumour registries3'4 estimate that only 
10% of all breast cancers diagnosed could 
be considered as minimal breast cancer 
(Table I). There is good reason to believe, 
however, that the overall detection of the 
three components of minimal breast 
cancer is changing as a direct result of the 
increasing popularity and implementation 
of screening programs. Data from the 
Breast Cancer Detection Demonstration 
Projects (BCDDP) disclosed that minimal 
breast cancer accounted for more than 
40% of cancers detected at the first 
screening.2 Of these, noninfiltrating 
cancer constituted more than 25% of all 
detected breast cancers. Of the nonin­
filtrating cancers, 80% were intraductal 
and 20% were lobular carcinomas in situ.
In-depth analysis of the individual 
components of minimal breast cancer is 
thus not only compelling, but necessary. 
With the development of screening 
modalities that can identify more patients 
with minimal breast cancer, well-con­
trolled prospective studies designed to as­
sess the biologic behaviour of noninfil­
trating breast cancer are essential.
Lobular Carcinoma in Situ
The therapeutic preferences for this 
type of cancer have largely been deter­
mined by how the disease was perceived 
biologically. Two mutually exclusive 
hypotheses have been formulated to 
describe the disease. Proponents of the 
first and most popular hypothesis regard 
lobular carcinoma in situ as the direct 
progenitor of invasive cancer, given 
enough time. Consequently, they have
treated this cancer by performing at least 
an ipsilateral mastectomy. In the second 
hypothesis, lobular carcinoma in situ is 
regarded simply as a marker of a popu­
lation at high risk for the development of 
subsequent invasive cancer which is not 
related to the initial lobular carcinoma in 
situ. The therapy that the surgeon selects 
invariably reflects his biologic under­
standing of the disease.
Before therapeutically relevant issues 
are considered, it is important to review 
the behaviour and natural history of the 
disease. Since lobular carcinoma in situ 
was defined as a distinct entity in 1941 by 
Foote and Stewart3 and independently 
by Muir,4 it has been known that the 
entity is inconspicuous, both on clinical 
and gross examinations. It occurs at an 
earlier age than ductal cancer, with 75% 
of all cases being documented between the 
ages of 40 and 54 years.5,6 The entity was 
observed predominantly, but not exclu­
sively, in premenopausal women.7,8 A 
property that has often been cited as a 
justification for performing mastectomy 
is the propensity towards multicentricity. 
Although noninfiltrating multicentric 
tumours were evident in 10% to 60% of 
all women with lobular carcinoma in situ, 
the incidence of multicentric infiltrating 
cancer was less than 5%.9'"  In addition, 
bilateral disease has been demonstrated 
in approximately 35% of cases.12,13
Because surgeons have generally 
regarded lobular carcinoma in situ as the 
progenitor of invasive cancer, mastec­
tomy has been the most popular therapy. 
This has eliminated the opportunity to 
study the consequences of the disease fol­
lowing biopsy only and thus an opportu­
nity to understand the natural history of 
the disease has been lost. All the data de­
rived for lobular carcinoma in situ not
treated by mastectomy were obtained 
from retrospective and anecdotal case 
reports.
A review of four of the principal ser­
ies dealing with patients who had lobu­
lar carcinoma in situ treated only by 
biopsy7,14'16 disclosed that the number of 
documented cases was inadequate, rang­
ing from 32 to 263; moreover, the mean 
follow-up varied from 15 to 24 years 
(Table II).
Clearly, the most critical property of 
lobular carcinoma in situ that will 
influence the choice of therapy is the inci­
dence of invasive cancer subsequently. 
Here, too, there is a wide variation rang­
ing from a 13% incidence of invasive 
cancer in the series of Wheeler and 
colleagues14 to a high of 31% in the ser­
ies reported by Rosen and associates.7 It 
is interesting that the interval from diag­
nosis of the lobular carcinoma to that of 
invasive cancer ranged from 15 to 20 
years. Perhaps, the most fascinating 
aspect of the subsequent infiltrating 
cancer is that it is not restricted to the 
ipsilateral breast, but occurs with equal 
frequency in the contralateral breast.7,16 
Curiously, the histologic features of the 
subsequent invasive cancer in the majority 
of instances is not lobular as one might 
expect if lobular carcinoma in situ had 
progressed to the invasive form, but is 
ductal in approximately 60% of cases. 
Despite some interesting theories suggest­
ing that lobular and ductal cancer have 
similar anatomic origins,17 the prepon­
derance of infiltrating ductal cancer fol­
lowing lobular carcinoma in situ supports 
the hypothesis that lobular cancer is a 
high-risk marker, not a precursor.
In summary, lobular carcinoma in situ 
is a fascinating multicentric and bilateral 
entity. Twenty-five percent of patients 
with this type of cancer will have invasive 
cancer subsequently and the majority of 
the invasive cancers will be of ductal type. 
On average, more than 15 years will pass 
before the development of invasive cancer 
and the contralateral breast is at equal 
isk for such development. Because inva­
sive cancer may develop bilaterally, 
whatever treatment is advocated for the 
ipsilateral breast should also be advocated 
for the contralateral breast. Based on the 
data, in the opinion of our group the risk 
o f invasive cancer does not justify 
bilateral prophylactic mastectomy; con­
sequently, a predefined follow-up regi­
men is the preferred method of dealing 
with this disease. At present, we perform 
an adequate local excision of the lobular 
carcinoma with no further operative treat­
ment. Because of the very low incidence 
(about 1%) of regional node metastases 
from this disease, we do not think that 
axillary node dissection is warranted.
With respect to treatment of the con­
tralateral breast, a random or mirror- 
image biopsy is meddlesome in our opin-
Table 1—Minimal Breast Cancer as Percentage of All Diagnosed Cases
Study
Type of cancer SEER, 197825 ACS, 19 805 BCDDP, 1 9 7 9 2
Minimal 9 12 41
Noninfiltrating 5 3 26
Infiltrating <  1 cm 4 9 15
SEER = Surveillance Epidemiology and End Results Reporting, ACS -  American College of Surgeons, 
BCDDP = Breast Cancer Detection Demonstration Projects.
Table II--Risk of Invasive Cancer Following Lobular Carcinoma in Situ
Series, yr
Wheeler and Andersen, Rosen and Haagensen and
colleagues. 1 9 7 7 15 colleagues, colleagues,
1 9 7 4 ,4 (n -  32) In -  44) 1 9 7 9 7 In -  99) 1 9 8 1 16 In -  263)
Mean follow up, yr 
Subsequent invasive
18 15 24 15
cancer risk 
Ipsilateral, % 4 20 18 11
Contralateral, % 9 9 14 9
Overall risk, % 13 25 31 17
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ion and has little place in our therapeutic 
approach. The current reappraisal of the 
therapy for invasive cancer will undoubt­
edly be a major influence on the treat­
ment of lobular carcinoma in situ. 
Preliminary results indicate that for some 
patients there is no disadvantage to 
breast-preserving operations. If these 
findings are substantiated, then the 
proponents of mastectomy for lobular 
carcinoma in situ will find themselves in 
the difficult position of advocating 
prophylactic therapy more severe than the 
treatment of the disease they are trying 
to prevent. Until a therapeutic regimen 
can be evolved, based on reliable prospec­
tive data, we recommend that patients 
with lobular carcinoma in situ not be sub­
jected to mastectomy but to local excision 
with follow-up consisting of physical 
examinations every 3 to 6 months and 
mammography annually.
Intraductal Cancer
If the data on lobular carcinoma in situ 
can be described as scanty, that on 
intraductal cancer may be characterized 
as seriously deficient. In the former case, 
because the disease was not recognized by 
all as a neoplastic entity until relatively 
recently, and because several investigators 
chose to regard the disease as a noncar­
cinoma, cases were available in which the 
patient had not undergone mastectomy. 
The same considerations are not applica­
ble to intraductal carcinoma. Patients 
with a diagnosis of intraductal carcinoma 
were invariably treated by mastectomy, 
and the major point of contention was 
not whether a mastectomy should be per­
formed, but whether a concomitant axil­
lary node dissection was necessary. As a 
result, few patients could be identified 
who had not had mastectomy; once 
again, an opportunity to evaluate the 
behaviour of the disease was lost. In spite 
of the paucity of definitive studies explor­
ing the natural history of intraductal car­
cinoma, there are sufficient examples in 
the literature to indicate that noninvasive 
intraductal cancer of the breast possesses 
biologic characteristics distinct from those 
of lobular carcinoma in situ.
Of those patients with noninfiltrating 
breast cancer, the ratio of intraductal car­
cinoma to lobular carcinoma is approxi­
mately 2 to 1. The diseases differ with 
respect to age distribution: the greatest 
number of patients with lobular carci­
noma is found in the 45- to 54-year age 
group with a rapid decrease in subsequent 
years, while the number of patients with 
intraductal cancer is fairly constant for 
women 55 years of age and older.5 
Whether this is a result of different etio- 
logic mechanisms for the two diseases or 
because lobular carcinoma is hormone 
dependent and intraductal cancer is not 
remains speculative. Irrespective of etio-
logic considerations, the differences 
underscore the distinct behavioural 
characteristics of the two conditions.
As with lobular cancer, the most 
important therapeutic property is the inci­
dence of invasive cancer following a diag­
nostic biopsy. Examples of the available 
data on this aspect of intraductal cancer 
are shown in Table III.18-20 All three 
studies were retrospective and suffered 
from small sample sizes. Of patients in 
whom a diagnosis of intraductal carci­
noma is made, 25% to 50% will allegedly 
have infiltrating cancer, on average 10 
years from the time of initial biopsy. 
Although this disease has a greater than 
50% frequency of ipsilateral multicentric­
ity, almost all the invasive cancers occur 
not only in the same breast, but in the 
same quadrant as the initial tumour.19’20 
The histologic type of invasive cancer is 
exclusively ductal.
In addition to the property of multicen­
tricity, from 5% to 20% of patients with 
intraductal cancer reportedly have 
residual foci of invasive cancer on exami­
nation of multiple histologic sections of 
the ipsilateral breast; however, when the 
criteria for intraductal carcinoma were 
rigidly defined, this figure was closer to 
5%.9 Finally, there have been docu­
mented instances21,22 in which 1% to 5% 
of patients with intraductal carcinoma 
and no evidence of infiltration on 
microscopy had ipsilateral axillary lymph- 
node metastases. A summary and con­
trast of the properties of lobular carci­
noma in situ and intraductal carcinoma 
appears in Table IV. The retrospective 
nature and methodologic weakness of the 
studies available on intraductal carcinoma 
emphasize the error of drawing firm con­
clusions on the behaviour of this disease.
Nevertheless, some of these characteris­
tics have been interpreted as suggesting 
that intraductal carcinoma is merely a 
precursor of invasive cancer and that, 
given sufficient time, invasive cancer will 
develop from a residual focus in a defined 
percentage of patients.
On the basis of this biologic interpre­
tation of the properties attributed to 
intraductal cancer, an ipsilateral mastec­
tomy with a low axillary dissection has 
become the most popular therapy for this 
disease. The lack of data documenting its 
natural history does not justify a compla­
cent attitude in accepting this therapeu­
tic approach. The pivotal question in the 
operative management concerns the role 
of breast-preserving operations with or 
without axillary node dissection. Several 
retrospective analyses address the value 
of breast-preserving operations in this dis­
ease. The American College of Surgeons 
National Breast Cancer Survey Study5 
reported on 202 patients with intraduc­
tal carcinoma treated according to the dic­
tates and preferences of the individual 
surgeon. Treatment failures were identi­
cal in patients treated with mastectomy 
(with and without axillary dissection) and 
those treated with breast-preserving oper­
ations, with 65% of the patients alive and 
free of disease at 5 years in both groups. 
In spite of these findings, indicating no 
difference, the American College of Sur­
geons group seems disinclined to accept 
its own analysis and concluded that total 
mastectomy with low axillary dissection 
or modified radical mastectomy repre­
sents the optimal therapy for intraductal 
carcinoma.
Preliminary results of the MD Ander­
son Hospital experience with intraductal 
carcinoma warrant further comment. In
Table 111-Risk of Invasive Cancer Following Intraductal Carcinoma
Series, yr
Betsill and Page and
Farrow, 1 9 7 0 18 colleagues, 1 9 7 8 19 colleagues, 19 8 2 20
(n -  2 5 ! In -  15 ) (n -  25 )
Mean fo llow -up, yr - 2 2 15
Subsequent invasive cancer, %  2 0 53 28
Interval to  subsequent cancer, yr 1 - 8 10 6
Table IV —Properties of Noninvasive Breast Cancer
Lobular carcinoma Intraductal
Property in situ carcinoma
Initial lesion
M ulticentricity , % 6 0 6 0
Residual invasive cancer, % 5 5 - 2 0
Subsequent invasive cancer
Occurrence, % 25 2 5 - 5 5
la te ra lity Bilateral Ipsilateral
Approximate interval to  occurrence, yr 20 10
Histologic type Ductal Ductal
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70 consecutive patients treated with local 
excision and radiotherapy to the ipsi- 
lateral breast, there has been only one 
recurrence in the untreated ipsilateral 
axilla after a minimum of 3 years follow­
up (Montague E: Personal communica­
tion, 1985).
The most compelling justification for 
performing mastectomy in women with 
intraductal carcinoma comes from two 
recently completed studies,23’24 assessing 
quandrantectomy and segmental mastec­
tomy in patients with invasive cancer. As 
with lobular carcinoma in situ, the 
increasing acceptance of breast-preserving 
operations for invasive disease will make 
prophylactic mastectomy considerably 
more difficult to justify. To resolve the 
therapeutic dilemma with respect to 
intraductal carcinoma, a carefully con­
trolled, prospective, randomized, clinical 
trial, designed to determine the natural 
history as well as the appropriate treat­
ment intervention, must be carried out. 
Such a trial has currently been proposed 
for implementation at a national level by 
the National Surgical Adjuvant Breast 
Project (NSABP) (Fig. 1). The inclusion 
of a group of patients treated by local 
excision (with free margins) will identify 
the role of putative prognostic dis­
criminants in the occurrence of subse­
quent invasive disease (such as tumour 
size and multifocality). The second arm 
will address the propriety of adjuvant 
radiotherapy to the remaining breast and 
determine whether this regimen represents 
acceptable therapy.
Invasive Adenocarcinoma
Clinically and biologically, patients 
with infiltrating tumours demonstrate no 
unique features that would justify the 
arbitrary designation of tumour diameter 
less than 1 cm. It is not tumour size but 
the histologic status of the axillary nodes 
that is the most important predictor of 
prognosis. Now that sampling of axillary 
nodes is almost routine, regardless of the 
primary breast operation, the use of 
tumour size alone as a prognostic varia­
ble is anachronistic, as may be illustrated 
by correlating tumour size with the 
presence or absence of histologically posi­
tive ipsilateral axillary nodes. Examina­
tion of data from more than 8000 patients 
in the SEER survey25 disclosed that more
| ELIGIBLE ON HISTOLOGIC CONFIRHAIION | 
| RANDOMIZE |
------------ 1------------ SEGMENTAL MASTECTOMY
SEGMENTAL MASTECTOMY AXILLARY NODE DISSECTION
AXILLARY NODE DISSECTION +.
FIG. 1—Proposed NSABP controlled, 
prospective, randomized, clinical trial for 
intraductal breast cancer.
than 17% of patients with tumours less 
than 0.5 cm in diameter had axillary 
nodes that were histologically positive for 
cancer; this figure rose to more than 20% 
in tumours less than 1 cm in diameter. 
Although tumour size provides some indi­
cation of the histologic status of the 
axilla, it should not be used alone to 
predict prognosis. The identification of 
patients according to tumour size (small 
or otherwise) without information on the 
status of axillary nodes should be 
avoided. The designation of patients with 
tumours less than 1 cm in diameter as a 
distinct subset and their inclusion in 
minimal breast cancer is inappropriate 
biologically. Therapeutically, it is equally 
misguided to include small invasive 
neoplasms in the same category as nonin­
filtrating cancer. The value of breast­
preserving operations for small invasive 
cancers as well as invasive cancers 4 cm 
in diameter or smaller will be defined by 
the recently completed NSABP, protocol 
B-06.24 In this study, a substantial 
proportion of the patients entered had 
invasive cancer 1 cm in diameter or 
smaller. Over 2100 patients were ran­
domized to three treatment arms: (a) 
modified radical mastectomy , (b) segmen­
tal mastectomy and axillary node dissec­
tion or (c) segmental mastectomy, axillary 
node dissection and radiotherapy to the 
remaining ipsilateral breast. The prelimi­
nary results from this study confirm that 
to categorize tumours less than 1 cm in 
diameter as a separate subset is specious.
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NOTICES
Cleft Palate and 
Related Craniofacial Anomalies
The 5th International Congress on Cleft 
Palate and Related Craniofacial Anoma­
lies will be held Sept. 2-7, 1985 at the 
Congress Center in Monte Carlo.
This congress will be of interest to all 
practitioners concerned with this subject, 
including plastic, dental, pediatric and 
maxillofacial surgeons, orthodontists and 
otorhinolaryngologists.
For further information contact Dr. 
Rene Malek, Chairman, International 
Congress on Cleft Palate and Related Cra­
niofacial Anomalies, 6, rue Erlanger, 
75016 Paris, France; or write SOCFI, 14, 
rue Mandar, 75002 Paris, France.
Reflux Esophagitis 
and the Angelchik Prosthesis
A medical and surgical review of reflux 
esophagitis and the Angelchik prosthesis, 
presented by the departments of surgery 
and continuing medical education at the 
University of Wisconsin, is being held 
June 14-15, 1985 at the Concourse Hotel 
in Madison, Wisconsin. The conference 
is accredited for 11 hours in AMA 
Category 1.
For further information contact: Sarah 
Z. Aslakson, Department of Continuing 
Medical Education, 465B Warf Building, 
610 Walnut St., Madjfon, WI 53705, 
USA; (608) 263-2856.
Thoracic and Cardiovascular 
Surgery
The 7th Asian Congress of Thoracic and 
continued on page 267
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4. Surgical Management of the Patient 
at High Risk for Breast Cancer
The most controversial aspect of breast 
disease centres around the management 
of patients who have either a strong fa­
mily history of breast cancer or a biopsy 
diagnosis of lobular carcinoma in situ or 
ductal carcinoma in situ. The current al­
ternatives for patients who have two or 
more relatives with breast cancer consist 
of close follow-up or prophylactic total 
mastectomies and reconstruction.
Invasive breast cancer in patients with 
lobular carcinoma in situ may occur in 
either breast and may be as high as 30%  
at 20 to 30 years. In these women it is 
reasonable to do a wide excision of the 
lobular carcinoma; in those without a fa­
mily history, close follow-up is adequate. 
Intraductal cancer treated by biopsy only 
is associated with a 40%  risk of cancer 
in the ipsilateral breast. Therefore, the 
usual management is total mastectomy. 
However, the information to support this 
therapy over a segmental resection has 
limited scientific validity.
Because the cosmetic appearance after 
total mastectomy and reconstruction is 
not as good as that of the normal breast, 
this procedure must be employed cau­
tiously and only with the total support of 
the patient and her husband or close fa­
mily. Subcutaneous mastectomy for 
prophylaxis leaves behind macroscopic 
glandular tissue and, therefore, is not 
considered by many to be optimal
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management. A total mastectomy, 
preserving the skin and resecting all 
macroscopic breast tissue and nipple, is 
the treatment of choice if the procedure 
is deemed appropriate.
L'aspect le plus discute des maladies 
du sein tourne autour du traitement de la 
patiente qui possede de solides antece­
dents familiaux de cancer du sein ou de 
cede chez qui on a diagnostique, a la 
biopsie, un carcinome lobulaire in situ ou 
un cancer canaliculaire in situ. Les choix 
qui s'offrent actuellement aux patientes 
qui comptent plus d'une victime du 
cancer du sein dans leur famille sont la 
surveillance etroite ou la mastectomie 
prophylactique totale avec conservation 
de la peau et reconstruction.
Chez la patiente atteinte d'un carci­
nome lobulaire in situ, un cancer invasif 
peut apparaftre dans un ou I'autre sein 
et sa frequence peut atteindre 30%  
apres 20 a 30 ans. II est raisonnable 
chez ces femmes de proceder a une 
excision large du carcinome lobulaire; 
chez cedes qui n'ont pas d'antecedents 
familiaux, une surveillance etroite est 
suffisante. Les cancers canaliculaires 
traites par biopsie seulement sont relies 
a un risque de 40%  de cancer dans le 
sein ipsilateral. En consequence, le traite­
ment habituel consiste a realiser une 
mastectomie totale. Toutefois la prefe­
rence pour cette intervention par rapport 
6 la resection segmentaire repose sur 
une preuve scientifique limitee.
Comme I'apparence cosmetique apres 
mastectomie totale et reconstruction 
n'est pas aussi bonne que cede d'un sein 
normal, on doit recourir a cette operation 
avec precaution et seulement apres avoir 
obtenu I'appui complet de la patiente et 
de son conjoint ou de sa famille imme­
diate. La mastectomie sous-cutanee a 
visees prophylactiques laisse du tissu 
glandulaire macroscopique et ne peut 
done etre consideree comme un traite­
ment optimum. Une mastectomie totale 
avec conservation de la peau et resec­
tion de tout le tissu mammaire macro­
scopique ainsi que du mamelon, 
represente le traitement de choix quand 
cette intervention semble appropriee.
The dilemma of how to treat the patient 
at high risk for invasive breast cancer has 
become increasingly apparent. As a result 
of breast screening programs, the acces­
sibility of mammography and, in general, 
a heightened awareness of health issues, 
the illness is now detected early in its 
course. In fact, many women, especially 
those with a family history of breast 
cancer, now consult the physician about 
the particular risk for breast cancer dis­
ease and request alternative management. 
Treatment at this stage continues to be an 
insoluble problem because our predictive 
ability for any one patient is far from per­
fect and the solutions are still unsatisfac­
tory. Nevertheless, a review of data cur­
rently available helps to formulate a plan 
for each situation.
Family History
Traditionally, we have considered the 
patient with a previous history of breast 
cancer as being at the highest risk for a 
subsequent metachronous lesion. This 
risk averages 1% per year or 15% in the 
woman’s lifetime. It has not been our 
practice to recommend prophylactic 
mastectomy in these circumstances, 
although its use has certainly been consi­
dered by surgeons in the past. However, 
it is now recognized that a particularly 
high-risk group for the development of 
a subsequent metachronous lesion are 
those patients who also have a family his­
tory of breast cancer.1 In a study of 198 
such patients, the incidence of a second 
cancer was three times that for patients 
with no family history of breast cancer. 
The projected cumulative risk at 20 years 
in premenopausal patients was 46% while 
the actual occurrence was 37% .’ In post­
menopausal patients who had a much 
shorter follow-up, the occurrence of 
breast cancer was only 5.8% after 4 years. 
Therefore, if one considers a prophylac­
tic contralateral mastectomy and recon­
struction as a reasonable form of manage­
ment in this subset of patients, candidates 
would certainly include premenopausal 
women with stage I breast cancer or those 
who have been followed up for at least 
5 years.
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Patients with a family history of breast 
cancer are also at risk for an initial 
primary breast cancer.2'3 This group 
comprises women with two or more first- 
degree relatives, including paternal rela­
tives, who have been affected by the dis­
ease. It is not generally realized that 
although men rarely have breast cancer, 
they readily transmit this tendency to their 
progeny. A family history results not only 
in a higher incidence of bilateral disease, 
as already discussed, but also a much 
younger age at presentation. This trans­
mission of risk is most potent (47-fold in 
one report) if the family members were 
premenopausal at the time of diagnosis 
and both breasts were ultimately affected. 
If the family members were post­
menopausal with bilateral foci of cancer, 
the risk was greater by a factor of four and 
translated into an 11 % incidence of breast 
cancer in the relatives.3 If only one 
breast was involved in the affected family 
member, the risk for the family was not 
much greater than in the normal popula­
tion. The study did not define the risk in 
women who present with three or more 
first-degree relatives with breast cancer. 
The risk in these women is much greater 
than 30%, probably approaching 100% 
in some. In such situations, the risk must 
be estimated more by clinical judgement 
than by available data. It is in these 
patients that one can make the strongest 
case for prophylactic mastectomy and 
reconstruction.
Fibrocystic Disease
The most frequent clinical problem that 
we deal with is fibrocystic disease which 
is reputed by some to be at high risk for 
progression to invasive cancer. Although 
fibrocystic disease has often been impli­
cated as a predisposing factor, the avail­
able data suggest that the increased risk 
is probably conferred only on those with 
a proliferative lesion who have required 
a breast biopsy. There is much less infor­
mation on the exact risk of other benign 
lesions, such as papillomatosis or atypi­
cal ductal hyperplasia. However, in the 
study of Haagensen and colleagues4 who 
had 51 patients with a follow-up ranging 
from 13 to 32 years, multiple sites of duc­
tal papillomatosis in the breast resulted 
in a higher incidence of breast cancer of 
approximately 10%. In general, when a 
biopsy shows a benign condition, a pro­
phylactic surgical procedure is not justi­
fied unless there are other extenuating 
circumstances.
Carcinomas in Situ
The most extensively documented 
group of high-risk women are those with 
carcinoma in situ. These women have 
traditionally been categorized as having 
minimal breast cancer and have included
patients with infiltrative cancers less than 
0.5 cm to 1.0 cm in diameter. These 
tumours should no longer be considered 
minimal, because the incidence of lymph- 
node metastases ranges from 10% to 
20%.5 The two in-situ lesions, ductal 
and lobular, have a different natural his­
tory. Ductal carcinoma in situ is the more 
aggressive lesion. In five series of approx­
imately 80 patients, a subsequent carci­
noma developed exclusively in the 
ipsilateral breast in 39%. This occurred 
in the first 10 years of follow-up.5,6 A 
more careful histologic examination of 
these lesions has revealed a microinfiltra- 
tive component in 20%. This also 
explains why 5% of these patients will 
have metastatic axillary lymph nodes. The 
opposite breast is not at inordinate risk 
for a second primary tumour.6
Lobular carcinoma in situ is a less- 
frequent diagnosis; 90% of these patients 
are younger than 55 years. A subsequent 
cancer is found in only 20% of these 
patients after 15 years of follow-up, with 
each breast being equally at risk.4 This is 
not surprising as a mirror-image biopsy 
is positive in about one third of these 
patients. Axillary involvement is found in 
less than 1% of these women. A rational 
management in these patients is particu­
larly controversial with treatments vary­
ing from the simple biopsy, to modified 
radical mastectomy, to bilateral sub­
cutaneous mastectomies. There is no con­
sensus as to the best treatment but it is 
fair to comment that there are two 
rational choices. One is to treat the diag­
nosis as an indication of future high risk 
and provide close clinical follow-up. The 
second option is to eliminate all subse­
quent potential for breast cancer by per­
forming bilateral total mastectomy.
Indications for Prophylactic Procedures
With these facts in hand, it is impor­
tant to emphasize that prophylactic 
mastectomies are only reasonable in very 
selected circumstances. First, a gradation 
of perceived risk exists for most of these 
patients and its determination is more 
often an educated guess than easily estab­
lished scientific fact. Some patients, such 
as those with a diagnosis of lobular car­
cinoma in situ, will be terrified by the 
prediction of a 20% risk of cancer, while 
others with a family history suggesting a 
50% risk or more will be comfortable 
with close follow-up. Any discussion of 
prophylactic surgery must be held with 
this in mind. The procedure should not 
be considered seriously unless the hus­
band and family give their full support 
and enough time has been taken to ensure 
a rational decision. Until plastic surgical 
reconstruction reliably mimics a real 
breast, one has to be convinced of the 
overall health benefits before doing a
procedure that may result in a cosmeti­
cally unattractive appearance. At the 
same time, one must realize that even in 
patients with stage I disease, long-term 
cure is only 54%, although at 10 years 
70% to 80% are disease free.7 This is a 
very reasonable risk at 60 to 70 years of 
age but not so palatable at 40 to 50 years.
If prophylactic surgery is determined to 
be the best course for a particular patient, 
then it is important to do the right oper­
ation. In women with multiple papilloma­
tosis or intraductal carcinoma, a uni­
lateral mastectomy is indicated. In the 
latter group, an axillary dissection is also 
reasonable.6 In patients with a high-risk 
family history or with lobular carcinoma 
in situ, a bilateral mastectomy is neces­
sary for prophylaxis. One must recognize 
that many surgical procedures have been 
used to treat in-situ carcinoma, ranging 
from biopsy to radical mastectomy for 
the ductal type or to bilateral total 
mastectomy for the lobular type. 
Although the findings of a survey con­
ducted by the American College of Sur­
geons on minimal breast cancer do not 
show an advantage for any approach, the 
short follow-up of 5 years renders this 
observation meaningless.8
Subcutaneous Mastectomy
The use of subcutaneous mastectomy 
for these women with our present state 
of knowledge is not optimal.913 This 
operation leaves breast tissue behind skin 
flaps, scars, nipples and probably in the 
axilla. Many plastic surgeons have had 
experience of carcinoma developing in 
one or two patients who had previous­
ly undergone subcutaneous mastecto­
my.10,11 In the animal model, partial 
excision of breast tissue does not lower 
the propensity for subsequent breast 
cancer.14 Therefore, a meticulous total 
mastectomy is essential to eliminate 
future worry of a subsequent cancer. 
Even this is tempered by the knowledge 
that, occasionally, microscopic rests in the 
muscle or adjacent to the dermis may 
remain.9 It has been suggested that injec­
tion of the lactiferous ductal system with 
methylene blue would provide a visual 
assurance of complete removal of all 
breast tissue. This should be examined 
further.9 A prophylactic total mastec­
tomy is, in fact, similar to a cancer oper­
ation except that the entire skin covering 
can be preserved. The best incision is a 
radial one encircling the nipple and 
extending laterally, as it is easily hidden 
by the brassiere. It provides equal surgi­
cal access to all parts of the breast, espe­
cially to the axillary tail. This incision 
does not diminish a subsequent satisfac­
tory cosmetic result. The reconstruction 
problems resulting from thin skin flaps 
are largely overcome by submuscular 
placement of the prosthesis.
VOLUME 28, NO. 3, M A Y  1985 /  THE CANADIAN JOURNAL OF SURGERY 257

should be employed and it is advisable to 
monitor serum levels in patients with severe 
impairment.
In adults with renal insufficiency, an initial 
loading dose of 1 g to 2 g should be given. 
A fte r  a lo a d in g  dose, the  fo llo w in g  
recommendations for maintenance dosage 
may be used as a guide:
RENAL CREATININE
FUNCTION CLEARANCE DOSE FREQUENCY
mL/min
Mild
impairment 50-30 1-2 g every 8-12 h
Moderate
impairment
Severe
29-10 1-2 g every 12-24 h
impairment 9-5 0.5-1 g every 12-24 h
Essentially 
no function <5 0.5-1 g every 24-48 h
In the patient undergoing hemodialysis, the 
loading dose of 1 -2 g  should be given after 
each hemodialysis, and the maintenance dose 
should be given as indicated in the Table 
above.
Neonates (Including Premature Infants), 
Infants and Children (See WARNINGS for 
Neonates under ADMINISTRATION in the
complete monograph.)
Premature Infants 
with Body Weights 
Above 1500 g 20-40 mg/kg every 12 h I.V.
Neonates
0- 1 week of age
1- 4 weeks of age
20-40 mg/kg every 12 h I.V. 
20-40 mg/kg every 8 h I.V.
Infants
1 month to 2 years 
of age
20-40 mg/kg every 6 h or 
every 8 h I.M. or I.V.
Children 20-40 mg/kg every 6 h or 
every 8 h I.M. or I.V.
In severe infections, the total daily dosage in 
infants and children may be increased to 
200 mg/kg, but not to exceed 12 g per day. 
MEFOXIN* is not recommended for the ther­
apy of meningitis. If meningitis is suspected, 
an appropriate antibiotic should be used.
At present there is insu ffic ien t data to 
recommend a specific dosage for children 
with impaired renal function.However, if the 
administration of MEFOXIN* is deemed to be 
essential the dosage should be modified 
consistent with the recommendations for 
adults (see Table above).
PROPHYLACTIC USE
For prophylactic use, a three-dose regimen of 
MEFOXIN4 is recommended as follows: 
Vaginal or abdominal hysterectomy and 
abdominal surgery
2 g a d m in is te re d  in tra m u s c u la r ly  or 
in tra v e n o u s ly  ju s t p r io r  to  su rg e ry  
(approximately one-half to one hour before 
initial incision).
The second and third 2g doses should be 
administered at 2-6hour intervals after the 
initial dose.
Cesarean Section
The first dose of 2 g should be administered 
intravenously as soon as the umbilical cord 
has been clamped. The second and third 
2 g doses should be given intravenously or 
intramuscularly four hours and eight hours 
after the first dose.
AVAILABILITY
MEFOXIN* (sterile cefoxitin sodium, Frosst 
Std.) is supplied as sterile powder in boxes of 
10 vials:
No. 3356 1 g cefoxitin as sodium salt 
No. 3357 2 g cefoxitin as sodium salt
Storage
MEFOXIN* in the dry state should be stored 
below 30° C.
PRODUCT MONOGRAPH AVAILABLE 
ON REQUEST
5-739
MEMBER
P M A C
| PAAB |
JlOMt
P.O. BOX 1005, POINTE-CLAIRE 
DORVAL, QUEBEC H9R 4P8
Conclusions
The concept of prophylactic breast sur­
gery is not new. It is used in certain 
patients to prevent colonic cancer, cervi­
cal cancer and thyroid cancer. Because of 
the psychosexual importance of the breast 
in our society and the fact that reconstruc­
tion has not been perfected, the ideal 
treatment for high-risk patients has not 
evolved. The indications for such a proce­
dure depend not only on the relative risk 
of breast cancer developing but, more 
importantly, on the patient’s feelings 
about this risk and her and her husband’s 
ability to cope with a potentially poor cos­
metic result. Prophylactic mastectomy is 
indicated, but only in very carefully 
selected patients. If there is any doubt, 
one’s bias should be towards careful, 
close follow-up.
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BOOK REVIEWS
CARDIAC PATHOLOGY. An Integrated 
Text and Colour Atlas. Anton E. Becker 
and Robert H. Anderson. 248 pp. Illust. 
Raven Press, New York, 1983. $80 (US). 
ISBN 0-89004-972-6.
The 16 chapters of this book are equally 
divided between acquired and congenital 
cardiac lesions. One, on cardiac adaptation, 
deals with hypertrophy and dilatation and 
another with interactions between the heart and 
lungs. In six chapters, a variety of acquired 
heart diseases and the pathologic features of 
the aging heart are considered. The separation 
of “ cardiac lacerations” into a chapter seemed 
artificial to me. The lesions illustrated could 
have been included in other sections.
Of the chapters devoted to congenital heart 
diseases, the anatomy of heart chambers and 
of vessels leaving the heart, allowing their 
recognition, is defined in one chapter, which 
also contains a discussion of chamber relation­
ships to permit definition of anomalies and to 
provide a basis for diagnosing congenital heart 
disease. The lesions so defined are dealt with 
in subsequent chapters. A non-expert, on first 
reading, might have difficulty in understand­
ing the text, but persistence is rewarding.
The illustrations are, for the most part, 
superb. The quality of reproduction of Fig. 
1.11 and some of the low-power photomicro­
graphs was poor in my copy. Most photo­
graphs are in colour. Many are complemented 
by explanatory line drawings. They and the dia­
grams, which are simple and pleasingly 
presented, are most useful. The text is succinct, 
emphasizing the functional, and has pertinent, 
if sometimes wonderfully selective, references.
I enjoyed the book and would recommend 
it to cardiovascular pathologists, cardiologists, 
cardiovascular surgeons, pediatricians and all 
interested in heart diseases. All pathology and 
cardiology department libraries should have a 
copy. Even if a reader is not satisfied with the 
text, because the book is not intended to be 
encyclopedic, it is worth having because it is 
a splendid atlas of heart lesions or, as the 
authors prefer, “ a work of art” .
M a lcolm  D . S il v e r , m d , ph  d , fr c pc
Professor and Chairman,
Department of Pathology,
University of Western Ontario,
London, Ont.
N6A 5C1
COLOR ATLAS OF CARDIAC SURGERY. 
Acquired Heart Disease. James L. Monro 
and Gerald Shore. 165 pp. Illust. Appleton- 
Century-Crofts, East Norwalk, Conn., 
1982. $110. ISBN 0-8385-1164-3.
This atlas follows commonly performed oper­
ations for acquired heart disease step by step. 
It covers the gamut of operations, beginning 
with median sternotomy and cardiopulmonary 
bypass and continuing through the various 
valve operations, coronary artery surgery, com­
plications of coronary disease such as left ven­
tricular aneurysm and acquired ventricular sep­
tal defect, and surgery of the intrathoracic 
aorta. General principles of cardiac surgery are 
well presented but the book reflects the bias 
of the authors by specifically pointing out their
continued on page 271
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5. Prophylactic Mastectomy for Precancerous 
and High-Risk Lesions of the Breast
The candidates for prophylactic mastec­
tomy are those who have a family his­
tory of breast cancer, multiple fibrocystic 
masses that have been biopsied or are 
too numerous to biopsy appropriately, or 
patients who previously have had cancer 
in one breast. The decision to perform 
the subcutaneous mastectomy is one 
that must be made by the surgeons 
involved, in consultation with the patient 
and her husband. The data from sub­
cutaneous mastectomies appear promis­
ing and the technical results have 
improved as experience has been gained. 
However, 5 to 10 more years are neces­
sary to determine whether this procedure 
decreases the incidence of breast cancer 
in these high-risk patients.
Les candidates a une mastectomie 
prophylactique sont les patientes qui ont 
des antecedents familiaux de cancer du 
sein, celles qui ont des masses fibrokys- 
tiques multiples qui ont ete biopsiees ou 
qui sont trop nombreuses pour I'etre, ou 
les patientes qui ont deja eu un cancer 
du sein. La decision de proceder a une 
mastectomie sous-cutanee doit etre prise 
par le chirurgien en consultation avec la 
patiente et son conjoint. Les resultats de 
la mastectomie sous-cutanee semblent 
prometteurs et les resultats techniques 
se sont ameliores avec ('experience. 
Toutefois, il faudra de 5 a 10 ans pour 
determiner si cette operation reduit la
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frequence du cancer du sein chez les 
patientes a risque.
In the mind of the public, breast recon­
struction is often a matter of surgery sad­
dled with myths. (Many patients have a 
great interest in the subject, and to advise 
them properly on the action to take, we 
need to re-evaluate the entire area.) To 
manage patients who undergo mam- 
maplasty with the sympathy and the 
empathy that they deserve requires an 
understanding of the multiple and com­
plex meanings of the breast to these 
patients. I shall try to cover this area first, 
to provide background for the decision­
making process and advice to the patients.
Understanding the Patient
It is in the field of breast augmentation 
that we can gain an understanding of the 
importance of this organ to women. Con­
trary to popular belief, the average 
woman seeking breast augmentation is 
not a young single woman who wishes to 
become a show girl, or a divorcee who is 
trying to have the operation to help find 
a new boyfriend or husband. It is usually 
an educated, upper middle-class, happily 
married mother with children who has 
considered the surgery for many years 
and wants the operation for her own 
needs. The husband is usually indifferent, 
although quite supportive of the wishes 
of his spouse.
The earliest reports on this subject were 
by Edgerton and colleagues.I>2 They
reported that the woman seeking breast 
enlargement had feelings of inadequacy 
about her small breasts and a lower self­
esteem and self-confidence than other 
women. Druss3 and Baker and associates4 
reported that following augmentation, the 
patients had more self-confidence, a bet­
ter image and self-esteem, had ready iden­
tification of the implant as part of their 
body and had a very high level of satis­
faction.
However, not until 1977 was a con­
trolled study on the psychological and 
psychiatric aspects of the patients seek­
ing augmentation reported, by Shipley 
and associates.5 They selected first a 
group of 28 patients who had sought aug­
mentation mammaplasty. Then they 
selected two separate control groups for 
comparison from a gynecologic practice, 
selected by a gynecologist who was not 
involved in the evaluation of the patients. 
The first control group comprised 28 
women who, in the opinion of the gyne­
cologist, had breasts of average size; these 
patients served to evaluate the effect of 
differing breast size. The second control 
was composed of 28 women selected at 
random who, in the opinion of the gyne­
cologist, had small breasts but who were 
not seeking augmentation; these patients 
served to evaluate the effect of differing 
motivation. Table I shows that these 
patients had similar basic characteristics. 
In the evaluation of the Ziller Social Self­
esteem Test, the authors found that 
women in the augmentation group (AUG) 
scored higher but admitted to greater self- 
consciousness about their bodies than the
Table 1-Comparison of Patients Seeking Augmentation and Control Groups*
Seeking 
augmentation 
(n -  28)
Control groups
Background
Average breastt 
(n -  28)
Small breastf 
in -  28)
Average age, yr 31 39 33
Married, % 64 61 57
Mean no. of children 2.7 2.9 2.7
Income, $ 16 000 16 000 17 000
"After Shipley and associates.5
tTo evaluate effect of differing breast size.
+To evaluate effect of differing motivation.
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average-breast control (ABC) patients 
and the small-breast control (SBC) 
women. This was in agreement with the 
previous reports by Edgerton1,2 in that 
those in the AUG group were generally 
attractive and aware of their attractive­
ness, but nevertheless were self-conscious 
about the small size of their breasts. More
Fig. la
Fig. lb
FIG. 1—(a) Patient with multiple fibro­
cystic masses referred by general surgeon 
for removal of breasts, (b) Using transverse 
incisions over dome, total mastectomy was per­
formed in subcutaneous plane leaving very thin 
layer of skin and subcutaneous tissue. Prosthe­
sis was placed underneath pectoralis major 
muscle in large pocket that included dissection 
under serratus anterior muscle.
FIG. 2—“ Hemispheric dome” deformity 
seen when fibrous tissues of healed surgical 
plane contracted around breast prosthesis 
placed in subcutaneous pocket.
importantly, however, the Attitude 
Towards Women Scores and the Califor­
nia Psychological Inventory Scores indi­
cated that patients in the AUG and ABC 
groups had similar personalities, whereas 
the SBC patients were more liberal, 
“ feminist” , independent, cognitively 
resourceful and intellectually oriented. 
The authors concluded that “ In contrast 
to the previous uncontrolled studies. . . 
mammaplasty women scored as psycho­
logically healthy and they were compara­
ble to the average breast size controls with 
whom they seek physical identifica­
tion.” 5'The SBC group was statistically 
the most different.
In a later study, Hetter6 found that 
women seeking augmentation mam­
maplasty identified with “ feminine 
women” , had a positive body image and 
a greater interest in styles and fashion 
than the average woman. Marcia Goin7 
pointed out in her book that “ the breast, 
while consciously representing sexuality 
and womanly attractiveness to adults, 
unconsciously really represents the 
mother” . This statement is based on the 
work of Sigmund Freud8 in which he 
pointed out that the mother’s breast is the 
first “ object” that the infant experiences 
in the awareness of the existence of 
others; as the infant grows emotionally 
and psychologically, the breast, which 
was only a part of the mother, is now 
completed into the “ total person” of the 
mother. All this and the importance that 
our society has placed on the beautifica­
tion of the breast in art and advertising 
have led to the prominence of the breast 
in representing womanliness and femi­
ninity.
Women at High Risk
To paraphrase Dr. Mayo, “ It is the 
right of every woman to want to look nor­
mal.” To achieve this, we must be able 
to advise our patients on the proper med­
ical care for diseases and lesions of the 
breasts, while at the same time be aware 
of the importance of reconstruction. The 
previous speakers in this symposium have 
already provided the data and docu­
mented the number of publications that 
have reported lesions and other factors 
pointing to the patients who are at high 
risk for breast cancer. In general, they are 
women who have a particular family his­
tory of breast cancer. The patient who has 
had cancer in one breast runs a higher risk 
of having cancer in the opposite breast 
and patients with severe fibrocystic dis­
ease also have a higher incidence of breast 
cancer than the general population.
The subject of familial breast cancer is 
beginning to receive more attention. In 
1980, Lynch and colleagues9 found that 
approximately 20% of the 75 consecutive 
women with breast cancer whom they 
evaluated had a family history of breast
cancer. Characteristically, these patients 
have breast cancer of early onset (i.e., in 
the third or fourth decade of life). Lynch 
and associates used several of these 
patients, whose families were in various 
stages of the cancer genetic evaluation, to 
illustrate a hypothetical cancer pedigree 
that was compatible with what was cus­
tomarily observed in families with 
autosomal dominant, inherited disorders. 
They postulated that the early onset of 
breast cancer in these cases may be a 
genetic mutation; approximately one half 
of the female descendants of a gene car­
rier may be similarly affected. These types 
of genetic evaluation are essential for our 
better understanding of the increasingly 
frequent occurrence of breast cancers of 
early onset. It is also essential that we 
have verification, if these findings are 
valid, from other centres as well.
Indications for Prophylactic 
Mastectomy
Prophylactic mastectomy now appears 
to be indicated in patients with lobular 
carcinoma in situ, intraductal carcinoma, 
cancer of the breast in the immediate 
family or chronic fibrocystic disease of 
the breast with multiple lesions in a given 
patient, or multiple previous biopsies with 
persistent breast cysts, or both. The last 
group presents a difficult problem for the 
general surgeon in trying to determine 
which cyst should be biopsied next. Mam­
mography becomes very difficult because 
of the multiple cysts; thus, one potential 
treatment is prophylactic mastectomy.
The Procedure
In general, these patients can be treated 
with either a simple mastectomy or a sub­
cutaneous mastectomy in which the skin 
over the breast is preserved with or 
without the nipple areola (Fig. I). The 
thinnest possible layer of breast skin is 
preserved so that not only is the breast 
gland removed but as much of the sub­
cutaneous tissue as possible between the 
overlying skin and the gland. This is done 
because it is very difficult to know where 
the breast gland begins or ends since it is 
not an encapsulated organ. The mound 
is best reconstructed with a Silastic breast 
prosthesis. The prosthesis used to be 
placed over the pectoralis major muscle 
and underneath the skin. However, sub­
sequent scarring resulted in capsular con­
tracture deformities in approximately 
80% of these patients (Fig. 2).
Our experience with breast reconstruc­
tions following simple or modified radi­
cal mastectomies demonstrated that the 
placement of the silicone prosthesis 
behind the pectoralis major muscle 
decreased the degree of capsular contrac­
ture and allowed for a more gradual con­
tour on the chest wall that made the result
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infinitely better. For that reason better 
cosmetic results are achieved when the 
prosthesis is placed behind the pectoralis 
major and serratus anterior muscles.
Subcutaneous mastectomy can also be 
performed in patients with a strong family 
history of breast cancer (Fig. 3). Occa­
sionally, patients with very large breasts 
seek prophylactic mastectomy and this 
presents a greater problem. In these cases, 
the operation is often a simple mastec­
tomy with reconstruction of the breast 
mounds using portions of the breast skin 
(Fig. 4). Indeed, the most difficult 
patients are those with asymmetry. For 
them a combination of subcutaneous 
mastectomy and a mastopexy may pro­
vide symmetry.
Finally, patients with intraductal car­
cinoma can be treated with bilateral sim­
ple mastectomy with immediate recon­
struction (Fig. 5). The nipple areola 
should be removed and reconstructed 
with local tissue and skin grafts when the 
scar around the prosthesis has matured 
and the dome is properly positioned.
Discussion
An important issue in the discussion of 
prophylactic mastectomy is the amount 
of breast tissue that is removed. Although 
we remove as much of the breast tissue 
and subcutaneous fat as we can without 
devascularizing the overlying skin, it is 
not possible to perform a true complete 
mastectomy. Goldman and Goldwyn10 
demonstrated in subcutaneous mastecto­
mies performed on cadaver specimens 
that samples of the fat taken from the 
breast skin occasionally showed micro­
scopic areas of breast tissue remaining. 
We estimate that at best we remove 
90% to 95% of the breast tissue. 
However, even in a simple mastectomy, 
it is unlikely that the mastectomy is com­
plete. Microscopic amounts of breast tis­
sue are left behind in the infraclavicular 
area as well as in the axillary tail of 
Spence; perhaps at best 95% to 98% of 
the breast tissue is removed with this tech­
nique. Even with a radical mastectomy 
where the chest skin is removed and may 
require a skin graft, at best 98% to 99% 
is being removed. The issue at hand is not 
whether 98% is better than 95% which 
is better than 90%, but whether or not the 
microscopic tissue that is left behind will 
undergo transformation to malignant 
tissue.
I contend that breast cancer develops 
from within the gland, and grows to the 
surface to involve the overlying skin only 
in advanced cases, rather than beginning 
as cancer in the breast tissue underlying 
the subcutaneous layer of the skin. If that 
is correct, then it is unlikely that cancer 
will develop in the remnant microscopic 
breast tissue. The opposite could also 
be true: that the small amount of breast
tissue remaining “ will take the on­
slaught” of the circulating hormones; 
however, there is no evidence that this is 
the mechanism of the development of 
breast cancer. If we are to assume that the 
earliest breast cancer that can be detected 
weighs 1 g, and 1 g of tissue in the body 
contains 109 cells, we can see that it 
takes approximately 30 doubling times to 
reach this number of cells from one origi­
nal malignant cell. Sparks11 has pointed 
out that the doubling time of breast 
cancer tissue cultures varies tremen­
dously: from 23 to 209 days. If this is the 
case, it will take between 2 and 17 years 
before the 30 doubling times are achieved 
to make the earliest detection of a malig­
nant tumour at 1 g. This appears to be 
the most logical explanation for the 
development of breast cancer, and if it is 
correct, the performance of subcutaneous 
mastectomy should lead to a decreased 
incidence. However, only long-term 
follow-up of these patients will be able to 
tell whether or not this is indeed correct.
Fig. 3b
FIG. 3—(a) Preoperative appearance of 
breast of married woman, 32 years old with 
family history of breast cancer, who desired 
subcutaneous mastectomy because she wished 
to have children and was concerned about 
effects of hormonal stimulation on her breast 
tissue during pregnancy, (b) Appearance 4 
years after operation. Patient has had two chil­
dren and does not wish to have nipples recon­
structed although this has been offered.
Another question is whether the nipple- 
areola complex should be removed with 
the gland. In one study by Parry and 
associates,12 250 breasts that were 
removed because of invasive breast cancer 
were thoroughly examined by multiple 
sections. Histologic evidence of nipple 
involvement was found in 16 cases, 14 of 
which were determined clinically before 
operation to be involved; only 2 cases 
were found histologically without clinical 
evidence preoperatively (Table II). It 
appears, therefore, that areolar involve­
ment is uncommon in the absence of clin­
ical manifestation and proximity of the 
primary tumour to the nipple areola.
FIG. 4—Postoperative view of breasts of 
woman in mid-30s who had multiple fibrocystic 
masses of both breasts. Her 48-year-old sister 
had undergone mastectomy for invasive cancer. 
Patient was treated by bilateral total mastec­
tomy, with prostheses placed behind pectoralis 
major muscle. Dome of mounds was de- 
epithelialized and skin grafts were used for nip­
ple and areolar reconstruction. ^
FIG. 5—Postoperative appearance of patient 
with intraductal carcinoma proven by inci­
sional biopsy. She was treated by bilateral sim­
ple mastectomy and immediate reconstruction 
of mounds. Following maturation of scar tis­
sue around operative site, nipples and areolas 
were reconstructed using local tissue for nip­
ple and thigh skin grafts for areola.
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can be removed from the wound in one piece without 
leaving fibrous residues. When left in wounds inside 
the body, it resorbs quickly, thus minimizing the 
formation of adhesions. In contact with blood it gels 
only at the boundary forming an occlusive layer. This 
layer physically blocks the ruptured vessels and 
reduces the undesirable tendency toward rapid 
saturation of the material, thereby retaining optimum 
hemostatic efficacy.
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The control of diffuse blood oozing in any tissue 
where it is impractical or impossible to use ligation or 
other conventional surgical procedures.
CONTRAINDICATIONS
After hemostasis is achieved, MALLITENE should not 
be left in the wound if used in infected or 
cosmetically important areas. This applies to all 
collagen or gelatin based topical hemostatic agents.
HANDLING INSTRUCTIONS
Dry MALLITENE of desired size is applied to a 
bleeding wound, under moderate pressure. It is 
preferable for excessive blood to be removed from 
the bleeding site before covering it with MALLITENE. 
The cohesiveness of MALLITENE allows the 
application by hand (it does not adhere to rubber 
gloves) or by forceps or clamp. MALLITENE can be 
cut with scissors or folded to the desired size. A 
patch of MALLITENE can be sutured over the 
bleeding tissue if so required. After achieving 
hemostasis, MALLITENE may be removed without 
leaving fibrous residues.
WARNINGS
The contents of the package are sterile until opened. 
No method of resterilization is recommended. In 
patients with low platelet count or low clotting factor 
activity, the efficacy of MALLITENE is reduced.
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Nevertheless, if there is any question, the 
nipple or areola, or both, should be 
removed with the breast since both can 
be reconstructed.
Data are now accumulating on patients 
treated by subcutaneous mastectomy. 
Pennisi and Capozzi13 in 1975 reported 
on 1385 patients treated by 50 surgeons; 
they reported 82 cases of occult carci­
noma (6% incidental finding of malig­
nant cells within the breast tissue). They 
also reported that carcinoma developed 
subsequently in 0.5% of 4179 patients. In 
1979, Pennisi14 reported an incidence of 
0.1 % among 1000 subcutaneous mastec­
tomies and in 1983 Woods15 reported a 
0.2% rate among 900 patients.
Subcutaneous mastectomy has been 
criticized by those who believe it is not 
“ prophylaxis” . The severest critic has 
been Louren J. Humphrey who wrote in 
an editorial16 that standards of surgical 
care “must. . . be developed from 
knowledge o f numbers, from critical 
analyses o f studies, and not from argu­
ments based on opinions or some quix­
otic use o f invalid data” . Nevertheless, 
he based the strength of his argument on 
a personal communication with Dr. Jer­
ome Urban who related his experience on 
a panel discussion on prophylactic 
mastectomy held in New York City in 
1982 by the American Society of Plastic 
and Reconstructive Surgeons. Report­
edly, Dr. Urban had asked for a show of 
hands of surgeons in the audience who 
had experienced the appearance of cancer 
in a patient who had previously under­
gone subcutaneous mastectomy, and that 
Dr. Urban told him that “ at least 90 to 
100 hands were raised (personal commu­
nication)” .16 Unfortunately, Dr. Hum­
phrey’s arguments are also not based on 
numbers.
Indeed, it will take an experience of 10 
to 20 years to be able to determine 
whether or not the incidence of breast 
cancer following subcutaneous mastec­
tomy is reduced in comparison with that 
in the normal population. Currently, the 
likelihood of a young woman suffering 
from breast cancer in her lifetime is 
9%.17 Women who undergo subcutaneous 
mastectomy are those who are considered 
to run a greater than 9% risk of having 
breast cancer. The reported data to date,
Table 11-Nipple Involvement in 
200 Cases of Breast Cancer*
No. of
Findings patients
Nipple involvement 16
Clinical observation preop 
Ulceration 4
Retraction 5
Fixation 5
Negative 2
‘ From Parry, Cochran and Wolfort.12
an experience between 5 to 10 years, indi­
cates that the incidence of breast cancer 
after prophylactic subcutaneous mastec­
tomy is less than 0.5% .13-15 Further col­
lection o f data will be able to substanti­
ate whether or not the incidence is kept 
low following subcutaneous mastectomy. 
Indeed, until this information is fully 
available, we cannot consider subcutane­
ous mastectomy to be truly “ prophyl­
axis” .
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Chairman’s Comments
Two types of data have been discussed in 
this symposium. First, scientific observa­
tions on the incidence and definition of 
these diseases have been presented and 
second, there has been discussion about 
the interpretation of some of these 
statistics.
It seems clear from the discussions of 
Drs. Schechter and Wolmark that some 
lesions can be categorized pathologically 
with respect to risk of frank carcinoma 
developing. These data, when compared 
to the established statistical risk for the 
average woman, give us a yardstick by 
which to make judgements. When we 
move to the area of intervention, we leave 
the security of statistical reliability and 
enter the uncertainty of interpretation, 
opinion and bias.
Dr. Ariyan has demonstrated the feasi­
bility of reconstructive surgery following 
mastectomy. The technique seems to be 
established for prophylactic or therapeu­
tic mastectomy and for the subcutaneous 
or total versions. However, the interven­
tion has been extended to women with 
ordinary fibrocystic disease — a type not 
normally associated with higher cancer 
risk; it is even suggested in some cases for 
women with multiple simple cysts whose 
management is difficult in terms of recur­
rence. Do all these clinical problems 
require a solution that seems to be 
radical?
When all these statistics and opinions 
are presented to an experienced clinical 
surgeon, it becomes very difficult to for­
mulate concrete proposals. Dr. Ketcham 
(see editorial in this issue, pages 194 and 
195) prefers to allow the patient a key role 
in the decision. He thinks that sufficient 
evidence is lacking to conclude that any 
of these lesions are precancerous, and he 
would like to obtain more scientific infor­
mation through follow-up, in order to 
acquire a better base for decision-making 
in the absence of reliable information. We 
cannot expect patients to make better 
medical decisions than doctors, so that, 
for the present, the patient’s decisions 
become choices based on personal prefer­
ence rather than scientific conclusions.
The essence of the problem for clini­
cians is that little clinical information 
exists. The large number of cases com­
piled by Pennisi and Woods (cited by 
Ariyan) are a pot-pourri of diagnoses 
ranging from minimal cancer and precan­
cerous lesions to benign fibrocystic dis­
ease, painful cystic change, family histo­
ries of uncertain risk and even cancer 
phobia. Without an adequate definition 
of the denominator, one cannot expect 
the numerator to give a reliable indica­
tion of the probability of cancer being 
prevented. Thus, the fact that few cancers 
appear in the follow-up years doesn’t 
necessarily mean that the operation is 
preventing cancer. We don’t know how 
many of those patients would have in­
vasive cancer without the operation.
This symposium has indicated that 
women with intraductal cancer, and to a 
certain extent those with lobular carci­
NO TICES
continued from page 255 
Cardiovascular Surgery will be held Nov. 
17-21, 1985, in Bangkok, Thailand. The 
meeting is sponsored by the Association 
of Thoracic and Cardiovascular Surgeons 
of Asia, hosted by the Society of Thoracic 
and Cardiovascular Surgeons of Thailand 
and supported by the Royal College of 
Surgeons of Thailand, the Heart Associ­
ation of Thailand and Chulalongkorn 
University. English will be the official lan­
guage for the congress, which will include 
guest speakers, plenary sessions, sympo­
sia, scientific films and exhibits.
Information concerning the congress 
and travel arrangements can be obtained 
from Interport, Ltd., PO Box 338, Sun­
set Beach, CA 90742; (213) 592-4446; 
Telex 910-380-5385 (Interport SSBH).
Breast and Endocrine Surgery
The Department of Surgery of the 
University of Minnesota Medical School 
is holding its 49th Annual Surgery Course, 
June 24-26, 1985, at Willey Hall, Univer­
sity of Minnesota, Minneapolis, Minn. 
The major topic of the course will be 
breast and endocrine surgery. The regis­
tration fee is $400 (1200 for residents) 
and accreditation will be 22 hours in 
AMA Category 1.
For more information contact: the 
Office of Continuing Medical Education,
noma in situ, run an increased risk of hav­
ing invasive cancer. Applying other risk 
factors can help define subgroups of 
patients who are at yet higher risk for 
future cancer development. Dr. Schechter 
suggests that this technique may help 
identify a smaller subgroup of patients in 
whom 80% of the potential cancers will 
occur. For the present, this seems to be 
the best lead we have towards a rational 
application of this procedure.
Although it can be assumed that total 
bilateral mastectomy can prevent cancer, 
it is not yet possible to predict which 
women are at high enough risk and we 
cannot achieve consensus on recommend­
ing this operation. There is even more 
uncertainty about relying on subcutane­
ous mastectomies instead of total mastec­
tomies. Finally, there is an unresolved 
controversy about the need to consider, 
for prevention, surgery that is more 
extreme than one would actually recom­
mend for treatment of invasive ductal 
cancer. Although prospective controlled 
studies would obviously contribute to our 
understanding, none are at present on the 
horizon.
Richard G. Margolese, md, frcsc
Symposium chairman
Department of Surgery,
Sir Mortimer B. Davis-
Jewish General Hospital,
Montreal, PQ 
H3T 1E2
University of Minnesota, Box 293, 420 
Delaware St. SE, Minneapolis, MN 
55455; (612) 373-8012.
American Association 
for Hand Surgery
The 15th annual meeting of the Ameri­
can Association for Hand Surgery will be 
held Oct. 24-27, 1985 at the Vista Inter­
national Hotel, Kansas City, Missouri.
For further information contact: Myra 
Josephson, Central Office Manager, 
American Association for Hand Surgery, 
Ste. 218, 2934 Fish Hatchery Rd., Madi­
son, WI 53713; (608) 272-8940.
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Ask fo r  lint-free Ask fo r  dye free
1. Rewashed laparotomy sponge
2. RAY-TEC* disposable laparotomy sponge
3. Imported disposable laparotomy sponge
Every time a laparotomy sponge is laundered, lint 
content increases. Lint has been shown to cause 
adhesions due to granulomas.12
AskforSAY-m
inoum  : ac
1. Optical brighteners in rewashed 
laparotomy sponge
2. No optical brighteners in RAY-TEC* 
disposable laparotomy sponge
3. Optical brighteners in imported \disposable 
laparotomy sponge
Optical brighteners found in most disposable 
laparotomy sponges or picked up from detergents 
during laundering are suspected o f affecting wound 
healing.3
•  virtually lint free
® no optical brighteners and dye 
softer, whiter
•  longer, softer and absorbent new tab 
9 guaranteed aseptic presentation
Yours for the asking
RAY-TEC' x-ray detectable disposable laparotomy sponges are totally 
Canadian made
1. Sturdy BCr. Surgical Sponges: A cause of granulomas
2. Ellis: The cause and prevention o f  post-operative int 
J. Baron H: The Danger from a Surgical Point o f View
Median, Akademie au Dusseldorf. Translation from
* Trademark o f  JOHNSON &  JOHNSON € ) Jol
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Splenic Abscess
Abscess of the spleen is a rare entity. It 
may develop after generalized infection, 
hematologic disorders and trauma. The 
authors report the case of a 7-year-old 
boy who presented with a 2-month his­
tory of spiking fever, anorexia, fatigue 
and weight loss. He had left subcostal 
tenderness and a palpable spleen. He 
had a history of trauma to the left flank 
5 months before admission but a splenic 
scan obtained at that time appeared nor­
mal. A splenic abscess was diagnosed 
by gallium scanning, computerized 
tomography and ultrasonography.
Although splenectomy has been advo­
cated as the treatment of choice for 
splenic abscess, this patient was treated 
successfully with appropriate antibiotics 
and simple drainage, preserving the 
spleen. Cultures grew Staphylococcus 
aureus. Of all the diagnostic methods 
available, ultrasonography is the least 
invasive study that will make the diagno­
sis and is less expensive than some 
methods.
L'abces splenique est rare. II peut surve- 
nir a la suite d'une infection generalisee, 
d'un probleme hematologique ou d'un 
traumatisme. Les auteurs decrivent le 
cas d'un garcon de 7 ans qui fut hospita­
lise souffrant des clochers thermiques, 
d'anorexie, de fatigue et de perte de 
poids. II presentait une douleur sous- 
costale gauche et sa rate etait palpable. 
On relevait des antecedents de contusion 
au cote gauche subi 5 mois avant 
I'entree a I'hopital mais une scintigraphie 
splenique pratiquee a ce moment avait 
semble normale. Un abces splenique fut 
diagnostique par scintigraphie au gallium.
From the *Department o f  Surgery and 
t Department o f  Radiology, Children’s 
Hospital o f Eastern Ontario, Ottawa, Ont.
Accepted fo r  publication July 27, 1984
Reprint requests to: Dr. G. Stringel, 
Department o f Surgery, Children’s Hospital 
o f  Eastern Ontario, 401 Smyth Rd.,
Ottawa, Ont. K1H 8LI
tomographie axiale par ordinateur et 
echographie ultrasonique.
Bien que la splenectomie ait ete preco- 
nisee comme traitement de choix de 
l'abces splenique, le patient fut traite 
avec succes par antibiotherapie approp- 
priee et simple drainage, avec conserva­
tion de la rate. Les cultures revelerent du 
Staphylococcus aureus. De tous les 
moyens diagnostiques disponibles, 
I'echographie ultrasonique est le moins 
envahissant et il est moins couteux que 
certaines methodes.
Splenic abscess, although it has long been 
recognized, is a rare condition. It may 
develop after generalized infection, 
hematologic disorders or trauma.1-3 The 
overall mortality is about 39%, ranging 
from 15% to 100%.1-3
We report the case of a child with a 
splenic abscess, accurately diagnosed by 
gallium scanning, computerized tomo­
graphy and ultrasonography, who was 
successfully treated by drainage and anti­
biotic therapy, thereby preserving the 
spleen.
Case Report
A 7-year-old boy was admitted with a 
2-month history of spiking fever, anorexia, 
fatigue and weight loss of 1.4 kg. Two days 
before admission a cough developed associat­
ed with vomiting. He appeared chronically ill, 
pale and tired. His temperature was 39.4°C 
and pulse 124 beats/min. He had moderate left 
subcostal tenderness and a palpable spleen.
He had been born with a cervical menin­
gocele, which was successfully repaired but 
required a ventriculoperitoneal shunt. At 1 year 
of age, he had a Staphylococcus aureus infec­
tion of the shunt, requiring removal and antibi­
otic treatment; reinsertion of the shunt was not 
necessary. Five months before admission he 
injured his left side in a fall. He suffered left 
shoulder-tip pain, which subsided rapidly. He 
was examined at the hospital but no other 
problem was found. Because of splenomegaly, 
splenic scanning was done. This did not show 
rupture; he was thought to have a “mononucle­
osis-like illness” , although his mononucleo­
sis spot test gave negative results. He remained 
asymptomatic for 2 months.
On admission, his leukocyte count was 19.5 
x 109/L  with 83% polymorphonuclear leu­
kocytes. The hemoglobin level was 97 g/L, the 
erythrocyte sedimentation rate was 58 m m /h 
and mononucleosis spot test gave negative 
results. The bone marrow was very active and 
cellular with increased plasma cells. Serum elec­
trolyte levels and results of liver function tests 
were normal; protein electrophoresis showed 
elevated levels of «] and cxi globulins; the 
immunoglobulin A level was also elevated. 
Blood and urine cultures did not grow any 
organisms. Haemophilus influenzae was iso­
lated from the tracheal aspirate and beta hemo­
lytic streptococcus from a throat swab.
The chest roentgenogram showed an 
infiltrate in the lower lobe of the left lung; plain 
abdominal films were not helpful.
Liver-spleen scanning showed splenomegaly 
(Fig. 1). Gallium scanning demonstrated 
intense focal uptake in the spleen (Fig. 2), and 
computerized tomography (Fig. 3) and 
ultrasonography (Fig. 4) showed a collection 
of fluid with solid elements along the superior 
medial aspect of the spleen that was considered 
to be subcapsular.
A large splenic abscess was drained of 200 
mL of pus through a left subcostal incision. 
Because the abscess was confined to the left 
upper quadrant of the abdomen and sealed by 
omentum, care was taken not to contaminate 
the peritoneal cavity; two large Penrose drains 
were inserted. Cultures grew S. aureus resis­
tant to ampicillin and penicillin but sensitive 
to cloxacillin, cefamandole and clindamycin.
FIG. 1—Liver and spleen scanning with 
technetium 99m (left posterior view) shows 
splenomegaly and displacement of spleen.
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Preoperatively the boy was treated with 
ampicillin and clindamycin. Postoperatively he 
received cefamandole intravenously for 2 weeks 
and subsequently cloxacillin orally for 2 more 
weeks. The Penrose drains were gradually 
removed over a period of 5 days, starting 5 
days after his operation.
Postoperatively the boy remained afebrile. 
His recovery was smooth and he returned home 
2 weeks after operation. Ultrasonography 2 
weeks and 6 weeks after operation showed 
gradual resolution of the splenic defect, and 
a final examination at 3 months gave normal 
findings. At follow-up 6 months after opera­
tion he was asymptomatic.
Discussion
Splenic abscess is a rare condition and 
most cases occur in adults. In a recent 
report by Chun and associates,1 only 27 
of 153 patients were under 19 years of age 
and only 9 were children under 10 years 
old.
The spleen is a critical line of defence 
when the host is invaded by blood-borne 
bacteria; the unique, sophisticated splenic 
filter, which receives 5% of the blood 
volume per minute, traps bacteria and 
particles larger than 2.5 /un which are 
subsequently eliminated by various 
mechanisms. The spleen is the main site 
of clearance of microorganisms when the 
host has little or no pre-existing antibody 
and it is where specific immunoglobulin 
M (IgM antibody) is initially synthe­
sized.1,4,5
Although the spleen is frequently in 
contact with blood-borne bacteria, it 
rarely becomes infected. This is supported 
by the rarity of splenic abscesses in clini­
cal practice and the low frequency of 
splenic abscesses in autopsy series.1
Bacteremia is the first requisite for 
splenic abscess and most likely a func­
tional or anatomical defect is present for 
the abscess to develop. Several predispos­
ing factors have been recognized, such as
FIG. 2—Gallium scanning shows intense 
focal uptake in spleen.
infarcts, trauma with hematoma forma­
tion and hemoglobinopathies. Another 
rare cause of splenic abscess is the direct 
extension of infection from contiguous 
organs.1
In our case, trauma was documented 
5 months before admission and although 
splenic rupture was considered, this was 
not demonstrated by scanning done 1 
week after injury. It is possible that the 
splenic laceration was too small to be 
detected by this examination.
The child had also had an S. aureus 
infection in a ventriculoperitoneal shunt 
at 1 year of age; we are not sure whether 
this infection played a role in the develop­
ment of the splenic abscess.
The most common signs and symptoms 
associated with splenic abscess are fever, 
abdominal pain, pleuritic chest pain, 
abdominal tenderness in the left upper 
quadrant, splenomegaly or a mass palpa­
ble in the left subcostal area and leukocy­
tosis. Other common symptoms and signs 
are weakness, nausea, vomiting, ano­
rexia, cough, diaphoresis, weight loss and 
altered bowel habit. Auscultatory abnor­
malities may be present on the left lower 
side of the chest as well as signs of pleural 
effusion or consolidation.13
Chest roentgenography may show a left 
pleural effusion and consolidation or 
pneumonic infiltration in the left lower 
lobe. Plain abdominal films may show a
FIG. 3—Computerized tomogram of upper 
abdomen reveals subcapsular collection of fluid 
in spleen. A = abscess.
FIG. 4—Transverse ultrasonogram of spleen 
also demonstrates subcapsular collection of 
fluid. A = abscess, L = left side.
mass in the left upper quadrant or dis­
placement of the gastric shadow, but 
these findings are not specific.
Ultrasonography, computerized tomo­
graphy, gallium and " mTc liver-spleen 
scanning and arteriography are specific 
studies to recognize splenic abscesses.1'3
In our case, the best of these methods 
were ultrasonography (Fig. 4) and com­
puterized tomography (Fig. 3). Both 
studies demonstrated the abscess and its 
subcapsular location. Gallium scanning 
(Fig. 2) showed intense uptake in the area 
of the spleen but this was not specific for 
splenic abscess. Liver-spleen scanning 
(Fig. 1) did not contribute to the diagno­
sis except to exclude splenic rupture and 
liver involvement. Arteriography was not 
done. Our findings confirmed the 
experience of others2 who recommended 
ultrasonography as the least-invasive 
study that will make the diagnosis and is 
also one of the less expensive methods.
Streptococcus is the most common 
organism in splenic abscess followed 
closely by S. aureus (as in our patient), 
Salmonella sp. and other gram-negative 
bacilli; the presence of pus with sterile cul­
ture has also been reported.1,3
Splenectomy has been advocated as the 
treatment of choice for splenic abscess;1,3 
our patient was successfully treated with 
appropriate antibiotics and simple 
drainage. We recommend this approach 
as the initial treatment of choice, espe­
cially in children in whom preservation of 
the spleen is vital, to avoid the dangers 
of overwhelming postsplenectomy infec­
tion that is associated with 50% mor­
tality.6 Care must be taken not to 
contaminate the peritoneal cavity. Broad- 
spectrum antibiotics should be given 
before operation until the final culture 
and sensitivity results are obtained. 
Antibiotics should be continued intra­
venously for 2 weeks then orally for 2 
more weeks. Follow-up ultrasonography 
should be done at intervals until the defect 
has resolved.
With the current emphasis on preserv­
ing the spleen in blunt abdominal trauma, 
we should see fewer overwhelming post­
splenectomy infections, but the frequency 
of splenic abscess may increase.
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Framycetin-Sulphate B.P. 1 % 
Antibiotic
Indications:
Treatment of infected or poten­
tially infected burns, crush injuries, 
lacerations. Also varicose ulcers, 
bedsores, ulcerated wounds and 
graft sites.
Contraindications:
Known allergy to lanolin of framy- 
cetin. Organisms resistant to 
framycetin.
Precautions:
In most cases where small areas 
are covered with the tulle, absorp­
tion of the antibiotic is so slight 
that it can be discounted. 
However, where very large body 
surface is involved (e.g. 30% or 
more body area), the possibility 
of ototoxicity and nephrotoxicity 
being eventually produced must 
be considered. Prolonged use of 
antibiotics may result in the 
overgrowth of non-susceptible 
organisms, including fungi. 
App'ropriate measures should 
be taken if this occurs.
Dosage:
A single layer to be applied di­
rectly to the wound and covered 
with an appropriate dressing. If 
exudative, dressing should be 
changed at least daily. In case of 
leg ulcers cut dressing accurately 
to size of ulcer.
Supplied:
A lightweight, lano-paraffin gauze 
dressing impregnated with 1 % 
framycetin sulphate B.P.: avail­
able in 2 sizes: 10 cm by 10 cm 
sterile single units, cartons of 10 
and 50; 10 cm by 30 cm sterile 
single units, cartons of 10.
Store in a cool place.
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techniques, which in many instances differ 
from those of other institutions around the 
world.
Only 165 pages long, the book can easily be 
read in a single evening. The quality of the 
colour photographs is excellent and the under­
lying legends are helpful.
A perusal of this book by junior residents 
in cardiovascular surgery early in their train­
ing program would be very appropriate. This 
book, therefore, should be in libraries of insti­
tutions concerned with training residents in 
cardiac surgery.
E lliot T. Gelfand , m d , facs, frcsc 
Ste. 550,
8409-112th Street,
Edmonton, Alta.
T6G 1K6
CO M PLICATIONS OF FRACTURE  
MANAGEMENT. Edited by Harry R. 
Gossling and Stephen L. Pillsbury. 565 pp. 
Illust. J.B. Lippincott Company, Philadel­
phia, 1984. $67.50 (US). ISBN 0-397- 
50584-1.
In the foreword to this book, the point is made 
that complications of fractures are to be 
expected given the nature of trauma (e.g., high- 
velocity injuries), old age, patient’s poor state 
of health and variations of early treatment. 
Also, complications will arise from treatment 
or failure of definitive treatment; these com­
plications are avoidable. Generally, this book 
is directed to those responsible for tertiary care 
of injured patients.
Andrew Bassett describes in detail current 
concepts of the physiology of fracture healing, 
including its bioelectric aspects. This serves as 
a basis for a general description of his recom­
mended electrical management of ununited 
fractures. The chapter on management of soft- 
tissue complications associated with fractures 
stresses the close mutual relationship now 
necessary between orthopedic and plastic sur­
geons, especially since the advent of microsur­
gery and use of free flaps.
Peter Trafton’s thoughtful and beautifully 
written chapter on infected fractures should be 
read frequently by orthopedic trainees and at 
least once a year by every orthopedic surgeon. 
There is a scholarly study of the theoretical 
aspects of shock and a detailed discussion of 
the modern methods of management of shock 
with no fewer than 263 references.
Neurologic, vascular and pulmonary com­
plications of fractures are adequately discussed 
in separate chapters. Injury to abdominal 
organs, and metabolic and gastrointestinal 
complications receive considered attention. 
Finally, a chapter on the general complications 
of fracture management constitutes one third 
of the book.
Based on an obviously extensive experience 
with metastatic bone disease, Harrington, in 
his chapter on the management of pathologic 
fractures, provides detailed information on 
the timing and effective use of internal fixa­
tion and methylmethacrylate. Salter’s clearly 
written and illustrated chapter on epiphyseal 
plate injuries reflects the author’s extensive 
knowledge and experience in pediatric ortho­
pedic surgery.
The last 13 chapters are concerned with 
regions and limb areas. Complications of cer­
vical spine injuries are well detailed with illus­
trative case reports and excellent roentgeno­
grams. Complications of fractures of the 
thoracic and lumbar spine are completely dis­
cussed, with special reference to the physiol­
ogy of patients with spinal cord injuries. 
Stabilization of these fractures with rods and 
sublaminar wire fixation is surprisingly omit­
ted. Hemorrhagic and urologic complications 
of sacral and pelvic fractures rightly take prece­
dence over the management of complex pel­
vic and acetabular fractures by internal or 
external skeletal fixation. The 10 chapters on 
fractures affecting specific limb areas are 
detailed, well edited and contain very few poor 
reproductions of roentgenograms. The biblio­
graphy includes the relevant modern publica­
tions and the index is sufficiently detailed to 
allow this book to be used efficiently as a refer­
ence text in orthopedic training centres and by 
orthopedic and trauma surgeons.
J .P . M oreau , m d , facs, frcsc
Chief of Orthopedic Surgery,
Edmonton General Hospital,
Edmonton, Alta.
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AN INTRODUCTION TO NEUROSUR­
GERY. 4th ed. Bryan Jennett and Sam Gal­
braith. 360 pp. Illust. William Heinemann 
Medical Books Ltd., London; Year Book 
Medical Publishers, Inc., Chicago, 1983. 
$49.95. ISBN 0-8151-4869-0.
This small-format text was first published in 
1964. The 360 pages of the fourth edition are 
divided into six sections: intracranial space- 
occupying lesions, particular intracranial 
lesions, head injuries, spinal lesions, congeni­
tal conditions and lesion-making in the nervous 
system.
As in past editions, the text is not compre­
hensive, but rather a “primer” designed to 
inform the nonspecialist about the recognition, 
diagnosis and management principles applica­
ble to neurosurgical conditions. Each chapter 
comprises an orderly progression from the neu­
rologic examination, through differential diag­
nosis and diagnostic tests to management prin­
ciples. All these are illustrated by clear, easily 
comprehensible line drawings and sketches. 
Suggestions for further reading are included 
at the end of each chapter. Topical subjects 
such as brain death, herpetic encephalitis and 
the management of pain are placed in their 
proper context. Minor omissions, such as 
chemonucleolysis, and a personal bias against 
surgery for brachial neuropathies associated 
with cervical spondylosis, may be forgiven.
This text is highly recommended for senior 
medical students, residents rotating on neu­
rosurgical services, neuroscience nurses, and 
those surgeons located away from neurosur­
gical centres, who may be called upon occa­
sionally to intervene in neurosurgical cases.
Brien G. Ben o it , md, facs, frcsc
Chief, Division of Neurosurgery,
Ottawa Civic Hospital,
1053 Carling Ave.,
Ottawa, Ont.
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Pneumatosis Cystoides Intestinalis Simulating 
Malignant Colonic Obstruction
Pneumatosis cystoides intestinalis is an 
uncommon condition in which pockets of 
gas occur intramurally in the gastrointes­
tinal tract. The authors describe the case 
of a 76-year-old man in whom this con­
dition caused low colonic obstruction, 
simulating a rectal carcinoma. The 
patient was successfully treated with 
high-flow oxygen therapy. This form of 
therapy has not previously been reported 
in obstructing lesions, but in this case it 
successfully relieved the obstruction and 
thus avoided a colostomy that might 
have been necessary.
La pneumatose kystique de I'intestin est 
une maladie rare au cours de laquelle des 
poches de gaz se forment dans la paroi 
des voies gastro-intestinales. Les auteurs 
decrivent le cas d'un homme de 76 ans 
chez qui cette affection causa une obs­
truction colique basse simulant un cancer 
du rectum. Le patient a repondu a un 
traitement d’oxygenotherapie a haut 
debit. Cette forme de traitement n'avait 
pas encore ete signalee dans les lesions 
obstructives mais, dans le present cas, 
elle a permis de soulager I'obstruction et, 
en consequence, d'eviter une colostomie 
qui aurait pu s'averer necessaire.
Pneumatosis cystoides intestinalis is a 
relatively rare condition characterized by 
the presence of multiple intramural 
pockets o f gas in any portion of the gas­
trointestinal tract and occasionally in the 
mesenteric attachments.1 It has been 
classified as primary (idiopathic) or 
secondary (coexisting lesion of the gas­
trointestinal tract) (Table I). About 15% 
of cases are considered primary; most of
From the *Department o f  Surgery and 
tDepartment o f Pathology, Hotel Dieu 
Hospital, Queen’s University, Kingston, 
Ont.
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these occur in adults and involve the 
colon, giving rise to the term we have used 
— pneumatosis coli.
Currently, the pathogenesis of pneuma­
tosis coli is thought to be either mechan­
ical or bacterial.1-4 The usual clinical 
presentation is of mild to moderate symp­
toms of diarrhea, cramping, discharge of 
mucus and occasional constipation. 
Hematochezia may occur, and occasion­
ally, be alarming.5 The findings on 
abdominal examination are usually 
unremarkable, although at times the cys­
tic colon may be palpable.5,6
We present the case of a patient who 
had low colonic obstruction that was ini­
tially thought to be due to a rectal carci­
noma, but proved to be pneumatosis coli.
Case Report
A 76-year-old man, known to have chronic 
obstructive pulmonary disease, was admitted 
with a low colonic obstruction. A benign polyp 
26 years previously had been managed by a 
colotomy and polypectomy, and 8 years previ­
ously sigmoidoscopic polypectomy was done. 
Follow-up colonoscopic examination 6 years 
before revealed no colonic abnormality. His 
presenting symptoms consisted of 5 days of 
increasing abdominal distension, generalized 
abdominal discomfort, absence of bowel move­
Table I—Gastrointestinal Conditions 
Associated With Pneumatosis Cystoides 
Intestinalis*
Peptic ulcer disease 
Intestinal obstruction 
Postsurgical bowel anastomosis 
Mesenteric vascular occlusion 
Acute necrotizing enterocolitis 
Chronic inflammatory disease (e.g., regional 
enteritis, ulcerative colitis, tuberculosis) 
Perforated diverticula
Collagen disorders (especially scleroderma!
Whipple's disease
Abdominal trauma
Ingestion of caustic agents
Intestinal parasites
Intestinal lymphosarcoma
Intestinal instrumentation
‘ Modified from Sleisenger and Fordtran.6
ments and very little flatus. Before this he 
noted a decrease in the calibre of his stool for 
about 2 weeks. There was no history of diar­
rhea, mucous discharge, tenesmus or rectal 
bleeding. He was not a known diabetic. He had 
recently had an exacerbation of his chronic 
obstructive pulmonary disease for which his 
prednisone dosage had been increased from 5 
mg twice daily to 60 mg once a day, then 
decreased to 20 mg daily.
He was a slightly obese, afebrile, mildly 
dehydrated man with a blood pressure of 
140/80 mm Hg, pulse 76 beats/min and regu­
lar. There was no adenopathy, pallor, cyano­
sis or icterus. The chest was increased in the 
anteroposterior diameter and he had bilateral 
expiratory wheezing. There was no jugular 
venous distension or abnormal heart sounds. 
The abdomen was distended, soft and non­
tender with increased bowel sounds. Rectal 
examination revealed an enlarged prostate as 
well as a separate mass situated anteriorly 
about 8 cm from the anal verge. This mass was 
nodular, firm and covered two thirds of the 
rectal circumference at its palpable lower 
margin.
Laboratory findings were as follows: 
hemoglobin 116 g/L , hematocrit 35.4%, leu­
kocyte count 10.4x 109/L , serum sodium 138 
mmol/L, potassium 4.4 mmol/L, chloride 103 
mmol/L and bicarbonate 20.1 mmol/L, blood 
urea nitrogen 125 mmol/L urea and blood glu­
cose 12.7 mmol/L. Results of arterial blood 
gas studies on room air were: pH 7.40, partial 
pressure of oxygen 71.3 mm Hg and partial 
pressure of carbon dioxide 32.5 mm Hg.
Plain films of the abdomen showed a dis­
tended colon, with air and stool from sigmoid 
to cecum but no gas in the rectum. Parts of 
the sigmoid colon showed linear streaks of gas 
within the wall. Roentgenograms after barium 
enema revealed an area of marked narrowing 
with shouldering and nodularity and nearly 
total retrograde obstruction (Fig. 1). We 
believed that this represented a carcinoma of 
the rectum with pneumatosis coli proximally.
Clinically, we thought this man had an 
obstructing malignant rectal carcinoma. Dur­
ing sigmoidoscopic examination, pale grey 
grape-like clusters were seen projecting circum­
ferentially into the rectal lumen. The diagno­
sis of pneumatosis coli was made at the time 
of biopsy when these lesions were seen to col­
lapse. Histologically, there were dilated sub­
mucosal spaces showing no evidence of malig­
nant change.
The patient was treated with nasogastric tube
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suction, intravenous infusion of crystalloids 
and 50% oxygen by venturi-mask for 48 hours. 
Twenty-four hours after initiation of oxygen 
therapy, he was passing gas and had a small 
bowel movement. All colonic symptoms 
resolved and a follow-up roentgenogram after 
barium enema obtained 6 days later showed 
resolution of the obstructing cysts (Fig. 2). He 
was well at 15 months after discharge.
Discussion
This case appeared to fall into the 
category of primary pneumatosis cys- 
toides intestinalis in that no associated 
gastrointestinal lesions were noted clini­
cally or pathologically. The rectal biopsy 
specimens showed dilated submucosal 
spaces without any recognizable cellular 
lining, which is the usual histologic 
appearance of this entity.1,6
The association between pneumatosis 
cystoides intestinalis and chronic obstruc­
tive pulmonary disease has often been 
reported. A suggested mechanism7-9
FIG. 1—Roentgenogram after barium 
enema shows obstructing lesion of distal rec­
tum simulating carcinoma. Proximal gas-filled 
cysts can be seen.
FIG. 2—After treatment with oxygen, 
obstructing cysts in distal rectum have resolved.
begins with rupture of pulmonary blebs 
into the subpulmonary space; the air then 
makes its way through the mediastinum 
and retroperitoneum, eventually reaching 
the bowel wall via its mesenteric attach­
ments. Our patient had chronic obstruc­
tive pulmonary disease, so he may fall 
into this category.
Important complications of pneumato­
sis cystoides intestinalis are quite unusual. 
They include pneumoperitoneum,2,10-15 
pneumopericardium,15 malabsorption16 
and extensive hemorrhage.5 In addition, 
obstruction has been associated with 
pneumatosis cystoides intestinalis in two 
contexts. The more common is when this 
condition is secondary to obstructing gas­
trointestinal lesions such as pyloroduo- 
denal disease,2,11,17-20 carcinoma,21 anas­
tomotic stricture,22 volvulus2,3,14,18-20,23,24 
and intussusception.15 The proposed 
mechanism here is that of increased 
intraluminal pressure secondary to the 
obstruction, in combination with some 
form of mucosal disruption, allowing gas 
to penetrate the intestinal wall and dis­
sect the tissue planes.2
The less common occurrence is that of 
pneumatosis coli causing colonic obstruc­
tion as in our case. Meikle10 reported a 
case of pneumatosis coli resulting in 
obstruction, stercoral ulceration and per­
foration that led to laparotomy. Gillon 
and associates3 described two patients in 
whom they believed pneumatosis coli led 
to sigmoid volvulus that required opera­
tive intervention. Jones and Cole4 and 
Paris and Fraire25 reported cases of 
small-bowel obstruction secondary to gas 
cysts involving the small intestine.
High-flow oxygen therapy has been 
used in the treatment of pneumatosis cys­
toides intestinalis since 197326-28 on the 
premise that raising arterial oxygen ten­
sion to between 200 and 300 mm Hg 
results in subatmospheric nitrogen pres­
sures in the end-capillary and venous 
blood, as the oxygen (which displaces 
much of the nitrogen) is readily utilized 
by the colonic tissues. The resultant 
nitrogen-pressure gradient between the 
cystic spaces and the venous blood pro­
motes collapse of the cysts. High-flow 
oxygen treatment appears to be widely 
accepted as being beneficial. It may be 
required for up to 6 days.26,27
The use of oxygen therapy in obstruct­
ing lesions due to pneumatosis coli has 
not previously been reported. Since there 
is no immediate danger of vascular com­
promise from the obstructing process, 
laparotomy is not thought necessary and 
release of the obstruction should occur 
when oxygen at a high flow rate is given, 
as happened in our case. The colonic 
obstruction was caused by a benign 
process so oxygen therapy avoided a 
colostomy that would have been neces­
sary if the obstruction had not resolved 
otherwise.
References
1. PRIEST RJ, BOCKUS HL (eds): Gastroenterology, Vol 2, 
3rd ed, Saunders, Philadelphia, 1976: 1097-104
2. E l id a n  J , G im m on  Z, Sc h w a r t z  A: Pneu­
moperitoneum induced by pneumatosis cystoides intes­
tinalis associated with volvulus of the stomach. Am  J  Gas­
troenterol 1980; 74: 189-95
3. G illon J, holt  S, Sircus W: Pneumatosis coli and sig­
moid volvulus: a report of 4 cases. Br J  Surg 1979; 66: 
802-5
4. JONES AW, COLE FM: Intestinal obstruction due to 
pneumatosis intestinalis. Postgrad Med J  1967; 43: 680-2
5. Smith  w g , Anderson MJ jr , Pemberton HW: 
Pneumatosis cystoides intestinalis involving the left por­
tion of the colon; report of four cases diagnosed at sig­
moidoscopy. Gastroenterology 1958; 35: 528-33
6. SLEISENGER MH, FORDTRAN JS: Gastrointestinal Dis­
ease, 3rd ed, Saunders, Philadelphia, 1983: 1302-7
7. DOUB HP, SHEA JJ: Pneumatosis cystoides intestinalis. 
JAM A  1960; 172: 1238-42
8. Keyting WS, McCarver RR, Kovarik JL, Daywitt 
AL: Pneumatosis intestinalis: a new concept. Radiology 
1961; 76: 733-41
9. DORSTEN JF: Pneumatosis cystoides intestinalis: report 
of three cases. J  Am  Osteopath Assoc 1981; 81: 123-31
10. MEIKLE G: A case of pneumatosis coli: pneumatosis cys­
toides intestinalis of the sigmoid colon causing intestinal 
obstruction, stercoral ulcer and perforation. J R  Coll Surg 
Edinb 1965; 11: 65-7
11. Ecker J A, W illiams RG, C lay KL: Pneumatosis cys­
toides intestinalis —bullous emphysema of the intestine. 
A review of the literatyre. A m  J  Gastroenterol 1971; 56: 
125-36
12. Cutler D, Maldonado P, Garcia-Luna J: Pneuma­
tosis cystoides intestinalis. Report of 22 cases. A m  J  Proc- 
tol 1969; 20: 261-8
13. BROECKER BH, Moore EE: Pneumoperitoneum due to 
pneumatosis cystoides intestinalis in idiopathic megaco­
lon. JAM A  1977; 237: 1963
14. JONES JD: Gas cysts of the intestine. Br J  Surg 1948; 36: 
49-50
15. HERRINGTON JL JR: Intestinal bypass enteritis causing 
pneumoperitoneum, pneumopericardium, and cervical 
emphysema. Am  Surg 1982; 48: 279-81
16. YUNICH AM, Frandkin NF: Fata! sprue (malabsorp­
tion) syndrome secondary to extensive pneumatosis cys­
toides intestinalis. Gastroenterology 1958; 35: 212-7
17. DHALL DP, Mahaffy RG, MATHESON NA: Intestinal 
pneumatosis treated by pyloroplasty. J  R Coll Surg Edinb 
1968; 13: 226-9
18. MEYERS MA, GHAHREMANI GG, CLEMENTS JL JR, 
GOODMAN K: Pneumatosis intestinalis. Gastrointest 
Radiol 1977; 2: 91-105
19. OLMSTEAD WW, Madwell JE: Pneumatosis cystoides 
intestinalis: a pathophysiologic explanation of the roent- 
genongraphic signs. Gastrointest Radiol 1976; 1: 177-81
20. KOSS LG: Abdominal gas cysts (pneumatosis cystoides 
intestinorum hominus): analysis with report of a case and 
critical review of literature. A M A Arch Pathol 1952; 53: 
523-49
21. Rabin MS, Bledin AG, P rice HI: Pneumatosis coli 
secondary to colonic obstruction. A case report. S A fr  
Med J  1978; 53: 1078-9
22. Kleinman PL, KING DR: Ischemic jejunitis and pneu­
matosis intestinalis secondary to anastomotic obstruction 
following jejunal atresia repair. Gastrointest Radiol 1977; 
2: 113-5
23. WERTKIN MG, WETCHLER BB, WAYE JD, BROWN LK: 
Pneumatosis coli associated with sigmoid volvulus and 
colonoscopy. Am  J Gastroenterol 1976; 65: 209-14
24. BURN JL, Jones BS: Pneumatosis cystoides intestinalis. 
Br Med J  1961; 2: 747-9
25. PARIS MD, FRAIRE AE: Intestinal obstruction from 
pneumatosis cystoides intestinalis (C). JAM A  1981; 246: 
622
26. Down  RHL, Castleden WM: Oxygen therapy for 
pneumatosis coli. Br Med J  1975; 1: 493-4
27. Forgacs P, Wright PH, Wyatt AP: Treatment of 
intestinal gas cysts by oxygen breathing. Lancet 1973; 1: 
579-81
28. BRITTEN-JONES R: A major advance in the management 
of pneumatosis coli. Aust N Z  J  Surg 1975; 45: 367-71
VOLUME 28, NO. 3, M A Y  1985 /  THE CANADIAN JOURNAL OF SURGERY 273
Dennis L. Modry, md, frcsc; Philip E. Oyer, md, facs; Stuart W. Jamieson, mb, frcs; 
Edward B. Stinson, md, facs; John C. Baldwin, md; Bruce A. Reitz, md; Keith D. Dawkins, mb; 
Christopher G.A. McGregor, md; Sharon A. Hunt, md; Marc Moran, md; Bryan Myers, md;
Norman E. Shumway, md, ph d, facs
Cyclosporine in Heart and Heart-Lung Transplantation
A t S tan fo rd  University M edical Center 
from  January 1968  until January 1984, 
288 pa tien ts  received 313  heart trans­
plants. The im munosuppressive regimen 
before December 1980 consisted o f 
azathioprine and prednisone, w ith  or 
w ith o u t rabbit an tithym ocyte  globulin. 
A fte r th a t tim e cyclosporine replaced 
azathioprine. In 92 recipients o f 95  heart 
a llogra fts, the 1- and 3-year survival 
rates w ere  8 2%  and 65%  to  70%  
respective ly. In the 3 years from  March 
1981 to  M arch 1984, successful heart- 
lung transp lanta tion  was accomplished in 
13 o f 19 recipients, using cyclosporine- 
based im munosuppression. Survival 
ranged from  1 to  38 m onths.
W hile  it  is true tha t cyclosporine has 
im proved survival in heart transplant 
recip ients, has allowed successful heart- 
lung transp lanta tion  to  be performed, has 
shortened intensive care un it and tota l 
hospita l stays and therefore hospital 
costs, and has allowed easier manage­
m ent o f rejection and in fection , several 
d isconcerting  problems have not yet 
been resolved. These include hyperten­
sion th a t is d iff ic u lt to  contro l and renal 
dys fu nc tio n  in all patients, and the fact 
tha t ce llu lar and humoral rejection still 
occurs, as m anifested by g ra ft athero­
sclerosis, bronchio litis obliterans and 
classic acute rejection. Better under­
standing and application o f cyclosporine 
im m unosuppression w ill undoubtedly 
m inim ize both cyclosporine- and non­
cyclosporine-related postoperative com ­
p lications and w ill improve survival even 
further.
De janv ier 1968  a janvier 1984, 288 
patients o n t recu 313  greffes cardiaques
From the Department o f Cardiovascular 
Surgery, Stanford University Medical 
Center, Stanford, Calif.
Accepted for publication Nov. 19, 1984
Reprint requests to: Dr. Dennis L. Modry, 
Division o f  Cardiovascular Surgery, 
University o f Alberta Hospitals, 112th 
Street and 84th Avenue, Edmonton, Alta. 
T6G 2B7
au Stanford U niversity Medical Center. 
A van t decembre 1980, le traitem ent 
im m unosuppresseur eta it compose d'aza- 
thioprine et de prednisone, associees ou 
non a de I'im m unoglobuline anti- 
thym ocyta ire  de lapin. Par la suite, la 
cyclosporine est venue remplacee I'aza- 
th ioprine. La survie a 1 et 3 ans chez 92 
receveurs de 95  allogreffes cardiaques 
fu t de 8 2 %  et de 6 5%  a 70%  respecti- 
vement. Au cours des 3 annees qui se 
son t ecoulees entre mars 1981 et mars 
1984, grace a la cyclosporine, des gref­
fes coeurs-poum ons ont ete reussies 
chez 13 des 19 receveurs. La survie va 
de 1 a 38 mois.
Meme s 'il est vrai que la cyclosporine 
a ameliore la survie des greffes cardia­
ques, rendu possible le succes des gref­
fes coeurs-poum ons, reduit le sejour aux 
soins in tensifs, la duree d'hospita lisation 
e t, par consequent, les couts, et, finale- 
m ent, perm is d 'a ffro n te r plus facilement 
les rejets et les in fections, il reste bon 
nombre de problemes deroutants a 
resoudre. Parmi ces complications, on 
note une hypertension d iffic ile  a tra iter et 
une insuffisance renale a ffectan t tous les 
patients, e t le fa it que surviennent 
encore des reactions de rejet a media­
tions cellulaire et humorale qui se mani- 
fes tent par de I'atherosclerose du gref- 
fon, une bronchio lite  obliterante et le 
rejet aigu classique. Une meilleure com ­
prehension de I'imm unosuppression a la 
cyclosporine et une meilleure utilisation 
de ce m edicam ent perm ettront sans nul 
doute de m inim iser les complications 
postoperatoires reliees ou non a la 
cyclosporine, et d 'am eliorer encore la 
survie.
The introduction in December 1980 at 
Stanford Medical Center of cyclosporine 
to suppress the immune response and the 
gradually improving survival rates of 
preceding years (Fig. 1) have contributed 
to the current revival of cardiac transplan­
tation around the world (Fig. 2) and have 
allowed successful heart-lung transplan­
tation to be performed, with long-term 
survival.1,2 To define the current advan­
tages and disadvantages of cyclosporine
use, the clinical data from all patients 
who had transplants and cyclosporine 
immunosuppression at Stanford Univer­
sity Medical Center between December 
1980 and January 1984 are reviewed and 
compared with the data generated from 
earlier transplantations when immuno­
suppression was based on the use of 
azathioprine, prednisone and antithymo­
cyte globulin of rabbit origin.
Cyclosporine in Heart Transplantation
From Jan. 1, 1968 to Dec. 31, 1983, 
313 heart transplantations were per­
formed in 288 patients. At the time of 
writing, the total number of 1-year sur­
vivors was 155 and 121 patients were alive
Y E A R
FIG. 1—Progressive improvement in 1-year 
survival rates of heart transplant recipients at 
Stanford University Medical Center.
FIG. 2—Total number of heart transplants 
performed by year. Open circles indicate proce­
dures carried out at Stanford University Medi­
cal Center, closed circles are those performed 
world wide.
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1 week to 14 years after transplantation. 
Nearly 90% of these patients were fully 
rehabilitated. From December 1980, 92 
patients (74 male, 18 female) who received 
cyclosporine for immunosuppression had 
95 transplants. These patients ranged in 
age from 13 to 52 years. There were six 
retransplantations.
The preoperative diagnoses included 
coronary artery disease (36 patients), idi­
opathic cardiomyopathy (40), viral or 
familial cardiomyopathy (11), congenital 
heart disease (3) and others (2).
Survival
To understand best the effect that 
cyclosporine has had on survival of heart 
recipients, one can contrast the survival 
curve generated in these patients with that 
of two previous immunosuppressive eras 
and of patients who did not have a trans­
plant (Fig. 3). Of patients selected 
for transplantation for whom a suitable 
donor was not available, all died in the 
first year (mean survival 44 days). From 
January 1969 until December 1973, the 
immunosuppressive regimen consisted of 
azathioprine and prednisone. One- and 
5-year survival rates were 42% and 15% 
respectively. With the introduction of 
prophylactic rabbit antithymocyte globu­
lin, given in the first few days after trans­
plantation, the 1- and 5-year survival rates 
increased to 62% and 42% respectively. 
From December 1980 until December 
1983, cyclosporine supplanted azathio­
prine, resulting in improved graft survival 
rates to 82% at 1 year and nearly 70% at 
3 years. Twenty patients who had 
cyclosporine for immunosuppression died 
for the following reasons: rejection 3, 
infection 8, malignant disease 3, coronary 
artery disease 2, pulmonary hypertension 
1, acute graft failure 1, cerebrovascular 
accident 1 and cerebral edema 1.
Immunosuppressive Regimen 
Immunosuppression consisted of the
YEAR
FIG. 3—Survival of patients in three 
immunosuppressive eras compared with that of 
patients who did not undergo transplantation. 
(Open squares = Jan. 1981 to Dec. 1983, open 
circles = Jan. 1974 to Dec. 1980, black circles 
= Jan. 1968 to Dec. 1973, black squares = not 
transplanted.)
administration of cyclosporine, 12 to 18 
mg/kg, orally, 6 hours before operation. 
Intraoperatively, after cardiopulmonary 
bypass was discontinued, 500 mg of 
methylprednisolone sodium succinate was 
administered intravenously. Postopera- 
tively, 15 mg of methylprednisolone 
sodium succinate was given (three doses 
at 8-hour intervals) and cyclosporine, 12 
to 18 mg/kg daily (in equal divided doses 
every 12 hours). The dose of cyclosporine 
was tapered gradually over several days 
to several weeks according to blood levels 
which were maintained between 100 and 
300 ng/mL. On day 1 postoperatively, 
following the third dose of methylpred­
nisolone, prednisone was begun at a rate 
of 1 mg/kg daily (in equal divided doses 
every 12 hours), along with the cyclospo­
rine. The prednisone dose was tapered to 
0.8 mg/kg daily by 2 weeks, 0.5 mg/kg 
by 4 weeks and 0.2 mg/kg by 8 weeks. 
Rabbit antithymocyte globulin (2.5 
mg/kg, intramuscularly, preoperatively 
and on postoperative days 1 and 2) was 
given prophylactically to the first 27 
patients, but not to the subsequent 65 
patients.
Rejection
Diagnosis. —With conventional immu­
nosuppression based on the use of 
azathioprine, antithymocyte globulin and 
prednisone, rejection could be suspected 
by noting a 20% or more decrease in the 
cumulative voltage of the electrocardio­
gram (leads I, II, III, V5 and V6).34 
Similarly, in the face of a markedly short­
ened half-life of circulating rabbit globu­
lin, or in the presence of a large volume 
of circulating T lymphocytes, rejection 
was likely occurring or was imminent.3 
Clinical signs indicative of graft dysfunc­
tion were those of congestive heart failure 
and were late findings. Definite diagno­
sis could be achieved only with endo­
cardial biopsy when rejection was sus­
pected, using the previously described 
criteria.3,4
Unfortunately, with cyclosporine, the 
electrocardiogram is not a reliable indi­
cator, circulating T-cell levels are unrelia­
ble and clinical findings are absent. 
Therefore, endocardial biopsy is the only 
currently reliable means of diagnosing 
rejection in most instances. Surveillance 
biopsies, therefore, must be performed 
weekly for the first 2 to 3 months, then 
bimonthly up to 6 months and every 3 to 
4 months thereafter. The endocardial 
bioptome is passed percutaneously by the 
Seldinger technique through the right 
internal jugular vein and under fluoro­
scopic control is positioned within the 
right ventricle; usually three biopsy speci­
mens are taken from the interventricular 
septum. More than 5000 biopsies have 
been performed at Stanford University 
Medical Center with no deaths and only
three perforations that required explo­
ration.
Differences in histologic findings be­
tween azathioprine- and cyclosporine- 
treated patients appear to correlate with 
differences in clinical findings. Fig. 4 
illustrates normal myocardium in a biopsy 
specimen. Acute severe rejection in a 
patient immunosuppressed with azathio­
prine and prednisone uniformly is mani­
fested by myocardial edema and lympho­
cytic infiltration (Fig. 5); this leads to a 
decrease in electrocardiographic voltage 
and a decrease in diastolic compliance 
with the ultimate appearance of S3 or S4 
gallop sounds;3 atrial arrhythmias and 
variable degrees of heart block often 
ensue. Congestive heart failure and death 
secondary to cardiogenic shock rapidly 
follow if treatment of the rejection is not 
optimal.
With cyclosporine, severe allograft 
rejection is not associated with myocardial 
edema (Fig. 6), hence the re­
jection is nearly always clinically silent. 
Recently, two patients who died of acute 
rejection presented with a low-grade 
fever, myalgia and weakness. In the first 
patient, rejection was not suspected, and 
a biopsy was not performed before his 
sudden cardiac arrest from which he 
could not be resuscitated. In the second 
patient, the severity of rejection seen in 
the biopsy specimen was not fully 
appreciated; the patient was undertreated. 
Although all rejection episodes that 
occurred in patients during their initial 
hospital stay were treated’with intra­
venous Solu-Medrol, once patients were 
discharged subsequent rejection episodes 
were treated by increasing the prednisone 
dosage to 100 mg/d for 3 days, then 
tapering the dosage schedule by 10 mg 
every other day until the dosage was 
approximately 10% above the previous 
maintenance dosage. Currently, for 
patients who have been discharged from 
hospital, important rejection episodes 
associated with cardiac dysfunction or 
echocardiographic evidence of rejection5 
or important clinical findings are treated 
with intravenous Solu-Medrol. It is 
peculiar that the mononuclear infiltrate 
in patients immunosuppressed with 
cyclosporine may persist for weeks or 
months following treatment. In the 
absence of myocyte necrosis, one can only 
speculate as to the biologic nature of these 
cells.
Nearly 25% of patients in the cyclospo­
rine group were free of rejection by 
postoperative day 60 as opposed to 
approximately 18% in the azathioprine 
group.6 Although this difference was not 
statistically significant, the severity, as 
reflected by cardiac dysfunction and 
death from rejection, was significantly 
less in patients receiving cyclosporine.7 
This was further reflected by decreased
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time spent in the intensive care unit and 
an overall shorter hospital stay.
Treatment.— Acute rejection during 
the initial hospital stay is treated with 
1000 mg of methylprednisolone sodium 
succinate, administered intravenously 
daily for 3 days. The prednisone reduc­
tion is interrupted and the dose is held 
constant. If serum levels of cyclosporine 
are below the targeted therapeutic range, 
the oral dose of cyclosporine is increased. 
Rabbit antithymocyte globulin is used 
only if extensive myocyte necrosis is noted 
in the very first cardiac biopsy specimen 
on postoperative day 7, if rejection with 
myocyte necrosis is still present follow­
ing two courses of methylprednisolone 
sodium succinate and in the presence of 
life-threatening acute rejection in patients 
in cardiogenic shock.
Infection
Infection accounted for 40% of all 
deaths in the cyclosporine-treated trans­
plant recipients as opposed to 66% of the 
deaths in the azathioprine group. The 
total number of infectious episodes, 
however, did not appear to be signifi­
cantly less than in the azathioprine group 
in the first 3 years after transplantation 
(Fig. 7). A trend towards fewer bacterial, 
fungal and protozoal infections is 
balanced by an increase in viral infections 
(mainly trivial mucocutaneous lesions) 
when cyclosporine is used. As with rejec­
tion, the infectious episodes are easier to 
treat and the hospital stay is shortened; 
overall, it is likely that a decrease in the 
severity of infectious episodes with 
cyclosporine and improved diagnosis and 
management have contributed to an 
improvement in survival.
FIG. 4—Normal myocardial biopsy speci­
men (hematoxylin and eosin, reduced by 53% 
from x 400).
Malignant Disease
In patients at risk more than 3 years 
after transplantation who received aza­
thioprine, prednisone and antithymocyte 
globulin for immunosuppression, 10 lym­
phomas developed, of which 6 followed 
primary transplantation in 124 patients 
(5%) and 4 followed retransplantation in 
10 patients (40%). The higher incidence 
following retransplantation likely re­
flected the longer period of immunosup­
pression. Leukemia occurred once after 
primary transplantation.
From December 1980 until January 
1982 the cyclosporine and prednisone 
immunosuppression was combined with 
a short prophylactic course of antithymo­
cyte globulin. Five lymphomas occurred 
after primary transplantation in 27 
patients for an incidence of 19%. The 
apparently synergistic oncogenic effect of 
antithymocyte globulin and cyclosporine 
was also noted in primates. Accordingly, 
from Jan. 1, 1982, the routine prophylac­
tic use of rabbit antithymocyte globulin 
has been stopped. In 67 patients, only one 
lymphoma occurred, a rate of 1.5%. Of 
the six patients with lymphomas, two are 
alive following local excision and radi­
otherapy. One patient also received acy­
clovir. Epstein-Barr virus has been impli­
cated in the pathogenesis of this 
lymphoproliferative disorder.8'10
Coronary Artery Disease
That graft atherosclerosis might be a 
problem was not recognized initially. The 
incidence, however, at 3 years was
FIG. 5—Myocardial biopsy specimen 
demonstrates acute severe rejection with 
marked myocardial edema and mononuclear 
infiltration in patient given azathioprine and 
prednisone for immunosuppression (hematox­
ylin and eosin, reduced by 53% from x 400).
100%.3 The generation of graft athero­
sclerosis was thought to be related to 
immunologically mediated intimal and 
endothelial injury, with subsequent depo­
sition of platelets followed by myointimal 
proliferation. Accordingly, antiplatelet 
agents combined with warfarin were 
administered prophylactically. This 
resulted in a 50% reduction in graft 
atherosclerosis at 3 years. Since 1979, 
dipyridamole alone has been used, 
because, in a subset of patients in whom 
warfarin could not be administered, the 
incidence of graft atherosclerosis was the 
same as in those who had received both 
warfarin and dipyridamole. One of the 
purported mechanisms of action of 
cyclosporine is to inhibit T-cell dependent 
antibody formation, and it was hoped 
early on that graft atherosclerosis might 
be markedly reduced or even eliminated. 
While the former may still be true, two 
patients have died of severe graft athero­
sclerosis and myocardial infarction and a 
third patient is currently awaiting re-
FIG. 6—Myocardial biopsy specimen 
demonstrates acute severe rejection with myo­
cyte necrosis and mononuclear infiltration but 
distinct absence of myocardial edema in patient 
given cyclosporine for immunosuppression 
(hemotoxylin and eosin, reduced by 53% from 
x 400).
FIG. 7—Total number of infectious episodes 
is similar in cyclosporine (open circles) and 
azathioprine (closed circles) groups.
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transplantation because of serious 
myocardial infarction.
Complications Related to the 
Use o f  Cyclosporine
Hypertension.—Hypertension in pa­
tients immunosuppressed with azathio- 
prine and prednisone was infrequent and 
tended to occur in older patients with 
atherosclerotic heart disease. However, 
with cyclosporine, severe hypertension 
was invariably present early after opera­
tion and required large doses of nitroprus- 
side frequently in combination with 
trimethaphan and occasionally even 
boluses of hydralazine. This hypertension 
is reflected by severe headaches that often 
develop as the blood pressure increases, 
and which, therefore, could be controlled 
by decreasing the blood pressure. Wel- 
lands (personal communication, 1983) 
has reported intracerebral hemorrhage 
early after operation as a result of uncon­
trolled hypertension. The mechanism of 
this hypertension is unclear, but nearly all 
patients are hypertensive within 2 or 3 
months of operation and require a vari­
ety of antihypertensive drugs or combi­
nation of drugs for its control. There is 
no single drug or combination, however, 
that is consistently effective for all 
patients.
Renal dysfunction.—This has occurred 
in most patients. There is a gradual 
increase in the serum creatinine level with 
time, with an associated time-related 
decrease in creatinine clearance. The rela­
tion between systemic hypertension and 
renal dysfunction is not yet clear.
To evaluate renal dysfunction further, 
47 patients who underwent transplanta­
tion before December 1980 and were 
given azathioprine and prednisone for 
immunosuppression were compared with 
32 recipients who received cyclosporine 
and prednisone.11 An adverse effect on 
kidney function of long-term cyclosporine 
therapy is suggested by the divergent plot 
of the reciprocal of the serum creatinine 
level in the two populations (Fig. 8). 
Glomerular filtration rate in the azathio­
prine group was significantly (p < 0.005, 
unpaired two-tailed f-test) higher at all 
times after the first post-transplant 
month.
To define the renal injury associated 
with long-term cyclosporine therapy, 
detailed physiologic studies were per­
formed in 17 consecutive 1-year survivors 
receiving.cyclosporine. For comparison, 
the same studies were performed in 13 
unselected, long-term, azathioprine- 
treated control patients." Inulin clear­
ance was determined as a precise meas­
ure of glomerular filtration rate in the two 
groups. Fig. 9 demonstrates that inulin 
clearance in azathioprine controls was 
usually normal and always exceeded 70 
mL/min. By contrast, inulin clearance in
cyclosporine recipients was invariably 
below normal, sometimes severely so. 
There was almost no overlap between the 
two populations, with the average 
glomerular filtration rate in cyclosporine 
recipients reduced to only 51 mL/min 
versus 92 mL/min after 1 year of therapy.
To examine tubular function, the para- 
amino hippurate extraction ratio was 
measured by sampling renal venous blood 
during the catheterization of the right side 
of the heart. Although not significantly 
different from azathioprine controls, 
para-amino hippurate extraction was 
depressed to a subnormal value of 72% 
in patients receiving cyclosporine. The 
patients’ ability to excrete a dilute urine 
was determined after giving 1.5 L of 
water orally during a 90-minute period. 
Both groups were able to lower urinary 
osmolarity below that in plasma. 
However, the free water clearance was 
appreciably reduced in cyclosporine- 
treated patients to 3 mL/min compared 
with 5.1 mL/min in azathioprine-treated 
patients. Thus, there was both proximal 
and distal tubular dysfunction in 
cyclosporine-treated patients.
To elucidate the cause of the reduced 
glomerular filtration rate associated with 
long-term cyclosporine therapy, several 
hemodynamic parameters were evaluated. 
Cardiac output was similar in the two 
groups, averaging just under 6 L/min. 
Cyclosporine-treated recipients differed, 
however, in that arterial hypertension was 
prevalent and renal blood flow, measured 
by the clearance and extraction of para- 
amino hippurate, was appreciably de­
pressed to 501 mL/min compared with 
836 mL/min. Dividing the renal pressure 
drop by blood flow showed that renal vas­
cular resistance more than doubled in 
cyclosporine-treated patients.
To determine whether the cyclosporine- 
induced reduction in glomerular filtration 
rate was hemodynamically mediated or 
whether alterations in the glomerular cell 
wall were responsible, the fractional clear­
ance of neutral dextrans of graded size 
was examined. It did not differ signifi­
cantly between the two groups. However, 
for the first 24 to 34 angstrom intervals 
in patients receiving cyclosporine, the 
fractional clearance profile tended to be 
depressed below that in the azathioprine 
group. If one compares the predicted 
effects of a selective reduction in renal 
perfusion, where all determinants of 
glomerular filtration, except renal blood 
flow, have been held constant, then a 
selective fall in blood flow should uni­
formly enhance, and not depress, the 
fractional dextran clearance. Thus, the 
fall in renal blood flow from 836 to 501 
mL/min in the cyclosporine group can­
not wholly account for the dextran- 
clearance profile. Accordingly, the frac­
tional clearances of dextran in each group 
were subjected to a theoretical analysis of
solute transport through an isoporous 
membrane. From this, two membrane 
parameters were derived: first, the mean 
radius of functional pores perforating the 
glomerular capillary wall was determined 
to approximate 61 A in each group, a 
value similar to that found previously in 
normal subjects; second, the ratio of total 
pore surface area to pore length may be 
equated with the total number of pores 
occupying the membrane to provide the 
pore “ density” . It was reduced from a 
normal value of 22 in azathioprine con­
trols to only 15 in cyclosporine recipients. 
The disparity in pore density is compara­
ble to the difference in glomerular filtra­
tion rate between the two groups, suggest­
ing that the loss of surface area for 
filtration may be the mechanism by which 
long-term cyclosporine therapy lowers the 
glomerular filtration rate. To explore fur­
ther the structural correlates of this find­
ing, five cyclosporine-treated patients in 
whom the glomerular filtration rate was 
substantially reduced underwent renal
FIG. 8—Renal function in heart transplan­
tation. Aza = azathioprine group, CyA = 
cyclosporine group.
FIG. 9—Mean glomerular filtration (GFR) 
rate at 1 year in cyclosporine-treated patients 
(CyA) was invariably below normal and nearly 
always less than that in unselected control 
patients treated on long-term basis with 
azathioprine (Aza).
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biopsy. Light microscopy revealed tubu­
lar atrophy and a remarkable fibrosis in 
the interstitium. Electron microscopy 
showed that the basement membrane of 
tubular cells was thickened and there was 
a variable loss of the brush border. Con­
voluted tubule cells revealed diffuse loss 
of organelles and nuclear swelling alter­
nating with nuclear pyknosis and loss of 
cytosol. Thus, growing evidence impli­
cates cyclosporine as a tubular cell toxin. 
Although these findings are striking, the 
apparent deterioration in renal function 
over the first year after transplantation 
does not appear to be progressive over the 
subsequent 1 to 2 years. Therefore, we are 
guardedly optimistic about the stabiliza­
tion of renal dysfunction in patients who 
received cyclosporine after heart trans­
plantation. We have not yet discounted 
the prospect of using cyclosporine in the 
first 2 to 3 months after transplantation, 
and then switching to azathioprine, but 
further long-term data are required before 
we implement this strategy.
Measures that we believe useful to 
minimize postoperative renal dysfunction 
include: (a) use of less than 18 mg/kg of 
cyclosporine preoperatively and postoper- 
atively in the presence of renal dysfunc­
tion; (b) daily monitoring of serum 
cyclosporine levels for at least 1 week 
postoperatively, aiming for levels of 150 
to 250 ng/mL; (c) use of mannitol dur­
ing cardiopulmonary bypass and then 
postoperatively with each dose of 
cyclosporine during the initial hospitali­
zation; (d) maintenance of an optimal 
cardiac filling pressure; (e) use of renal 
effective doses of dopamine and (f) use 
of diuretics to maintain an hourly urine 
output of at least 1 mL/kg.
Myocardial fibrosis.—As in the kidney, 
a fine interstitial myocardial fibrosis starts 
within several weeks of treatment with 
cyclosporine.12 At least 10 patients at 6 
months, 18 at 1 year and 2 at 2 years have 
been assessed for evidence of myocardial 
restriction, both before and after volume 
loading with 0.9% saline. Although the 
long-term results of this fibrosis are not 
known, there is no evidence that it leads 
to myocardial damage of physiologic 
importance.
Headaches.—Although headaches are 
common early on in the course of 
cyclosporine therapy, they are generally 
thought to be due to a hyperdynamic cir­
culation, hypertension and perhaps cere­
bral edema. In general, headaches can be 
controlled with antihypertensive therapy 
and analgesics. Usually within 1 to 3 
weeks after transplantation, headaches 
are no longer a problem.
Hirsutism.—Hair growth may be strik­
ing with a general increase in body and 
scalp hair that becomes darker, thicker 
and wavier. This may be of concern to 
women, cosmetically.
Tremor.—A fine resting tremor is 
occasionally present for the first few 
weeks after transplantation, but it also 
resolves with time.
Hepatic dysfunction.—Transient eleva­
tion of liver enzymes and total bilirubin 
levels occur in most patients early after 
transplantation, but both usually return 
to baseline levels within 2 to 4 weeks after 
transplantation.
Interaction with rifampin.—Rifampin 
has been demonstrated to induce produc­
tion of liver microsomal enzymes13 and 
enhance the metabolic effect of predni­
sone.14 In two patients with Aspergillus 
fumigatus pulmonary infection, in-vitro 
synergy studies demonstrated a potential 
benefit for them with amphotericin B 
combined with rifampin. In both patients, 
the requirements for cyclosporine in­
creased three to fivefold within several 
days of beginning rifampin therapy.15 In 
one patient, it was difficult to maintain 
satisfactory cyclosporine levels, and acute 
rejection occurred. Despite several treat­
ment courses, the rejection never satisfac­
torily resolved and the patient ultimately 
died of acute and chronic rejection. In the 
second patient, the infection appeared to 
resolve and it was anticipated that renal 
dysfunction would ensue if the rifampin 
was discontinued without first lowering 
the cyclosporine dosage. Accordingly, the 
cyclosporine was returned to the original 
maintenance dosage at the same time that 
the rifampin was discontinued. Neverthe­
less, the serum creatinine level doubled 
and the creatinine clearance decreased to 
one half of its baseline value for several 
days before recovery. Others14 have also 
reported a marked increase in cyclospo­
rine requirements in renal transplant 
recipients who have required rifampin 
therapy.
Comparative Costs for  
Heart Transplantation
As of March 1983, the average cost per 
patient for cardiac transplantation in 48 
patients treated with cyclosporine was 
nearly $30 000 less than in 97 patients 
given azathioprine. This difference was 
also reflected in the median cost of 
$63 000 as opposed to $91 000.
Cyclosporine in Heart-Lung 
Transplantation
Historically, the results of human 
heart-lung transplantation and lung trans­
plantation have been disappointing. In 
three heart-lung transplantations done in 
1968, 1969 and 1971, no patient survived 
beyond 23 days and each died from 
respiratory complications.16'18 Similarly, 
of 39 patients who have undergone lung 
transplantation, only 2 have survived 
beyond 2 months (6 and 10 months).19 
Use of steroid immunosuppression con­
tributed importantly to each patient’s 
death of pneumonia or tracheobronchial 
disruption, by preventing anastomotic 
healing. With the successful introduction 
of cyclosporine in animal cardiac trans­
plantation20-22 and human renal trans­
plantation,23 the elimination or reduc­
tion of the requirements for steroids in 
solid-organ transplantation became a pos­
sibility. Experiments begun in 1979 using 
cyclosporine in primate heart-lung trans­
plantation by Reitz and associates24 at 
Stanford strongly supported a move 
towards clinical application of the proce­
dure. Two primates are still alive and well 
at 4.5 and 5 years after transplantation. 
Stimulated by the primate experience and 
the success with cyclosporine in human 
heart transplantation, a program in 
human heart-lung transplantation was 
begun in March 1981.25
Recipient Selection
From March 1981 until May 1984, 19 
heart-lung transplantations were per­
formed in 13 men and 6 women ranging 
in age from 22 to 45 years (Table I). 
Twelve had congenital heart disease with 
secondary pulmonary hypertension, and 
7 patients had primary pulmonary hyper­
tension. Although a large group of 
patients with chronic obstructive pulmo­
nary disease, pulmonary fibrosis or cys­
tic fibrosis are conceivably suitable can­
didates, none in this group have yet 
undergone transplantation at Stanford 
University.
Operative Technique and 
Postoperative Management
The details of operative technique and 
postoperative management of heart-lung 
transplantations have been reported 
previously.26 The operative technique 
has been modified in the last 13 patients 
so that: the lungs are cooled with modi­
fied Collins II solution; the heart and 
both lungs in the recipient are removed 
separately so that visualization of the 
bronchial arteries and of both the vagal 
and phrenic nerves is better; the back wall 
of the left pulmonary artery is left intact 
thereby minimizing the likelihood of 
injuring the recurrent laryngeal nerve 
and, during implantation, both lungs are 
bathed with cold (4°C) Physiosol (bal­
anced salt) rather than Collins II (bal­
anced salt, high in potassium) solution, 
to prevent undesirable potassium absorp­
tion and hyperkalemia. Modification of 
the operative technique, however, has not 
alleviated the problem of bleeding requir­
ing re-exploration (nine patients). All 
patients received antibiotics (cefaman- 
dole, nafcillin and erythromycin) peri- 
operatively.
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Immunosuppression
The immunosuppressive regimen used 
in all patients consisted of cyclosporine, 
14 to 18 mg/kg, orally 6 hours before 
transplantation, and then postoperatively 
in divided doses according to targeted 
serum levels between 100 and 300 ng/mL. 
Three doses of antithymocyte globulin of 
rabbit origin (2.5 mg/kg) were given 
intramuscularly to each patient, immedi­
ately following induction of anesthesia, 
then on postoperative days 1 and 2. The 
determining factor for the second 
postoperative dose of rabbit antithymo­
cyte globulin was an absolute T-rosette 
level exceeding 100/mm3 the day after 
the first postoperative dose. Methylpred- 
nisolone sodium succinate, 500 mg intra­
venously, was given after cardiopulmo­
nary bypass, then 125 mg intravenously 
every 8 hours for three doses. No further
steroids were given in the subsequent 2 
weeks, during which azathioprine, 1 to 2 
mg/kg orally, was given daily if the leu­
kocyte count was greater than 4 x 109/L. 
After 2 weeks, prednisone was begun at 
0.2 to 0.3 mg/kg daily and the azathio­
prine was discontinued. Rejection epi­
sodes were diagnosed by endocardial 
biopsy.
Results
Of the 19 patients transplanted, as of 
March 1984, 13 survived the operation 
(operative mortality defined as death 
within 30 days of transplantation) (Table 
I) and were fully rehabilitated; 12 were 
still alive.
Of the six operative deaths, two 
patients died of multisystem organ 
failure, one of lung failure manifested, 
immediately following attempts to discon­
tinue cardiopulmonary bypass, as a severe 
loss of alveolar-capillary integrity and 
massive pulmonary edema, two of pul­
monary insufficiency on postoperative 
days 16 and 33 from undetermined causes 
(implantation response and rejection or 
infection, or both?) and one patient died 
of a myocardial infarction 15 months 
after transplantation.
Fourteen episodes of cardiac rejection 
have been diagnosed by cardiac biopsy, 
demonstrating a mononuclear cellular 
infiltrate with myocyte necrosis on histo­
logic examination. Thirteen of the epi­
sodes occurred within 90 days of trans­
plantation. Each episode was treated 
successfully with three 1-g/d pulses of 
methylprednisolone sodium succinate.
Until recently, we believed that both 
pulmonary and cardiac rejection were 
accurately reflected in all cases by 
endocardial biopsy. We also assumed that
Table I—Clinical Summary of the Heart-Lung Transplant Recipients
Treated rejection Initial
Patient Age, episodes, Form of hospital Survival,
no. yr Sex Diagnosis postop. day rejection Infection discharge, d d
1 45 F PPH 11, 25, 45 Cardiac cellular Herpes (cutaneous) 85 1146
infiltrate, MN
2 30 M E 235, 1041 Cardiac cellular CMV (systemic) 46 1090
infiltrate, MN 
(pulmonary infiltrate, 
pulmonary HPT, 
cardiac graft 
atherosclerosis)
3 29 F E X X 4 4
4 40 M E 86 Cardiac cellular Recurrent lung infection 46 961
infiltrate, MN (bronchiectasis)
5 37 F PPH 21, 52 Cardiac cellular — 64 881
infiltrate, MN
6 29 F PPH X X X 23 23
7 22 M E X X X 0 0
8 40 M E — — Bacteroides (blood and 40 542
lung), CMV (systemic)
9 22 M E 15, 22, 211 Cardiac cellular Enterococcus (lung) 38 538
infiltrate, MN, 
pulmonary infiltrate
10 28 M E 23, 29, 56, 443 Cardiac cellular — 39 443
infiltrate, MN, 
cardiac graft athero­
sclerosis, myocardial 
infarction
11 38 M E — — — 38 476
12 32 M E — — CMV (systemic), 46 347
Klebsiella (pulmonary), 
recurrent lung infec­
tion (bronchiectasis)
13 33 M E 14 Cardiac cellular Serratia (pulmonary), 51 344
infiltrate, MN CMV (systemic)
14 28 F PPH X X Candida (pulmonary) 16 16
15 42 M E X X Legionella (pulmonary), 33 33
Serratia, Enterococcus 
(pulmonary)
16 22 M PPH 29 Cardiac cellular Serratia, Hafnia alvei 49 177
infiltrate, MN (pulmonary)
17 37 M PPH — — Enterobacter, Serratia, 63 150
Staphylococcus
(pulmonary)
18 33 F PPH
19 40 M E In hospital---------------------------
PPH -  primary pulmonary hypertension, E -  Eisenmenger's syndrome, MN -  myocyte necrosis, HPT -  hypertension, CMV -  cytomegalovirus, X = not 
applicable.
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pathologic lung rejection would invaria­
bly demonstrate a classic cellular pattern. 
Although in general these two assump­
tions hold true, it appears that, with 
cyclosporine immunosuppression, neither 
is entirely accurate. Primate heart-lung 
transplantation studies have demon­
strated that severe cellular lung rejection 
may occur without appreciable heart 
rejection.27 Furthermore, two patients 
(cases 2 and 9) suffered late pulmonary 
infiltration on lung biopsy but no cardiac 
rejection. Over the previous 4 months, 
both had had serum cyclosporine levels 
below 150 ng/mL and in patient no. 9 a 
restrictive pattern that had developed 
along with the infiltration partially 
resolved with a return towards normal 
lung volumes, compliance and roentgeno- 
graphic appearance following steroid 
therapy; in patient no. 2, severe coronary 
atherosclerosis and pulmonary hyperten­
sion were documented shortly after the 
development of the lung infiltration. A 
third patient who had cyclosporine levels 
below 150 ng/mL for 7 months died sud­
denly and was found to have an extensive 
myocardial infarction and graft athero­
sclerosis. The occurrence of pulmonary 
hypertension and graft atherosclerosis 
and perhaps even the late pulmonary 
infiltration may represent a less-common 
form of vascular rejection, perhaps 
immorally mediated. That the pulmonary 
changes and graft atherosclerosis oc­
curred only in these three patients follow­
ing a 4- to 6-month period with low 
cyclosporine levels (less than 150 ng/mL) 
suggests, but does not prove, cause and 
effect. Nevertheless, stimulated by these 
findings, our current recommendation is 
to aim for serum trough cyclosporine 
levels of 200 to 300 ng/mL, rather than 
our previous range of 100 to 300 ng/mL.
A similar degree of renal dysfunction 
(elevated creatinine and blood urea nitro­
gen levels) and hypertension requiring 
therapy occurred in heart-lung recipients 
as in the heart recipients.
Perhaps the most unusual complication 
following heart-lung transplantation was 
the development of the “ implantation” 
response in the lungs of 9 of the 13 long­
term survivors. This reponse, which has 
been described previously,28 is character­
ized by perihilar infiltration that may 
become confluent and must be distin­
guished from infection and rejection. 
These changes generally occur and resolve 
between 7 and 28 days after transplanta­
tion, and are associated with hypoxemia 
and decreased lung compliance. Factors 
exclusive of rejection and infection that 
have been considered possible in the 
pathogenesis include lymphatic, bronchial 
arterial or neural interruption, or both, 
mechanical trauma from handling of 
lungs, and the perfusate used to cool the 
lungs. The etiology of this pulmonary 
response, however, is unclear since no
patients or primates have yet had a diag­
nostic lung biopsy. In fact, rejection or 
immune complex disease could still be a 
factor since all patients appear to improve 
when azathioprine is discontinued and use 
of prednisone is started on postoperative 
day 14; one patient has been documented 
as having elevated levels of circulating 
immune complexes and decreased serum 
complement (unpublished data).
Infection during the initial hospitaliza­
tion has been of grave concern, particu­
larly in recipients who had an implanta­
tion response. Table I documents only a 
modest number of non-fatal infectious 
episodes. Scrupulous donor selection, 
vigorous investigation and surveillance 
for infection, use of antibiotics prophy- 
lactically and in many instances, pro­
longed use of broad-spectrum antibiotics 
during the implantation response likely 
contributed to the relatively low fre­
quency of infectious episodes. Localized 
bronchiectasis with recurrent episodes of 
pneumonia have developed in two long­
term survivors but no malignant process 
has been found.
Summary
In summary, 13 of 19 patients are alive 
1 to 38 months after heart-lung transplan­
tation. Notwithstanding the important 
efforts by the many investigators involved 
with the heart-lung transplantation pro­
gram, none of this would be possible were 
it not for the unique immunosuppressive 
properties of cyclosporine.
Experience with the use of cyclosporine 
in both heart and heart-lung transplan­
tation indicates that when used in com­
bination with low doses of prednisone, 
important improvement in allograft sur­
vival can be achieved. That both early and 
late rejection (cellular and humoral) and 
infection still occur in both groups of 
patients, along with hypertension and 
renal dysfunction secondary to cyclospo­
rine use, demands that we continue our 
efforts to control the immune system and 
eliminate unwanted drug side effects.
Addendum
As of January 1985, 352 heart allografts had 
been placed in 325 recipients, and 24 patients 
had received 25 heart-lung transplants. 
Conclusions based on data generated as of 
January and March 1984 for the two groups 
respectively, with regard to survival and 
complications, still applied and they support 
the continued use of cyclosporine, with the 
guidelines suggested to minimize toxicity. In 
some patients with declining renal function, 
azathioprine may have to replace cyclosporine 
for immunosuppression.
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anesthetics.
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patients with severe liver disease.
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the combined action o f both agents upon the myocardium, the concen­
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Local anesthetics which contain preservatives, i.e. those supplied in mul­
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In the event of spinal injection clinical signs of spinal block would 
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In the event of intravascular injection a transient increase in pulse rate 
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"epinephrine response” are less dependable. The effects of other medi­
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When reinforcing doses are required the test dose should be used 
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Use in Ophthalmic Surgery: When Marcaine 0.75% is used for retrobul- 
bar block, com plete corneal anesthesia usually precedes onset of clini­
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jv e r  dosage, inadvertent intravascular injection, or slow metabolic 
degradation. Other causes o f reactions to  these local anesthetics may 
be hypersensitivity, idiosyncrasy, or diminished tolerance.
..xcessive plasma levels cause systemic reactions involving the central
nervous system and the cardiovascular system. The central nervous 
system effects are characterized by excitation or depression. The first 
manifestation may be nervousness, dizziness, blurred vision, or tre ­
mors, followed by drowsiness, convulsions, unconsciousness, and pos­
sibly respiratory arrest. Since excitement may be transient o r absent, 
the f irs t manifestation may be drowsiness, sometimes merging into 
unconsciousness and respiratory arrest.
Other central nervous system effects may be nausea, vomiting, chills, 
constriction of the pupils, or tinnitus. The cardiovascular manifesta­
tions of excessive plasma levels may include depression of the myocar- 
dium, blood pressure changes (usually hypotension), and cardiac 
arrest. Recent clinical reports and animal studies suggest this may be 
m ore likely to occur with the long acting amide local anesthetics such 
as bupivacaine.
Allergic reactions are characterized by cutaneous lesions (e.g. urticaria, 
edema) and other manifestations of allergy.
Reactions following epidural or caudal anesthesia may include: high or 
tota l spinal block, urinary retention; fecal incontinence, loss o f perineal 
sensation and sexual function; persistent analgesia, paresthesia, and 
paralysis of the lower extremities; headache and backache; and slow­
ing o f labor and increased incidence of forceps delivery.
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Cost of Coronary Artery Bypass Surgery: a Pilot Study
The increasing concern about the high 
cost of health care led the authors to 
conduct a pilot study on the overall cost 
and cost variability for patients who 
underwent coronary artery bypass graft­
ing. They reviewed the charts of 50 ran­
domly selected patients to determine 
actual costs of catheterization and 
bypass grafting. Four patients had single- 
vessel disease, 12 double- and 34 triple­
vessel disease and 13 had moderate to 
severe impairment of ventricular func­
tion. The length of hospital stay ranged 
from 8 to 43 days (mean 16.5 days).
The duration of stay in the recovery 
room and intensive care unit ranged from 
21 to 356 hours (mean 91.6 hours). 
Operative time ranged from 2 to 6.5  
hours (mean 3.95 hours). Using several 
accepted cost-allocation methods, the 
authors developed a valid, complete 
breakdown of clinical and nonclinical 
costs. Total cost was directly related to 
the length of hospital stay, left ventricu­
lar function, secondary diagnosis and 
number of diseased vessels. Further 
studies will address clinical factors 
related to cost and cost effectiveness of 
coronary artery bypass grafting as 
opposed to other forms of treatment for 
coronary artery disease.
Les couts eleves des soins de sante font 
I'objet d'un souci croissant. Les auteurs 
ont done mene une etude pilote des 
couts globaux et de leur variation chez 
des patients soumis a un pontage aorto- 
coronarien. Its ont etudie les dossiers de 
50 patients choisis au hasard afin d'eta- 
blir les couts d'un catheterisme et d'un 
pontage. L'oblit6ration coronarienne etait 
simple chez 4 patients, double chez 12 
et triple chez 34; 13 malades presen-
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taient une insuffisance ventriculaire 
moyenne a severe. La duree d'hospitali- 
sation a varie de 8 a 43 jours (16.5 jours 
en moyenne). Le sejour en salle de reveil 
et aux soins intensifs a dure de 21 a 
356 heures (moyenne de 91 .6  heures). 
L'operation a dure de 2 a 6 .5  heures 
(moyenne de 3.95 heures). A I'aide de 
plusieurs methodes de facturation recon- 
nue, les auteurs ont etabli une repartition 
complete et acceptable des couts clini- 
ques et non cliniques. Le cout total etait 
directement relie a la duree du sejour a 
I'hopital. a I'etat de la fonction ventricu­
laire gauche, aux diagnostics secondaires 
et au nombre de pontages requis. Des 
etudes subsequentes s'interesseront aux 
facteurs cliniques relies aux couts et au 
rapport couts/benefices du pontage 
aorto-coronarien par rapport a d'autres 
formes de traitement de la maladie coro­
narienne.
The high cost of health care is causing 
increasing concern to the public, govern­
ment and health-care professionals. Coro­
nary artery disease, particularly its sur­
gical treatment, places an enormous 
burden on all. The University of Ottawa 
Heart Institute, in conjunction with the 
Health Administration Program of the 
Faculty of Administration, University of 
Ottawa, has embarked on studies to 
determine the cost and cost effectiveness 
of coronary artery bypass grafting. The 
first step has been a pilot study to deter­
mine the overall cost and cost variability 
for patients who undergo bypass grafting. 
The question of the cost of heart surgery 
is of interest in Canada because we lack 
the basic data for public decision-making 
about funding for increases or changes, 
or both, in this area. The lack of data is 
common to the health-care system in all 
provinces and has specific impact on 
cardiovascular disease, Canada’s number 
one health-care problem. It is well recog­
nized how widely costs vary among 
health-care institutions, even among those 
providing a similar type or range of serv­
ices. While such institutions may face 
identical market prices for their goods 
and services, the degree of efficiency in
the use of resources will ultimately deter­
mine the net cost of care. Identifying and 
measuring the many interrelated input 
factors and tracing the connection 
between them and specific medical serv­
ices require a tailored approach in each 
health-care facility. To complicate cost 
analysis further, and this is especially true 
of hospitals, management systems are not 
designed to provide the requisite informa­
tion. Accounting procedures typically 
aggregate costs, so that it is difficult to 
determine the relation between resource 
consumption and production of those 
resources. Cost analysis must often start 
at the bottom and work up, adapting the 
methodology to the obstacles of incom­
plete, invalid or inaccurate primary data.
Methodology
The University of Ottawa Heart Insti­
tute at the Ottawa Civic Hospital is a free­
standing structure devoted to the preven­
tion, investigation, treatment — both 
medical and surgical — and the rehabili­
tation of patients with cardiovascular dis­
ease. It has 125 set-up beds, including 
8 surgical and 8 medical intensive-care 
beds with an additional 6 recovery room 
beds, 8 day-care and 4 emergency resus­
citation beds. We perform more than 
1000 operative procedures annually of 
which 750 are bypass grafting.
Cost for the services provided for 
patients who undergo coronary artery 
bypass grafting were determined accord­
ing to accepted disease-costing methodol­
ogy.1 The first step was to design a cost- 
centre matrix that integrated six arbitrary 
stages of the patient’s hospital stay into 
admission, preoperative, ward, operating 
room, recovery room and surgical inten­
sive care, and postoperative ward and dis­
charge. With the hospital cost centres 
defined in previous research at the Ottawa 
Civic Hospital,2 these cost centres were 
divided into three categories: support 
departments, diagnostic and therapeutic 
departments and patient-care depart­
ments. All hospital operating costs and 
treatment elements applicable to the 
procedure were identified and classified
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as direct, indirect or overhead. Costs were 
assigned to an individual patient and 
aggregated to obtain the cost of an epi­
sode of illness for coronary artery bypass 
grafting (Fig. I).3 The cost of labour on 
the wards before and after operation was 
determined using a work-sampling ratio 
delay study over a 7-day period.4'5 The 
hospital charts of 50 randomly selected 
patients who underwent coronary artery 
bypass were reviewed in detail to deter­
mine the actual cost of admission for 
catheterization or separate admission for 
operation, or both. Professional fees were 
determined by recording the actual 
amounts reimbursed by the provincial 
government plans to the medical staff 
involved in the treatment: surgeons, 
anesthetists, surgical assistants, cardiol­
ogists and radiologists.
Clinical Profile o f  Patients
and September 1983, excluding patients 
who underwent reoperation or who died 
in hospital. The mean age of the patients 
was 55.3 years (ranging from 39 to 73 
years). This is representative of the male 
to female ratio and age range of our total 
patient population. Four patients had 
single-vessel, 12 double-vessel and 34 
triple-vessel disease. Seven had been oper­
ated upon urgently and 43 electively. 
Thirteen had poor ventricular function 
(class III or IV6) and the remaining 37 
had normal function or mild impairment. 
Seven patients underwent additional 
procedures: coronary endarterectomy in 
six and left ventricular aneurysm resec­
tion in one; two patients required intra­
aortic balloon pump assistance early 
postoperatively. The total length of hospi­
tal stay including the stay for cardiac 
catheterization averaged 16.5 days (rang­
ing from 8 to 43 days).
We reviewed the charts of 50 patients Total Episode Cost 
(42 men, 8 women) who underwent coro­
nary artery bypass grafting between April An episode of illness for this costing
FIG- 1—Direct method of cost allocation. CABG = coronary artery bypass grafting.
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O p e ra t io n  a lo n e 1 7 0 0 1 9 4 3 1 8 1 7
* 0 n e  c h a r g e  o n ly .
T a b le  I I— E p is o d e  C o s t  V e r s u s  L e n g th  o f  H o s p it a l  S t a y
L e n g t h  o f 
s t a y ,  d N o . R a n g e , $ M e a n , $
9 5 6 3 8 9 -  8  1 4 3 7 5 8 4
1 0 - 1 2 15 6 9 4 9 - 1 6  1 8 3 9 3 1 9
1 4  16 6 8 4 5 8 - 1 0  3 6 3 9 7 0 2
1 7 - 1 9 7 7 5 6 8 - 1 0  8 0 4 9 1 2 6
2 0 - 2 9 1 0 8 9 3 1 - 1 8  4 1 5 13 0 6 7
3 0 - 4 3 3 1 0  8 7 2 - 1 4  9 9 7 1 3  1 5 9
study is defined as a stay in hospital for 
the surgical procedure and separate 
admission for cardiac catheterization. 
Twenty-five patients underwent catheteri­
zation during the admission for opera­
tion, three had catheterization as outpa­
tients and one at a different hospital (that 
single procedure was not costed). The epi­
sode costs are the total costs for all treat­
ment elements during the hospital stay. 
The total costs varied from $6387. to 
$18 415. (Canadian 1983 dollars) with an 
average cost of $9595. This total com­
prises two parts: professional fees and 
hospital costs.
The hospital costs were broken down 
into five categories: cardiac catheteriza­
tion; laboratory, radiologic and phar­
maceutical expenses; surgical ward 
(including preoperative coronary care 
unit); operative procedure; recovery room 
and surgical intensive care unit. The mini­
mum, maximum and mean costs in each 
of these subcategories are summarized in 
Table I.
The total episode cost, not surprisingly, 
was directly related to length of hospital 
stay (Table II). It was also directly related 
to the number of diseased vessels, secon­
dary diagnoses, left ventricular dysfunc­
tion and age (Table III). It was not related 
to sex, emergency category of a patient, 
number of bypass grafts placed or aux­
iliary procedures performed.
Discussion
Establishing a firm estimate for the sur­
gical cost of treatment for coronary artery 
disease is the first step in analysing cost 
effectiveness. We carried out a detailed 
study of the cost of treating 50 patients 
who underwent coronary artery bypass 
grafting. Fig. 2 shows the distribution of 
total costs ranging from the lowest to the 
highest for each patient. For the first time 
we know the actual costs of treating a 
group of patients who had heart surgery 
in Canada. We studied the treatment 
process for patients who underwent coro­
nary artery bypass grafting, carrying out 
a detailed cost analysis in every depart­
ment of the hospital participating in their 
treatment. We studied their cost patterns 
and developed unit costs for every iden­
tifiable component of patient care as it 
appeared on the patient’s medical chart 
and others such as administrative, over­
head and capital equipment costs that 
were not recorded on the charts. We 
covered all direct and indirect aspects of 
care. These costs were then used together 
with a detailed chart review to develop an 
accounting for each patient.
In two other detailed costing studies 
done in the United States, the method of 
costing and reimbursement for patients’ 
services was different from our own.7'8 
However, a broad comparison is possi­
ble after adding an annual inflationary
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factor (10%) and converting American to 
1983 Canadian dollars (25%). Although 
the institutions and the methodology were 
different, professional fees remain at a 
fairly constant percentage of the total 
hospital cost (Table IV), with professional 
fees representing 20% to 30% and hospi­
tal charges 70% to 80% of total costs. 
Stoney and colleagues,8 reporting from 
Vanderbilt University School of Medicine 
in Nashville, showed a considerable 
difference in hospital costs when they 
were subdivided. Most notably, nursing 
costs on the ward were half our costs, 
operating room expenses twice, catheteri­
zation procedures three times and blood 
16 times our costs. It must be noted, 
however, that the cost of $21 per patient 
for blood in our institute refers only to 
the charges for cross-matching since the 
blood itself is free of charge. In a more 
recent American study, Jang and 
colleagues9 compared the cost of surgery 
for single-vessel disease as opposed to per­
cutaneous transluminal coronary angio­
plasty and quoted a cost for coronary 
artery bypass grafting of $15 580 in 1983 
US dollars. There are no published Cana­
dian costing studies in this area.
This pilot study is our first step towards 
dealing with disease costing and analysis 
of cost effectiveness at the University of 
Ottawa Heart Institute. We expect to 
refine further the costing components of 
care and to develop a patient care infor­
mation system that will generate data for 
medical peer review. This will be of use 
in discussions of both the medical and 
economic aspects and will eventually lead 
to a study of the cost effectiveness of 
alternative forms of treatment for coro­
nary artery disease.
Hospital inform ation systems in 
Canada are in their infancy in the area of 
clinical patient information systems. With 
the development of cost data, not only 
will physicians and surgeons be able to 
present their cases from the clinical point 
of view, but they will also have the pre­
cise cost data with which to judge the eco­
nomic implications of their decisions to 
use one form of investigation and treat­
ment as opposed to another. An exam­
ple of the potential for such knowledge 
is the development of a system for 
estimating the day of discharge, focusing 
on expeditious treatment and discharge of 
patients and thus reducing unnecessarily
lengthy stays to which cost is directly 
related. This frees up beds to allow flexi­
bility in the flow of patients. Other alter­
natives to investigate are the performance 
of cardiac catheterizations on an outpa­
tient basis and the provision of less- 
expensive hostel-type inpatient care for 
patients from out of town or for those 
with minor complications who do not 
require the resources of the normal inpa­
tient facilities.
One area of continuing concern is 
whether particular courses of treatment 
have long-term cost benefits for the 
individual patient and for society as a 
whole. So far, we have simply addressed 
ourselves to the cost of one mode of treat­
ment. However, the proposed research 
will encompass the broader questions. 
The objective is to continue to treat 
patients as effectively, but also as eco­
nomically, as possible. The added bonus 
of a clinical information system would be 
for administrative use in planning patient 
load and workloads in each department 
and institution as well as in budgeting and 
forecasting.
The days of open-ended financial atti­
tudes on planning health care have 
passed. Improvements must come from 
within the system and be initiated by the 
physicians and surgeons concerned and 
must not be imposed by the funding bod­
ies. Accurate and responsible disease cost­
ing studies are a prerequisite to this intel­
ligent planning.
We thank Jann Darlington, David Kay, 
John MacIntyre, Janie Reed and Melissa Son- 
berg, master’s degree students in the Health 
Administration Program, and Mrs. Katrin 
Smith, Research Assistant, University of 
Ottawa Heart Institute, for their assistance in 
this study.
FIG. 2—Variability of costs of coronary 
artery bypass grafting for each of 50 patients. 
1 = cost of coronary angiography (+  separate 
stay), 2 = laboratory, radiologic and phar­
maceutical costs, 3 = surgical ward nursing,
4 = cost in coronary care unit preoperatively,
5 = recovery room and surgical intensive care 
unit costs, 6 = professional fees.
Table III—Variables Affecting Episode Cost
Variable No. Range of cost, $ Mean cost, $
Age, yr
37-49 15 6 387-16 183 8 616
50-59 17 7 329-16 224 9 603
60-73 18 7 317-18 415 10 404
No. of diseased vessels
1 4 6 387- 8 143 7 624
2 12 7 329-18 415 9319
3 34 6 949-16 224 9 702
Left ventricular function
Poor 13 7 341-14 998 10 196
Good 37 6 387-18 415 9 383
Secondary diagnoses
Diabetes 6 6 387-13 174 11 059
Hypertension 5 7 979-14 999 10 599
Peripheral vascular disease 5 7 317- 8 885 7 905
Transient ischemic attacks 2 8 303- 9 154 8 728
Chronic obstructive pulmonary disease 2 16 225-18 415 17 320
Total secondary diagnosis 20 6 387-18 415 10 549
Coronary artery disease alone 30 6 949-16 412 8 495
Table IV—Comparison of Hospital Costs (1983 Canadian Dollars)
Cost Nashville,8 $ Birmingham,7 $ Ottawa, $ Loma Linda,*9 $
Ward 1 268 — 2 749 -
Intensive care unit/d 684 - 474 —
Electrocardiogram 254 - 46 —
Operating room 3 729 — 1 800 3 600
Catheterization 1 151 — 408 —
Blood 324 - 21 —
Radiology 160 — 117 —
Pharmacy - 800 (4.4%) 144(1.5%) -
Professional fees 6 344(30%) 3 860 (20.6%) 2 254 (23.5%) 6 130(31%)
Total in hospital 14 983(70%) 14 104(75%) 7 345 (76.5%) 13 350(69%)
Total/episode 21 332 18 764 9 595 19 480
‘ Combined national study.
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Liver Transplantation: the Initial Experience 
of a Canadian Centre
At the University Hospital in London, 
Ont., 19 patients have received 24 liver 
transplants. The commonest indications 
for transplantation were primary biliary 
cirrhosis and cirrhosis from chronic 
active hepatitis. The first three patients 
in the series died of infectious complica­
tions. Eleven of the subsequent 16 
recipients are alive from 5 months to 2'h 
years after transplantation. Eight 
patients who are alive more than 1 year 
after the operation have an excellent 
quality of life. Cyclosporine and steroids 
in combination are used for immunosup­
pression.
With current surgical techniques, 
modern immunosuppression and good 
patient selection, the restoration of 
patients with advanced irreversible liver 
disease to good health by liver transplan­
tation is a realistic goal. Much effort and 
considerable resources are required to 
run a liver transplant program.
A I'Hospitalier Universitaire de London, 
Ont., 24 transplantations de foie ont ete 
executees dans 19 beneficiaires. Les 
indications les plus communes pour la
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transplantation etaient le cirrhose biliaire 
primaire et le cirrhose resultant de 
I'hepatite active chronique. Les trois pre­
miers patients de la serie moururent de 
complications infectieuses. Onze des 16 
destinataires ulterieurs sont actuellement 
vivants apres des periodes d'entre 5 
mois et 2 'A ans apres la transplanta­
tion. Huit patients sont vivants apr&s 
plus d'un an, et la qualite de leur vie est 
excellente. L'immunosuppression em­
ployee actuellement est une combinaison 
de cyclosporine et de steroides.
A cause des techniques actuelles de 
chirurgie, et de l'immunosuppression 
moderne, ainsi que d'une selection parti- 
culi&rement efficace de patients, le reta- 
blissement a la bonne sante des patients 
souffrant de maladies de foie irreversi- 
bles par la transplantation de foie est un 
but realiste. L'effort et les ressources 
necessaires a mettre sur pied un pro­
gramme de transplantation sont en effet 
importants.
Almost 1000 human liver transplants have 
been performed since Starzl’s first report 
more than 20 years ago.1 The early 
procedures were plagued by technical 
complications, uncontrollable bleeding, 
infection and poor organ preservation, all 
of which resulted in high operative mor­
tality and morbidity. Recently, however, 
results have improved substantially and 
1-year survival rates following liver trans­
plantation now approximate 70% in 
experienced hands.2 The main reasons 
for the improved results have been bet­
ter immunosuppression and more critical 
selection of recipients.
In the late 1970s we became convinced 
that some individuals with certain types 
of liver disease could benefit from liver 
transplantation. We believed that there 
was a need for this service in our area and 
that the results justified starting a pro­
gram. This was an expansion of an 
already established program in renal
transplantation at University Hospital in 
London, Ont., that now includes trans­
plantations of heart, heart-lung and pan­
creas.3-4 This report details our 
experience to date in transplantation of the liver.
Patients
Twenty-four orthotopic liver trans­
plants have been performed in 19 patients 
(13 females, 6 males) (Table I). Three 
patients received two transplants and one 
patient received three. The recipients 
ranged in age from 14 to 58 years. The 
majority had primary biliary cirrhosis or 
cirrhosis from chronic active hepatitis 
(surface antigen negative) (Tables II and 
III). Recipients with a chronic liver 
condition had advanced disease with 
uncontrolled ascites, hypoalbuminemia, 
malnutrition, increasing jaundice, coagu­
lopathy and encephalopathy in spite of 
ideal medical therapy. Two patients had 
previously undergone portacaval shunt­
ing for bleeding esophageal varices. Six­
teen of the 19 recipients were hospitalized 
while awaiting transplantation because 
they were too sick to be managed at 
home. Transplantation was not recom­
mended to patients with chronic liver dis­
ease until it seemed that life expectancy 
was measured in months or less. Three 
patients had acute liver failure from 
extensive liver necrosis and were trans-
T a b le  1— L ive r T r a n sp la n t s
Y ea r
N o. of N o. of
re c ip ie n ts s u rv iv o rs
1 9 7 7 1 0
1 9 7 8 1 0
1 9 8 1 1 0
11 9 8 2 1
1 9 8 3 4 3
1 9 8 4 11 7
T o ta ls 1 9 11
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planted when they were in grade 4 liver 
coma, were ventilator-dependent, and 
had associated renal failure. The patients 
with acute liver failure were deemed to be 
dying and would not survive without a 
transplant. Important considerations in 
selecting patients were a stable psychoso­
cial background and the absence of car­
diopulmonary disease. Only one patient 
with malignant disease received a trans­
plant. She had a multifocal, fibrolamel- 
lar hepatoma that was shown grossly to 
be confined to the liver.
Donor Operation
Livers were removed from donors in 
whom brain death had occurred as a 
result of head trauma or spontaneous 
intracranial hemorrhage. In 17 cases the 
donors were in hospitals outside London 
and the transplant team travelled to the 
donor hospital to remove the liver. The 
round-trip distances travelled by the 
donor team ranged from 290 to 3520 km. 
Livers were preserved in ice-cold Collins 
solution, using the in-situ flush technique 
and hypothermic storage.5 The preserva­
tion times of the donor livers ranged from 
1 h 51 min to 5 h 21 min (average 3 h 54 
min). With one exception the kidneys 
were also removed from each liver donor 
for transplantation and in five of the 
donors the heart was also used for trans­
plantation. The liver donors were blood- 
group compatible with the recipients but 
no other tissue matching was attempted.
Recipient Operation
The diseased recipient liver was 
removed and the donor organ placed in 
the orthotopic position. No pumping or 
venous bypass was used. The vascular 
anastomoses were performed in the fol­
lowing sequence: suprahepatic vena cava, 
portal vein, infrahepatic vena cava and 
hepatic artery. The bile duct was 
anastomosed end-to-end without a stent 
in all cases but one. One patient (no. 6) 
had a duct-to-Roux loop as a primary 
procedure. A fine polyethylene catheter 
was left in the common duct or gallblad­
der, or both, for postoperative cholan­
giography. The recipient anesthesia time 
ranged from 5 h 55 min to 10 h 55 min 
(average 7 h 24 min).
Immunosuppression
The first two patients in the series 
received Imuran and steroids for 
immunosuppression. All subsequent 
recipients received cyclosporine and 
steroids. Cyclosporine was given 
intravenously (2 to 3 mg/kg daily) after 
operation until the recipients could take 
it by mouth (10 to 15 mg/kg daily) in two 
divided doses, usually at the end of the 
first week after operation. Cyclosporine
doses were aimed at maintaining serum 
trough levels of 150 to 200 ng/mL in the 
immediate postoperative period. Several 
months after transplantation, main­
tenance levels of 80 to 150 ng/mL were 
accepted. Serum levels were monitored by 
radioimmunoassay. Recently, concurrent 
high-pressure liquid chromatography 
(HPLC) assay has been used as a better 
indicator of parent compound only.6 
Methylprednisolone, 500 mg, was given 
intraoperatively after revascularization of 
the liver. Post operatively, prednisone, 1 
mg/kg daily, was given, tapering to 0.2 
mg/kg daily by the fourth or fifth week. 
Rejection episodes were treated by bolus 
steroid therapy consisting of 250 to 500 
mg of methylprednisolone daily for 3 
days. Steroid-resistant rejection was 
treated with Minnesota equine antilym­
phocyte globulin (15 to 20 mg/kg daily) 
for 7 to 10 days, aiming to keep the blood
lymphocyte count at 100 to 200 cells/mL. 
Rejection was diagnosed by a sudden 
increase in serum bilirubin and amino­
transferase levels, accompanied by posi­
tive immunologic responses in the 
recipient.7 Liver biopsies were performed 
selectively in patients whose rejection was 
difficult or impossible to reverse.
Results
The first three patients in the series died 
of overwhelming fungal infections 
between 1 and 3 months after transplan­
tation. Two of them (nos. 1 and 3) had 
bacterial infections following transplan­
tation and required prolonged antibiotic 
therapy which resulted in fatal oppor­
tunistic Candida infections. The third 
patient (no. 2) had an undiagnosed cryp- 
tococcal meningitis before transplanta­
tion, complicating her liver coma; the
T a b le  I I — D a ta  o n  1 1  S u rv iv o rs  o f L iv e r  T r a n s p la n t a t io n
P a t ie n t
n o .
A g e ,
y r S e x D is e a s e C o m m e n t
4 2 6 F C h ro n ic  a c t iv e  h e p a t i t is A liv e  a n d  w e l l  a t  3 0  m o , a t  w o r k  
( r a d io g r a p h e r ) ,  n o rm a l l iv e r  f u n c t io n
5 2 9 F C h ro n ic  a c t iv e  h e p a t i t is A liv e  a n d  w e l l  a t  2 6  m o , a t  w o r k  (n u r s e ) ,  
n o rm a l liv e r  f u n c t io n
6 3 0 F B ilia ry  h y p o p la s ia  a n d  c irrh o s is A liv e  a n d  w e l l  a t  2 2  m o , a t  w o r k  
(s a le s c le rk  a n d  h o u s e w i f e ) ,  n o r m a l l iv e r  
f u n c t io n
7 3 9 M P o s t  n e c ro t ic  c ir r h o s is A liv e  a n d  w e l l  a t  1 8  m o , a t  w o r k  
( r e s ta u r a n t  m a n a g e r ) , n o rm a l liv e r  fu n c t io n
9 5 6 M P r im a r y  b il ia ry  c ir r h o s is A liv e  a n d  w e l l  a t  1 5  m o , a t  w o r k  
( a c c o u n t a n t ) ,  d e v e lo p e d  h e p a t i t is  B  6  m o  
a f t e r  t r a n s p la n t ,  m ild  ja u n d ic e
1 0 5 0 M P r im a r y  b il ia ry  c ir r h o s is A liv e  a t  1 3  m o , a t  h o m e , r e c e iv e d  t w o  
m o re  t r a n s p la n t s  b e c a u s e  o f  r e je c t io n .  
N o w  5  m o  a f t e r  th ir d  t r a n s p la n t  w i t h  
n o rm a l liv e r  f u n c t io n
11 4 4 M S c le r o s in g  c h o la n g it is A liv e  a t  1 2  m o , a t  w o r k  ( e n g in e e r ) ,  
r e t r a n s p la n t e d  b e c a u s e  o f  r e je c t io n ,  
n o rm a l liv e r  fu n c t io n
1 4 1 4 M C h ro n ic  a c t iv e  h e p a t i t is A liv e  a t  1 2  m o , a t  s c h o o l, n o r m a l l iv e r  
f u n c t io n
1 6 3 4 F P r im a r y  b il ia ry  c ir r h o s is A liv e  a t  8  m o , a t  h o m e , c h r o n ic  r e je c t io n  
a n d  ja u n d ic e , w i l l  n e e d  r e t r a n s p la n t a t io n
1 7 1 9 F H e p a to m a A liv e  a t  7  m o , a t  h o m e , n o r m a l l iv e r  f u n c ­
t io n
1 9 4 8 F P r im a r y  b ilia ry  c ir r h o s is A liv e  a t  5  m o , a t  h o m e
T a b le  I l l - D a t a  on  8  R e c ip ie n ts  o f  L iv e r  T r a n s p la n t  W h o  D ie d
P a t ie n t
n o .
A g e ,
V t S e x D is e a s e
S u r v iv a l,
d C a u s e  o f  d e a th
1 2 8 M M a s s iv e  n e c ro s is , ? t o x ic  
h e p a t i t is
5 8 C a n d i d a  s e p t ic e m ia
2 1 6 F C h ro n ic  a c t iv e  h e p a t i t is 4 3 C r y p t o c o c c u s  s e p t ic e m ia
3 4 9 F S e c o n d a r y  b il ia ry  c ir r h o s is 8 4 C a n d i d a  s e p t ic e m ia
8 2 4 F C h ro n ic  a c t iv e  h e p a t i t is 3 6 R e je c t io n  o f  t r a n s p la n t e d  liv e r
1 2 1 6 F W ils o n 's  d is e a s e , a c u te  liv e r  
f a i lu r e
1 0 2 R e je c t io n  o f  t r a n s p la n t e d  liv e r
1 3 5 8 F P r im a r y  b il ia ry  c ir r h o s is 7 3 S e r r a t i a  s e p t ic e m ia
1 5 2 9 F M a s s iv e  n e c ro s is , a c u t e  n o n -A , 
n o n -B , v ira l h e p a t i t is
9 R e in fe c t io n  o f  g r a f t e d  l iv e r  
w i t h  n o n -A , n o n -B , v ir a l  
h e p a t i t is
1 8 1 6 F C h ro n ic  a c t iv e  h e p a t i t is 2 1 R e je c t io n  o f  t r a n s p la n t e d  liv e r
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infection disseminated following the oper­
ation.
Eleven of the subsequent 16 recipients 
are currently alive (Table II). Of these 11, 
7 have returned to work or school and 4 
are convalescing at home (1 has chronic 
rejection). The patients who have re­
turned to their previous occupation are 
well and have excellent quality of life. The 
period of convalescence before patients 
returned to work or school was usually 
between 4 and 6 months but was as short 
as 8 weeks after transplantation.
Four patients received more than one 
transplant. Patient no. 4, who is alive 
2 Vi years after operation, required a 
second emergency transplant 9 days after 
the first because thrombosis of the hepatic 
artery and liver infarction occurred. She 
is well at present and has normal liver 
function. Two patients (nos. 11 and 12) 
required a second transplant because of 
rejection. One of them (no. 12) was in 
extremis at the time of the second trans­
plant and died within 24 hours of the 
operation. The other patient made a good 
recovery following the second procedure; 
he remains well and has returned to work. 
Patient no. 10 had to be retransplanted 
‘twice because of rejection; he is making
T a b le  IV — S u r g ic a l C o m p lic a t io n s  
in  1 9  L iv e r  R e c ip ie n ts
C o m p lic a t io n
N o . o f  
p a t ie n ts
B il ia r y  f is t u la 1
B i l ia r y  s t r ic t u r e 2
W o u n d  d e h is c e n c e 2
P o s t o p e r a t iv e  b le e d in g  re q u ir in g  
la p a r o t o m y 2
T h r o m b o s is  o f  h e p a t ic  a r te r y 1
a satisfactory recovery at home 5 months 
after receiving his third transplant.
Biliary tract complications developed 
in three patients (Table IV): a biliary 
fistula in one and strictures and obstruc­
tion at the site of the duct-to-duct anasto­
mosis in two. In each of these patients the 
biliary drainage was revised to a Roux- 
en-Y choledochojejunostomy.
Six episodes of acute irreversible rejec­
tion occurred in five patients. Three of 
these patients had another transplant and 
two are alive. Two patients (nos. 8 and 
18) died of rejection and liver failure 
before another transplant could be done. 
The overall incidence of irreversible rejec­
tion in cyclosporine-treated patients was 
30% (six livers lost from rejection in 20 
transplants placed in 17 patients).
There have been no long-term survivors 
in the patients transplanted for acute liver 
failure from extensive liver necrosis (nos. 
1, 12 and 15). These patients were mori­
bund when transplanted and although 
each of them had immediate recovery 
with resolution of coma, correction of 
coagulopathy and reversal of renal 
failure, they died 9, 58 and 102 days after 
transplantation (Table III). Patient no. 
15, who was transplanted for fulminant, 
non-A, non-B, viral hepatitis, died when 
acute massive necrosis and failure of the 
transplanted liver occurred suddenly 7 
days after transplantation. Clinically and 
histologically, the injury in the grafted 
liver was similar to that of her original 
diseased liver.
Serious bacterial infections have been 
infrequent since cyclosporine was intro­
duced for immunosuppression. Two pa­
tients (nos. 3 and 13) in the cyclosporine- 
treated group had severe bacterial infec­
tions that eventually proved fatal. 
Troublesome viral infections occurred in
FKT 1—Postoperative duration of hospitalization for each of 19 liver recipients. Hatched 
area indicates time spent in intensive care unit. * = transplanted twice during same admission, 
* -  third liver transplant for this patient, • = second liver transplant for this patient, + = died.
four recipients in the early postoperative 
period but eventually resolved. Three 
patients had mucocutaneous herpes infec­
tions and one patient had a cytomegalovi­
rus infection. Three of the four patients 
who had viral infections required antilym­
phocyte globulin as part of their immu­
nosuppressive therapy. Hirsutism deve­
loped in five patients in the cyclosporine 
group and two patients had isolated sei­
zures in the immediate post-transplant 
period. Patient no. 9 suffered from 
cyclosporine nephrotoxicity and hyper­
tension so the cyclosporine was replaced 
by Imuran 4 months after transplan­
tation.
The length of stay in hospital follow­
ing operation is shown in Fig. 1. The 
mean (±  SD) postoperative stay was 
52.3 ± 20.3 days with an average of
16.6 ± 18 days in the intensive care unit. 
Excluding the first three patients in the 
series, the average length of stay after 
operation was 50.6 ± 20.4 days, with an 
average of 11.6 ± 8.0 days in the inten­
sive care unit. The average volume of 
blood transfused during surgery was
19.6 ± 19 units. Excluding the two 
patients with the largest and smallest 
number of transfusions, the average was 
16.8 ± 8.9 units.
Of the 19 recipients, 9 required one or 
more operations in addition to the trans­
plant procedure during the same hospi­
tal admission.
Discussion
The object of liver transplantation is to 
restore patients with advanced irreversi­
ble liver disease to good health and return 
them to a productive life in the commu­
nity. Our experience has shown that this 
is possible for the majority of such 
patients. Indeed, if this were not possi­
ble, the value of liver transplantation 
would be questionable. The vigour and 
well-being these patients have enjoyed 
several months after a successful trans­
plant has been very encouraging. Because 
we have concentrated our efforts on 
patients with nonmalignant liver disease, 
it is anticipated that those who are alive 
1 year after transplantation can look for­
ward to many years of worthwhile and 
trouble-free survival. Unfortunately, 
most patients who have received a liver 
transplant for a malignant condition have 
had recurrent or metastatic disease, and 
cure is unusual.8-9 We are not enthusias­
tic about this indication for transplanta­
tion, but some patients with well- 
differentiated hepatomas appear to be 
exceptions and may be considered candi­
dates.10
Liver transplantation has its major 
therapeutic role in the management of 
children with biliary atresia and adults 
with nonalcoholic cirrhosis, although 
patients with liver disease in many other
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categories may benefit by transplanta­
tion.2,11 In general, candidates should be 
less than 50 years of age. The timing of 
transplantation is particularly crucial in 
patients with cirrhosis. Transplantation 
needs to be performed before patients 
reach a terminal stage when severe mal­
nutrition and profound coagulopathy 
make them unacceptably high operative 
risks. In hindsight, two of our first three 
patients were probably too ill to undergo 
the procedure. On the other hand, the 
operation should not be recommended 
too early, when the patient’s quality of 
life and prognosis are still relatively good. 
Patients with primary biliary cirrhosis are 
perhaps the best candidates in this respect 
because clinical deterioration is more 
progressive and predictable, and choos­
ing a time to intervene can be done more 
precisely than in some other forms of liver 
disease. Patients dying of acute liver 
failure are formidable operative risks for 
transplantation. The patient and family 
need to be clearly informed about the 
risks and benefits of the procedure. It is 
important for the patient to have a posi­
tive attitude and strong self-motivation.
Transplantation for alcoholic cirrhosis 
may be considered in those rare individ­
uals who have shown their rehabilitation 
potential and who abstain from alcohol 
for 6 to 12 months but continue to deteri­
orate from progression of their liver 
disease.
The presence of hepatitis B antigene- 
mia is regarded as a contraindication to 
liver transplantation because of reinfec­
tion of the grafted liver.12,13 The one 
patient in this series in whom fatal hepa­
titis developed following transplantation 
for non-A non-B hepatitis suggests this 
too should be a contraindication to trans­
plantation.
The time, effort, resources and com­
mitment to run a liver transplant program 
are substantial. The operation is long, 
technically demanding and allows little 
margin for error. Most of the operations 
are done during off hours so that regular 
operating-room schedules are minimally 
disrupted. Operative management is 
difficult because of the debilitated state 
of the patient’s health and the complex­
ity of metabolic and hemodynamic alter­
ations inherent in the operation. Post­
operative care requires balancing the 
intricacies of immunosuppressive therapy 
against rejection in patients who are 
already at special risk of infection. 
Postoperative complications are frequent. 
Approximately half the recipients in this 
series required additional surgery in the 
postoperative period, an experience simi­
lar to that reported by Starzl’s group.14 
Long distances may need to be travelled 
to retrieve donor organs. Patients can 
expect to spend 6 to 10 weeks in hospital 
following transplantation, although much 
of this time is spent in monitoring liver
function and adjusting immunosuppres­
sion. The blood bank has to be able to 
respond to sudden and unpredictable 
demands. An aggressive policy of retran­
splantation is necessary when irreversible 
rejection occurs. In spite of these factors 
and the problems they create, the suc­
cesses obtained in liver transplantation are 
extremely gratifying. In patients who have 
made a good recovery by the time of their 
discharge from hospital, follow-up care 
is neither extensive nor a burden and the 
lifestyle enjoyed by the patients is essen­
tially normal.
Cyclosporine has been a major advance 
in organ transplantation.1517 We have 
used it in combination with steroids, 
tapering the steroid dose quickly to low 
maintenance doses. The selective immu­
nosuppressive effect of cyclosporine on 
T lymphocytes appears functionally to 
permit control of rejection without seri­
ously predisposing to bacterial infection. 
This has special importance for liver 
recipients who are at high risk of bacterial 
infections in the early postoperative 
period. In White’s experience18 and ours, 
cyclosporine is not an easy drug to use 
immediately after liver transplantation 
when hepatic function is stabilizing but 
abnormal. Absorption, metabolism and 
excretion of the drug are variable during 
this period and calculations of the amount 
of drug needed to maintain therapeutic 
levels are difficult. Daily adjustment of 
the dose is required according to serum 
levels. Levels of recirculating metabolites 
(detected by radioimmunoassay) can be 
high and may not correlate with levels of 
the parent compound (as measured by 
HPLC assay).6 The 30% incidence of 
irreversible rejection in this series reflects 
these difficulties. In some of the patients 
immunosuppression was undoubtedly 
inadequate. We are currently focussing 
our attention on the HPLC assay of 
cyclosporine in an attempt to provide 
ideal immunosuppressive levels of the 
drug in liver recipients.
In summary, liver transplantation has 
been used to treat patients with advanced 
nonalcoholic liver disease. Of 19 patients 
transplanted, 11 are alive at 5 months to 
2Vi years after the operation. Three 
patients required a second and one a third 
transplant. Rejection is the commonest 
cause of graft failure and remains a 
problem despite the use of cyclosporine. 
In those who survive, the quality of life 
is excellent.
We are grateful to the many residents, 
interns, nurses, physiotherapists and other 
health-care personnel who participated in the 
care of these patients. The liver transplants 
could not have been performed without the 
superb cooperation provided by the staff of the 
donor hospitals. The technical assistance 
provided by K. Rycroft, M. Bloch and A. Hell- 
strom is acknowledged.
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Correction
In the January 1985 issue of the Journal, 
in the article “ Head injuries: a prospective, 
computerized study” by D. Parkinson, S. 
Stephensen and S. Phillips, two references, 
not cited in the text, were omitted from the 
reference list. On page 80, right-hand 
column, under the section “Age”, the final 
sentence that begins “ In children younger 
than 9 years...”  should read “ Head inju­
ries due to traffic accidents occurred most 
frequently in pedestrians under 9 years of 
age (54. 2%) and over 70 years (52.4%).” 
This statement is supported by the follow­
ing two references: D o w n s  A R ,  B u r n s  
CM: Manitoba accident investigation and 
accident health care project. Department 
of Surgery, Faculty of Medicine, Univer­
sity of Manitoba, February 1980, and 
K a l s b e e k  WD, M c L a u r in  R L ,  H a r r is  BS 
h i . M il l e r  JD: The National Head and 
Spinal Cord Injury Survey: major findings. 
J  Neurosurg 1980; 53 (suppl): SI9-31.
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NEW APPROACHES TO THE STUDY OF 
BENIGN PROSTATIC HYPERPLASIA. 
Proceedings of the Ninth Brook Lodge 
Workshop on Problems in Reproductive 
Physiology, held in Augusta, Michigan, 
September 26-27, 1983. Edited by Frances 
A. Kimball, Allen E. Buhl and Donald B. 
Carter. 394 pp. Illust. Alan R. Liss, Inc., 
New York, 1984. $56 (US). ISBN 
0-8451-0145-5.
This book represents the proceedings of a 
workshop on problems in reproductive phys­
iology held in 1983. Its contents reflect the 
varied background of the participants and, 
although of potential interest to a wide 
audience, its appeal to the clinician is only 
modest. The initial chapters on the etiology, 
anatomy and morphogenesis of benign 
prostatic hypertrophy are of utmost interest 
and are replete with new information relevant 
to individuals dealing with this problem. In 
addition, the discussion at the end of each 
chapter is crisp, direct and helpful in under­
standing the concepts expressed by the authors.
The remaining two thirds o f the book are 
devoted to results of basic research into 
prostatic hyperplasia in vitro and in animal 
models. These chapters are highly specialized 
and are directed towards individuals with 
expertise in biochemistry and endocrinology. 
The main interest for the clinical urologist lies 
in the compilation of current knowledge on the 
basic aspects of benign prostatic hyperplasia 
and the assurance that a great deal of interest 
exists in the elucidation of an aging process, 
which, according to one of the contributors, 
may start during puberty! For the basic scien­
tist, on the other hand, there is a wealth of 
information that updates the present under­
standing of the pathophysiologic mechanisms 
involved in the development of benign prostatic 
hyperplasia that may be manipulated to stop 
or reverse this process. The inescapable con­
clusion is that although we have a better under­
standing of prostate physiology, the means and 
ways to control the development of prostatic 
hyperplasia are not yet within our reach.
This volume deserves a place in academic 
libraries but its usefulness to the clinician is 
limited.
A . M orales, m d , fa cs , frcsc
Department of Urology,
Queen’s University,
Kingston, Ont.
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ORTHOPAEDICS. Principles and Their 
Application. 2 vols. 4th ed. Samuel L. 
Turek. 1756 pp. Illust. J.B. Lippincott 
Company, Philadelphia, 1984. $125 (US). 
ISBN 0-397-50604-X.
The fourth edition of this well-known book on 
orthopedic surgery is most welcome. Its pub­
lication in two volumes, rather than the one 
volume of the previous edition, allows the use 
o f larger print and thus easier reading. The 
author has updated it consistent with current 
knowledge.
Chapter three now includes a discussion of 
the progenitor cell principle, with discussion
of the autoradiographic studies of DNA and 
RNA. The section on delayed union and 
nonunion and the use of electric stimulation 
has been well written. Included here is a con­
sideration of homogeneous and autogenous 
transplantation. The section on osteonecrosis 
is also well written. The chapter on collagen 
pays particular attention to details and the 
references are complete. The chapter dealing 
with the blood supply of long bones is new; 
this is a most important subject and is well 
covered. Chapter eight has a pertinent addi­
tion concerning the biophysical properties of 
bone and cartilage.
I believe that the short paragraph in chap­
ter 11 on the treatment of old subluxation of 
the hip should be removed. The new addition 
on proximal femoral focal deficiency is per­
tinent.
The chapter on rheumatoid arthritis is well 
done and informative and has been updated 
with regard to the use of nonsteroidal anti­
inflammatory drugs and immunosuppressive 
agents. Of extreme value is the inclusion in 
chapter 14 of the section on compression of 
the ulnar nerve at the wrist. The material on 
tumours of bone has been revised to a great 
extent, with a discussion of new techniques that 
adds substance to the chapter. Unfortunately, 
computerized axial tomography as an investiga­
tive tool was not considered.
I welcome the addition on the surgical treat­
ment of Paget’s disease, discussing the prob­
lems of surgical intervention and management.
The author has presented valuable and rele­
vant material on the small blood vessel supply 
of the upper end of the femur. The section on 
idiopathic avascular necrosis of the femoral 
head has been expanded. The chapter dealing 
with knee ligaments is well documented and has 
been expanded, giving a description of the 
methods of assessment and reconstruction of 
specific ligaments. The section on total knee 
arthroplasty has also been updated.
I strongly recommend this textbook to the 
orthopedic surgeon in training and in practice. 
It is well written and illustrated and it main­
tains the high standard of the previous editions.
Leon  H ell er , m d , frcsc
Department of Orthopedic Surgery,
The Sir Mortimer B. Davis-
Jewish General Hospital,
Montreal, PQ 
H3T 1E2
TEXTBOOK OF DISORDERS AND INJU­
RIES OF THE MUSCULOSKELETAL 
SYSTEM. An Introduction to Orthopae­
dics, Fractures and Joint Injuries, Rheuma­
tology, Metabolic Bone Disease and Re­
habilitation. 2nd ed. Robert Bruce Salter. 
578 pp. Illust. Williams & Wilkins, Balti­
more, 1983, $39.75 (US). ISBN 0-683- 
07500-4.
The second edition of Professor Salter’s text 
is as welcome to this decade of undergraduate 
students and their teachers as was the original 
edition. In the foreword, Dr. Paul Curtiss, Edi­
tor of the American Journal o f  Bone and Joint 
Surgery, lists some of the scientific and tech­
nical advances that have occurred since the first 
edition was published 13 years ago. These
continued page 292
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